|
Delaware
(State or other jurisdiction of
incorporation or organization) |
| |
6770
(Primary Standard Industrial
Classification Code Number) |
| |
35-2284050
(I.R.S. Employer
Identification No.) |
|
|
M. Ali Panjwani, Esq.
Pryor Cashman LLP 7 Times Square New York, New York 10036 Tel: (212) 326-0820 |
| |
Jonathan J. Russo, Esq.
Alexandra F. Calcado, Esq. Pillsbury Winthrop Shaw Pittman LLP 31 West 52nd Street New York, New York 10019 (212) 858-1000 |
|
| Large accelerated filer ☐ | | | Accelerated filer ☐ | |
| Non-accelerated filer ☒ | | | Smaller reporting company ☒ | |
| | | | Emerging growth company ☒ | |
| | | | | 1 | | | |
| | | | | 17 | | | |
| | | | | 50 | | | |
| | | | | 51 | | | |
| | | | | 52 | | | |
| | | | | 53 | | | |
| | | | | 55 | | | |
| | | | | 58 | | | |
| | | | | 81 | | | |
| | | | | 90 | | | |
| | | | | 106 | | | |
| | | | | 111 | | | |
| | | | | 114 | | | |
| | | | | 117 | | | |
| | | | | 123 | | | |
| | | | | 126 | | | |
| | | | | 130 | | | |
| | | | | 139 | | | |
| | | | | 139 | | | |
| | | | | 139 | | | |
| | | | | F-1 | | |
| | |
Three Months Ended March 31,
|
| |
Year Ended December 31,
|
| ||||||||||||||||||
(Dollar Amounts In Thousands)
|
| |
2024
|
| |
2023
|
| |
2023
|
| |
2022
|
| ||||||||||||
Revenues
|
| | | $ | 7,841 | | | | | $ | 7,549 | | | | | $ | 43,922 | | | | | $ | 35,784 | | |
Cost of goods sold
|
| | | | 5,139 | | | | | | 4,266 | | | | | | 27,028 | | | | | | 22,656 | | |
Gross profit
|
| | | | 2,702 | | | | | | 3,283 | | | | | | 16,894 | | | | | | 13,128 | | |
Operating expenses: | | | | | | | | | | | | | | | | ||||||||||
Research and development
|
| | | | 1,977 | | | | | | 1,113 | | | | | | 4,218 | | | | | | 4,666 | | |
Selling and marketing
|
| | | | 5,254 | | | | | | 3,278 | | | | | | 12,898 | | | | | | 11,585 | | |
General and administrative
|
| | | | 6,860 | | | | | | 1,715 | | | | | | 6,710 | | | | | | 6,780 | | |
Other operating expenses
|
| | | | — | | | | | | — | | | | | | 1,683 | | | | | | — | | |
Total operating expenses
|
| | | | 14,091 | | | | | | 6,106 | | | | | | 25,509 | | | | | | 23,031 | | |
Loss from operations
|
| | | | (11,389) | | | | | | (2,823) | | | | | | (8,615) | | | | | | (9,903) | | |
Other (expense) income: | | | | | | | | | | | | | | | | ||||||||||
Interest expense
|
| | | | (729) | | | | | | (599) | | | | | | (2,900) | | | | | | (3,696) | | |
Other income (expense), net
|
| | | | (82) | | | | | | 5 | | | | | | 23 | | | | | | (196) | | |
Loss on extinguishment of debt
|
| | | | (52) | | | | | | — | | | | | | (1,541) | | | | | | (3,346) | | |
Forgiveness of paycheck protection program loan
|
| | | | — | | | | | | — | | | | | | — | | | | | | 2,012 | | |
Loss, before income taxes
|
| | | | (12,252) | | | | | | (3,417) | | | | | | (13,033) | | | | | | (15,129) | | |
Income tax benefit (expense)
|
| | | | 5 | | | | | | — | | | | | | (3) | | | | | | (44) | | |
Net loss
|
| | | $ | (12,247) | | | | | $ | (3,417) | | | | | $ | (13,036) | | | | | $ | (15,173) | | |
Other comprehensive loss, net of tax: | | | | | | | | | | | | | | | | ||||||||||
Foreign currency translation adjustment
|
| | | | 74 | | | | | | (11) | | | | | | 64 | | | | | | 212 | | |
Comprehensive loss
|
| | | $ | (12,173) | | | | | $ | (3,428) | | | | | $ | (12,972) | | | | | $ | (14,961) | | |
Net loss per common share – basic and diluted
|
| | | $ | (70.83) | | | | | $ | (55.96) | | | | | $ | (113.21) | | | | | $ | (156.71) | | |
Weighted average shares outstanding – basic and diluted
|
| | | | 174,077 | | | | | | 168,046 | | | | | | 170,212 | | | | | | 161,683 | | |
Pro forma as adjusted net loss per share, basic and diluted (unaudited)(1)
|
| | | $ | (0.62) | | | | | | | | | | | $ | (0.64) | | | | |||||
Weighted average shares outstanding used in computing
pro forma as adjusted net loss per share, basic and diluted (unaudited) |
| | | | 20,460,428 | | | | | | | | | | | | 20,456,565 | | | |
| | |
As of March 31, 2024
|
| |||||||||||||||
(In Thousands)
|
| |
2024
|
| |
Pro Forma(1)
|
| |
Pro Forma
As Adjusted(2) |
| |||||||||
Cash and cash equivalents
|
| | | $ | 1,188 | | | | | $ | 1,188 | | | | | $ | 13,369 | | |
Working capital(3)
|
| | | | (21,856) | | | | | | (13,959) | | | | | | (1,777) | | |
Total assets
|
| | | | 14,352 | | | | | | 13,940 | | | | | | 26,121 | | |
Convertible debt
|
| | | | 10,000 | | | | | | 5,000 | | | | | | 5,000 | | |
Other current debt
|
| | | | 6,422 | | | | | | 6,422 | | | | | | 6,422 | | |
SAFE liabilities
|
| | | | — | | | | | | — | | | | | | — | | |
Noncurrent debt
|
| | | | 1,644 | | | | | | 1,644 | | | | | | 1,644 | | |
Total liabilities
|
| | | | 37,601 | | | | | | 29,704 | | | | | | 29,704 | | |
Preferred stock
|
| | | | 112,142 | | | | | | — | | | | | | — | | |
Common Stock
|
| | | | — | | | | | | 1 | | | | | | 1 | | |
Additional paid-in capital
|
| | | | 146,132 | | | | | | 266,112 | | | | | | 278,293 | | |
Accumulated deficit
|
| | | | (281,825) | | | | | | (282,178) | | | | | | (282,178) | | |
Total stockholders’ deficit
|
| | | $ | (135,391) | | | | | $ | (15,764) | | | | | $ | (3,582) | | |
| | |
Three Months Ended
March 31, |
| |
Year Ended
December 31, |
| ||||||||||||||||||
| | |
2024
|
| |
2023
|
| |
2023
|
| |
2022
|
| ||||||||||||
GAAP Net Loss
|
| | | $ | (12,247) | | | | | $ | (3,417) | | | | | $ | (13,036) | | | | | $ | (15,173) | | |
Add back (deduct): | | | | | | | | | | | | | | | | ||||||||||
Interest expense
|
| | | | 729 | | | | | | 599 | | | | | | 2,900 | | | | | | 3,696 | | |
Depreciation and amortization
|
| | | | 4 | | | | | | 11 | | | | | | 32 | | | | | | 49 | | |
Income tax expense (benefit)
|
| | | | (5) | | | | | | — | | | | | | 3 | | | | | | 44 | | |
Write-off of deferred offering costs
|
| | | | — | | | | | | — | | | | | | 1,683 | | | | | | — | | |
Stock-based compensation
|
| | | | 7,253 | | | | | | — | | | | | | 1 | | | | | | 20 | | |
Forgiveness of paycheck protection program loan
|
| | | | — | | | | | | — | | | | | | — | | | | | | (2,012) | | |
Loss on extinguishment of debt
|
| | | | 52 | | | | | | — | | | | | | 1,541 | | | | | | 3,346 | | |
Adjusted EBITDA
|
| | | $ | (4,214) | | | | | $ | (2,807) | | | | | $ | (6,876) | | | | | $ | (10,030) | | |
| | |
As of March 31, 2024
|
| |||||||||||||||
| | |
Actual
|
| |
Pro Forma
|
| |
Pro Forma,
As Adjusted |
| |||||||||
Cash and cash equivalents
|
| | | $ | 1,188 | | | | | $ | 1,188 | | | | | $ | 13,369 | | |
Debt Liabilities | | | | | | | | | | | | | | | | | | | |
Convertible debt
|
| | | $ | 10,000 | | | | | $ | 5,000 | | | | | $ | 5,000 | | |
SAFE liabilities
|
| | | $ | — | | | | | $ | — | | | | | $ | — | | |
Other current debt
|
| | | $ | 6,422 | | | | | $ | 6,422 | | | | | $ | 6,422 | | |
Accrued interest
|
| | | $ | 1,439 | | | | | $ | 1,384 | | | | | $ | 1,384 | | |
Other non-current debt
|
| | | $ | 1,644 | | | | | $ | 1,644 | | | | | $ | 1,644 | | |
Total Debt Liabilities
|
| | | $ | 19,505 | | | | | $ | 14,450 | | | | | $ | 14,450 | | |
| | |
As of March 31, 2024
|
| |||||||||||||||
| | |
Actual
|
| |
Pro Forma
|
| |
Pro Forma,
As Adjusted |
| |||||||||
Temporary redeemable preferred stock: | | | | | | | | | | | | | | | | | | | |
Series A preferred stock
|
| | | $ | 3,000 | | | | | $ | — | | | | | $ | — | | |
NCNV 1, NCNV 2 and NCNV 3 preferred stock
|
| | | $ | 109,142 | | | | | $ | — | | | | | $ | — | | |
Total temporary redeemable preferred stock:
|
| | | $ | 112,142 | | | | | $ | — | | | | | $ | — | | |
Stockholders’ Deficit | | | | | | | | | | | | | | | | | | | |
Common stock
|
| | | $ | — | | | | | $ | 1 | | | | | $ | 1 | | |
Additional paid in capital
|
| | | $ | 146,132 | | | | | $ | 266,112 | | | | | $ | 278,293 | | |
Accumulated other comprehensive income (loss)
|
| | | $ | 302 | | | | | $ | 302 | | | | | $ | 302 | | |
Accumulated deficit
|
| | | $ | (281,825) | | | | | $ | (282,178) | | | | | $ | (282,178) | | |
Total stockholders’ deficit
|
| | | $ | (135,391) | | | | | $ | (15,764) | | | | | $ | (3,582) | | |
Total capitalization
|
| | | $ | (23,249) | | | | | $ | (15,764) | | | | | $ | (3,582) | | |
|
|
Assumed initial public offering price per share of common stock
|
| | | | | | | | | $ | 5.00 | | |
|
Pro forma net tangible book deficit per share of common stock as of March 31, 2024
|
| | | $ | (777.77) | | | | | | | | |
|
Increase in pro forma net tangible book value per share of common stock attributable to pro forma adjustments
|
| | | $ | 777.00 | | | | | | | | |
|
Increase in pro forma as adjusted net tangible book value attributable to new investors in this offering
|
| | | $ | 0.62 | | | | | | | | |
|
Pro forma as adjusted net tangible book deficit per share of common stock after giving
effect to this offering |
| | | | | | | | | $ | (0.15) | | |
|
Dilution per share of common stock to investors in this offering
|
| | | | | | | | | $ | 5.15 | | |
| | |
Purchased
|
| |
Total Consideration
|
| |
Average
Price Per Share |
| |||||||||||||||||||||
| | |
Number
|
| |
Percent
|
| |
Amount
|
| |
Percent
|
| ||||||||||||||||||
| | |
(in thousands)
|
| |||||||||||||||||||||||||||
Existing stockholders
|
| | | | 18,459,851 | | | | | | 79% | | | | | $ | 69,638 | | | | | | 75% | | | | | $ | 3.77 | | |
SAFE investors
|
| | | | 650,029 | | | | | | 3% | | | | | | 3,250 | | | | | | 3% | | | | | $ | 5.00 | | |
Debt conversion
|
| | | | 1,176,471 | | | | | | 5% | | | | | | 5,000 | | | | | | 5% | | | | | $ | 4.25 | | |
New investors in this offering
|
| | | | 3,000,000 | | | | | | 13% | | | | | | 15,000 | | | | | | 16% | | | | | $ | 5.00 | | |
Total
|
| | | | 23,286,351 | | | | | | 100% | | | | | $ | 92,889 | | | | | | 100% | | | | | | | | |
| | |
Three months ended
March 31, |
| |
Year Ended
December 31, |
| ||||||||||||||||||
(in thousands)
|
| |
2024
|
| |
2023
|
| |
2023
|
| |
2022
|
| ||||||||||||
Bookings
|
| | | $ | 8,903 | | | | | $ | 10,922 | | | | | $ | 42,721 | | | | | $ | 36,956 | | |
| | |
Three Months Ended
March 31, |
| |
Year Ended December 31,
|
| ||||||||||||||||||
| | |
2024
|
| |
2023
|
| |
2023
|
| |
2022
|
| ||||||||||||
GAAP Net Loss
|
| | | $ | (12,247) | | | | | $ | (3,417) | | | | | $ | (13,036) | | | | | $ | (15,173) | | |
Add back (deduct): | | | | | | | | | | | | | | | | | | | | | | | | | |
Interest expense
|
| | | | 729 | | | | | | 599 | | | | | | 2,900 | | | | | | 3,696 | | |
Depreciation and amortization
|
| | | | 4 | | | | | | 11 | | | | | | 32 | | | | | | 49 | | |
Income tax expense (benefit)
|
| | | | (5) | | | | | | — | | | | | | 3 | | | | | | 44 | | |
Write-off of deferred offering costs
|
| | | | — | | | | | | — | | | | | | 1,683 | | | | | | — | | |
Stock-based compensation
|
| | | | 7,253 | | | | | | — | | | | | | 1 | | | | | | 20 | | |
Forgiveness of paycheck protection program loan
|
| | | | — | | | | | | — | | | | | | — | | | | | | (2,012) | | |
Loss on extinguishment of debt
|
| | | | 52 | | | | | | — | | | | | | 1,541 | | | | | | 3,346 | | |
Adjusted EBITDA
|
| | | $ | (4,214) | | | | | $ | (2,807) | | | | | $ | (6,876) | | | | | $ | (10,030) | | |
| | |
Three Months Ended
March 31, |
| |
Change
|
| |
Year Ended
December 31, |
| |
Change
|
| ||||||||||||||||||||||||||||||||||||
(dollar amounts in thousands)
|
| |
2024
|
| |
2023
|
| |
$
|
| |
%
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
| ||||||||||||||||||||||||
Revenues: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Hardware
|
| | | | 5,195 | | | | | $ | 4,756 | | | | | $ | 439 | | | | | | 9% | | | | | $ | 27,461 | | | | | $ | 23,038 | | | | | $ | 4,423 | | | | | | 19% | | |
Software
|
| | | | 1,961 | | | | | | 2,235 | | | | | | (274) | | | | | | (12)% | | | | | | 13,229 | | | | | | 10,697 | | | | | | 2,532 | | | | | | 24% | | |
Services
|
| | | | 685 | | | | | | 558 | | | | | | 127 | | | | | | 23% | | | | | | 3,232 | | | | | | 2,049 | | | | | | 1,183 | | | | | | 58% | | |
Total Revenues
|
| | | | 7,841 | | | | | | 7,549 | | | | | | 292 | | | | | | 4% | | | | | | 43,922 | | | | | | 35,784 | | | | | | 8,138 | | | | | | 23% | | |
Cost of goods sold(1)
|
| | | | 5,139 | | | | | | 4,266 | | | | | | 873 | | | | | | 20% | | | | | | 27,028 | | | | | | 22,656 | | | | | | 4,372 | | | | | | 19% | | |
Gross profit
|
| | | | 2,702 | | | | | | 3,283 | | | | | | (581) | | | | | | (18)% | | | | | | 16,894 | | | | | | 13,128 | | | | | | 3,766 | | | | | | 29% | | |
Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and development(1)
|
| | | | 1,977 | | | | | | 1,113 | | | | | | 864 | | | | | | 78% | | | | | | 4,218 | | | | | | 4,666 | | | | | | (448) | | | | | | (10)% | | |
Selling and marketing(1)
|
| | | | 5,505 | | | | | | 3,278 | | | | | | 2,227 | | | | | | 68% | | | | | | 12,898 | | | | | | 11,585 | | | | | | 1,313 | | | | | | 11% | | |
General and administrative(1)
|
| | | | 6,609 | | | | | | 1,715 | | | | | | 4,894 | | | | | | 285% | | | | | | 6,710 | | | | | | 6,780 | | | | | | (70) | | | | | | (1)% | | |
Other operating expenses
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,683 | | | | | | — | | | | | | 1,683 | | | | | | 100% | | |
Total operating expenses
|
| | | | 14,091 | | | | | | 6,106 | | | | | | 7,985 | | | | | | 131% | | | | | | 25,509 | | | | | | 23,031 | | | | | | 2,478 | | | | | | 11% | | |
Loss from operations
|
| | | | (11,389) | | | | | | (2,823) | | | | | | (8,566) | | | | | | 303% | | | | | | (8,615) | | | | | | (9,903) | | | | | | 1,288 | | | | | | (13)% | | |
Other (expense) income: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Interest expense
|
| | | | (729) | | | | | | (599) | | | | | | (130) | | | | | | 22% | | | | | | (2,900) | | | | | | (3,696) | | | | | | 796 | | | | | | (22)% | | |
Other income (expense), net
|
| | | | (82) | | | | | | 5 | | | | | | (87) | | | | | | (1,740)% | | | | | | 23 | | | | | | (196) | | | | | | 219 | | | | | | 112% | | |
Loss on extinguishment of debt
|
| | | | (52) | | | | | | — | | | | | | (52) | | | | | | (100)% | | | | | | (1,541) | | | | | | (3,346) | | | | | | 1,805 | | | | | | (54)% | | |
Forgiveness of paycheck protection program loan
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 2,012 | | | | | | (2,012) | | | | | | (100)% | | |
Loss before income taxes
|
| | | | (12,252) | | | | | | (3,417) | | | | | | (8,835) | | | | | | 259% | | | | | | (13,033) | | | | | | (15,129) | | | | | | 2,096 | | | | | | (14)% | | |
Income tax (expense) benefit
|
| | | | 5 | | | | | | — | | | | | | 5 | | | | | | 100% | | | | | | (3) | | | | | | (44) | | | | | | 41 | | | | | | (93)% | | |
Net loss
|
| | | $ | (12,247) | | | | | $ | (3,417) | | | | | $ | (8,830) | | | | | | 258% | | | | | $ | (13,036) | | | | | $ | (15,173) | | | | | $ | 2,137 | | | | | | 14% | | |
| | |
Three Months Ended
March 31, |
| |
Year Ended
December 31, |
| ||||||||||||||||||
(in thousands)
|
| |
2024
|
| |
2023
|
| |
2023
|
| |
2022
|
| ||||||||||||
| | |
(unaudited)
|
| | | | ||||||||||||||||||
Cost of goods sold
|
| | | $ | 116 | | | | | $ | — | | | | | $ | — | | | | | $ | 1 | | |
Research and development
|
| | | | 693 | | | | | | — | | | | | | — | | | | | | 5 | | |
Sales and marketing
|
| | | | 2,561 | | | | | | — | | | | | | 1 | | | | | | 16 | | |
General and administrative
|
| | | | 3,883 | | | | | | — | | | | | | — | | | | | | (1) | | |
Total stock-based compensation expense
|
| | | $ | 7,253 | | | | | $ | — | | | | | $ | 1 | | | | | $ | 20 | | |
| | |
Three Months Ended
March 31, |
| |
Change
|
| ||||||||||||||||||
(dollar amounts in thousands)
|
| |
2024
|
| |
2023
|
| |
$
|
| |
%
|
| ||||||||||||
Revenues: | | | | | | | | | | | | | | | | | | | | | | | | | |
Hardware
|
| | | $ | 5,195 | | | | | $ | 4,756 | | | | | $ | 439 | | | | | | 9% | | |
Software
|
| | | | 1,961 | | | | | | 2,235 | | | | | | (274) | | | | | | (12)% | | |
Services
|
| | | | 685 | | | | | | 558 | | | | | | 127 | | | | | | 23% | | |
Total Revenues
|
| | | $ | 7,841 | | | | | $ | 7,549 | | | | | $ | 292 | | | | | | 4% | | |
Retention and Expansion Metrics | | | | | | | | | | | | | | | | | | | | | | | | | |
Annualized Contract Value (ACV)
|
| | | $ | 10,570 | | | | | $ | 9,342 | | | | | $ | 1,228 | | | | | | 13% | | |
Net Dollar Retention Rate (NDRR)
|
| | | | 112% | | | | | | 95% | | | | | | 17% | | | | | | | | |
| | |
Year Ended
December 31, |
| |
Change
|
| ||||||||||||||||||
(dollar amounts in thousands)
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
| ||||||||||||
Revenues: | | | | | | | | | | | | | | | | | | | | | | | | | |
Hardware
|
| | | $ | 27,461 | | | | | $ | 23,038 | | | | | $ | 4,423 | | | | | | 19% | | |
Software
|
| | | | 13,229 | | | | | | 10,697 | | | | | | 2,532 | | | | | | 24% | | |
Services
|
| | | | 3,232 | | | | | | 2,049 | | | | | | 1,183 | | | | | | 58% | | |
Total Revenues
|
| | | $ | 43,922 | | | | | $ | 35,784 | | | | | $ | 8,138 | | | | | | 23% | | |
Retention and Expansion Metrics | | | | | | | | | | | | | | | | | | | | | | | | | |
Annualized Contract Value (ACV)
|
| | | $ | 10,621 | | | | | $ | 8,982 | | | | | $ | 1,639 | | | | | | 18% | | |
Net Dollar Retention Rate (NDRR)
|
| | | | 112% | | | | | | 101% | | | | | | 11% | | | | | | | | |
| | |
Three Months Ended
March 31, |
| |
Change
|
| ||||||||||||||||||
(in thousands)
|
| |
2024
|
| |
2023
|
| |
$
|
| |
%
|
| ||||||||||||
| | |
(unaudited)
|
| | | |||||||||||||||||||
Cost of goods sold
|
| | | | 5,139 | | | | | | 4,266 | | | | | | 873 | | | | | | 20% | | |
| | |
Year Ended
December 31, |
| |
Change
|
| ||||||||||||||||||
(in thousands)
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
| ||||||||||||
Cost of goods sold: | | | | | | | | | | | | | | | | | | | | | | | | | |
Hardware
|
| | | $ | 19,740 | | | | | $ | 16,850 | | | | | $ | 2,890 | | | | | | 17% | | |
Software
|
| | | | 5,545 | | | | | | 3,864 | | | | | | 1,681 | | | | | | 44% | | |
Services
|
| | | | 779 | | | | | | 616 | | | | | | 163 | | | | | | 26% | | |
Excess and obsolete
|
| | | | 948 | | | | | | 1,320 | | | | | | (372) | | | | | | (28)% | | |
Other
|
| | | | 15 | | | | | | 6 | | | | | | 9 | | | | | | 150% | | |
Total cost of goods sold
|
| | | $ | 27,028 | | | | | $ | 22,656 | | | | | $ | 4,371 | | | | | | 19% | | |
| | |
Three Months Ended
March 31, |
| |
Change
|
| ||||||||||||||||||
(in thousands)
|
| |
2024
|
| |
2023
|
| |
$
|
| |
%
|
| ||||||||||||
| | |
(unaudited)
|
| | | |||||||||||||||||||
Operating Expenses: | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and development
|
| | | $ | 1,977 | | | | | $ | 1,113 | | | | | $ | 864 | | | | | | 78% | | |
Selling and marketing
|
| | | | 5,505 | | | | | | 3,278 | | | | | | 2,227 | | | | | | 68% | | |
General and administrative
|
| | | | 6,609 | | | | | | 1,715 | | | | | | 4,894 | | | | | | 285% | | |
Total operating expenses
|
| | | $ | 14,091 | | | | | $ | 6,106 | | | | | $ | 7,985 | | | | | | 131% | | |
| | |
Year Ended
December 31, |
| |
Change
|
| ||||||||||||||||||
(in thousands)
|
| |
2024
|
| |
2023
|
| |
$
|
| |
%
|
| ||||||||||||
Operating Expenses: | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and development
|
| | | | 4,218 | | | | | | 4,666 | | | | | | (448) | | | | | | (10)% | | |
Selling and marketing
|
| | | | 12,898 | | | | | | 11,585 | | | | | | 1,313 | | | | | | 11% | | |
General and administrative
|
| | | | 6,710 | | | | | | 6,780 | | | | | | (70) | | | | | | (1)% | | |
Other operating expenses
|
| | | | 1,683 | | | | | | — | | | | | | 1,683 | | | | | | 100% | | |
Total operating expenses
|
| | | | 25,509 | | | | | | 23,031 | | | | | | 2,478 | | | | | | 11% | | |
| | |
Three Months Ended
March 31, |
| |
Change
|
| |
Year Ended
December 31, |
| |
Change
|
| ||||||||||||||||||||||||||||||||||||
(in thousands)
|
| |
2024
|
| |
2023
|
| |
$
|
| |
%
|
| |
2023
|
| |
2022
|
| |
$
|
| |
%
|
| ||||||||||||||||||||||||
| | |
(unaudited)
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||
Interest expense
|
| | | | (729) | | | | | | (599) | | | | | | (130) | | | | | | 22% | | | | | | (2,900) | | | | | | (3,696) | | | | | | 796 | | | | | | (22)% | | |
| | |
March 31,
|
| |
December 31,
|
| ||||||||||||||||||
(in thousands)
|
| |
2024
|
| |
2023
|
| |
2023
|
| |
2022
|
| ||||||||||||
Net cash used in operating activities
|
| | | $ | (5,414) | | | | | $ | (4,366) | | | | | $ | (6,410) | | | | | $ | (8,902) | | |
Net cash used in investing activities
|
| | | $ | — | | | | | $ | — | | | | | $ | (5) | | | | | $ | (11) | | |
Net cash provided by financing activities
|
| | | $ | 3,714 | | | | | $ | 2,798 | | | | | $ | 5,587 | | | | | $ | 6,942 | | |
Name
|
| |
Age
|
| |
Position
|
|
Paul Kellenberger | | |
64
|
| | Chief Executive Officer and Director | |
Erick DeOliveira | | |
54
|
| | Chief Financial Officer | |
Michael Harper | | |
57
|
| |
Chief Product, Engineering and Marketing Officer
|
|
Ron Rheinheimer | | |
59
|
| | Chief Sales Officer | |
Pankaj Gupta | | |
49
|
| | Director | |
Amit Jain | | |
44
|
| | Director | |
Joanna Morris | | |
58
|
| | Director | |
Abhay Pande | | |
56
|
| | Director | |
Angela Prince | | |
41
|
| | Director | |
Jane Swift | | |
59
|
| | Director | |
Name and Principal Position
|
| |
Base Salary
|
| |
Bonus(1)
|
| |
Non-equity
Sales Incentive Compensation(2) |
| |
All other
compensation(3) |
| |
Total
|
| |||||||||||||||
Paul Kellenberger
|
| | | $ | 400,000 | | | | | $ | 133,000 | | | | | | | | | | | $ | 2,900 | | | | | $ | 535,900 | | |
Chief Executive Officer and Director | | | | | | | |||||||||||||||||||||||||
Mike Harper
|
| | | $ | 325,000 | | | | | $ | 108,000 | | | | | | | | | | | $ | 2,900 | | | | | $ | 435,900 | | |
Chief Product, Engineering and Marketing Officer | | | | | | | |||||||||||||||||||||||||
Ron Rheinheimer
|
| | | $ | 250,000 | | | | | $ | 62,500 | | | | | $ | 190,560 | | | | | $ | 2,900 | | | | | $ | 505,960 | | |
Chief Sales Officer | | | | | | |
| | | | | | | | | | | | | | |
Option Awards
|
| |||||||||||||||
| | | | | | | | | | | | | | |
Number of
Securities Underlying Unexercised Options |
| | | | | | | | | | | | | |||
Name
|
| |
Grant Date(1)
|
| |
Vesting
Commencement Date(2) |
| |
Exercisable
(#) |
| |
Exercise Price
($) |
| |
Expiration
Date |
| |||||||||||||||
Paul Kellenberger*
|
| | | | 04/22/2015 | | | | | | 02/16/2007 | | | | | | 199 | | | | | $ | 330.00 | | | | | | 04/21/2025 | | |
| | | | | 07/07/2015 | | | | | | 07/07/2015 | | | | | | 92 | | | | | $ | 330.00 | | | | | | 07/07/2025 | | |
| | | | | 04/22/2015 | | | | | | 09/01/2014 | | | | | | 1,393 | | | | | $ | 330.00 | | | | | | 09/01/2024 | | |
| | | | | 10/24/2017 | | | | | | 10/24/2017 | | | | | | 233 | | | | | $ | 720.00 | | | | | | 10/23/2027 | | |
| | | | | 10/24/2017 | | | | | | 10/24/2017 | | | | | | 266 | | | | | $ | 720.00 | | | | | | 10/23/2027 | | |
| | | | | 02/27/2018 | | | | | | 02/27/2018 | | | | | | 3,000 | | | | | $ | 720.00 | | | | | | 02/27/2028 | | |
| | | | | 04/14/2021 | | | | | | 04/14/2021 | | | | | | 433,760 | | | | | $ | 0.53 | | | | | | 04/13/2031 | | |
Mike Harper
|
| | | | 04/17/2015 | | | | | | 02/01/2011 | | | | | | 424 | | | | | $ | 330.00 | | | | | | 04/16/2025 | | |
| | | | | 04/22/2015 | | | | | | 09/01/2014 | | | | | | 264 | | | | | $ | 330.00 | | | | | | 04/21/2025 | | |
| | | | | 10/24/2017 | | | | | | 10/24/2017 | | | | | | 71 | | | | | $ | 720.00 | | | | | | 10/23/2027 | | |
| | | | | 02/27/2018 | | | | | | 02/27/2018 | | | | | | 333 | | | | | $ | 720.00 | | | | | | 02/27/2028 | | |
| | | | | 04/14/2021 | | | | | | 04/14/2021 | | | | | | 97,173 | | | | | $ | 0.53 | | | | | | 04/13/2031 | | |
Ron Rheinheimer
|
| | | | 06/23/2016 | | | | | | 04/04/2016 | | | | | | 578 | | | | | $ | 600.00 | | | | | | 06/23/2026 | | |
| | | | | 10/24/2017 | | | | | | 02/26/2017 | | | | | | 28 | | | | | $ | 720.00 | | | | | | 10/23/2027 | | |
| | | | | 02/27/2018 | | | | | | 02/27/2018 | | | | | | 200 | | | | | $ | 720.00 | | | | | | 02/27/2028 | | |
| | | | | 04/14/2021 | | | | | | 04/14/2021 | | | | | | 69,906 | | | | | $ | 0.53 | | | | | | 04/13/2031 | | |
| | |
Prior to this Offering
|
| |
Pro Forma(1)
|
| |
Pro Forma as adjusted(2)
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
Common Stock
|
| |
Series A
Preferred Stock |
| |
NCNV 1
Preferred Stock |
| |
NCNV 2
Preferred Stock |
| |
NCNV 3
Preferred Stock |
| |
Common Stock
|
| |
Common Stock
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name of Beneficial Owner
|
| |
No. of
Shares |
| |
%
|
| |
No. of
Shares |
| |
%
|
| |
No. of
Shares |
| |
%
|
| |
No. of
Shares |
| |
%
|
| |
No. of
Shares |
| |
%
|
| |
No. of
Shares |
| |
%
|
| |
No. of
Shares |
| |
%
|
| ||||||||||||||||||||||||||||||||||||||||||
Named Executive Officers and Directors | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Paul Kellenberger(3)
|
| | | | 2,303,933 | | | | | | 93.0 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 2,303,933 | | | | | | 10.1 | | | | | | 2,303,933 | | | | | | 8.9 | | |
Chief Executive Officer and Director
|
| | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Erick DeOliveira
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Chief Financial Officer
|
| | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Michael Harper(4)
|
| | | | 518,577 | | | | | | 74.9 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 518,577 | | | | | | 2.5 | | | | | | 518,577 | | | | | | 2.2 | | |
Chief Product, Engineering and Marketing Officer
|
| | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ronald Rheinheimer(5)
|
| | | | 373,124 | | | | | | 68.2 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 373,124 | | | | | | 1.8 | | | | | | 373,124 | | | | | | 1.6 | | |
Chief Sales Officer
|
| | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pankaj Gupta(6)
|
| | | | — | | | | | | — | | | | | | 3,874,946 | | | | | | 100.0 | | | | | | 47,250 | | | | | | 86.3 | | | | | | — | | | | | | — | | | | | | 2,750 | | | | | | 5.7 | | | | | | 11,362,811 | | | | | | 35.7 | | | | | | 11,362,811 | | | | | | 32.6 | | |
Director
|
| | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amit Jain
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Director
|
| | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Executive Officers and Directors as a Group (6 persons)
|
| | | | 3,195,634 | | | | | | 94.8 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 14,558,445 | | | | | | 41.6 | | | | | | 14,558,445 | | | | | | 38.3 | | |
Other 5% Beneficial Owners: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
bSpace Investments Limited(7)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | | | | — | | | | | | — | | | | | | 45,890 | | | | | | 94.3 | | | | | | 5,506,800 | | | | | | 21.2 | | | | | | 5,506,800 | | | | | | 19.0 | | |
dSpace Investments Limited(8)
|
| | | | — | | | | | | — | | | | | | 3,874,946 | | | | | | 100.0 | | | | | | 47,250 | | | | | | 86.3 | | | | | | — | | | | | | — | | | | | | 2,750 | | | | | | 5.7 | | | | | | 11,362,811 | | | | | | 35.7 | | | | | | 11,362,811 | | | | | | 32.6 | | |
Kuwait Investment Authority(9)
|
| | | | 11,257 | | | | | | 6.5 | | | | | | — | | | | | | — | | | | | | 7,500 | | | | | | 13.7 | | | | | | 5,752 | | | | | | 100.0 | | | | | | — | | | | | | — | | | | | | 1,590,240 | | | | | | 7.2 | | | | | | 1,590,240 | | | | | | 6.3 | | |
Fiza Investments Limited(10)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,176,471 | | | | | | 4.8 | | |
Joseph Powers(11)
|
| | | | 501,531 | | | | | | 74.2 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 501,531 | | | | | | 37.8 | | | | | | 501,531 | | | | | | 2.1 | | |
Selling Stockholder
|
| |
Number of
Shares of Common Stock owned by Selling Shareholder(3) |
| |
Number of
Shares being Registered |
| |
Number of
Shares owned after the Offering |
| |
Percentage
owned after the Offering(4) |
| ||||||||||||
1 Kuwait Investment Authority(1)
|
| | | | 1,766,933 | | | | | | 1,766,933 | | | | | | 0 | | | | | | 0% | | |
2 Compal Electronics, Inc.(2)
|
| | | | 453,037 | | | | | | 453,037 | | | | | | 0 | | | | | | 0% | | |
Underwriters
|
| |
Number of Shares
|
| |||
Roth Capital Partners, LLC
|
| | | | | | |
Craig-Hallum Capital Group LLC
|
| | | | | | |
Barrington Research Associates, Inc.
|
| | | | | | |
Total
|
| | | | 3,000,000 | | |
| | | | | |
Total
|
| |||
| | |
Per Share
|
| |
Without
Over-Allotment |
| |
With
Over-Allotment |
|
Underwriting discounts and commissions paid by us
|
| | | | | | | | | |
Proceeds, before expenses, to us
|
| | | | | | | | | |
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | |
| | |
March 31,
2024 |
| |
December 31,
2023 |
| ||||||
ASSETS | | | | | | | | | | | | | |
Current assets | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 1,188 | | | | | $ | 3,128 | | |
Accounts receivable, net of allowance of $217 and $217
|
| | | | 6,483 | | | | | | 5,040 | | |
Inventory, net
|
| | | | 4,043 | | | | | | 3,535 | | |
Prepaid and other current assets
|
| | | | 2,208 | | | | | | 1,975 | | |
Total current assets
|
| | | | 13,922 | | | | | | 13,678 | | |
Property and equipment, net
|
| | | | 18 | | | | | | 21 | | |
Deferred offering costs
|
| | | | 412 | | | | | | 148 | | |
Total assets
|
| | | $ | 14,352 | | | | | $ | 13,847 | | |
LIABILITIES, TEMPORARY REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
|
| | | | | | | | | | | | |
Current liabilities | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 5,192 | | | | | $ | 4,735 | | |
Accrued expenses and other liabilities
|
| | | | 9,167 | | | | | | 9,229 | | |
Convertible debt
|
| | | | 10,000 | | | | | | 5,000 | | |
Other current debt
|
| | | | 6,422 | | | | | | 7,017 | | |
Current accrued interest
|
| | | | 1,439 | | | | | | 1,152 | | |
Deferred revenue, current portion
|
| | | | 3,558 | | | | | | 2,754 | | |
Total current liabilities
|
| | | | 35,778 | | | | | | 29,887 | | |
Noncurrent related party debt
|
| | | | — | | | | | | 5,000 | | |
Other noncurrent debt
|
| | | | 1,644 | | | | | | 2,053 | | |
Noncurrent accrued interest
|
| | | | — | | | | | | 138 | | |
Deferred revenue, net of current portion
|
| | | | 179 | | | | | | 288 | | |
Total liabilities
|
| | | | 37,601 | | | | | | 37,366 | | |
Commitments and contingencies (Note 11) | | | | | | | | | | | | | |
Temporary redeemable preferred stock: | | | | | | | | | | | | | |
Series A preferred stock, $0.00001 par value; 3,874,946 shares authorized; 3,874,946 issued
and outstanding as of March 31, 2024 and December 31, 2023; liquidation value of $4,097 as of March 31, 2024 |
| | | | 3,000 | | | | | | 3,000 | | |
NCNV 1, NCNV 2, and NCNV 3 preferred stock, $0.00001 par value; 140,000 shares authorized; 109,142 and 103,952 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively; liquidation value of $109,142 as of March 31, 2024
|
| | | | 109,142 | | | | | | 103,952 | | |
Stockholders’ deficit: | | | | | | | | | | | | | |
Common stock, $0.00001 par value; 13,333,333 shares authorized, 174,077 issued and outstanding as of March 31, 2024 and December 31, 2023
|
| | | | — | | | | | | — | | |
Additional paid-in capital
|
| | | | 146,132 | | | | | | 138,878 | | |
Accumulated other comprehensive income
|
| | | | 302 | | | | | | 228 | | |
Accumulated deficit
|
| | | | (281,825) | | | | | | (269,577) | | |
Total stockholders’ deficit
|
| | | | (135,391) | | | | | | (130,471) | | |
Total liabilities, temporary redeemable preferred stock and stockholders’ deficit
|
| | | $ | 14,352 | | | | | $ | 13,847 | | |
| | |
Three Months Ended March 31,
|
| |||||||||
| | |
2024
|
| |
2023
|
| ||||||
Revenue
|
| | | $ | 7,841 | | | | | $ | 7,549 | | |
Cost of goods sold
|
| | | | 5,139 | | | | | | 4,266 | | |
Gross profit
|
| | | | 2,702 | | | | | | 3,283 | | |
Operating expenses: | | | | | | | | | | | | | |
Research and development
|
| | | | 1,977 | | | | | | 1,113 | | |
Selling and marketing
|
| | | | 5,505 | | | | | | 3,278 | | |
General and administrative
|
| | | | 6,609 | | | | | | 1,715 | | |
Total operating expenses
|
| | | | 14,091 | | | | | | 6,106 | | |
Loss from operations
|
| | | | (11,389) | | | | | | (2,823) | | |
Other (expense) income: | | | | | | | | | | | | | |
Interest expense
|
| | | | (729) | | | | | | (599) | | |
Other income (expense), net
|
| | | | (82) | | | | | | 5 | | |
Loss on extinguishment of debt
|
| | | | (52) | | | | | | — | | |
Loss before income taxes
|
| | | | (12,252) | | | | | | (3,417) | | |
Income tax benefit
|
| | | | 5 | | | | | | — | | |
Net loss
|
| | | | (12,247) | | | | | | (3,417) | | |
Other comprehensive loss, net of tax: | | | | | | | | | | | | | |
Foreign currency translation adjustment
|
| | | | 74 | | | | | | (11) | | |
Comprehensive loss
|
| | | $ | (12,173) | | | | | $ | (3,428) | | |
Net loss per common share – basic and diluted
|
| | | | (70.83) | | | | | | (55.96) | | |
Weighted-average common shares outstanding – basic and diluted
|
| | | | 174,077 | | | | | | 168,046 | | |
| | |
Temporary Redeemable
Preferred Stock |
| | |
Common Stock
|
| |
Additional
Paid-in Capital |
| |
Accumulated
Other Comprehensive Income |
| |
Accumulated
Deficit |
| |
Total
Stockholders’ Deficit |
| ||||||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||
Balance, January 1, 2023
|
| | | | 3,941,980 | | | | | $ | 64,131 | | | | | | | 167,666 | | | | | $ | — | | | | | $ | 144,777 | | | | | $ | 164 | | | | | $ | (256,541) | | | | | $ | (111,600) | | |
Issuance of common stock from options exercised
|
| | | | — | | | | | | — | | | | | | | 387 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Accretion of NCNV preferred stock
|
| | | | — | | | | | | 5,903 | | | | | | | — | | | | | | — | | | | | | (5,903) | | | | | | — | | | | | | — | | | | | | (5,903) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (3,417) | | | | | | (3,417) | | |
Foreign currency translation adjustments
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | (11) | | | | | | — | | | | | | (11) | | |
Balance, March 31, 2023
|
| | | | 3,941,980 | | | | | $ | 70,034 | | | | | | | 168,053 | | | | | $ | — | | | | | $ | 138,874 | | | | | $ | 153 | | | | | $ | (259,958) | | | | | $ | (120,931) | | |
Balance, January 1, 2024
|
| | | | 3,978,898 | | | | | $ | 106,952 | | | | | | | 174,077 | | | | | $ | — | | | | | $ | 138,878 | | | | | $ | 228 | | | | | $ | (269,577) | | | | | $ | (130,471) | | |
Stock-based compensation expense
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 7,253 | | | | | | — | | | | | | — | | | | | | 7,253 | | |
Cancellation of NCNV 1 preferred stock
|
| | | | (562) | | | | | | (562) | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Issuance of NCNV 2 preferred stock
|
| | | | 5,752 | | | | | | 5,752 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Net loss
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (12,247) | | | | | | (12,247) | | |
Foreign currency translation adjustments
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | 74 | | | | | | — | | | | | | 74 | | |
Balance, March 31, 2024
|
| | | | 3,984,088 | | | | | $ | 112,142 | | | | | | | 174,077 | | | | | $ | — | | | | | $ | 146,132 | | | | | $ | 302 | | | | | $ | (281,825) | | | | | $ | (135,391) | | |
| | |
Three months ended March 31,
|
| |||||||||
| | |
2024
|
| |
2023
|
| ||||||
Cash flows from operating activities: | | | | | | | | | | | | | |
Net loss
|
| | | $ | (12,247) | | | | | $ | (3,417) | | |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | | | | | |
Amortization of revolving line of credit commitment fee asset
|
| | | | — | | | | | | 61 | | |
Non-cash amortization of other debt discount
|
| | | | 18 | | | | | | 9 | | |
Stock-based compensation expense
|
| | | | 7,253 | | | | | | — | | |
Depreciation
|
| | | | 4 | | | | | | 11 | | |
Loss on extinguishment of debt
|
| | | | 52 | | | | | | — | | |
Changes in operating assets and liabilities:
Accounts receivable |
| | | | (1,443) | | | | | | 113 | | |
Inventory
|
| | | | (508) | | | | | | 4 | | |
Prepaids and other current assets
|
| | | | (233) | | | | | | (787) | | |
Accounts payable
|
| | | | 457 | | | | | | (568) | | |
Accrued expenses
|
| | | | 251 | | | | | | 108 | | |
Deferred revenue
|
| | | | 695 | | | | | | (148) | | |
Accrued interest
|
| | | | 287 | | | | | | 248 | | |
Net cash used in operating activities
|
| | | | (5,414) | | | | | | (4,366) | | |
Cash flows from investing activities: | | | | | | | | | | | | | |
Capital expenditures
|
| | | | — | | | | | | — | | |
Net cash used in investing activities
|
| | | | — | | | | | | — | | |
Cash flows from financing activities: | | | | | | | | | | | | | |
Proceeds from convertible note
|
| | | | 5,000 | | | | | | — | | |
Repayment of revolving line of credit
|
| | | | — | | | | | | (3,000) | | |
Proceeds from other debt issuances
|
| | | | — | | | | | | 6,398 | | |
Fees paid for debt issuance
|
| | | | — | | | | | | (130) | | |
Repayment of other debt issuances
|
| | | | (1,022) | | | | | | (392) | | |
Fees paid for deferred offering costs
|
| | | | (264) | | | | | | (77) | | |
Fees paid to creditors
|
| | | | — | | | | | | (2) | | |
Net cash provided by financing activities
|
| | | | 3,714 | | | | | | 2,798 | | |
Effects of exchange rate changes on cash and cash equivalents
|
| | | | (240) | | | | | | (11) | | |
Net decrease in cash, cash equivalents and restricted cash
|
| | | | (1,940) | | | | | | (1,579) | | |
Cash, cash equivalents and restricted cash at beginning of year
|
| | | | 3,128 | | | | | | 4,061 | | |
Cash, cash equivalents and restricted cash at end of year
|
| | | $ | 1,188 | | | | | $ | 2,482 | | |
Supplemental disclosure of cash flow information: | | | | | | | | | | | | | |
Cash paid for interest
|
| | | $ | 424 | | | | | $ | 281 | | |
Cash paid for income taxes
|
| | | | — | | | | | | — | | |
Non-cash investing and financing activities: | | | | | | | | | | | | | |
Leased assets obtained in exchange for new operating lease liabilities
|
| | | $ | 295 | | | | | $ | — | | |
Accretion of NCNV preferred stock
|
| | | | — | | | | | $ | 5,903 | | |
Issuance of NCNV in exchange for related party debt and accrued interest
|
| | | $ | 5,190 | | | | | | — | | |
Unpaid deferred offering costs
|
| | | $ | 161 | | | | | $ | 298 | | |
| | |
March 31, 2024
|
| |
December 31, 2023
|
| ||||||
Cash and cash equivalents
|
| | | $ | 881 | | | | | $ | 2,821 | | |
Restricted cash
|
| | | | 307 | | | | | | 307 | | |
Total cash, cash equivalents and restricted cash
|
| | | $ | 1,188 | | | | | $ | 3,128 | | |
| | |
As of March 31, 2024
|
| |||||||||||||||||||||
| | |
Level 1
|
| |
Level 2
|
| |
Level 3
|
| |
Total
|
| ||||||||||||
Money market funds
|
| | | $ | 229 | | | | | $ | — | | | | | $ | — | | | | | $ | 229 | | |
Total financial assets
|
| | | $ | 229 | | | | | $ | — | | | | | $ | — | | | | | $ | 229 | | |
| | |
As of December 31, 2023
|
| |||||||||||||||||||||
| | |
Level 1
|
| |
Level 2
|
| |
Level 3
|
| |
Total
|
| ||||||||||||
Money market funds
|
| | | $ | 378 | | | | | $ | — | | | | | $ | — | | | | | $ | 378 | | |
Total financial assets
|
| | | $ | 378 | | | | | $ | — | | | | | $ | — | | | | | $ | 378 | | |
| | |
Three Months Ended
March 31, |
| |||||||||
| | |
2024
|
| |
2023
|
| ||||||
Point in time
|
| | | $ | 7,370 | | | | | $ | 7,026 | | |
Over time
|
| | | | 471 | | | | | | 523 | | |
Total
|
| | |
$
|
7,841
|
| | | |
$
|
7,549
|
| |
| | | | ||||||||||
| | |
2024
|
| |
2023
|
| ||||||
United States
|
| | | $ | 6,669 | | | | | $ | 6,398 | | |
International
|
| | | | 1,172 | | | | | | 1,151 | | |
Total
|
| | |
$
|
7,841
|
| | | |
$
|
7,549
|
| |
| | |
March 31,
2024 |
| |
December 31,
2023 |
| ||||||
Finished goods
|
| | | $ | 3,843 | | | | | $ | 3,266 | | |
Raw materials
|
| | | | 200 | | | | | | 269 | | |
Total inventory
|
| | | $ | 4,043 | | | | | $ | 3,535 | | |
| | |
March 31,
2024 |
| |
December 31,
2023 |
| ||||||
Advances to suppliers
|
| | | $ | 534 | | | | | $ | 797 | | |
Deferred software costs
|
| | | | 634 | | | | | | 382 | | |
Prepaid operating expense
|
| | | | 1,040 | | | | | | 796 | | |
Total prepaid expenses and other assets
|
| | | $ | 2,208 | | | | | $ | 1,975 | | |
| | |
March 31,
2024 |
| |
December 31,
2023 |
| ||||||
Accrued purchases
|
| | | $ | 4,361 | | | | | $ | 4,361 | | |
Accrued compensation
|
| | | | 2,273 | | | | | | 2,315 | | |
Other current liabilities
|
| | | | 2,533 | | | | | | 2,553 | | |
Total accrued expenses and other liabilities
|
| | | $ | 9,167 | | | | | $ | 9,229 | | |
| | |
March 31,
2024 |
| |
December 31,
2023 |
| ||||||
Short-term debt: | | | | | | | | | | | | | |
Fiza Investments Limited Loans, convertible debt
|
| | | $ | 10,000 | | | | | $ | 5,000 | | |
Other current debt: | | | | | | | | | | | | | |
Fiza Investments Limited Loans, term debt
|
| | | | 3,895 | | | | | | 4,189 | | |
Other term loans
|
| | | | 2,527 | | | | | | 2,828 | | |
Total other current debt
|
| | | | 6,422 | | | | | | 7,017 | | |
Total short-term debt
|
| | | $ | 16,422 | | | | | $ | 12,017 | | |
Noncurrent related party debt: | | | | | | | | | | | | | |
Kuwait Investment Authority Debt
|
| | | $ | — | | | | | $ | 5,000 | | |
Total noncurrent related party debt
|
| | | $ | — | | | | | $ | 5,000 | | |
Other noncurrent debt: | | | | | | | | | | | | | |
Other term Loans
|
| | | $ | 4,221 | | | | | $ | 4,949 | | |
Less: debt issuance costs
|
| | | | (50) | | | | | | (68) | | |
Less: current portion
|
| | | | (2,527) | | | | | | (2,828) | | |
Total other noncurrent debt
|
| | | $ | 1,644 | | | | | $ | 2,053 | | |
| | |
March 31,
2024 |
| |
December 31,
2023 |
| ||||||
Convertible debt: | | | | | | | | | | | | | |
bSpace Investments Limited Loan
|
| | | $ | — | | | | | $ | — | | |
Kuwait Investment Authority Debt
|
| | | | — | | | | | | 5,000 | | |
Fiza Investments Limited Loan
|
| | | | 10,000 | | | | | | 5,000 | | |
Total Convertible debt
|
| | | $ | 10,000 | | | | | $ | 10,000 | | |
| | |
Series A Preferred Stock
|
| |
NCNV Preferred Stock
|
| ||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||
Balance at January 1, 2023:.
|
| | | | 3,874,946 | | | | | $ | 3,000 | | | | | | 67,034 | | | | | $ | 61,131 | | |
Accretion of NCNV preferred stock
|
| | | | — | | | | | | — | | | | | | — | | | | | | 5,903 | | |
Balance at March 31, 2023:
|
| | | | 3,874,946 | | | | | $ | 3,000 | | | | | | 67,034 | | | | | $ | 67,034 | | |
Balance at January 1, 2024:
|
| | | | 3,874,946 | | | | | $ | 3,000 | | | | |
|
—
|
| | | | $ | — | | |
Balance at March 31, 2024:
|
| | | | 3,874,946 | | | | | $ | 3,000 | | | | |
|
—
|
| | | | $ | — | | |
| | |
March 31, 2024
|
| |
March 31, 2023
|
|
Dividend yield
|
| |
—
|
| |
—
|
|
Expected term
|
| |
5.0 − 6.1 years
|
| |
5.9 − 6.1 years
|
|
Risk-free interest rates
|
| |
1.0% − 4.1%
|
| |
1.0% − 1.9%
|
|
Expected volatility
|
| |
54.9% − 65.1%
|
| |
54.9% − 57.2%
|
|
| | |
Number of
Outstanding Options |
| |
Weighted
Average Exercise Price |
| |
Weighted
Average Grant Date Fair Value |
| |
Weighted
Average Remaining Contractual Years |
| |
Aggregate
Intrinsic Value |
| |||||||||||||||
Balance, January 1, 2024
|
| | | | 948,464 | | | | | $ | 6.20 | | | | | | | | | | | | 7.25 | | | | | $ | 1,919,582 | | |
Granted
|
| | | | 5,028,756 | | | | | | 2.57 | | | | | | 1.61 | | | | | | | | | | | | | | |
Balance, March 31, 2024
|
| | | | 5,977,220 | | | | | $ | 3.17 | | | | | | | | | | | | 9.41 | | | | | $ | 1,919,582 | | |
Vested and Exercisable, March 31, 2024
|
| | | | 5,433,845 | | | | | $ | 3.19 | | | | | | | | | | | | 9.39 | | | | | $ | 1,900,259 | | |
Vested and Expected to Vest, March 31, 2024
|
| | | | 5,977,220 | | | | | $ | 3.17 | | | | | | | | | | | | 9.41 | | | | | $ | 1,919,582 | | |
| | |
March 31, 2024
|
| |
March 31, 2023
|
| ||||||
Cost of goods sold
|
| | | $ | 115 | | | | | | — | | |
Research and development
|
| | | $ | 693 | | | | | | — | | |
Sales and marketing
|
| | | $ | 2,561 | | | | | | — | | |
General and administrative
|
| | | $ | 3,884 | | | | | | — | | |
Total stock-based compensation expense
|
| | | $ | 7,253 | | | | | | — | | |
Three Months Ended March 31:
|
| |
2024
|
| |
2023
|
| ||||||
Net loss
|
| | | $ | (12,247) | | | | | $ | (3,417) | | |
Accretion of NCNV preferred stock
|
| | | | — | | | | | | (5,903) | | |
Cumulative preferred stock dividends
|
| | | | (83) | | | | | | (83) | | |
Net loss available to common shareholders used in basic and diluted EPS
|
| | | $ | (12,330) | | | | | $ | (9,403) | | |
Weighted average number of common shares used in basic and diluted EPS
|
| | | | 174,077 | | | | | | 168,046 | | |
Loss per common share – basic and diluted
|
| | | $ | (70.83) | | | | | $ | (55.96) | | |
Three Months Ended March 31:
|
| |
2024
|
| |
2023
|
| ||||||
Incentive stock options
|
| | | | 5,977,220 | | | | | | 8,512,225 | | |
Temporary redeemable preferred stock
|
| | | | 3,984,088 | | | | | | 3,941,980 | | |
Total | | | | | 9,961,308 | | | | | | 12,454,205 | | |
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | |
| | |
December 31,
2023 |
| |
December 31,
2022 |
| ||||||
ASSETS | | | | | | | | | | | | | |
Current assets | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 3,128 | | | | | $ | 4,061 | | |
Accounts receivable, net of allowance of $217 and $150
|
| | | | 5,040 | | | | | | 6,854 | | |
Inventory, net
|
| | | | 3,535 | | | | | | 4,273 | | |
Prepaid and other current assets
|
| | | | 1,975 | | | | | | 1,543 | | |
Total current assets
|
| | | | 13,678 | | | | | | 16,731 | | |
Property and equipment, net
|
| | | | 21 | | | | | | 48 | | |
Deferred offering costs
|
| | | | 148 | | | | | | 1,429 | | |
Total assets
|
| | | $ | 13,847 | | | | | $ | 18,208 | | |
LIABILITIES, TEMPORARY REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
|
| | | | | | | | | | | | |
Current liabilities | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 4,735 | | | | | $ | 4,177 | | |
Accrued expenses and other liabilities
|
| | | | 9,229 | | | | | | 8,721 | | |
Revolving line-of-credit
|
| | | | — | | | | | | 3,000 | | |
Related party debt
|
| | | | — | | | | | | 36,500 | | |
Convertible debt
|
| | | | 5,000 | | | | | | 5,000 | | |
Other current debt
|
| | | | 7,017 | | | | | | — | | |
Current accrued interest
|
| | | | 1,152 | | | | | | 3,834 | | |
Deferred revenue, current portion
|
| | | | 2,754 | | | | | | 3,804 | | |
Total current liabilities
|
| | | | 29,887 | | | | | | 65,036 | | |
Noncurrent related party debt
|
| | | | 5,000 | | | | | | — | | |
Other noncurrent debt
|
| | | | 2,053 | | | | | | — | | |
Noncurrent accrued interest
|
| | | | 138 | | | | | | — | | |
Deferred revenue, net of current portion
|
| | | | 288 | | | | | | 641 | | |
Total liabilities
|
| | | | 37,366 | | | | | | 65,677 | | |
Commitments and contingencies (Note 11) | | | | | | | | | | | | | |
Temporary redeemable preferred stock: | | | | | | | | | | | | | |
Series A preferred stock, $0.00001 par value; 3,874,946 shares authorized; 3,874,946
issued and outstanding as of December 31 2023 and December 31, 2022; liquidation value of $4,014 as of December 31, 2023 |
| | | | 3,000 | | | | | | 3,000 | | |
NCNV 1, NCNV 2 and NCNV 3 preferred stock, $0.00001 par value; 140,000 authorized; 103,952 and 0 issued and outstanding as of December 31, 2023 and 2022, respectively; liquidation value of $103,952 as of December 31, 2023
|
| | | | 103,952 | | | | | | — | | |
NCNV preferred stock, $0.00001 par value; 78,534 authorized as of December 31, 2022; 0 and 67,034 issued and outstanding as of December 31, 2023 and 2022, respectively
|
| | | | — | | | | | | 61,131 | | |
Stockholders’ deficit: | | | | | | | | | | | | | |
Common stock, $0.00001 par value; 13,333,333 shares authorized, 174,077 and 167,666
issued and outstanding as of December 31, 2023 and 2022, respectively |
| | | | — | | | | | | — | | |
Additional paid-in capital
|
| | | | 138,878 | | | | | | 144,777 | | |
Accumulated other comprehensive income
|
| | | | 228 | | | | | | 164 | | |
Accumulated deficit
|
| | | | (269,577) | | | | | | (256,541) | | |
Total stockholders’ deficit
|
| | | | (130,471) | | | | | | (111,600) | | |
Total liabilities, temporary redeemable preferred stock and stockholders’ deficit
|
| | | $ | 13,847 | | | | | $ | 18,208 | | |
| | |
Year Ended December 31,
|
| |||||||||
| | |
2023
|
| |
2022
|
| ||||||
Revenue
|
| | | $ | 43,922 | | | | | $ | 35,784 | | |
Cost of goods sold
|
| | | | 27,028 | | | | | | 22,656 | | |
Gross profit
|
| | | | 16,894 | | | | | | 13,128 | | |
Operating expenses: | | | | | | | | | | | | | |
Research and development
|
| | | | 4,218 | | | | | | 4,666 | | |
Selling and marketing
|
| | | | 12,898 | | | | | | 11,585 | | |
General and administrative
|
| | | | 6,710 | | | | | | 6,780 | | |
Other operating expenses
|
| | | | 1,683 | | | | | | — | | |
Total operating expenses
|
| | | | 25,509 | | | | | | 23,031 | | |
Loss from operations
|
| | | | (8,615) | | | | | | (9,903) | | |
Other (expense) income: | | | | | | | | | | | | | |
Interest expense
|
| | | | (2,900) | | | | | | (3,696) | | |
Other income (expense), net
|
| | | | 23 | | | | | | (196) | | |
Loss on extinguishment of debt
|
| | | | (1,541) | | | | | | (3,346) | | |
Forgiveness of paycheck protection program loan
|
| | | | — | | | | | | 2,012 | | |
Loss before income taxes
|
| | | | (13,033) | | | | | | (15,129) | | |
Income tax expense
|
| | | | (3) | | | | | | (44) | | |
Net loss
|
| | | | (13,036) | | | | | | (15,173) | | |
Other comprehensive loss, net of tax: | | | | | | | | | | | | | |
Foreign currency translation adjustment
|
| | | | 64 | | | | | | 212 | | |
Comprehensive loss
|
| | | $ | (12,972) | | | | | | (14,961) | | |
Net loss per common share – basic and diluted
|
| | | | (113.21) | | | | | | (156.71) | | |
Weighted-average common shares outstanding – basic and diluted
|
| | | | 170,212 | | | | | | 161,683 | | |
| | |
Temporary Redeemable
Preferred Stock |
| | |
Common Stock
|
| |
Additional
Paid-in Capital |
| |
Accumulated
Other Comprehensive Income (Loss) |
| |
Accumulated
Deficit |
| |
Total
Stockholders’ Deficit |
| ||||||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||||||
Balance, December 31, 2021
|
| | | | 3,874,946 | | | | | $ | 3,000 | | | | | | | 151,982 | | | | | $ | — | | | | | $ | 150,416 | | | | | $ | (48) | | | | | $ | (241,368) | | | | | $ | (91,000) | | |
Stock based compensation
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 20 | | | | | | — | | | | | | — | | | | | | 20 | | |
Issuance of common stock from options exercised
|
| | | | — | | | | | | — | | | | | | | 15,684 | | | | | | — | | | | | | 8 | | | | | | — | | | | | | — | | | | | | 8 | | |
Issuance of NCNV preferred stock
|
| | | | 67,034 | | | | | | 51,296 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Accretion of NCNV preferred stock
|
| | | | — | | | | | | 9,835 | | | | | | | — | | | | | | — | | | | | | (9,835) | | | | | | — | | | | | | — | | | | | | (9,835) | | |
Convertible debt extinguishment
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,346 | | | | | | | | | | | | | | | | | | 3,346 | | |
KIA restructuring
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 822 | | | | | | — | | | | | | — | | | | | | 822 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (15,173) | | | | | | (15,173) | | |
Foreign currency translation adjustments
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | 212 | | | | | | — | | | | | | 212 | | |
Balance, December 31, 2022
|
| | | | 3,941,980 | | | | | $ | 64,131 | | | | | | | 167,666 | | | | | $ | — | | | | | $ | 144,777 | | | | | $ | 164 | | | | | $ | (256,541) | | | | | $ | (111,600) | | |
Stock based compensation
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 1 | | | | | | — | | | | | | — | | | | | | 1 | | |
Issuance of common stock from options exercised
|
| | | | — | | | | | | — | | | | | | | 6,411 | | | | | | — | | | | | | 3 | | | | | | — | | | | | | — | | | | | | 3 | | |
Accretion of NCNV preferred stock
|
| | | | — | | | | | | 5,903 | | | | | | | — | | | | | | — | | | | | | (5,903) | | | | | | — | | | | | | — | | | | | | (5,903) | | |
Cancellation of NCNV preferred stock
|
| | | | (67,034) | | | | | | (67,034) | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Issuance of NCNV1, NCNV2, and NCNV3 preferred stock
|
| | | | 103,952 | | | | | | 103,952 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Net loss
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (13,036) | | | | | | (13,036) | | |
Foreign currency translation adjustments
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | 64 | | | | | | — | | | | | | 64 | | |
Balance, December 31, 2023
|
| | | | 3,978,898 | | | | | $ | 106,952 | | | | | | | 174,077 | | | | | $ | — | | | | | $ | 138,878 | | | | | $ | 228 | | | | | $ | (269,577) | | | | | $ | (130,471) | | |
| | |
Year ended December 31,
|
| |||||||||
| | |
2023
|
| |
2022
|
| ||||||
Cash flows from operating activities: | | | | | | | | | | | | | |
Net loss
|
| | | $ | (13,036) | | | | | $ | (15,173) | | |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | | | | | |
Amortization of revolving line of credit commitment fee asset
|
| | | | 61 | | | | | | 58 | | |
Non-cash amortization of convertible debt discount
|
| | | | — | | | | | | 1,577 | | |
Non-cash amortization of other debt discount
|
| | | | 82 | | | | | | — | | |
Gain on forgiveness of PPP loan
|
| | | | — | | | | | | (2,012) | | |
Stock-based compensation expense
|
| | | | 1 | | | | | | 20 | | |
Provision for excess and obsolete inventory
|
| | | | 807 | | | | | | 252 | | |
Cancellation of purchase obligations
|
| | | | 141 | | | | | | 1,068 | | |
Depreciation
|
| | | | 32 | | | | | | 49 | | |
Bad debt expense (recovery)
|
| | | | — | | | | | | 10 | | |
Write-off of deferred offering costs
|
| | | | 1,683 | | | | | | — | | |
Loss on extinguishment of debt
|
| | | | 1,541 | | | | | | 3,346 | | |
Changes in operating assets and liabilities: | | | | | | | | | | | | | |
Accounts receivable
|
| | | | 1,814 | | | | | | (2,066) | | |
Inventory
|
| | | | (210) | | | | | | (1,485) | | |
Prepaids and other current assets
|
| | | | (491) | | | | | | 66 | | |
Accounts payable
|
| | | | 558 | | | | | | 2,344 | | |
Accrued expenses
|
| | | | 707 | | | | | | 36 | | |
Deferred revenue
|
| | | | (1,403) | | | | | | 947 | | |
Accrued interest
|
| | | | 1,303 | | | | | | 2,061 | | |
Net cash used in operating activities
|
| | | | (6,410) | | | | | | (8,902) | | |
Cash flows from investing activities: | | | | | | | | | | | | | |
Capital expenditures
|
| | | | (5) | | | | | | (11) | | |
Net cash used in investing activities
|
| | | | (5) | | | | | | (11) | | |
Cash flows from financing activities: | | | | | | | | | | | | | |
Proceeds from convertible notes
|
| | | | — | | | | | | 5,000 | | |
Proceeds from revolving line of credit
|
| | | | — | | | | | | 3,000 | | |
Repayment of revolving line of credit
|
| | | | (3,000) | | | | | | — | | |
Proceeds from other debt issuances
|
| | | | 11,378 | | | | | | — | | |
Fees paid for debt issuance
|
| | | | (151) | | | | | | — | | |
Repayment of other debt issuances
|
| | | | (2,239) | | | | | | — | | |
Fees paid for deferred offering costs
|
| | | | (402) | | | | | | (1,045) | | |
Fees paid to creditors
|
| | | | (2) | | | | | | (21) | | |
Proceeds from exercise of common stock options
|
| | | | 3 | | | | | | 8 | | |
Net cash provided by financing activities
|
| | | | 5,587 | | | | | | 6,942 | | |
Effects of exchange rate changes on cash and cash equivalents
|
| | | | (105) | | | | | | 212 | | |
Net decrease in cash, cash equivalents and restricted cash
|
| | | | (933) | | | | | | (1,759) | | |
Cash, cash equivalents and restricted cash at beginning of year
|
| | | | 4,061 | | | | | | 5,820 | | |
Cash, cash equivalents and restricted cash at end of year
|
| | | $ | 3,128 | | | | | $ | 4,061 | | |
Supplemental disclosure of cash flow information: | | | | | | | | | | | | | |
Cash paid for interest
|
| | | $ | 1,457 | | | | | | — | | |
Cash paid for income taxes
|
| | | | — | | | | | | — | | |
Non-cash investing and financing activities: | | | | | | | | | | | | | |
Leased assets obtained in exchange for new operating lease liabilities
|
| | | | — | | | | | $ | 225 | | |
KIA restructuring gain
|
| | | | — | | | | | $ | 822 | | |
Accretion of NCNV preferred stock
|
| | | $ | 5,903 | | | | | $ | 9,835 | | |
Issuance of NCNV in exchange for related party debt and accrued interest
|
| | | $ | 36,918 | | | | | $ | 51,296 | | |
Unpaid deferred offering costs
|
| | | $ | 120 | | | | | $ | 384 | | |
| | |
December 31,
|
| |||||||||
| | |
2023
|
| |
2022
|
| ||||||
Cash and cash equivalents
|
| | | $ | 2,821 | | | | | $ | 3,836 | | |
Restricted cash
|
| | | | 307 | | | | | | 225 | | |
Total cash, cash equivalents and restricted cash
|
| | | $ | 3,128 | | | | | $ | 4,061 | | |
Asset Type
|
| |
Years
|
| |||
Lab equipment
|
| | | | 5 | | |
Furniture and fixtures
|
| | | | 7 | | |
Computer equipment
|
| | | | 5 | | |
| | |
As of December 31, 2023
|
| |||||||||||||||||||||
| | |
Level 1
|
| |
Level 2
|
| |
Level 3
|
| |
Total
|
| ||||||||||||
Money market funds
|
| | | $ | 378 | | | | | $ | — | | | | | $ | — | | | | | $ | 378 | | |
Total financial assets
|
| | | $ | 378 | | | | | $ | — | | | | | $ | — | | | | | $ | 378 | | |
| | |
As of December 31, 2022
|
| |||||||||||||||||||||
| | |
Level 1
|
| |
Level 2
|
| |
Level 3
|
| |
Total
|
| ||||||||||||
Money market funds
|
| | | $ | 231 | | | | | $ | — | | | | | $ | — | | | | | $ | 231 | | |
Total financial assets
|
| | | $ | 231 | | | | | $ | — | | | | | $ | — | | | | | $ | 231 | | |
| | |
Years Ended December 31,
|
| |||||||||
| | |
2023
|
| |
2022
|
| ||||||
Point in time
|
| | | $ | 41,951 | | | | | $ | 33,968 | | |
Over time
|
| | | | 1,971 | | | | | | 1,816 | | |
Total
|
| | |
$
|
43,922
|
| | | |
$
|
35,784
|
| |
| | |
Years Ended December 31,
|
| |||||||||
| | |
2023
|
| |
2022
|
| ||||||
United States
|
| | | $ | 38,715 | | | | | $ | 27,336 | | |
International
|
| | | | 5,207 | | | | | | 8,448 | | |
Total
|
| | |
$
|
43,922
|
| | | |
$
|
35,784
|
| |
| | |
December 31,
2023 |
| |
December 31,
2022 |
| ||||||
Finished goods
|
| | | $ | 3,266 | | | | | $ | 2,923 | | |
Raw materials
|
| | | | 269 | | | | | | 1,350 | | |
Total inventory
|
| | | $ | 3,535 | | | | | $ | 4,273 | | |
| | |
December 31,
2023 |
| |
December 31,
2022 |
| ||||||
Advances to suppliers
|
| | | $ | 797 | | | | | $ | 715 | | |
Deferred software costs
|
| | | | 382 | | | | | | 76 | | |
Prepaid operating expense
|
| | | | 796 | | | | | | 752 | | |
Total prepaid expenses and other assets
|
| | | $ | 1,975 | | | | | $ | 1,543 | | |
| | |
December 31,
2023 |
| |
December 31,
2022 |
| ||||||
Accrued purchases
|
| | | $ | 4,361 | | | | | $ | 4,472 | | |
Accrued compensation
|
| | | | 2,315 | | | | | | 2,509 | | |
Other current liabilities
|
| | | | 2,553 | | | | | | 1,740 | | |
Total accrued expenses and other liabilities
|
| | | $ | 9,229 | | | | | $ | 8,721 | | |
| | |
December 31,
2023 |
| |
December 31,
2022 |
| ||||||
Short-term debt: | | | | | | | | | | | | | |
Revolving line-of-credit
|
| | | $ | — | | | | | $ | 3,000 | | |
Fiza Investments Limited Loans, convertible debt
|
| | | | 5,000 | | | | | | 5,000 | | |
Other current debt: | | | | ||||||||||
Fiza Investments Limited Loans, term debt
|
| | | | 4,189 | | | | | | — | | |
Other term loans
|
| | | | 2,828 | | | | | | — | | |
Total other current debt
|
| | | | 7,017 | | | | | | — | | |
Total short-term debt
|
| | | $ | 12,017 | | | | | $ | 8,000 | | |
Short-term related party debt: | | | | | | | | | | | | | |
bSpace Investment Limited Loan
|
| | | $ | — | | | | | $ | 31,500 | | |
Kuwait Investment Authority Debt
|
| | | | — | | | | | | 5,000 | | |
Total short-term related party debt
|
| | | $ | — | | | | | $ | 36,500 | | |
Noncurent related party debt: | | | | | | | | | | | | | |
Kuwait Investment Authority Debt
|
| | | $ | 5,000 | | | | | | — | | |
Total noncurrent related party debt
|
| | | $ | 5,000 | | | | | $ | — | | |
Other noncurrent debt: | | | | | | | | | | | | | |
Other term Loans
|
| | | $ | 4,949 | | | | | $ | — | | |
Less: debt issuance costs
|
| | | | (68) | | | | | | — | | |
Less: current portion
|
| | | | (2,828) | | | | | | — | | |
Total other noncurrent debt
|
| | | $ | 2,053 | | | | | $ | — | | |
| | |
December 31,
2023 |
| |
December 31,
2022 |
| ||||||
Convertible debt:
|
| | | | | | | | | | | | |
bSpace Investments Limited Loan
|
| | | $ | — | | | | | $ | 31,500 | | |
Kuwait Investment Authority Debt
|
| | | | 5,000 | | | | | | 5,000 | | |
Fiza Investments Limited Loan
|
| | | | 5,000 | | | | | | 5,000 | | |
Total Convertible debt
|
| | | $ | 10,000 | | | | | $ | 41,500 | | |
| | |
December 31,
2023 |
| |
December 31,
2022 |
| ||||||
Contractual interest
|
| | | $ | 4,955 | | | | | $ | 4,268 | | |
Amortization of debt discount and issuance costs
|
| | | | — | | | | | | 1,577 | | |
Total
|
| | | $ | 4,955 | | | | | $ | 5,845 | | |
Interest recorded in expense
|
| | | | 1,170 | | | | | | 1,885 | | |
Amortization of debt discount and issuance costs recorded in expense
|
| | | | — | | | | | | 1,577 | | |
Total
|
| | | $ | 1,170 | | | | | $ | 3,462 | | |
| | |
Series A Preferred Stock
|
| |
NCNV Preferred Stock
|
| ||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||
Balance at December 31, 2021:
|
| | | | 3,874,946 | | | | | $ | 3,000 | | | | | | — | | | | | $ | — | | |
Issuance of NCNV preferred stock
|
| | |
|
—
|
| | | |
|
—
|
| | | | | 67,034 | | | | | $ | 51,296 | | |
Accretion of NCNV preferred stock
|
| | | | — | | | | | | — | | | | | | — | | | | | | 9,835 | | |
Balance at December 31, 2022:
|
| | | | 3,874,946 | | | | | $ | 3,000 | | | | | | 67,034 | | | | | $ | 61,131 | | |
Accretion of NCNV preferred stock
|
| | | | — | | | | | | — | | | | | | — | | | | | | 5,903 | | |
Cancellation of NCNV preferred stock
|
| | | | — | | | | | | — | | | | | | (67,034) | | | | | | (67,034) | | |
Balance at December 31, 2023:
|
| | | | 3,874,946 | | | | | $ | 3,000 | | | | | | — | | | | | $ | — | | |
| | |
NCNV Preferred
Stock 1 |
| |
NCNV Preferred Stock 2
|
| |
NCNV Preferred
Stock 3 |
| |||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||
Balance at December 31, 2022:
|
| | | | — | | | | | $ | — | | | | | | — | | | | | $ | — | | | | | | — | | | | | $ | — | | |
Conversion of NCNV Preferred Stock for NCN Preferred Stock 1
|
| | | | 67,034 | | | | | $ | 67,034 | | | | | | | | | | | | | | | | | | | | | | | | | | |
Exchange of NCNV Preferred Stock 1 for NCNV Preferred Stock 3
|
| | | | (11,722) | | | | | | (11,722) | | | | | | | | | | | | | | | | | | 11,722 | | | | | | 11,722 | | |
Issuance of Preferred Stock in exchange for Debt Forgiveness
|
| | | | — | | | | | | — | | | | | | | | | | | | | | | | | | 36,918 | | | | | | 36,918 | | |
Balance at December 31, 2023:
|
| | | | 55,312 | | | | | $ | 55,312 | | | | | | — | | | | | $ | — | | | | | | 48,640 | | | | | $ | 48,640 | | |
| | |
December 31,
|
| |||
| | |
2023
|
| |
2022
|
|
Dividend yield
|
| |
—
|
| |
—
|
|
Expected term
|
| |
5.2 − 6.0 years
|
| |
5.2 − 6.1 years
|
|
Risk-free interest rates
|
| |
1.0% − 1.9%
|
| |
1.6% − 3.4%
|
|
Expected volatility
|
| |
54.9% − 57.2%
|
| |
54.9% − 56.5%
|
|
| | |
Number of
Outstanding Options |
| |
Weighted
Average Exercise Price |
| |
Weighted
Average Grant Date Fair Value |
| |
Weighted
Average Remaining Contractual Years |
| |
Aggregate
Intrinsic Value |
| |||||||||||||||
Balance, January 1, 2022
|
| | | | 967,590 | | | | | $ | 6.75 | | | | | | | | | | | | 9.13 | | | | | | | | |
Granted
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Solely Time-based Vesting
|
| | | | 38,280 | | | | | | 0.53 | | | | | $ | 0.27 | | | | | | | | | | | | | | |
Performance Conditioned Vesting
|
| | | | 7,533,334 | | | | | | 3.00 | | | | | $ | 1.63 | | | | | | | | | | | | | | |
Total Options Granted
|
| | | | 7,571,614 | | | | | | 3.00 | | | | | | | | | | | | | | | | | | | | |
Forfeited
|
| | | | (4,800) | | | | | | 0.53 | | | | | | | | | | | | | | | | | | | | |
Expired
|
| | | | (6,494) | | | | | | 30.00 | | | | | | | | | | | | | | | | | | | | |
Exercised
|
| | | | (15,684) | | | | | | 0.53 | | | | | | | | | | | | | | | | | | | | |
Balance, December 31, 2022
|
| | | | 8,512,225 | | | | | $ | 3.75 | | | | | | | | | | | | 9.58 | | | | | | | | |
Vested and Exercisable, December 31, 2022
|
| | | | 948,024 | | | | | $ | 6.75 | | | | | | | | | | | | 8.24 | | | | | | | | |
Vested and Expected to Vest, December 31, 2022
|
| | | | 978,891 | | | | | $ | 6.75 | | | | | | | | | | | | 8.28 | | | | | | | | |
Granted
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | | | |
Forfeited
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Solely time-based vesting
|
| | | | (17,506) | | | | | | | | | | | | | | | | | | | | | | | | | | |
Performance conditioned vesting
|
| | | | (7,533,334) | | | | | | 3.00 | | | | | | | | | | | | | | | | | | | | |
Total Options Forfeited
|
| | | | (7,550,840) | | | | | | 3.00 | | | | | | | | | | | | | | | | | | | | |
Expired
|
| | | | (6,510) | | | | | | 49.83 | | | | | | | | | | | | | | | | | | | | |
Exercised
|
| | | | (6,411) | | | | | | 0.53 | | | | | | | | | | | | | | | | | | | | |
Balance, December 31, 2023
|
| | | | 948,464 | | | | | $ | 6.20 | | | | | | | | | | | | 7.25 | | | | | $ | 1,919,582 | | |
Vested and Exercisable, December 31, 2023
|
| | | | 937,592 | | | | | $ | 6.26 | | | | | | | | | | | | 7.24 | | | | | $ | 1,897,349 | | |
Vested and Expected to Vest, December 31, 2023
|
| | | | 948,464 | | | | | $ | 6.20 | | | | | | | | | | | | 7.25 | | | | | $ | 1,919,582 | | |
| | |
December 31,
|
| |||||||||
| | |
2023
|
| |
2022
|
| ||||||
Current | | | | | | | | | | | | | |
Federal
|
| | | $ | — | | | | | $ | — | | |
State | | | | | 3 | | | | | | 1 | | |
Foreign | | | | | — | | | | | | 43 | | |
Total current
|
| | | $ | 3 | | | | | $ | 44 | | |
Deferred | | | | | | | | | | | | | |
Federal | | | | $ | (2,031) | | | | | $ | (1,891) | | |
State | | | | | (525) | | | | | | (179) | | |
Foreign | | | | | (6) | | | | | | (16) | | |
Change in valuation allowance
|
| | | | 2,562 | | | | | | 2,086 | | |
Total deferred
|
| | | $ | — | | | | | $ | — | | |
Total income tax expense
|
| | | $ | 3 | | | | | $ | 44 | | |
| | |
2023
|
| |
2022
|
| ||||||
Tax computed at federal statutory rate
|
| | | | 21.0% | | | | | | 21.0% | | |
State, net of federal benefit
|
| | | | 3.0% | | | | | | 0.9% | | |
Non-deductible interest expense
|
| | | | (0.5)% | | | | | | (4.5)% | | |
PPP loan forgiveness
|
| | | | — | | | | | | 2.8% | | |
Extinguishment of debt
|
| | | | (4.0)% | | | | | | (4.6)% | | |
Change in valuation allowance
|
| | | | (18.0)% | | | | | | (13.7)% | | |
Other
|
| | | | (1.5)% | | | | | | (1.9)% | | |
Effective income tax rate
|
| | | | — | | | | | | — | | |
| | |
December 31,
|
| |||||||||
Deferred tax assets
|
| |
2023
|
| |
2022
|
| ||||||
Accruals and revenues . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | | $ | 646 | | | | | $ | 564 | | |
Stock based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | | | 92 | | | | | | 88 | | |
Deferred revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | | | 731 | | | | | | 1,004 | | |
Net operating loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | | | 8,786 | | | | | | 6,141 | | |
Unrealized gain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | | | 11 | | | | | | — | | |
Section 163(j) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | | | — | | | | | | — | | |
Capitalized research & development expenses . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | | | 214 | | | | | | 123 | | |
Property and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | | | 2 | | | | | | 18 | | |
Total gross deferred assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | | $ | 10,482 | | | | | $ | 7,938 | | |
Valuation allowance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | | | (10,479) | | | | | | (7,918) | | |
Total deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | | $ | 3 | | | | | $ | 20 | | |
Deferred tax liabilities | | | | | | | | | | | | | |
Right of use asset . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | |
|
(3)
|
| | | |
|
(20)
|
| |
Total deferred tax liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | | | (3) | | | | | | (20) | | |
Net deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
|
| | | $ | — | | | | | $ | — | | |
Years Ended December 31:
|
| |
2023
|
| |
2022
|
| ||||||
Net loss
|
| | | $ | (13,036) | | | | | $ | (15,173) | | |
Accretion of NCNV preferred stock
|
| | | | (5,903) | | | | | | (9,835) | | |
Cumulative preferred stock dividends
|
| | | | (330) | | | | | | (330) | | |
Net loss available to common shareholders used in basic and diluted EPS
|
| | | $ | (19,269) | | | | | $ | (25,338) | | |
Weighted average number of common shares used in basic and diluted EPS
|
| | | | 170,212 | | | | | | 161,683 | | |
Loss per common share – basic and diluted
|
| | | $ | (113.21) | | | | | $ | (156.71) | | |
Years Ended December 31:
|
| |
2023
|
| |
2022
|
| ||||||
Incentive stock options
|
| | | | 948,464 | | | | | | 8,512,225 | | |
Temporary redeemable preferred stock
|
| | | | 3,978,898 | | | | | | 3,874,946 | | |
Total | | | | | 4,927,362 | | | | | | 12,387,171 | | |
|
SEC registration fee
|
| | | $ | 4,459 | | |
|
FINRA filing fee
|
| | | $ | 5,675 | | |
|
Exchange Listing fee
|
| | | $ | 311,375 | | |
|
Printing and engraving expenses
|
| | | $ | 291,565 | | |
|
Legal fees and expenses
|
| | | $ | 891,110 | | |
|
Accounting fees and expensed
|
| | | $ | 506,650 | | |
|
Transfer agent and registrar fees
|
| | | $ | 35,000 | | |
|
Total*
|
| | | $ | 2,045,834 | | |
|
Exhibit
Number |
| |
Description
|
|
| 1.1 | | | | |
| 3.1+ | | | | |
| 3.2 | | | | |
| 3.3+ | | | | |
| 3.4+ | | | | |
| 3.5 | | | | |
| 4.1 | | | | |
| 4.2 | | | | |
| 5.1 | | | | |
| 10.1#+ | | | | |
| 10.2#+ | | | | |
| 10.3#+ | | | | |
| 10.4# | | | | |
| 10.5# | | | | |
| 10.6# | | | | |
| 10.7#+ | | | | |
| 10.8#+ | | | | |
| 10.9#+ | | | | |
| 10.10#+ | | | | |
| 10.11#+ | | | | |
| 10.12#+ | | | | |
| 10.13+ | | | | |
| 10.14+ | | | | |
| 10.15+ | | | | |
| 10.16+ | | | | |
| 10.17 | | | | |
| 10.18+ | | | | |
| 10.19+ | | | |
|
Exhibit
Number |
| |
Description
|
|
| 10.20+ | | | | |
| 10.21+ | | | | |
| 10.22+ | | | | |
| 10.23+ | | | | |
| 10.24+ | | | | |
| 10.25+ | | | | |
| 10.26+ | | | | |
| 10.27+ | | | | |
| 10.28+ | | | | |
| 10.29+ | | | | |
| 10.30+ | | | | |
| 10.31+ | | | | |
| 10.32+ | | | | |
| 10.33+ | | | | |
| 10.34† | | | | |
| 10.35† | | | | |
| 10.36† | | | | |
| 10.37† | | | | |
| 10.38 | | | | |
| 23.1 | | | | |
| 23.2 | | | | |
| 24.1+ | | | | |
| 99.1+ | | | | |
| 99.2+ | | | | |
| 99.3+ | | | | |
| 99.4+ | | | | |
| 107 | | | |
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ Paul Kellenberger
Paul Kellenberger
|
| |
Chief Executive Officer and Director
(Principal Executive Officer) |
| |
July 22, 2024
|
|
|
/s/ Erick DeOliveira
Erick DeOliveira
|
| |
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer) |
| |
July 22, 2024
|
|
|
*
Pankaj Gupta
|
| | Director | | |
July 22, 2024
|
|
|
*
Amit Jain
|
| | Director | | |
July 22, 2024
|
|
|
*By:
/s/ Paul Kellenberger
Paul Kellenberger
Attorney-in-fact |
| | |
Exhibit 1.1
ZSPACE, INC.
Underwriting Agreement
[●] Shares of Common Stock
[●], 2024
Roth Capital Partners, LLC
Craig-Hallum Capital Group LLC
As the Representatives of the
Several Underwriters Named on Schedule I hereto
c/o | Roth Capital Partners, LLC |
888 San Clemente Drive, Suite 400 | |
Newport Beach, CA 92660 | |
Craig-Hallum Capital Group LLC | |
222 South Ninth Street, Suite 350 | |
Minneapolis, MN 55402 |
Ladies and Gentlemen:
zSpace, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom Roth Capital Partners, LLC (“Roth Capital”) and Craig-Hallum Capital Group LLC are acting as the representatives (the “Representatives”), an aggregate of [●] authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.00001 per share (the “Common Stock”) of the Company. The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 4 hereof, up to an additional [●] shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares”. The Shares, the Representative’s Warrants (as defined below) and the Representative’s Warrant Shares (as defined below) are collectively referred to as the “Securities.”
The Company and the several Underwriters hereby confirm their agreement (this “Agreement”) as follows:
1
1. | Registration Statement and Prospectus. |
The Company has prepared and filed with the Securities and Exchange Commission (the “Commission”) a registration statement covering the Securities on Form S-1 (File No. 333- 280427) under the Securities Act of 1933, as amended (the “Securities Act”), and the rules and regulations (the “Rules and Regulations”) of the Commission thereunder, and such amendments to such registration statement (including post effective amendments) as may have been required to the date of this Agreement. Such registration statement, as amended (including any post effective amendments), has been declared effective by the Commission. Such registration statement, including amendments thereto (including post effective amendments thereto) at the time of effectiveness thereof (the “Effective Time”), the exhibits and any schedules thereto at the Effective Time or thereafter during the period of effectiveness and the documents and information otherwise deemed to be a part thereof or included therein by the Securities Act or otherwise pursuant to the Rules and Regulations at the Effective Time or thereafter during the period of effectiveness, is herein called the “Registration Statement.” If the Company has filed or files an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the “Rule 462 Registration Statement”), then any reference herein to the term Registration Statement shall include such Rule 462 Registration Statement. Any preliminary prospectus included in the Registration Statement or filed with the Commission pursuant to Rule 424(a) under the Securities Act is hereinafter called a “Preliminary Prospectus.” The Preliminary Prospectus relating to the Securities that was included in the Registration Statement immediately prior to the pricing of the offering contemplated hereby is hereinafter called the “Pricing Prospectus.”
The Company is filing with the Commission pursuant to Rule 424 under the Securities Act a final prospectus covering the Securities, which includes the information permitted to be omitted therefrom at the Effective Time by Rule 430A under the Securities Act. Such final prospectus, as so filed, is hereinafter called the “Final Prospectus.” The Final Prospectus, the Pricing Prospectus and any preliminary prospectus in the form in which they were included in the Registration Statement or filed with the Commission pursuant to Rule 424 under the Securities Act is hereinafter called a “Prospectus.”
2. | Representations and Warranties of the Company Regarding the Offering. |
(a) The Company represents and warrants to, and agrees with, the several Underwriters, as of the date hereof and as of the Closing Date (as defined in Section 4(b) below) and as of each Option Closing Date (as defined in Section 4(c) below), as follows:
(i) Effectiveness. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of any Preliminary Prospectus, the Prospectus or any “free writing prospectus”, as defined in Rule 405 under the Rules and Regulations, has been issued by the Commission and no proceedings for that purpose have been instituted or are, to the knowledge of the Company, threatened under the Securities Act. Any required filing of any Preliminary Prospectus and/or the Prospectus and any supplement thereto pursuant to Rule 424(b) of the Rules and Regulations has been or will be made in the manner and within the time period required by such Rule 424(b) of the Rules and Regulations. Any material required to be filed by the Company pursuant to Rule 433(d) or Rule 163(b)(2) of the Rules and Regulations has been or will be made in the manner and within the time period required by such Rules and Regulations. The Commission has not notified the Company of any objection to the use of or the form of the Registration Statement or any post-effective amendment thereto.
2
(ii) No Material Misstatements or Omissions. At the Effective Time, at the date hereof, at the Closing Date, and at each Option Closing Date, if any, the Registration Statement and any post-effective amendment thereto complied or will comply in all material respects with the requirements of the Securities Act and the Rules and Regulations and did not, does not, and will not, as the case may be, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, not misleading. The Time of Sale Disclosure Package (as defined below) as of [●] [a.m.][p.m.] (Eastern time) (the “Applicable Time”) on the date hereof and at the Closing Date and on each Option Closing Date, if any, and the Final Prospectus, as amended or supplemented, as of its date, at the time of filing pursuant to Rule 424(b) under the Securities Act and at the Closing Date and at each Option Closing Date, if any, and any individual Written Testing-the-Waters Communication, when considered together with the Time of Sale Disclosure Package, did not, does not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the two immediately preceding sentences shall not apply to statements in or omissions from the Registration Statement, the Time of Sale Disclosure Package or any Prospectus in reliance upon, and in conformity with, written information furnished to the Company by any Underwriter specifically for use in the preparation thereof, which written information is described in Section 7(f). The Registration Statement contains all exhibits and schedules required to be filed by the Securities Act or the Rules and Regulations. No order preventing or suspending the effectiveness or use of the Registration Statement or any Prospectus is in effect and no proceedings for such purpose have been instituted or are pending, or, to the knowledge of the Company, are contemplated or threatened by the Commission. As used in this paragraph and elsewhere in this Agreement: “Time of Sale Disclosure Package” means the Pricing Prospectus, each Issuer Free Writing Prospectus, and the description of the transaction provided by the Underwriters included on Schedule II.
(iii) Marketing Materials. The Company has not distributed any prospectus or other offering material in connection with the offering and sale of the Shares other than the Time of Sale Disclosure Package and the electronic roadshow or investor presentations delivered to and approved by the Representatives for use in connection with the marketing of the offering of the Shares (the “Marketing Materials”).
(iv) Smaller Reporting Company. From the time of the initial filing of the Registration Statement with the Commission through the date hereof, the Company has been and is a “smaller reporting company,” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
(v) Emerging Growth Company. The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).
3
(vi) Testing-the-Waters Communications. The Company (i) has not alone engaged in any Testing-the-Waters Communication other than Testing-the-Waters Communications with the prior consent of Roth Capital with entities that are qualified institutional buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under the Securities Act and (ii) has not authorized anyone other than the Underwriters to engage in Testing-the-Waters Communications. The Company has not distributed any Testing-the-Waters Communications that is a written communication within the meaning of Rule 405 under the Securities Act (“Written Testing-the-Waters Communications”), other than those previously provided to the Representatives and listed on Schedule III hereto. As used in this paragraph and elsewhere in this Agreement: “Testing-the-Waters Communication” means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act. The Company has filed publicly on the Electronic Data Gathering, Analysis, and Retrieval system (“EDGAR”) at least 15 calendar days prior to any “road show” (as defined in Rule 433 under the Securities Act), any confidentially submitted registration statement and registration statement amendments relating to the offer and sale of Securities. Each Written Testing-the-Waters Communication complied in all material respects with the Securities Act and did not, as of the Applicable Time, and at all times through the completion of the public offer and sale of Shares will not, include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus and when taken together with the Time of Sale Disclosure Package as of the Applicable Time, did not contain any untrue statement of material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
(vii) Issuer Free Writing Prospectus. (A) The Company has provided a copy to the Underwriters of each Issuer Free Writing Prospectus (as defined below) used in the sale of Securities. The Company has filed all Issuer Free Writing Prospectuses required to be so filed with the Commission, and no order preventing or suspending the effectiveness or use of any Issuer Free Writing Prospectus is in effect and no proceedings for such purpose have been instituted or are pending, or, to the knowledge of the Company, are contemplated or threatened by the Commission. Each Issuer Free Writing Prospectus complied in all material respects with the Securities Act and did not, as of the Applicable Time, and at all times through the completion of the public offer and sale of Shares will not, include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus and when taken together with the Time of Sale Disclosure Package as of the Applicable Time, did not contain any untrue statement of material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. As used in this paragraph and elsewhere in this Agreement: “Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 under the Securities Act, relating to the Securities that (x) is required to be filed with the Commission by the Company, or (y) is exempt from filing pursuant to Rule 433(d)(5)(i) or (d)(8) under the Securities Act, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g) under the Securities Act.
(B) At the time of filing of the Registration Statement and at the date hereof, the Company was not and is not an “ineligible issuer” as defined in Rule 405 under the Securities Act or an “excluded issuer” as defined in Rule 164 under the Securities Act.
(C) Each Issuer Free Writing Prospectus listed on Schedule IV satisfied, as of its issue date and at all subsequent times through the Prospectus Delivery Period, all other conditions as may be applicable to its use as set forth in Rules 164 and 433 under the Securities Act, including any legend, record-keeping or other requirements.
4
(viii) Financial Statements. The financial statements of the Company, together with the related notes and schedules, included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act, and the rules and regulations of the Commission thereunder, and fairly present the financial condition of the Company as of the dates indicated and the results of operations and changes in cash flows for the periods therein specified in conformity with U.S. generally accepted accounting principles (“GAAP”) consistently applied throughout the periods involved. No other financial statements or schedules are required under the Securities Act, the Exchange Act, or the Rules and Regulations to be included in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus.
(ix) Independent Accountants. To the Company’s knowledge, BDO USA, P.C., which has expressed its opinion with respect to the financial statements and schedules included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, is an independent registered public accounting firm with respect to the Company within the meaning of the Securities Act and the Rules and Regulations.
(x) Accounting and Disclosure Controls. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, the Company and its subsidiaries maintain systems of “internal control over financial reporting” (as defined under Rules 13a-15 and 15d-15 under the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) the interactive data in eXtensible Business Reporting Language included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus fairly present the information called for in all material respects and are prepared in accordance with the Commission’s rules and guidelines applicable thereto. Since the date of the audited financial statements included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, there has been no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. It is understood that this section shall not require the Company to comply with Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended (together with the rules and regulations promulgated thereunder, the “Sarbanes-Oxley Act”), as of an earlier date than it would otherwise be required to so comply under applicable law.
Based on the evaluation of its disclosure controls and procedures as of the most recent evaluation date, except as specifically disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, the Company is not aware of (i) any material weakness or significant deficiency in the design or operation of internal controls which could adversely affect the Company’s or any subsidiary’s ability to record, process, summarize and report financial data or any material weaknesses in internal controls; or (ii) any fraud, whether or not material, that involves management or other employees who have a role in the Company’s or its subsidiaries’ internal controls.
5
Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, the Company maintains disclosure controls and procedures that (i) have been designed to ensure that material information relating to the Company and any subsidiaries is made known to the Company’s principal executive officer and principal financial officer by others within those entities; (ii) provide for the periodic evaluation of the effectiveness of such disclosure controls and procedures at the end of the periods in which the periodic reports are required to be prepared; and (iii) are effective in all material respects to perform the functions for which they were established.
(xi) Forward-Looking Statements. The Company had a reasonable basis for, and made in good faith, each “forward-looking statement” (within the meaning of Section 27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Disclosure Package, the Final Prospectus or the Marketing Materials.
(xii) Statistical and Marketing-Related Data. All statistical or market-related data included in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, or included in the Marketing Materials, are based on or derived from sources that the Company reasonably believes to be reliable and accurate, and the Company has obtained written consent to the use of such data from such sources, to the extent required.
(xiii) Form 8-A Registration Statement. The Company has filed a registration statement on Form 8-A (File No. [●]) in respect of the registration of the Shares under the Exchange Act with the Commission; such registration statement in the form heretofore delivered to the Underwriters has become effective in such form; no stop order suspending the effectiveness of such registration statement has been issued and no proceeding for that purpose has been initiated or, to the Company’s knowledge, threatened by the Commission.
(xiv) Trading Market. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on the [Nasdaq Global Market] ( “Nasdaq”). There is no action pending by the Company or, to the Company’s knowledge, Nasdaq to delist the Common Stock from Nasdaq, nor has the Company received any notification that Nasdaq is contemplating terminating such listing. When issued, the Shares and the Representative’s Warrant Shares will be listed on Nasdaq. The Company has taken all actions it deems reasonably necessary or advisable to take on or prior to the date of this Agreement to assure that it will be in compliance in all material respects with all applicable corporate governance requirements set forth in the rules of Nasdaq that are then in effect and will take all actions it deems reasonably necessary or advisable to ensure that it will be in compliance in all material respects with other applicable corporate governance requirements set forth in Nasdaq rules not currently in effect upon and all times after the date on which such requirements apply to the Company.
6
(xv) Absence of Manipulation. The Company has not taken, directly or indirectly, any action that is designed to or that has constituted or that would reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares.
(xvi) Investment Company Act. The Company is not, and after giving effect to the offering and sale of the Securities and the application of the net proceeds thereof will not be, an “investment company,” as such term is defined in the Investment Company Act of 1940, as amended.
3. | Representations and Warranties Regarding the Company. |
(a) The Company represents and warrants to and agrees with each Underwriter as of the date hereof and as of the Closing Date and as of each Option Closing Date, as follows:
(i) Good Standing. Each of the Company and its subsidiaries has been duly organized and is validly existing as a corporation or other entity in good standing under the laws of its jurisdiction of incorporation. Each of the Company and its subsidiaries has the power and authority (corporate or otherwise) to own its properties and conduct its business as currently being carried on and as described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, and is duly qualified to do business as a foreign corporation or other entity in good standing in each jurisdiction in which it owns or leases real property or in which the conduct of its business makes such qualification necessary, except where the failure to so qualify would not have or be reasonably likely to result in a material adverse effect upon the business, prospects, properties, operations, condition (financial or otherwise) or results of operations of the Company and its subsidiaries, taken as a whole, or in its ability to perform its obligations under this Agreement (“Material Adverse Effect”).
(ii) Authorization. The Company has the power and authority to enter into this Agreement and the Representative’s Warrants and to authorize, issue and sell the Securities as contemplated by this Agreement and the Representative’s Warrants. This Agreement and the Representative’s Warrants have been duly authorized by the Company, and when executed and delivered by the Company, as applicable, will constitute the valid, legal and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except as rights to indemnity hereunder may be limited by federal or state securities laws and except as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and subject to general principles of equity.
(iii) Contracts. The execution, delivery and performance of this Agreement and the Representative’s Warrants, by the Company and the consummation of the transactions herein contemplated will not (A) result in a breach or violation of any of the terms and provisions of, or constitute a default under, any law, order, rule or regulation to which the Company or any subsidiary is subject, or by which any property or asset of the Company or any subsidiary is bound or affected, (B) conflict with, result in any violation or breach of, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any right of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) (a “Default Acceleration Event”) of, any agreement, lease, credit facility, debt, note, bond, mortgage, indenture or other instrument (the “Contracts”) or obligation or other understanding to which the Company or any subsidiary is a party or by which any property or asset of the Company or any subsidiary is bound or affected, except to the extent that such conflict, default, or Default Acceleration Event has been effectively waived in full prior to the date hereof or is not reasonably likely to result in a Material Adverse Effect, or (C) result in a breach or violation of any of the terms and provisions of, or constitute a default under, the Company’s amended and restated certificate of incorporation and amended and restated bylaws.
7
(iv) No Violations of Governing Documents. Neither the Company nor any of its subsidiaries is in violation, breach or default under its amended and restated certificate of incorporation and amended and restated bylaws or other equivalent organizational or governing documents (including any certificate of designation).
(v) Consents. No consents, approvals, orders, authorizations or filings are required on the part of the Company in connection with the execution, delivery or performance of this Agreement and the Representative’s Warrants and the issue and sale of the Securities, except (A) the registration under the Securities Act of the Securities, which has been effected, (B) the necessary filings, notices and approvals from Nasdaq to list the Shares and the Representative’s Warrant Shares, (C) such consents, approvals, authorizations, registrations or qualifications as may be required under state or foreign securities or Blue Sky laws and the rules of the Financial Industry Regulatory Authority, Inc. (“FINRA”) in connection with the purchase and distribution of the Securities by the several Underwriters, (D) such consents and approvals as have been obtained and are in full force and effect, and (E) such consents, approvals, orders, authorizations and filings the failure of which to make or obtain is not reasonably likely to result in a Material Adverse Effect.
(vi) Capitalization. The Company has an authorized capitalization as set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus. All of the issued and outstanding shares of capital stock of the Company are duly authorized and validly issued, fully paid and nonassessable, and have been issued in compliance with all applicable securities laws, and conform in all material respects to the description thereof in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus. All of the issued shares of capital stock of each subsidiary of the Company have been duly and validly authorized and issued, are fully paid and non-assessable and, except as set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus and except for the issuances of options or restricted stock in the ordinary course of business, since the respective dates as of which information is provided in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, the Company has not entered into or granted any convertible or exchangeable securities, options, warrants, agreements, contracts or other rights in existence to purchase or acquire from the Company any shares of the capital stock of the Company. The Shares, when issued and paid for as provided herein, will be duly authorized and validly issued, fully paid for and nonassessable, will be issued in compliance with all applicable securities laws, and will be free of preemptive, registration or similar rights and will conform to the description of the capital stock of the Company contained in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus. All corporate action taken for the authorization, issuance and sale of the Representative’s Warrants and the Representative’s Warrant Shares has been duly and validly taken. The shares of Common Stock issuable upon the exercise of the Representative’s Warrants (the “Representative’s Warrant Shares”), which, when issued, paid and delivered upon due exercise of the Representative’s Warrants, will be duly authorized and validly issued, fully paid and nonassessable, will be issued in compliance with all applicable securities laws, and will be free of preemptive, registration or similar rights. The Representative’s Warrants Shares have been reserved for issuance. The Representative’s Warrants, when issued, will conform in all material respects to the description thereof set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus.
8
(vii) Taxes. Each of the Company and its subsidiaries has (a) filed all foreign, federal, state and local tax returns (as hereinafter defined) required to be filed with taxing authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof and (b) paid all taxes (as hereinafter defined) shown as due and payable on such returns that were filed and has paid all taxes imposed on or assessed against the Company or such respective subsidiary. The provisions for taxes payable, if any, shown on the financial statements included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such consolidated financial statements. No tax audits or investigations are pending and, to the knowledge of the Company, no issues have been raised (and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted as due from the Company or its subsidiaries, and no waivers of statutes of limitation with respect to the returns or collection of taxes have been given by or requested from the Company or its subsidiaries. The term “taxes” means all federal, state, local, foreign, and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments, or charges of any kind whatever, together with any interest and any penalties, additions to tax, or additional amounts with respect thereto. The term “returns” means all returns, declarations, reports, statements, and other documents required to be filed in respect to taxes.
(viii) Material Change. Since the respective dates as of which information is given in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, (a) neither the Company nor any of its subsidiaries has incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the ordinary course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind with respect to its capital stock; (c) there has not been any change in the capital stock of the Company or any of its subsidiaries (other than a change in the number of outstanding shares of Common Stock due to the issuance of shares upon the exercise of outstanding options, warrants or restricted stock, upon the conversion of outstanding shares of preferred stock or other convertible securities or the issuance of restricted stock awards or restricted stock units under the Company’s existing stock awards plan, or any new grants of equity awards under the Company’s existing stock awards plan in the ordinary course of business), (d) there has not been any material change in the Company’s long-term or short-term debt, (e) no material oral or written agreement or other transaction has been entered into by the Company or its subsidiaries that is not in the ordinary course of business or that could reasonably be expected to result in a material reduction in the future earnings of the Company, (f) no loss or damage (whether or not insured) to the property of the Company or any subsidiary has been sustained that has or could reasonably be expected to be material to the Company and its subsidiaries taken as a whole, (g) no legal or governmental action, suit or proceeding affecting the Company, any of its subsidiaries taken as a whole or any of their respective properties that is material to the Company or any of its subsidiaries or that materially and adversely affects or could reasonably be expected to materially and adversely affect the transactions contemplated by this Agreement has been instituted or threatened, and (h) there has not been the occurrence of any Material Adverse Effect.
9
(ix) Absence of Proceedings. There is not pending or, to the knowledge of the Company, threatened, any action, suit or proceeding to which the Company or any of its subsidiaries is a party or of which any property or assets of the Company or any of its subsidiaries is the subject before or by any court or governmental agency, authority or body, or any arbitrator or mediator, which, if adversely determined, is reasonably likely to result in a Material Adverse Effect.
(x) Permits. The Company and each of its subsidiaries holds, and is in compliance with, all franchises, grants, authorizations, licenses, permits, easements, consents, certificates and orders (“Permits”) of any foreign, federal, state or local governmental or self-regulatory agency, authority or body required for the conduct of its business as currently conducted as described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, and all such Permits are in full force and effect, in each case except where the failure to hold, or comply with, any of them or the failure of any of them to be in full force and effect, is not reasonably likely to result in a Material Adverse Effect or adversely affect the consummation of the transactions contemplated by this Agreement.
(xi) Good Title. The Company and each of its subsidiaries have good and marketable title to all property (whether real or personal) described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus as being owned by them that are material to the business of the Company, in each case free and clear of all liens, claims, security interests, other encumbrances or defects, except those that are disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus and those that are not reasonably likely to result in a Material Adverse Effect. The property held under lease by the Company and each of its subsidiaries is held by them under valid, subsisting and enforceable leases with only such exceptions with respect to any particular lease as do not interfere in any material respect with the conduct of the business of the Company and each of its subsidiaries.
(xii) Intellectual Property. The Company and each of its subsidiaries owns or possesses or has valid right to use all material patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions, trade secrets and similar rights (“Intellectual Property”) necessary for the conduct of the business of the Company or any of its subsidiaries as currently conducted and as described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus. To the Company’s knowledge, no action or use by the Company or any of its subsidiaries involves or gives rise to any infringement of, or license or similar fees for, any Intellectual Property of others. There is no claim, action or proceeding made, brought, or, to the Company’s knowledge, threatened against the Company or any of its subsidiaries regarding the infringement of Intellectual Property. The Company is not aware of any facts or circumstances which may reasonably be expected to give rise to a claim, action or proceeding regarding the foregoing. To the Company’s knowledge, none of the technology employed by the Company or any of its subsidiaries has been obtained or is being used by the Company or such subsidiary in violation of any contractual obligation binding on the Company or such subsidiary, or, to the Company’s knowledge, any of the officers, directors or employees of the Company or any subsidiary, or, to the Company’s knowledge, otherwise in violation of the rights of any persons.
10
(xiii) Employment Matters. There is (A) no unfair labor practice complaint pending against the Company, or any of its subsidiaries, nor to the Company’s knowledge, threatened against it or any of its subsidiaries, before the National Labor Relations Board, any state or local labor relation board or any foreign labor relations board, and no grievance or arbitration proceeding arising out of or under any collective bargaining agreement is so pending against the Company or any of its subsidiaries, or, to the Company’s knowledge, threatened against it and (B) no labor disturbance by the employees of the Company or any of its subsidiaries exists or, to the Company’s knowledge, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of the Company or any of its subsidiaries, principal suppliers, manufacturers, customers or contractors, that could reasonably be expected, singularly or in the aggregate, to have a Material Adverse Effect. The Company is not aware that any key employee or significant group of employees of the Company or any subsidiary plans to terminate employment with the Company or any such subsidiary.
(xiv) ERISA Compliance. No “prohibited transaction” (as defined in Section 406 of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (“ERISA”), or Section 4975 of the Internal Revenue Code of 1986, as amended from time to time (the “Code”)) or “accumulated funding deficiency” (as defined in Section 302 of ERISA) or any of the events set forth in Section 4043(b) of ERISA (other than events with respect to which the thirty (30)-day notice requirement under Section 4043 of ERISA has been waived) has occurred or could reasonably be expected to occur with respect to any employee benefit plan of the Company or any of its subsidiaries which would reasonably be expected to, singularly or in the aggregate, have a Material Adverse Effect. Each employee benefit plan of the Company or any of its subsidiaries is in compliance in all material respects with applicable law, including ERISA and the Code (to the extent applicable). The Company and its subsidiaries have not incurred and could not reasonably be expected to incur liability under Title IV of ERISA with respect to the termination of, or withdrawal from, any pension plan (as defined in ERISA). Each pension plan for which the Company or any of its subsidiaries would have any liability that is intended to be qualified under Section 401(a) of the Code is so qualified, and, to the Company’ knowledge, nothing has occurred whether by action or by failure to act, which could, singularly or in the aggregate, cause the loss of such qualification.
(xv) Environmental Matters. Each of the Company and its subsidiaries are in compliance with all foreign, federal, state and local rules, laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety (with respect to exposure to hazardous or toxic substances) or the environment which are applicable to their businesses, except where the failure to comply has not had and would not reasonably be expected to have, singularly or in the aggregate, a Material Adverse Effect. There has been no storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or hazardous substances or wastes by, due to, or caused by the Company or any of its subsidiaries (or, to the Company’s knowledge, any other entity for whose acts or omissions the Company or any of its subsidiaries is or may otherwise be liable) upon any of the property now or previously owned or leased by the Company or any of its subsidiaries, or upon any other property, in violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which would, under any law, statute, ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any liability, except for any violation or liability which has not had and would not reasonably be expected to have, singularly or in the aggregate, a Material Adverse Effect; and there has been no disposal, discharge, emission or other release of any kind onto such property or into the environment surrounding such property of any toxic or hazardous substances or wastes with respect to which the Company or any of its subsidiaries has knowledge.
11
(xvi) SOX Compliance. The Company is in compliance in all material respects with all applicable provisions of the Sarbanes-Oxley Act and all rules and regulations promulgated thereunder and will take all action it deems reasonably necessary to assure that it will be in compliance in all material respects with other applicable provisions of the Sarbanes-Oxley Act not currently in effect at all times after the date on which such provisions apply to the Company.
(xvii) Money Laundering Laws. The operations of each of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”); and no action, suit or proceeding by or before any Governmental Entity involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened. “Governmental Entity” shall be defined as any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency (whether foreign or domestic) having jurisdiction over the Company or any of its subsidiaries or any of their respective properties, assets or operations.
(xviii) Foreign Corrupt Practices Act. Neither the Company nor any of its subsidiaries, nor any director or officer of the Company or any subsidiary, nor, to the knowledge of the Company, any employee, representative, agent, affiliate of the Company or any of its subsidiaries or any other person acting on behalf of the Company or any of its subsidiaries, is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of (i) the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company and its subsidiaries and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith, (ii) OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or (iii) any similar laws in any other jurisdiction.
12
(xix) Sanctions. Neither the Company nor any of its subsidiaries nor any director or officer of the Company or any subsidiary, nor, to the knowledge of the Company, any employee, representative, agent or affiliate of the Company or any of its subsidiaries or any other person acting on behalf of the Company or any of its subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department; (ii) any equivalent European Union measure, including sanctions imposed against certain states, organizations and individuals under the European Union’s Common Foreign & Security Policy; (iii) any economic sanctions administered by Her Majesty’s Treasury; or (iv) any sanctions administered by the United Nations Security Council; or any other relevant sanctions authority (collectively, “Sanctions”); and neither the Company nor any of its subsidiaries will directly or indirectly use the proceeds of the offering of the Securities contemplated hereby, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person, or in any country or territory, that currently is the subject or target of Sanctions or in any other manner that will result in a violation by any person (including any person participating in the transaction whether as an underwriter, advisor, investor or otherwise) of Sanctions.
(xx) Source of Funds. Neither the Company nor any of its subsidiaries have, to the Company’s knowledge, received any funds that have been or are related to or derived from unlawful sources or terrorist or sanctioned-parties or activities, with respect to any applicable jurisdiction, including any funds that may have been identified in connection with the enforcement action of the United Arab Emirates Securities & Commodities Authority, Reference No. إ ت/خ/1845/2023 dated 26/06/2023.
(xxi) Insurance. The Company and each of its subsidiaries carries, or is covered by, insurance in such amounts and covering such risks as is commercially reasonable for the conduct of its business and the value of its properties and as is customary for companies engaged in similar businesses in similar industries.
(xxii) Books and Records. The minute books of the Company and each of its subsidiaries from and after January 1, 2019 have been made available to the Underwriters and counsel for the Underwriters, and such books (i) contain a complete summary of all meetings and actions of the board of directors (including each board committee) and stockholders of the Company (or analogous governing bodies and interest holders, as applicable), and each of its subsidiaries since January 1, 2019 through the date of the latest meeting and action, and (ii) accurately in all material respects reflect all transactions referred to in such minutes.
(xxiii) No Undisclosed Contracts. There is no Contract or document required by the Securities Act or by the Rules and Regulations to be described in the Registration Statement, the Time of Sale Disclosure Package or in the Final Prospectus or to be filed as an exhibit to the Registration Statement which is not so described or filed therein as required; and all descriptions of any such Contracts or documents contained in the Registration Statement, the Time of Sale Disclosure Package and in the Final Prospectus are accurate and complete descriptions of such documents in all material respects. Other than as described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, no such Contract has been suspended or terminated for convenience or default by the Company or any subsidiary party thereto or any of the other parties thereto, and neither the Company nor any of its subsidiaries has received notice, and the Company has no knowledge, of any such pending or threatened suspension or termination.
13
(xxiv) No Undisclosed Relationships. No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries on the one hand, and the directors, officers, stockholders (or analogous interest holders), customers or suppliers of the Company or any of its subsidiaries on the other hand, which is required to be described in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus and which is not so described.
(xxv) Insider Transactions. There are no outstanding loans, advances (except normal advances for business expenses in the ordinary course of business) or guarantees of indebtedness by the Company or any of its subsidiaries to or for the benefit of any of the officers or directors of the Company, any of its subsidiaries or any of their respective family members, except as specifically disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus. All transactions by the Company with office holders or control persons of the Company have been duly approved by the board of directors of the Company, or duly appointed committees or officers thereof, if and to the extent required under applicable law.
(xxvi) No Registration Rights. No person or entity has the right to require registration of shares of Common Stock or other securities of the Company or any of its subsidiaries within one hundred and eighty (180) days after the date hereof because of the filing or effectiveness of the Registration Statement or otherwise, except for persons and entities who have expressly waived such right in writing or who have been given timely and proper written notice and have failed to exercise such right within the time or times required under the terms and conditions of such right. Except as described in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, there are no persons with registration rights or similar rights to have any securities registered by the Company or any of its subsidiaries under the Securities Act.
(xxvii) Continued Business. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, no supplier, customer, distributor or sales agent of the Company or any subsidiary has notified the Company or any subsidiary that it intends to discontinue or decrease the rate of business done with the Company or any subsidiary, except where such discontinuation or decrease has not resulted in, and could not reasonably be expected to result in, a Material Adverse Effect.
(xxviii) No Finder’s Fee. There are no claims, payments, issuances, arrangements or understandings for services in the nature of a finder’s, consulting or origination fee with respect to the introduction of the Company to the Underwriters or the sale of the Securities hereunder or any other arrangements, agreements, understandings, payments or issuances with respect to the Company that may affect the Underwriters’ compensation, as determined by FINRA.
(xxix) No Fees. The Company has not made any direct or indirect payments (in cash, securities or otherwise) to (i) any person, as a finder’s fee, investing fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who provided capital to the Company, (ii) any FINRA member, or (iii) any person or entity that has any direct or indirect affiliation or association with any FINRA member within the 12-month period prior to the date on which the Registration Statement was filed with the Commission (“Filing Date”) or thereafter.
14
(xxx) Proceeds. None of the net proceeds of the offering will be paid by the Company to any participating FINRA member or any affiliate or associate of any participating FINRA member, except as specifically authorized herein.
(xxxi) No FINRA Affiliations. To the Company’s knowledge, no (i) officer or director of the Company or any of its subsidiaries, (ii) owner of ten percent (10.0%) or more of any class of the Company’s securities or (iii) owner of any amount of the Company’s unregistered securities acquired within the one hundred and eighty day (180-day) period prior to the Filing Date, has any direct or indirect affiliation or association with any FINRA member. The Company will advise the Representatives and counsel to the Underwriters if it becomes aware that any officer, director of the Company or any of its subsidiaries or any owner of ten percent (10.0%) or more of any class of the Company’s securities is or becomes an affiliate or associated person of a FINRA member participating in the offering.
(xxxii) No Financial Advisor. Other than the Underwriters, no person has the right to act as an underwriter or as a financial advisor to the Company in connection with the transactions contemplated hereby.
(xxxiii) Certain Statements. The statements included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus insofar as they purport to describe the provisions of laws and the documents referred to therein, are accurate and complete in all material respects and fair, and the statements under the caption “Description of Capital Stock” insofar as they purport to constitute a summary of (i) the terms of the Company’s outstanding securities, (ii) the terms of the Shares, and (iii) the terms of the documents referred to therein, are accurate, complete and fair in all material respects.
(xxxiv) Prior Sales of Securities. Except as set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, the Company has not sold or issued any shares of Common Stock during the six-month period preceding the date hereof, including any sales pursuant to Rule 144A under, or Regulations D or S of, the Securities Act, other than shares issued pursuant to employee benefit plans, stock option plans or other employee compensation plans or pursuant to outstanding preferred stock, options, rights or warrants or other outstanding convertible securities.
15
(xxxv) IT Systems and Data Security. The Company and its subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications and databases (collectively, “IT Systems”) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants except where such bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants have not resulted in, and could not reasonably be expected to result in, a Material Adverse Effect. The Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (“Personal Data”)) used in connection with their businesses, and there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person (which notification was not made), nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.
(xxxv) Compliance with Laws. Except as would not, or is not reasonably likely to, have a material current or future adverse effect on the business, prospects, financial condition, results of operations, liquidity or capital resources of the Company and its subsidiaries taken as a whole, the Company and each of its subsidiary: (i) is and at all times has been operating and conducting its business in compliance with all statutes, rules, regulations, ordinances, judgments, orders and decrees of all Governmental Entities applicable to the Company and such Subsidiary (“Applicable Laws”); (ii) has not received any warning letter, untitled letter or other correspondence or notice from any Governmental Entity alleging or asserting noncompliance with any Applicable Laws or any licenses, consents, certificates, approvals, clearances, authorizations, permits, orders and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”); (iii) possesses all Authorizations and such Authorizations are valid and in full force and effect and is not in violation of any term of any such Authorizations; (iv) has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, inquiry, arbitration or other action from any Governmental Entity or third party alleging that any operation or activity is in violation of any Applicable Laws or Authorizations and has no knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (v) has not received written notice that any Governmental Entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental Entity is considering such action; and (vi) has filed, obtained, maintained or submitted all reports, documents, forms, filings, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and correct respects on the date filed (or were corrected or supplemented by a subsequent submission).
(xxxvii) Prohibited Activities. BDO USA, P.C. has not been engaged by the Company to perform any “prohibited activities” (as defined in Section 10A of the Exchange Act).
(xxxviii) Off-Balance Sheet Arrangements. There are no material off-balance sheet arrangements (as defined in Item 303 of Regulation S-K) that, individually or in the aggregate, have or are reasonably likely to have a material current or future effect on the business, prospects, financial condition, revenues or expenses, changes in financial condition, results of operations, liquidity, capital expenditures or capital resources of the Company and its subsidiaries taken as a whole.
16
(b) Any certificate signed by any officer of the Company and delivered to the Representatives on behalf of the Underwriters or to counsel for the Underwriters shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered thereby.
4. | Purchase, Sale and Delivery of Shares. |
(a) On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company agrees to issue and sell the Firm Shares to the several Underwriters, and the several Underwriters agree, severally and not jointly, to purchase the Firm Shares set forth opposite the names of the Underwriters in Schedule I hereto. The purchase price to be paid by the Underwriters to the Company for the Firm Shares shall be $[●] per share (which for the avoidance of doubt equals ninety-three percent (93.0%) of the per Firm Shares public offering price)(the “Initial Price”).
(b) The Firm Shares will be delivered by the Company to the Representatives, for the respective accounts of the several Underwriters, against payment of the purchase price therefor by wire transfer of same day funds payable to the order of the Company at the offices of Roth Capital Partners, LLC, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660, or such other location as may be mutually acceptable, at 9:00 a.m. (Eastern Time), on the first (or if the Firm Shares are priced, as contemplated by Rule 15c6-1(c) under the Exchange Act, after 4:30 p.m. (Eastern time), the second) full business day following the date hereof, or at such other time and date as the Representatives and the Company determine pursuant to Rule 15c6-1(a) under the Exchange Act, or, in the case of the Option Shares, at such date and time set forth in the Option Notice. The time and date of delivery of the Firm Shares is referred to herein as the “Closing Date.” On the Closing Date, the Company shall deliver the Firm Shares, which shall be registered in the name or names and shall be in such denominations as the Representatives may request on behalf of the Underwriters at least one (1) business day before the Closing Date, to the respective accounts of the several Underwriters, which delivery shall be made through the facilities of the Depository Trust Company’s DWAC system.
(c) The Company hereby grants to the Underwriters the option to purchase some or all of the Option Shares and, upon the basis of the warranties and representations and subject to the terms and conditions herein set forth, the Underwriters shall have the right, severally and not jointly, to purchase all or any portion of the Option Shares as may be necessary to cover over-allotments made in connection with the transactions contemplated hereby. The purchase price to be paid by the Underwriters for the Option Shares shall be the Initial Price. This option may be exercised by the Underwriters at any time and from time to time on or before the thirtieth (30th) day following the date hereof, by written notice to the Company (the “Option Notice”). The Option Notice shall set forth the aggregate number of Option Shares as to which the option is being exercised, and the date and time when the Option Shares are to be delivered (such date and time being herein referred to as the “Option Closing Date”); provided, however, that the Option Closing Date shall not be earlier than the Closing Date (as defined below) nor earlier than the first business day after the date on which the option shall have been exercised nor later than the fifth business day after the date on which the option shall have been exercised unless the Company and the Representatives otherwise agree. If the Underwriters elect to purchase less than all of the Option Shares, the Company agrees to sell to each Underwriter the number of Option Shares obtained by multiplying the number of Option Shares specified in such notice by a fraction, the numerator of which is the number of Option Shares set forth opposite the name of the Underwriter in Schedule I hereto under the caption “Number of Option Shares to be Purchased” and the denominator of which is the total number of Option Shares.
17
(d) Payment of the purchase price for and delivery of the Option Shares shall be made on an Option Closing Date in the same manner and at the same office as the payment for the Firm Shares as set forth in subparagraph (b) above.
(e) It is understood that the Representatives have been authorized, for its own account and the accounts of the several Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Securities the Underwriters have agreed to purchase. Each of the Representatives, individually and not as a Representative of the Underwriters, may (but shall not be obligated to) make payment for any Securities to be purchased by any Underwriter whose funds shall not have been received by the Representatives by the Closing Date or any Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement.
(f) On the Closing Date and on each Option Closing Date, if any, the Company shall issue to Roth Capital (and/or its designees), a warrant (the “Representative’s Warrants”), in form and substance acceptable to Roth Capital for the purchase of an aggregate of [●] shares of Common Stock, which shall represent five percent (5%) of the Shares sold on the Closing Date and Option Closing Date, as applicable, which shall be registered in the name or names and shall be in such denominations as Roth Capital may request at least one (1) business day before the Closing Date or Option Closing Date, as applicable.
5. | Covenants of the Company. |
The Company covenants and agrees with each Underwriter as follows:
(a) The Company shall prepare the Final Prospectus in a form approved by the Representatives and file such Final Prospectus pursuant to Rule 424(b) under the Securities Act not later than 9:30 a.m. (Eastern time) on the second business day following the execution and delivery of this Agreement, or, if applicable, such earlier time as may be required by the Rules and Regulations.
(b) During the period beginning on the date hereof and ending on the later of the Closing Date or such date as determined by the Representatives the Final Prospectus is no longer required by law to be delivered in connection with sales by an underwriter or dealer (the “Prospectus Delivery Period”), prior to amending or supplementing the Registration Statement, including any Rule 462 Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, the Company shall furnish to the Representatives for review and comment a copy of each such proposed amendment or supplement, and the Company shall not file any such proposed amendment or supplement to which the Representatives reasonably objects.
18
(c) From the date of this Agreement until the end of the Prospectus Delivery Period, the Company shall promptly advise the Representatives in writing (A) of the receipt of any comments of, or requests for additional or supplemental information from, the Commission, (B) of the time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to the Time of Sale Disclosure Package or the Final Prospectus, (C) of the time and date that any post-effective amendment to the Registration Statement becomes effective and (D) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or of any order preventing or suspending its use or the use of the Time of Sale Disclosure Package or the Final Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Common Stock from any securities exchange upon which it is listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time during the Prospectus Delivery Period, the Company will use its reasonable efforts to obtain the lifting of such order at the earliest possible moment. Additionally, the Company agrees that it shall comply with the provisions of Rules 424(b) or 430A as applicable, under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a timely manner by the Commission (without reliance on Rule 424(b)(8) or 164(b) of the Securities Act).
(d) (A) During the Prospectus Delivery Period, the Company will comply with all requirements imposed upon it by the Securities Act, as now and hereafter amended, and by the Rules and Regulations, as from time to time in force, and by the Exchange Act, as now and hereafter amended, so far as necessary to permit the continuance of sales of or dealings in the Shares as contemplated by the provisions hereof, the Time of Sale Disclosure Package, the Registration Statement and the Final Prospectus. If during the Prospectus Delivery Period any event occurs the result of which would cause the Final Prospectus (or if the Final Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package ) to include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during such period it is necessary or appropriate in the opinion of the Company or its counsel or the Representatives or counsel to the Underwriters to amend the Registration Statement or supplement the Final Prospectus (or if the Final Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package ) to comply with the Securities Act, the Company will promptly notify the Representatives, allow the Representatives the opportunity to provide reasonable comments on such amendment, prospectus supplement or document, and will amend the Registration Statement or supplement the Final Prospectus (or if the Final Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package) or file such document (at the expense of the Company) so as to correct such statement or omission or effect such compliance.
(B) If at any time during the Prospectus Delivery Period there occurred or occurs an event or development the result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement or any Prospectus or included or would include, when taken together with the Time of Sale Disclosure Package, an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.
19
(e) The Company shall take or cause to be taken all necessary action to qualify the Securities for sale under the securities laws of such jurisdictions as the Representatives reasonably designates and to continue such qualifications in effect so long as required for the distribution of the Securities, except that the Company shall not be required in connection therewith to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified, to execute a general consent to service of process in any state or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise subject.
(f) The Company will furnish to the Underwriters and counsel to the Underwriters copies of the Registration Statement, each Prospectus, any Issuer Free Writing Prospectus, and all amendments and supplements to such documents, in each case as soon as available and in such quantities as the Underwriters may from time to time reasonably request.
(g) The Company will make generally available to its security holders as soon as practicable, but in any event not later than 15 months after the end of the Company’s current fiscal quarter, an earnings statement (which need not be audited) covering a 12-month period that shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 of the Rules and Regulations.
(h) The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will promptly pay or cause to be paid (A) all expenses (including transfer taxes allocated to the respective transferees) incurred by the Company in connection with the delivery to the Underwriters of the Securities (including all fees and expenses of the registrar and transfer agent of the Shares and the registrar and transfer agent of the Representative’s Warrants (if other than the Company), and the cost of preparing and printing stock certificates and warrant certificates), (B) all expenses and fees (including, without limitation, fees and expenses of the Company’s counsel) in connection with the preparation, printing, filing, delivery, and shipping of the Registration Statement (including the financial statements therein and all amendments, schedules, and exhibits thereto), the Securities, the Time of Sale Disclosure Package, any Prospectus or the Final Prospectus, and any amendment thereof or supplement thereto, (C) all reasonable filing fees and reasonable fees and disbursements of the Underwriters’ counsel incurred in connection with the qualification of the Securities for offering and sale by the Underwriters or by dealers under the securities or blue sky laws of the states and other jurisdictions that the Representatives shall designate, (D) the filing fees and reasonable fees and disbursements of counsel to the Underwriters incident to any required review and approval by FINRA, of the terms of the sale of the Securities, (F) listing fees related to the Shares, and (G) all other costs and expenses incident to the performance of its obligations hereunder that are not otherwise specifically provided for herein. The Company will reimburse the Representatives for the Underwriters’ reasonable out-of-pocket expenses, including legal fees and disbursements, in connection with the purchase and sale of the Securities contemplated hereby up to an aggregate of $350,000 (including reasonable fees and expenses of counsel payable pursuant to clauses (C) and (D) above) (the “Cap”). If this Agreement is terminated by the Representatives in accordance with the provisions of Section 6, Section 9 or Section 10, the Company will reimburse the Underwriters for all out-of-pocket fees, expenses and disbursements (including, but not limited to, fees and expenses of counsel, travel expenses, postage, facsimile and telephone charges) incurred by the Underwriters in connection with their investigation, preparing to market and marketing the Shares or in contemplation of performing their obligations hereunder (without regard to the Cap, other than in the case of termination in accordance with the provisions of Section 10).
20
(i) The Company intends to apply the net proceeds from the sale of the Securities to be sold by it hereunder for the purposes set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus under the heading “Use of Proceeds”.
(j) The Company has not taken and will not take, directly or indirectly, during the Prospectus Delivery Period, any action designed to or which might reasonably be expected to cause or result in, or that has constituted, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.
(k) The Company represents and agrees that, unless it obtains the prior written consent of the Representatives, and each Underwriter, severally and not jointly, represents and agrees that, unless it obtains the prior written consent of the Company, it has not made and will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus; provided that the prior written consent of the parties hereto shall be deemed to have been given in respect of the free writing prospectuses included in Schedule IV. Any such free writing prospectus consented to by the Company and the Representatives is hereinafter to as a “Permitted Free Writing Prospectus.” The Company represents that it has treated or agrees that it will treat each Permitted Free Writing Prospectus as an “issuer free writing prospectus,” as defined in Rule 433, and has complied or will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely Commission filing where required, legending and record-keeping.
(k) The Company hereby agrees that, without the prior written consent of the Representatives, it will not, during the period ending one hundred and eighty (180) days after the date hereof (“Lock-Up Period”), (i) offer, pledge, issue, sell, contract to sell, purchase, contract to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock; or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise; or (iii) file any registration statement with the Commission relating to the offering of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock except for any registration statements on Form S-8. The restrictions contained in the preceding sentence shall not apply to (1) the Securities to be sold hereunder, (2) the issuance of Common Stock upon the exercise of options or warrants or the conversion of outstanding preferred stock or other outstanding convertible securities disclosed as outstanding in the Registration Statement (excluding exhibits thereto), the Time of Sale Disclosure Package, and the Final Prospectus, (3) the issuance of stock options not exercisable during the Lock-Up Period and the grant of restricted stock awards or restricted stock units or shares of Common Stock pursuant to equity incentive plans described in the Registration Statement (excluding exhibits thereto), the Time of Sale Disclosure Package, and the Final Prospectus or (4) the issuance of or entry into an agreement to issue shares of Common Stock in connection with one or more mergers, acquisitions of securities, businesses, property or other assets, products or technologies, joint ventures, commercial relationships or other strategic corporate transactions or alliances, provided that (a) the recipients thereof shall execute a Lock-Up Agreement (as defined below) in the form set forth on Exhibit A hereto prior to the issuance of such shares of Common Stock and (b) any such issuances pursuant to this clause (4), individually or in the aggregate, shall not exceed 7.5% of the outstanding Common Stock as of the Closing Date.
21
(l) The Company hereby agrees, during a period of three (3) years from the effective date of the Registration Statement, to furnish to the Representatives copies of all reports or other communications (financial or other) furnished to stockholders, and to deliver to the Representatives as soon as reasonably practicable upon availability, copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange on which any class of securities of the Company is listed; provided, that any information or documents available on EDGAR shall be considered furnished for purposes of this Section 5(l).
(m) Prior to the Closing Date, the Company shall not issue any press release or other communications directly or indirectly and shall not hold any press conference with respect to the Company or its subsidiaries, or the condition, financial or otherwise, or the earnings, business affairs or business prospects of any of them, or the offering of the Shares, without the prior written consent of the Representatives unless in the judgment of the Company and its counsel, and after notification to the Representatives, such press release or communication is required by law or applicable rules or regulations.
(n) The Company hereby agrees to engage and maintain, at its expense, a registrar and transfer agent for the Common Stock and a registrar and transfer agent for the Representative’s Warrants (if other than the Company).
(o) The Company hereby agrees to use its reasonable best efforts to obtain approval to list the Shares and the Representative’s Warrants Shares on Nasdaq. The Company further agrees to use its reasonable best efforts to effect and maintain the listing of the Shares and its Common Stock on Nasdaq for at least three years from the date of this Agreement.
(p) The Company will promptly notify the Representatives if it ceases to be an Emerging Growth Company or a Smaller Reporting Company at any time prior to the later of (a) the end of the Prospectus Delivery Period and (b) the expiration of the lock-up period described in Section 5(k) above.
(q) The Company hereby agrees not to take, directly or indirectly, any action designed to cause or result in, or that has constituted or might reasonably be expected to constitute, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any securities of the Company to facilitate the sale or resale of the Securities.
(r) The Company, during the Prospectus Delivery Period, will file all reports and other documents required to be filed with the Commission pursuant to Section 13, 14 or 15 of the Exchange Act within the time periods required by the Exchange Act and the regulations promulgated thereunder.
22
6. | Conditions of the Underwriter’s Obligations. |
The respective obligations of each Underwriter hereunder to purchase the Securities are subject to the accuracy, as of the date hereof and at all times through the Closing Date, and on each Option Closing Date (as if made on the Closing Date or such Option Closing Date, as applicable), of and compliance with all representations, warranties and agreements of the Company contained herein, the performance by the Company of its obligations hereunder and the following additional conditions:
(a) If filing of the Final Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, is required under the Securities Act or the Rules and Regulations, the Company shall have filed the Final Prospectus (or such amendment or supplement) or such Issuer Free Writing Prospectus with the Commission in the manner and within the time period so required (without reliance on Rule 424(b)(8) or 164(b) under the Securities Act); the Registration Statement shall remain effective; no stop order suspending the effectiveness of the Registration Statement or any part thereof, any Rule 462 Registration Statement, or any amendment thereof, nor suspending or preventing the use of the Time of Sale Disclosure Package, any Prospectus or the Final Prospectus shall have been issued; no proceedings for the issuance of such an order shall have been initiated or threatened by the Commission; any request of the Commission or the Representatives for additional information (to be included in the Registration Statement, the Time of Sale Disclosure Package, any Prospectus, the Final Prospectus or otherwise) shall have been complied with to the satisfaction of the Representatives.
(b) The Shares and the Representative’s Warrant Shares shall be approved for listing on Nasdaq, subject to official notice of issuance.
(c) FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.
(d) The Representatives shall not have reasonably determined, and advised the Company, that the Registration Statement, the Time of Sale Disclosure Package, any Prospectus or the Final Prospectus, or any amendment thereof or supplement thereto, contains an untrue statement of fact which, in the reasonable opinion of the Representatives, is material, or omits to state a fact which, in the reasonable opinion of the Representatives, is material and is required to be stated therein or necessary to make the statements therein not misleading.
(e) On the Closing Date and on each Option Closing Date, there shall have been furnished to the Representatives, for the benefit of the Underwriters, the opinion and negative assurance letters of Pryor Cashman LLP, counsel to the Company, each dated the Closing Date or the Option Closing Date, as applicable, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives.
(f) On the Closing Date and on each Option Closing Date, there shall have been furnished to the Representatives, for the benefit of the Underwriters, the opinion and negative assurance letter of Pillsbury Winthrop Shaw Pittman LLP, counsel to the Underwriters, dated the Closing Date or the Option Closing Date, as applicable, and addressed to the Underwriters, in form and substance reasonably satisfactory to Representatives.
23
(g) The Representatives, for the benefit of the Underwriters, shall have received a letter of BDO USA, P.C., on the date hereof and on the Closing Date and on each Option Closing Date, addressed to the Underwriters, confirming that they are independent public accountants within the meaning of the Securities Act and are in compliance with the applicable requirements relating to the qualifications of accountants under Rule 2-01 of Regulation S-X of the Commission, and confirming, as of the date of each such letter (or, with respect to matters involving changes or developments since the respective dates as of which specified financial information is given in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, as of a date not prior to the date hereof or more than five days prior to the date of such letter), the conclusions and findings of said firm with respect to the financial information and other matters required by the Underwriters.
(h) The Representatives shall have received, simultaneously with the execution of this Agreement and on the Closing Date and each Option Closing Date, a certificate of the chief financial officer of the Company addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, with respect to certain financial information related to the Company included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, as well as the Marketing Materials, and certain other information contained in the Registration Statement, the Prospectus and the Marketing Materials.
(i) The representations and warranties of the Company contained in this Agreement and the representations and warranties of the Company contained in the certificates delivered pursuant to Sections 6(h) and 6(j) shall be true and correct, when made and on and as of each Closing Date as if made on such date. The Company shall have performed all covenants and agreements and satisfied all the conditions contained in this Agreement required to be performed or satisfied by it at or before such Closing Date.
(j) On the Closing Date and on each Option Closing Date, there shall have been furnished to the Representatives, for the benefit of the Underwriters, a certificate, dated the Closing Date and on each Option Closing Date and addressed to the Underwriters, signed by the chief executive officer and the chief financial officer of the Company, in their capacity as officers of the Company, to the effect that:
(i) the representations, warranties and agreements of the Company in this Agreement were true and correct when made and are true and correct in all material respects as of such Closing Date (provided, that each representation and warranty that contains a materiality qualifier shall be true and correct in all respects as of such Closing Date);
(ii) the Company has performed all covenants and agreements and satisfied all conditions contained herein;
24
(iii) they have carefully examined the Registration Statement, the Prospectus, and the Time of Sale Disclosure Package and, in their opinion (A) (1) as of the Effective Time, the Registration Statement did not or will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading, (2) as of the date thereof or as of the date hereof, the Prospectus did not contain and does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, and (3) as of the Applicable Time, the Time of Sale Disclosure Package did not include any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, and (B) since the Effective Time, no event has occurred which should have been set forth in a supplement or otherwise required an amendment to the Registration Statement, the Time of Sale Disclosure Package or the Prospectus;
(iv) no stop order or other order (A) suspending the effectiveness of the Registration Statement, (B) suspending the qualification of the Securities for offering or sale, or (C) suspending or preventing the use of the Time of Sale Disclosure Package, any Prospectus or the Final Prospectus has been issued, and to the Company’s knowledge, no proceedings for that purpose have been instituted or are pending under the Securities Act; and
(v) there has been no occurrence of any event resulting or reasonably likely to result in a Material Adverse Effect during the period from and after the date of this Agreement and prior to the Closing Date or on the Option Closing Date, as applicable.
(k) On or before the date hereof, the Representatives shall have received duly executed lock-up agreements (each a “Lock-Up Agreement”) in the form set forth on Exhibit A hereto, by and between the Representatives and each of the parties specified in Schedule V.
(l) The Company shall have furnished to the Underwriters and their counsel such additional documents, certificates and evidence as the Underwriters or their counsel may have reasonably requested.
If any condition specified in this Section 6 shall not have been fulfilled when and as required to be fulfilled, this Agreement may be terminated by the Representatives by notice to the Company at any time at or prior to the Closing Date or on or prior to the Option Closing Date, as applicable, and such termination shall be without liability of any party to any other party, except that Section 5(h) and Sections 7 through 18, inclusive, shall survive any such termination and remain in full force and effect.
25
7. | Indemnification and Contribution. |
(a) The Company agrees to indemnify, defend and hold harmless each Underwriter, its affiliates, directors and officers and employees, and each person, if any, who controls such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any losses, claims, damages or liabilities to which such party may become subject, under the Securities Act or otherwise (including in settlement of any litigation if such settlement is effected with the written consent of the Company), insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, including the information deemed to be a part of the Registration Statement at the time of effectiveness and at any subsequent time pursuant to Rules 430A, 430B and 430C of the Rules and Regulations, or arise out of or are based upon the omission from the Registration Statement, or alleged omission to state therein, a material fact required to be stated therein or necessary to make the statements therein not misleading (ii) an untrue statement or alleged untrue statement of a material fact contained in the Time of Sale Disclosure Package, any Written Testing-the-Waters Communications, any Prospectus or the Final Prospectus, or any amendment or supplement thereto, or the Marketing Materials or in any other materials used in connection with the offering of the Securities, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, (iii) in whole or in part, any inaccuracy in or breach of the representations and warranties of the Company contained herein, or (iv) in whole or in part, any failure of the Company to perform its obligations hereunder or under law, and will reimburse such party for any legal or other expenses reasonably incurred by such party in connection with evaluating, investigating or defending against such loss, claim, damage, liability or action; provided, however, that such indemnity shall not inure to the benefit of any Underwriter (or any person controlling such Underwriter) in any such case to the extent that any such loss, claim, damage, liability or action arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, the Time of Sale Disclosure Package, any Written Testing-the-Waters Communications, any Prospectus or the Final Prospectus, or any amendment or supplement thereto, in reliance upon and in conformity with written information furnished to the Company by the Underwriters specifically for use in the preparation thereof, which written information is set forth in Section 7(f).
(b) Each Underwriter, severally and not jointly, will indemnify, defend and hold harmless the Company, its directors and each officer of the Company who signs the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any losses, claims, damages or liabilities to which such party may become subject, under the Securities Act or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, the Time of Sale Disclosure Package, any Prospectus or the Final Prospectus, or any amendment or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, the Time of Sale Disclosure Package, any Prospectus or the Final Prospectus, or any amendment or supplement thereto in reliance upon and in conformity with written information furnished to the Company by such Underwriter specifically for use in the preparation thereof, which written information is set forth in Section 7(f), and will reimburse such party for any legal or other expenses reasonably incurred by such party in connection with evaluating, investigating, and defending against any such loss, claim, damage, liability or action. The obligation of each Underwriter to indemnify the Company (including any controlling person, director or officer thereof) shall be limited to the amount of the underwriting discount applicable to the Shares to be purchased by such Underwriter hereunder actually received by such Underwriter.
26
(c) Promptly after receipt by an indemnified party under subsection (a) or (b) above of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof; but the failure to notify the indemnifying party shall not relieve the indemnifying party from any liability that it may have to any indemnified party except to the extent such indemnifying party has been materially prejudiced by such failure. In case any such action shall be brought against any indemnified party, and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate in, and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel satisfactory to such indemnified party, and after notice from the indemnifying party to such indemnified party of the indemnifying party’s election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof; provided, however, that if (i) the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (ii) a conflict or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified party), or (iii) the indemnifying party has not in fact employed counsel reasonably satisfactory to the indemnified party to assume the defense of such action within a reasonable time after receiving notice of the commencement of the action, the indemnified party shall have the right to employ a single counsel to represent it in any claim in respect of which indemnity may be sought under subsection (a) or (b) of this Section 7, in which event the reasonable and documented fees and expenses of such separate counsel shall be borne by the indemnifying party or parties and reimbursed to the indemnified party as incurred.
The indemnifying party under this Section 7 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is a party or could be named and indemnity was or would be sought hereunder by such indemnified party, unless such settlement, compromise or consent (a) includes an unconditional release of such indemnified party from all liability for claims that are the subject matter of such action, suit or proceeding and (b) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.
27
(d) If the indemnification provided for in this Section 7 is unavailable or insufficient to hold harmless an indemnified party under subsection (a) or (b) above, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of the losses, claims, damages or liabilities referred to in subsection (a) or (b) above, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering and sale of the Shares or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) received by the Company bear to the total underwriting discount received by the Underwriters, in each case as set forth in the table on the cover page of the Final Prospectus. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or the Underwriters and the parties’ relevant intent, knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. The Company and the Underwriters agree that it would not be just and equitable if contributions pursuant to this subsection (d) were to be determined by pro rata allocation or by any other method of allocation that does not take account of the equitable considerations referred to in the first sentence of this subsection (d). The amount paid by an indemnified party as a result of the losses, claims, damages or liabilities referred to in the first sentence of this subsection (d) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending against any action or claim that is the subject of this subsection (d). Notwithstanding the provisions of this subsection (d), no Underwriter shall be required to contribute any amount in excess of the amount of the underwriting discount applicable to the Shares to be purchased by such Underwriter hereunder actually received by such Underwriter. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’ respective obligations to contribute as provided in this Section 7 are several in proportion to their respective underwriting commitments and not joint.
(e) The obligations of the Company under this Section 7 shall be in addition to any liability that the Company may otherwise have and the benefits of such obligations shall extend, upon the same terms and conditions, to each person, if any, who controls any Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act; and the obligations of each Underwriter under this Section 7 shall be in addition to any liability that each Underwriter may otherwise have and the benefits of such obligations shall extend, upon the same terms and conditions, to the Company’s directors, the officers of the Company signing the Registration Statement and each person who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act.
(f) For purposes of this Agreement, each Underwriter severally confirms, and the Company acknowledges and agrees, that there is no information concerning such Underwriter furnished in writing to the Company by such Underwriter specifically for preparation of or inclusion in the Registration Statement, the Time of Sale Disclosure Package, any Prospectus or the Final Prospectus, other than the statement set forth in the last paragraph on the cover page of the Prospectus, the marketing and legal names of each Underwriter, and the statements set forth in the “Underwriting” section of the Registration Statement, the Time of Sale Disclosure Package, and the Final Prospectus only insofar as such statements relate to the amount of selling concession and re-allowance, if any, or to over-allotment, stabilization and related activities that may be undertaken by such Underwriter.
28
8. | Representations and Agreements to Survive Delivery. |
All representations, warranties, and agreements of the Company contained herein or in certificates delivered pursuant hereto, including, but not limited to, the agreements of the several Underwriters and the Company contained in Section 5(h) and Sections 7 through 18 hereof, shall remain operative and in full force and effect regardless of any investigation made by or on behalf of the several Underwriters or any controlling person thereof, or the Company or any of its officers, directors, or controlling persons, and shall survive delivery of, and payment for, the Shares to and by the several Underwriters hereunder.
9. | Termination of this Agreement. |
(a) The Representatives shall have the right to terminate this Agreement by giving notice to the Company as hereinafter specified at any time at or prior to the Closing Date or any Option Closing Date (as to the Option Shares to be purchased on such Option Closing Date only), if in the discretion of the Representatives, (i) there has occurred any material adverse change in the securities markets or any event, act or occurrence that has materially disrupted, or in the opinion of the Representatives, will in the future materially disrupt, the securities markets or there shall be such a material adverse change in general financial, political or economic conditions or the effect of international conditions on the financial markets in the United States is such as to make it, in the judgment of the Representatives, inadvisable or impracticable to market the Shares or enforce contracts for the sale of the Shares (ii) trading in or quotation of the Company’s Common Stock shall have been suspended by the Commission or Nasdaq or trading in securities generally on the Nasdaq Stock Market, the New York Stock Exchange (“NYSE”) shall have been suspended, (iii) minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall have been required, on the Nasdaq Stock Market or the NYSE, by such exchange or by order of the Commission or any other governmental authority having jurisdiction, (iv) a banking moratorium shall have been declared by federal or state authorities, (v) there shall have occurred any attack on, outbreak or escalation of hostilities or act of terrorism involving the United States, any declaration by the United States of a national emergency or war, any substantial change or development involving a prospective substantial change in United States or international political, financial or economic conditions or any other calamity or crisis, or (vi) the Company suffers any loss by strike, fire, flood, earthquake, accident or other calamity, whether or not covered by insurance, or (vii) in the judgment of the Representatives, there has been, since the time of execution of this Agreement or since the respective dates as of which information is given in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, any material adverse change in the assets, properties, condition, financial or otherwise, or in the results of operations, business affairs or business prospects of the Company and its subsidiaries considered as a whole, whether or not arising in the ordinary course of business. Any such termination shall be without liability of any party to any other party except that the provisions of Section 5(h) and Sections 7 through 18, inclusive, hereof shall at all times be effective and shall survive such termination.
(b) If the Representatives elect to terminate this Agreement as provided in this Section, the Company and the other Underwriters shall be notified promptly by the Representatives by telephone, confirmed by letter.
29
10. | Substitution of Underwriters. |
If any Underwriter or Underwriters shall default in its or their obligations to purchase Shares hereunder on the Closing Date or any Option Closing Date and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed to purchase does not exceed ten percent (10%) of the total number of Shares to be purchased by all Underwriters on such Closing Date or Option Closing Date, the other Underwriters shall be obligated severally, in proportion to their respective commitments hereunder, to purchase the Shares which such defaulting Underwriter or Underwriters agreed but failed to purchase on such Closing Date or Option Closing Date. If any Underwriter or Underwriters shall so default and the aggregate number of Shares with respect to which such default or defaults occur is more than ten percent (10%) of the total number of Shares to be purchased by all Underwriters on such Closing Date or Option Closing Date and arrangements satisfactory to the remaining Underwriters and the Company for the purchase of such Shares by other persons are not made within forty-eight (48) hours after such default, this Agreement shall terminate.
If the remaining Underwriters or substituted Underwriters are required hereby or agree to take up all or part of the Shares of a defaulting Underwriter or Underwriters on such Closing Date or Option Closing Date as provided in this Section 10, (i) the Company shall have the right to postpone such Closing Date or Option Closing Date for a period of not more than five (5) full business days in order to permit the Company to effect whatever changes in the Registration Statement, the Final Prospectus, or in any other documents or arrangements, which may thereby be made necessary, and the Company agrees to promptly file any amendments to the Registration Statement or the Final Prospectus which may thereby be made necessary, and (ii) the respective numbers of Shares to be purchased by the remaining Underwriters or substituted Underwriters shall be taken as the basis of their underwriting obligation for all purposes of this Agreement. Nothing herein contained shall relieve any defaulting Underwriter of its liability to the Company or any other Underwriter for damages occasioned by its default hereunder. Any termination of this Agreement pursuant to this Section 10 shall be without liability on the part of any non-defaulting Underwriters or the Company, except that the representations, warranties, covenants, indemnities, agreements and other statements set forth in Section 2 and 3, the obligations with respect to expenses to be paid or reimbursed pursuant to Section 5 and the provisions of Sections 7 through 18, inclusive, shall not terminate and shall remain in full force and effect.
As used in this Agreement, the term “Underwriter” shall be deemed to include any person substituted for a defaulting Underwriter under this Section 10. Any action taken under this Section 10 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement.
11. | Notices. |
All notices and communications hereunder shall be in writing and mailed or delivered or by telephone or facsimile if subsequently confirmed in writing, (a) if to the Representatives, (i) Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, CA 92660, Facsimile: (949) 720-7227, Attention: Equity Capital Markets and (ii) Craig-Hallum Capital Group LLC, 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, Facsimile: (612) 334-6399, with a copy to Pillsbury Winthrop Shaw Pittman LLP, 31 W. 52nd Street, New York, NY 10019, Attention: Jonathan J. Russo, Esq. and Alexandra F. Calcado, Esq., Facsimile: (212) 858-1500 and (b) if to the Company, to its agent for service as such agent’s address appears on the cover page of the Registration Statement with a copy to Pryor Cashman LLP, 7 Times Square, New York, NY 10036, Attention: M. Ali Panjwani, Esq., Facsimile: (212) 326-0806.
30
12. | Persons Entitled to Benefit of Agreement. |
This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and assigns and the controlling persons, officers and directors referred to in Section 7. Nothing in this Agreement is intended or shall be construed to give to any other person, firm or corporation any legal or equitable remedy or claim under or in respect of this Agreement or any provision herein contained. The term “successors and assigns” as herein used shall not include any purchaser, as such purchaser, of any of the Shares from any Underwriter.
13. | Absence of Fiduciary Relationship. |
The Company acknowledges and agrees that: (a) each Underwriter has been retained solely to act as underwriter in connection with the sale of the Shares and that no fiduciary, advisory or agency relationship between the Company and any Underwriter has been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether the Underwriter has advised or is advising the Company on other matters; (b) the price and other terms of the Shares set forth in this Agreement were established by the Company following discussions and arms-length negotiations with the Underwriters and the Company is capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated by this Agreement; (c) it has been advised that the Underwriters and their affiliates are engaged in a broad range of transactions that may involve interests that differ from those of the Company and that no Underwriter has no obligation to disclose such interest and transactions to the Company by virtue of any fiduciary, advisory or agency relationship; and (d) it has been advised that each Underwriter is acting, in respect of the transactions contemplated by this Agreement, solely for the benefit of such Underwriter, and not on behalf of the Company. Additionally, the Company acknowledges and agrees that the Underwriter has not and will not advise the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company has consulted with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and the Underwriters shall have no responsibility or liability to the Company or any other person with respect thereto, whether arising prior to or after the date hereof. Any review by the Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions have been and will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company. The Company agrees that it will not claim that the Underwriters have rendered advisory services of any nature or respect, or owe a fiduciary duty to the Company or any other person in connection with any such transaction or the process leading thereto.
14. | Amendments and Waivers. |
No supplement, modification or waiver of this Agreement shall be binding unless executed in writing by the party to be bound thereby. The failure of a party to exercise any right or remedy shall not be deemed or constitute a waiver of such right or remedy in the future. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (regardless of whether similar), nor shall any such waiver be deemed or constitute a continuing waiver unless otherwise expressly provided.
31
15. | Partial Unenforceability. |
The invalidity or unenforceability of any section, paragraph, clause or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph, clause or provision.
16. | Governing Law. |
This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof.
17. | Submission to Jurisdiction. |
The Company irrevocably (a) submits to the jurisdiction of the Supreme Court of the State of New York, Borough of Manhattan or the United States District Court for the Southern District of New York for the purpose of any suit, action, or other proceeding arising out of this Agreement, or any of the agreements or transactions contemplated by this Agreement, the Registration Statement, the Time of Sale Disclosure Package and any Prospectus (each a “Proceeding”), (b) agrees that all claims in respect of any Proceeding may be heard and determined in any such court, (c) waives, to the fullest extent permitted by law, any immunity from jurisdiction of any such court or from any legal process therein, (d) agrees not to commence any Proceeding other than in such courts, and (e) waives, to the fullest extent permitted by law, any claim that such Proceeding is brought in an inconvenient forum. THE COMPANY HEREBY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED UPON, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, THE REGISTRATION STATEMENT, THE TIME OF SALE DISCLOSURE PACKAGE, ANY PROSPECTUS AND THE FINAL PROSPECTUS.
18. | Entire Agreement. |
This Agreement (together with the other agreements and documents being delivered pursuant to or in connection with this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof. Notwithstanding anything to the contrary set forth herein, it is understood and agreed by the parties hereto that all other terms and conditions of that certain engagement letter between the Company and Roth Capital, dated January 4, 2024 and as amended to date, shall remain in full force and effect.
32
19. | Counterparts. |
This Agreement may be executed and delivered (including by facsimile transmission or electronic mail) in one or more counterparts and, if executed in more than one counterpart, the executed counterparts shall each be deemed to be an original and all such counterparts shall together constitute one and the same instrument.
[Signature Page Follows]
33
Please sign and return to the Company the enclosed duplicates of this letter whereupon this letter will become a binding agreement between the Company and the several Underwriters in accordance with its terms.
Very truly yours, | ||
ZSPACE, INC. | ||
By: | ||
Name: | ||
Title: |
Confirmed as of the date first above-mentioned by the Representatives of the several Underwriters: |
By: | ROTH CAPITAL PARTNERS, LLC | ||
By: | |||
Name: Aaron M. Gurewitz | |||
Title: Head of Equity Capital Markets | |||
By: | Craig-Hallum Capital Group LLC | ||
By: | |||
Name: | |||
Title: |
{Signature Page to Underwriting Agreement}
SCHEDULE I
Underwriters
Name | Number of Firm Shares to be Purchased |
Number of Option Shares to be Purchased | ||
Roth Capital Partners, LLC | [●] | [●] | ||
Craig-Hallum Capital Group LLC | [●] | [●] | ||
Barrington Research Associates, Inc. | [●] | [●] |
SCHEDULE II
Final Term Sheet
Issuer: | zSpace, Inc. (the “Company”) |
Symbol: | ZSPC |
Securities: | [●] shares of common stock, par value $0.00001 per share (the “Common Stock”), of the Company |
Over-allotment option: | Up to an additional [●] shares of Common Stock |
Public offering price: | $[●] per share of Common Stock |
Underwriting discount: | $[●] per share of Common Stock |
Expected net proceeds: | Approximately $[●] million (or $[●] million if the overallotment option is exercised in full)(before deducting estimated offering expenses but after deducting the underwriting discount) |
Trade date: | [●], 2024 |
Settlement date: | [●], 2024 |
SCHEDULE III
Written Testing-the-Waters Communications
Investor Presentation, dated March 2024
SCHEDULE IV
Free Writing Prospectus
[None.]
SCHEDULE V
List of Officers, Directors and Stockholders
Executing Lock-Up Agreements
1. | dSpace Investments Limited |
2. | bSpace Investments Limited |
3. | Gulf Islamic Investments, LLC |
4. | Fiza Investments Limited |
5. | Innotron Technology Corporation Ltd. |
6. | TimeSpeed Technology Corporation |
7. | Paul Kellenberger |
8. | Erick DeOliveira |
9. | Michael Harper |
10. | Ron Rheinheimer |
11. | Pankaj Gupta |
12. | Amit Jain |
13. | Joanna Morris |
14. | Abhay Pande |
15. | Angela Prince |
16. | Jane Swift |
EXHIBIT A
Form of Representative’s Warrants
See attached.
EXHIBIT B
Form of Lock-Up Agreement
_______, 2024
Roth Capital Partners, LLC
Craig-Hallum Capital Group LLC
As the Representatives of the
Several Underwriters Named on Schedule I hereto
c/o | Roth Capital Partners, LLC |
888 San Clemente Drive, Suite 400 | |
Newport Beach, CA 92660 | |
Craig-Hallum Capital Group LLC | |
222 South Ninth Street, Suite 350 | |
Minneapolis, MN 55402 |
Re: zSpace, Inc. Registered Public Offering of Common Stock
Ladies and Gentlemen:
In order to induce Roth Capital Partners, LLC (the “Roth Capital”) and Craig-Hallum Capital Group LLC to enter into a certain underwriting agreement (the “Underwriting Agreement”) with zSpace, Inc., a Delaware corporation (the “Company”), with respect to a registered public offering of shares (the “Offering”) of the Company’s Common Stock, par value $0.00001 per share (“Common Stock”), the undersigned hereby enters into this letter agreement (this “Lock-Up Agreement”) and agrees that for a period (the “Lock-Up Period”) commencing on the date hereof and continuing through the close of trading on the date [one hundred and eighty (180)]1[three hundred sixty-five (365)]2 days following the date of the final prospectus filed by the Company with the Securities and Exchange Commission in connection with the Offering, the undersigned will not, without the prior written consent of Roth Capital, directly or indirectly, (i) sell, assign, transfer, pledge, offer to sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option for sale (including any short sale), right or warrant to purchase, lend, establish an open “put equivalent position” (within the meaning of Rule 16a-1(h) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), or otherwise dispose of, or enter into any transaction which is designed to or could be expected to result in the disposition of, any shares of Common Stock or securities convertible into or exercisable or exchangeable for any equity securities of the Company (including, without limitation, shares of Common Stock or any such securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations promulgated by the Securities and Exchange Commission from time to time (such shares or securities, the “Beneficially Owned Shares”)), or publicly announce any intention to do any of the foregoing, other than the exercise of options or warrants so long as there is no sale or disposition of the Common Stock underlying such options or warrants during the Lock-Up Period, (ii) enter into any swap, hedge or other agreement or arrangement that transfers in whole or in part, the economic risk of ownership of any Beneficially Owned Shares, Common Stock or securities convertible into or exercisable or exchangeable for any equity securities of the Company, or (iii) engage in any short selling of any Beneficially Owned Shares, Common Stock or securities convertible into or exercisable or exchangeable for any equity securities of the Company, whether any such transaction described in clause (i), (ii) or (iii) above is to be settled by delivery of shares of Common Stock or such other securities, in cash or otherwise. [After the date one hundred and eighty (180) days following the date of the final prospectus filed by the Company with the Securities and Exchange Commission in connection with the Offering and continuing through the close of trading on the date three hundred sixty-five (365) days following the date of the final prospectus filed by the Company with the Securities and Exchange Commission in connection with the Offering, the undersigned will not, without the prior written consent of Roth Capital, directly or indirectly effect a transaction described in clause (i), (ii) or (iii) above with regard to more than 50% of the Beneficially Owned Shares.]3
1 To be included for employees and directors of the Company and for Kuwait Investment Authority.
2 To be included for Gulf Islamic Investments, LLC, dSpace Investments Ltd. and bSpace Investments Ltd.
3 To be included for employees and directors of the Company and for Kuwait Investment Authority.
B-1
In addition, notwithstanding the foregoing, the restrictions set forth herein shall not apply to the establishment of a trading plan that complies with Rule 10b5-1 under the Exchange Act; provided, however, that the restrictions shall apply in full force to sales pursuant to the trading plan during the Lock-Up Period. Furthermore, notwithstanding anything herein to the contrary, the restrictions will not apply to the sale of shares of Common Stock pursuant to a trading plan that complies with Rule 10b5-1 and existing on the date of this Lock-Up Agreement.
Anything contained herein to the contrary notwithstanding, any person to whom shares of Common Stock, securities convertible into or exercisable or exchangeable for any equity securities of the Company or Beneficially Owned Shares are transferred from the undersigned during the Lock-Up Period shall be bound by the terms of this Lock-Up Agreement. This Lock-Up Agreement is irrevocable and will be binding on the undersigned and the respective successors, heirs, personal representatives, and assigns of the undersigned.
In addition, the undersigned hereby waives, from the date hereof until the expiration of the Lock-Up Period, any and all rights, if any, to request or demand registration pursuant to the Securities Act of 1933, as the same may be amended or supplemented from time to time, of any shares of Common Stock or securities convertible into or exercisable or exchangeable for any equity securities of the Company that are registered in the name of the undersigned or that are Beneficially Owned Shares. In order to enable the aforesaid covenants to be enforced, the undersigned hereby consents to the placing of legends and/or stop transfer orders with the transfer agent of the Common Stock with respect to any shares of Common Stock, securities convertible into or exercisable or exchangeable for any equity securities of the Company or Beneficially Owned Shares.
B-2
Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer the Beneficially Owned Shares in the transactions listed as clauses (i) - (vi) below without the prior written consent of Roth Capital, provided that (1) prior to each such transfer, Roth Capital shall have received a duplicate form of this Lock-Up Agreement executed and delivered by each donee, trustee, distributee or transferee, as the case may be, (2) no such transfer shall involve a disposition for value, (3) each such transfer (other than transfers under clauses (ii) and (v) below) shall not be required to be reported as a reduction in beneficial ownership in any public report, announcement or filing made or to be made with the Securities and Exchange Commission or otherwise during the Lock-Up Period and (4) the undersigned does not otherwise voluntarily effect any public filing, announcement or report regarding any such transfer during the Lock-Up Period: (i) as a bona fide gift or gifts; (ii) by operation of law, including pursuant to a qualified domestic order or in connection with a divorce settlement; (iii) to the immediate family of the undersigned (for purposes of this Lock-Up Agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin); (iv) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned; (v) to any beneficiary of the undersigned pursuant to a will or other testamentary document or applicable laws of descent; or (vi) to any corporation, partnership, limited liability company or other entity all of the beneficial ownership interests of which are held by the undersigned or the immediate family of the undersigned.
This Lock-Up Agreement shall not apply to: (i) the transfer of Beneficially Owned Shares pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the Common Stock involving a change of control (as defined below) of the Company, provided that in the event that the tender offer, merger, consolidation or other such transaction is not completed, the Beneficially Owned Shares owned by the undersigned shall remain subject to the restrictions contained herein; (ii) transactions relating to shares of Common Stock or other securities acquired in open market transactions after the completion of the Offering, provided that no filing under Section 16(a) of the Exchange Act shall be required or shall be voluntarily made in connection with subsequent sales of Common Stock or other securities acquired in such open market transactions; or (iii) transfers to the Company in connection with the exercise of options or warrants on a “cashless” or “net exercise” basis or to cover tax withholding obligations upon the exercise of options or warrants or the vesting of restricted stock units, provided that any related filing under Section 16(a) of the Exchange Act reporting a disposition of shares of Common Stock made in connection with such exercise shall contain a description of the transaction and indicate that the disposition was made as part of such exercise or to cover tax withholding obligations in connection therewith.
This Lock-Up Agreement shall automatically terminate upon the earlier of (i) August 31, 2024, in the event that no shares of Common Stock have been sold pursuant to the Offering by such date, (ii) the termination of the Underwriting Agreement if such agreement is terminated prior to the Closing Date (as such term is defined in the Underwriting Agreement) in accordance with its terms, (iii) Roth Capital, on the one hand, or the Company, on the other hand, advising the other in writing, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Offering, and (iv) the consummation of a change of control of the Company, meaning (a) the consummation of a reorganization, merger or consolidation, or sale or other disposition of all or substantially all of the assets of the Company, or (b) the acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under such Act) of more than fifty percent (50%) of either (i) the then outstanding shares of Common Stock of the Company; or (ii) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors.
This Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without regard to the principles of conflict of laws.
{Signature page follows}
B-3
This Lock-Up Agreement has been executed as of the date first written above.
Printed Name of Holder | ||
By: | ||
Signature | ||
Printed Name of Person Signing | ||
(and indicate capacity of person signing if | ||
signing as custodian, trustee, or on behalf | ||
of an entity) |
B-4
Exhibit 3.2
CERTIFICATE OF AMENDMENT
OF
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
ZSPACE, INC.
zSpace, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY:
FIRST: The name of the Corporation is zSpace, Inc., and the name under which the Corporation was originally incorporated is Infinite Z, Inc.
SECOND: The date on which the Certificate of Incorporation of the Corporation was originally filed with the Secretary of State of the State of Delaware is October 26, 2006 and was amended and restated by that certain Amended and Restated Certificate of Incorporation, filed with the Secretary of State of the state of Delaware on December 29, 2023.
THIRD: The Board of Directors of the Corporation, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending its Certificate of Incorporation as follows:
The first paragraph of Article FOURTH is hereby amended and restated to read in its entirety as follows:
“FOURTH: Immediately upon the effective time of this Amended and Restated Certificate of Incorporation (the “Restated Certificate of Incorporation” and such time, the “Effective Time”), (i) (A) each 75 shares of the Corporation’s Common Stock then outstanding, par value $0.00001 per share, shall be and hereby is automatically converted and reconstituted into one (1) share of such Common Stock and (B) and each 75 shares of the Corporation’s Series A Preferred Stock then outstanding, par value $0.00001 per share, shall be and hereby is automatically converted and reconstituted into one (1) share of such Series A Preferred Stock, in each case, which shares shall be fully paid and nonassessable, without any action on the part of the holders thereof (the “Reverse Stock Split”) and (ii) each share of the Corporation’s Non-Convertible Non-Voting Preferred Stock then outstanding, par value $0.00001 per share, shall be and hereby is automatically reclassified and reconstituted into one (1) share of such Non-Convertible Non-Voting Preferred Stock 1, par value $0.00001, which shares shall be fully paid and nonassessable, without any action on the part of the holders thereof (the “Reclassification”). No fractional shares shall be issued upon the Reverse Stock Split and, in lieu of issuing fractional shares upon the Reverse Stock Split, the Corporation shall pay each holder the fair value, as of the Effective Time, of the fractional shares that would otherwise be issued upon the Reverse Stock Split. Whether or not fractional shares would have been issuable (but for the preceding sentence) upon the Reverse Stock Split shall be determined on the basis of the total number of shares represented by each stock certificate. Each outstanding stock certificate of the Corporation, which, immediately prior to the Effective Time, represents one or more shares of the Corporation’s capital stock shall thereafter be deemed to represent the appropriate number and type of shares of the Corporation’s capital stock, taking into account the Reverse Stock Split and Reclassification, until such stock certificate is exchanged for a new stock certificate, if such shares are certificated, or if the shares are uncertificated, the stock records maintained by the Company shall be appropriately adjusted to reflect the number and type of shares resulting from the Reverse Stock Split and Reclassification. Except as otherwise noted, all numbers and class and series references herein shall reflect the Reverse Stock Split and Reclassification. The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 40,000,000 shares of Common Stock, $0.00001 par value per share (“Common Stock”), (ii) 4,014,946 shares of Preferred Stock, $0.00001 par value per share (“Preferred Stock”).”
Paragraph 1.1 in paragraph B of Article FOURTH is hereby amended and restated to read in its entirety as follows:
“1.1 Prior to any dividends being paid on the Non-Voting Preferred Stock 2, Non-Voting Preferred Stock 1, Series A Preferred or Common Stock, from and after the date of the issuance of any shares of Non-Convertible Non-Voting Preferred Stock 3, the holders of Non-Convertible Non-Voting Preferred Stock 3 shall be entitled to receive non-cumulative dividends in an amount equal to five percent (5%) per annum of the original issue price per Non-Convertible Non-Voting Preferred Stock 3 of $600 per share of Non-Convertible Non-Voting Preferred Stock 3 (subject to adjustments for stock splits, stock dividends and similar events) (the “Non-Convertible Non-Voting Preferred Stock Original Issue Price”) when and only if declared by the Board of Directors; provided, for purposes of clarity, the holders of the Non-Convertible Non-Voting Preferred Stock 3 shall not be entitled to participate in any dividends paid on any other shares of the Corporation’s capital stock.”
Paragraph 5.1.1 in Paragraph B of Article FOURTH is hereby amended and restated to read in its entirety as follows:
“5.1.1 Trigger Events. Upon either (a) immediately prior to the closing of the sale of shares of Common Stock to the public in a firm-commitment underwritten public offering (i) pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $15,000,000 of gross proceeds to the Corporation or (ii) pursuant to a similar regulatory framework applicable to a non-U.S. public offering resulting in at least $10,000,000 of gross proceeds to the Corporation, in either case, with such offering resulting in the Common Stock being listed for trading on an exchange or marketplace approved by the Board of Directors (a “Qualified Public Offering”) or (b) the date and time, or the occurrence of an event, specified by a vote or written consent of the Requisite Holders (the time of such closing or the date and time specified or the time of the event specified in such vote or written consent is referred to herein as the “Mandatory Conversion Time”), then (i) all outstanding shares of Series A Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate as calculated pursuant to Section 4.1.1 and (ii) such shares may not be reissued by the Corporation.”
2
FOURTH: Thereafter pursuant to a resolution of the Sole Director and the Stockholders of the Corporation this Certificate of Amendment was submitted to the stockholders of the Corporation for their approval, and the Corporation’s stockholders, in lieu of a meeting, duly adopted this Certificate of Amendment by the written consent of the holders of a majority of the issued and outstanding stock of the Corporation entitled to vote thereon, in accordance with the provisions of Sections 228 and 242 of the General Corporation Law of the State of Delaware.
IN WITNESS WHEREOF, zSpace, Inc. has caused this Certificate of Amendment to be duly signed by its Chief Operating Officer as of this 12th day of July, 2024.
ZSPACE, INC. | ||
By: | /s/ Paul Kellenberger |
Name: | Paul Kellenberger | |
Title: | Chief Executive Officer |
3
Exhibit 3.5
Second Amended and Restated Bylaws
of
zSpace, Inc.
(a Delaware corporation)
Effective [ ], 2024
Table of Contents
Page
Article I - Corporate Offices | 1 | |
1.1 | Registered Office | 1 |
1.2 | Other Offices | 1 |
Article II - Meetings of Stockholders | 1 | |
2.1 | Place of Meetings | 1 |
2.2 | Annual Meeting | 1 |
2.3 | Special Meeting | 1 |
2.4 | Notice of Business to be Brought before a Meeting | 2 |
2.5 | Notice of Nominations for Election to the Board of Directors | 5 |
2.6 | Additional Requirements for Valid Nomination of Candidates to Serve as Director and, if Elected, to be Seated as Directors | 7 |
2.7 | Notice of Stockholders’ Meetings | 8 |
2.8 | Quorum | 9 |
2.9 | Adjourned Meeting; Notice | 9 |
2.10 | Conduct of Business | 9 |
2.11 | Voting | 10 |
2.12 | Record Date for Stockholder Meetings and Other Purposes | 10 |
2.13 | Proxies | 11 |
2.14 | List of Stockholders Entitled to Vote | 11 |
2.15 | Inspectors of Election | 11 |
2.16 | Delivery to the Corporation | 12 |
Article III - Directors | 12 | |
3.1 | Powers | 12 |
3.2 | Number of Directors | 12 |
3.3 | Chairperson of the Board; Vice Chairperson of the Board; Executive Chairman | 13 |
3.4 | Election, Qualification and Term of Office of Directors | 13 |
3.5 | Resignation and Vacancies | 13 |
3.6 | Place of Meetings; Meetings by Telephone | 13 |
3.7 | Regular Meetings | 14 |
3.8 | Special Meetings; Notice | 14 |
3.9 | Quorum | 15 |
3.10 | Board Action without a Meeting | 15 |
3.11 | Fees and Compensation of Directors | 15 |
Article IV - Committees | 15 | |
4.1 | Committees of Directors | 15 |
4.2 | Subcommittees | 16 |
Article V - Officers | 16 | |
5.1 | Officers | 16 |
5.2 | Appointment of Officers | 16 |
5.3 | Subordinate Officers | 16 |
i
TABLE OF CONTENTS
(continued)
Page
5.4 | Removal and Resignation of Officers | 17 |
5.5 | Vacancies in Offices | 17 |
5.6 | Representation of Shares of Other Corporations | 17 |
5.7 | Chief Executive Officer | 17 |
5.8 | Other Officers | 17 |
5.9 | Compensation | 18 |
Article VI - Records | 18 | |
Article VII - General Matters | 18 | |
7.1 | Execution of Corporate Contracts and Instruments | 18 |
7.2 | Stock Certificates | 18 |
7.3 | Special Designation of Certificates | 19 |
7.4 | Lost Certificates | 19 |
7.5 | Shares Without Certificates | 19 |
7.6 | Construction; Definitions | 19 |
7.7 | Dividends | 19 |
7.8 | Fiscal Year | 20 |
7.9 | Seal | 20 |
7.10 | Transfer of Stock | 20 |
7.11 | Stock Transfer Agreements | 20 |
7.12 | Registered Stockholders | 20 |
7.13 | Waiver of Notice | 20 |
7.14 | Lock-up | 20 |
Article VIII - Notice | 21 | |
8.1 | Delivery of Notice; Notice by Electronic Transmission | 21 |
Article IX - Indemnification | 22 | |
9.1 | Power to Indemnify in Actions, Suits or Proceedings other than Those by or in the Right of the Corporation | 22 |
9.2 | Power to Indemnify in Actions, Suits or Proceedings by or in the Right of the Corporation | 22 |
9.3 | Authorization of Indemnification | 23 |
9.4 | Good Faith Defined | 23 |
9.5 | Indemnification by a Court | 23 |
9.6 | Expenses Payable in Advance | 24 |
9.7 | Nonexclusivity of Indemnification and Advancement of Expenses | 24 |
9.8 | Insurance | 24 |
9.9 | Certain Definitions | 24 |
9.10 | Survival of Indemnification and Advancement of Expenses | 25 |
9.11 | Limitation on Indemnification | 25 |
9.12 | Indemnification of Employees and Agents | 25 |
9.13 | Primacy of Indemnification | 25 |
ii
TABLE OF CONTENTS
(continued)
Page
Article X - Amendments | 25 | |
Article XI - Definitions | 26 |
iii
Second Amended and Restated
Bylaws
of
zSpace, Inc.
Article I - Corporate Offices
1.1 Registered Office.
The address of the registered office of zSpace, Inc. (the “Corporation”) in the State of Delaware, and the name of its registered agent at such address, shall be as set forth in the Corporation’s certificate of incorporation, as the same may be amended and/or restated from time to time (the “Certificate of Incorporation”).
1.2 Other Offices.
The Corporation may have additional offices and places of business at any place or places, within or outside the State of Delaware, as the Corporation’s board of directors (the “Board”) may from time to time determine or as the affairs of the Corporation may require.
Article II - Meetings of Stockholders
2.1 Place of Meetings.
Meetings of stockholders shall be held at any place within or outside the State of Delaware, designated by the Board, provided that the Board may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section 211(a)(2) of the General Corporation Law of the State of Delaware (the “DGCL”). In the absence of any such designation or determination, stockholders’ meetings shall be held at the Corporation’s principal executive office.
2.2 Annual Meeting.
The Board shall designate the date and time of the annual meeting. At the annual meeting, directors shall be elected and other proper business properly brought before the meeting in accordance with Section 2.4 of these bylaws may be transacted. The Board may postpone or reschedule any previously scheduled annual meeting of stockholders.
2.3 Special Meeting.
Subject to the rights of the holders of any outstanding series of the preferred stock of the Corporation and to the requirements of applicable law, special meetings of the stockholders for any purpose or purposes may be called, postponed, rescheduled or cancelled only by (i) the Board pursuant to a resolution adopted by a majority of the Board, (ii) the Chairperson of the Board, (iii) the Chief Executive Officer, (iv) the President or (v) stockholders collectively holding more than 30% of the voting securities of the Corporation. Special meetings shall be held at such place, either within or without the State of Delaware, and at such time and on such date as shall be determined by the Board and stated in the Corporation’s notice of the meeting, provided that the Board may in its sole discretion determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication pursuant to Section 211(a)(2) of the DGCL.
No business may be transacted at any special meeting of stockholders other than the business specified in the notice of such meeting.
2.4 Notice of Business to be Brought before a Meeting.
(i) At an annual meeting of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual meeting, business (other than the nominations of persons for election to the Board) must constitute a proper matter for stockholder action and must be (a) specified in a notice of meeting given by or at the direction of the Board or any duly authorized committee thereof, (b) if not specified in a notice of meeting, otherwise brought before the meeting by the Board or any duly authorized committee thereof, the Executive Chairman of the Board or Chairperson of the Board or (c) otherwise properly brought before the meeting by a stockholder present in person who (A) (1) was a record owner of shares of the Corporation both at the time of giving the notice provided for in this Section 2.4 and at the time of the meeting, (2) is entitled to vote at the meeting, and (3) has complied with this Section 2.4 in all applicable respects or (B) properly made such proposal in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (as so amended and inclusive of such rules and regulations, the “Exchange Act”). The foregoing clause (c) shall be the exclusive means for a stockholder to propose business to be brought before an annual meeting of the stockholders. For purposes of this Section 2.4, “present in person” shall mean that the stockholder proposing that the business be brought before the annual meeting of the Corporation, or a qualified representative of such proposing stockholder, appear at such annual meeting. A “qualified representative” of such proposing stockholder shall be a duly authorized officer, manager or partner of such stockholder or any other person authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders. Stockholders seeking to nominate persons for election to the Board must comply with Section 2.5 and Section 2.6, and this Section 2.4 shall not be applicable to nominations except as expressly provided in Section 2.5 and Section 2.6.
(ii) Without qualification, for business to be properly brought before an annual meeting by a stockholder, the stockholder must (a) provide Timely Notice (as defined below) thereof in writing and in proper form to the Secretary of the Corporation and (b) provide any updates or supplements to such notice at the times and in the forms required by this Section 2.4. To be timely, a stockholder’s notice must be delivered to, or mailed and received at, the principal executive offices of the Corporation not less than the close of business on the 90th day nor more than the opening of business on the 120th day prior to the one-year anniversary of the immediately preceding year’s annual meeting of the stockholders; provided, however, that if the date of the annual meeting is more than 30 days before or more than 60 days after such anniversary date, notice by the stockholder to be timely must be so delivered, or mailed and received, not earlier than the close of business on the 120th day before the meeting and not later than the later of (x) the close of business on the 90th day prior to such annual meeting or(y) the close of business on the 10th day following the day on which public disclosure of the date of such annual meeting was first made by the Corporation (such notice within such time periods, “Timely Notice”). In no event shall any adjournment or postponement of an annual meeting or the announcement thereof commence a new time period (or extend any time period) for the giving of Timely Notice as described above.
2
(iii) To be in proper form for purposes of this Section 2.4, a stockholder’s notice to the Secretary shall set forth:
(a) As to each Proposing Person (as defined below), (1) the name and record address of such Proposing Person (including, if applicable, the name and address that appear on the Corporation’s books and records) and the name and address of the beneficial owner, if any, on whose behalf the proposal is made; and (2) the class or series and number of shares of the Corporation that are, directly or indirectly, owned of record or beneficially owned (within the meaning of Rule 13d-3 under the Exchange Act) by such Proposing Person, except that such Proposing Person shall in all events be deemed to beneficially own any shares of any class or series of the Corporation as to which such Proposing Person has a right to acquire beneficial ownership at any time in the future (the disclosures to be made pursuant to the foregoing clauses (1) and (2) are referred to as “Stockholder Information”);
(b) As to each Proposing Person, (1) the full notional amount of any securities that, directly or indirectly, underlie any “derivative security” (as such term is defined in Rule 16a-1(c) under the Exchange Act) that constitutes a “call equivalent position” (as such term is defined in Rule 16a-1(b) under the Exchange Act) (“Synthetic Equity Position”) and that is, directly or indirectly, held or maintained by such Proposing Person with respect to any shares of any class or series of shares of the Corporation; provided that, for the purposes of the definition of “Synthetic Equity Position,” the term “derivative security” shall also include any security or instrument that would not otherwise constitute a “derivative security” as a result of any feature that would make any conversion, exercise or similar right or privilege of such security or instrument becoming determinable only at some future date or upon the happening of a future occurrence, in which case the determination of the amount of securities into which such security or instrument would be convertible or exercisable shall be made assuming that such security or instrument is immediately convertible or exercisable at the time of such determination; and, provided, further, that any Proposing Person satisfying the requirements of Rule 13d-1(b)(1) under the Exchange Act (other than a Proposing Person that so satisfies Rule 13d-1(b)(1) under the Exchange Act solely by reason of Rule 13d-1(b)(1)(ii)(E)) shall not be deemed to hold or maintain the notional amount of any securities that underlie a Synthetic Equity Position held by such Proposing Person as a hedge with respect to a bona fide derivatives trade or position of such Proposing Person arising in the ordinary course of such Proposing Person’s business as a derivatives dealer, (2) any rights to dividends on the shares of any class or series of shares of the Corporation owned beneficially by such Proposing Person that are separated or separable from the underlying shares of the Corporation, (3) any material pending or threatened legal proceeding in which such Proposing Person is a party or material participant involving the Corporation or any of its officers or directors, or any affiliate of the Corporation, (4) any other material relationship between such Proposing Person, on the one hand, and the Corporation, or any of its officers or directors, or any affiliate of the Corporation, on the other hand, (5) any direct or indirect material interest in any material contract or agreement of such Proposing Person with the Corporation or any affiliate of the Corporation (including, in any such case, any employment agreement, collective bargaining agreement or consulting agreement), (6) a representation that such Proposing Person is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to propose such business, (7) a representation that such Proposing Person intends or is part of a group which intends to deliver a proxy statement or form of proxy to holders of at least the percentage of the Corporation’s outstanding capital stock required to approve or adopt the proposal or otherwise solicit proxies from stockholders in support of such proposal and (8) any other information relating to such Proposing Person that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies or consents by such Proposing Person in support of the business proposed to be brought before the meeting pursuant to Section 14(a) of the Exchange Act (the disclosures to be made pursuant to the foregoing clauses (1) through (8) are referred to as “Disclosable Interests”); provided, however, that Disclosable Interests shall not include any such disclosures with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder directed to prepare and submit the notice required by these bylaws on behalf of a beneficial owner; and
3
(c) As to each item of business that the Proposing Person proposes to bring before the annual meeting, (1) a brief description of the business desired to be brought before the annual meeting, the reasons for conducting such business at the annual meeting and any material interest in such business of each Proposing Person, (2) the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that such business includes a proposal to amend the bylaws of the Corporation, the language of the proposed amendment), and (3) a reasonably detailed description of all agreements, arrangements and understandings (x) between or among any of the Proposing Persons or (y) between or among any Proposing Person and any other record or beneficial holder(s) or persons(s) who have a right to acquire beneficial ownership at any time in the future of the shares of any class or series of the Corporation or any other person or entity (including their names) in connection with the proposal of such business by such stockholder; and (4) any other information relating to such item of business that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies in support of the business proposed to be brought before the meeting pursuant to Section 14(a) of the Exchange Act; provided, however, that the disclosures required by this paragraph (c) shall not include any disclosures with respect to any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder directed to prepare and submit the notice required by these bylaws on behalf of a beneficial owner.
For purposes of this Section 2.4, the term “Proposing Person” shall mean (i) the stockholder providing the notice of business proposed to be brought before an annual meeting, (ii) the beneficial owner or beneficial owners, if different, on whose behalf the notice of the business proposed to be brought before the annual meeting is made, and (iii) any participant (as defined in paragraphs (a)(ii)-(vi) of Instruction 3 to Item 4 of Schedule 14A) with such stockholder in such solicitation.
(iv) A Proposing Person shall update and supplement its notice to the Corporation of its intent to propose business at an annual meeting, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section 2.4 shall be true and correct as of the record date for stockholders entitled to vote at the meeting and as of the date that is 10 business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary at the principal executive offices of the Corporation not later than five business days after the record date for stockholders entitled to vote at the meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of 10 business days prior to the meeting or any adjournment or postponement thereof). For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other Section of these bylaws shall not limit the Corporation’s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or to submit any new proposal, including by changing or adding matters, business or resolutions proposed to be brought before a meeting of the stockholders.
(v) Notwithstanding anything in these bylaws to the contrary, no business shall be conducted at an annual meeting that is not properly brought before the meeting in accordance with this Section 2.4. The presiding officer of the meeting shall, if the facts warrant, determine that the business was not properly brought before the meeting in accordance with this Section 2.4, and if he or she should so determine, he or she shall so declare to the meeting and any such business not properly brought before the meeting shall not be transacted. Without limiting the foregoing, in advance of any meeting of stockholders, the Board shall also have the power to determine whether any proposed business was made in accordance with the provisions of this Section 2.4.
4
(vi) This Section 2.4 is expressly intended to apply to any business proposed to be brought before an annual meeting of stockholders other than any proposal made in accordance with Rule 14a-8 under the Exchange Act and included in the Corporation’s proxy statement. In addition to the requirements of this Section 2.4 with respect to any business proposed to be brought before an annual meeting, each Proposing Person shall comply with all applicable requirements of the Exchange Act with respect to any such business. Nothing in this Section 2.4 shall be deemed to affect the rights of stockholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under the Exchange Act.
(vii) For purposes of these bylaws, “public disclosure” shall mean disclosure in a press release reported by a national news service, in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d) of the Exchange Act or by such other means as is reasonably designed to inform the public or securityholders of the Corporation in general of such information including, without limitation, posting on the Corporation’s investor relations website.
2.5 Notice of Nominations for Election to the Board of Directors.
(i) Subject in all respects to the provisions of the Certificate of Incorporation, nominations of any person for election to the Board at an annual meeting or at a special meeting (but only if the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling such special meeting) may be made at such meeting only (x) by or at the direction of the Board, including by any committee or persons authorized to do so by the Board or these bylaws, or (y) by a stockholder present in person (A) who was a record owner of shares of the Corporation both at the time of giving the notice provided for in this Section 2.5 and at the time of the meeting, (B) is entitled to vote at the meeting, and (C) has complied with this Section 2.5 and Section 2.6 as to such notice and nomination. For purposes of this Section 2.5, “present in person” shall mean that the stockholder proposing that the business be brought before the meeting of the Corporation, or a qualified representative of such stockholder, appear at such meeting. A “qualified representative” of such proposing stockholder shall be a duly authorized officer, manager or partner of such stockholder or any other person authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders. The foregoing clause (y) shall be the exclusive means for a stockholder to make any nomination of a person or persons for election to the Board at an annual meeting or special meeting.
(ii) Without qualification, for a stockholder to make any nomination of a person or persons for election to the Board at an annual meeting, the stockholder must (1) provide Timely Notice (as defined in Section 2.4) thereof in writing and in proper form to the Secretary of the Corporation, (2) provide the information, agreements and questionnaires with respect to such stockholder and its candidate for nomination as required to be set forth by this Section 2.5 and Section 2.7 and (3) provide any updates or supplements to such notice at the times and in the forms required by this Section 2.5 and Section 2.6.
(a) Without qualification, if the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling a special meeting in accordance with the Certificate of Incorporation, then for a stockholder to make any nomination of a person or persons for election to the Board at a special meeting, the stockholder must (1) provide timely notice thereof in writing and in proper form to the Secretary of the Corporation at the principal executive offices of the Corporation, (2) provide the information with respect to such stockholder and its candidate for nomination as required by this Section 2.5 and Section 2.6 and (3) provide any updates or supplements to such notice at the times and in the forms required by this Section 2.5. To be timely, a stockholder’s notice for nominations to be made at a special meeting must be delivered to, or mailed and received at, the principal executive offices of the Corporation not earlier than the close of business on the 120th day prior to such special meeting and not later than the later of (x) close of business on the 90th day prior to such special meeting or (y) the close of business on the 10th day following the day on which public disclosure (as defined in Section 2.4) of the date of such special meeting was first made.
5
(b) In no event shall any adjournment or postponement of an annual meeting or special meeting or the announcement thereof commence a new time period for the giving of a stockholder’s notice as described above.
(c) In no event may a Nominating Person provide Timely Notice with respect to a greater number of director candidates than are subject to election by shareholders at the applicable meeting. If the Corporation shall, subsequent to such notice, increase the number of directors subject to election at the meeting, such notice as to any additional nominees shall be due on the later of (1) the conclusion of the time period for Timely Notice, (2) the date set forth in Section 2.5(ii)(a), or (3) the tenth day following the date of public disclosure (as defined in Section 2.4) of such increase.
(iii) To be in proper form for purposes of this Section 2.5, a stockholder’s notice to the Secretary shall set forth:
(a) As to each Nominating Person (as defined below), the Stockholder Information (as defined in Section 2.4(iii)(a), except that for purposes of this Section 2.5 the term “Nominating Person” shall be substituted for the term “Proposing Person” in all places it appears in Section 2.4(iii)(a));
(b) As to each Nominating Person, any Disclosable Interests (as defined in Section 2.4(iii)(b), except that for purposes of this Section 2.5 the term “Nominating Person” shall be substituted for the term “Proposing Person” in all places it appears in Section 2.4(iii)(b) and the disclosure with respect to the business to be brought before the meeting in Section 2.4(iii)(b) shall be made with respect to the election of directors at the meeting); and
(c) As to each candidate whom a Nominating Person proposes to nominate for election as a director, (1) all information with respect to such candidate for nomination that would be required to be set forth in a stockholder’s notice pursuant to this Section 2.5 and Section 2.6 if such candidate for nomination were a Nominating Person, (2) all information relating to such candidate for nomination that is required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors in a contested election pursuant to Section 14(a) under the Exchange Act (including such candidate’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected), (3) a description of any direct or indirect material interest in any material contract or agreement between or among any Nominating Person, on the one hand, and each candidate for nomination or his or her respective associates or any other participants in such solicitation, on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Item 404 under Regulation S-K if such Nominating Person were the “registrant” for purposes of such rule and the candidate for nomination were a director or executive officer of such registrant (the disclosures to be made pursuant to the foregoing clauses (1) through (3) are referred to as “Nominee Information”), and (4) a completed and signed questionnaire, representation and agreement as provided in Section 2.6(i).
6
For purposes of this Section 2.5, the term “Nominating Person” shall mean (i) the stockholder providing the notice of the nomination proposed to be made at the meeting, (ii) the beneficial owner or beneficial owners, if different, on whose behalf the notice of the nomination proposed to be made at the meeting is made, and (iii) any other participant in such solicitation.
(iv) A stockholder providing notice of any nomination proposed to be made at a meeting shall further update and supplement such notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section 2.5 shall be true and correct as of the record date for stockholders entitled to vote at the meeting and as of the date that is 10 business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary at the principal executive offices of the Corporation not later than five business days after the record date for stockholders entitled to vote at the meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of 10 business days prior to the meeting or any adjournment or postponement thereof). For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other Section of these bylaws shall not limit the Corporation’s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any nomination or to submit any new nomination.
(v) In addition to the requirements of this Section 2.5 with respect to any nomination proposed to be made at a meeting, each Nominating Person shall comply with all applicable requirements of the Exchange Act with respect to any such nominations.
2.6 Additional Requirements for Valid Nomination of Candidates to Serve as Director and, if Elected, to be Seated as Directors.
(i) To be eligible to be a candidate for election as a director of the Corporation at an annual or special meeting, a candidate must be nominated in the manner prescribed in Section 2.5 and the candidate for nomination, whether nominated by the Board or by a stockholder of record, must have previously delivered (in accordance with the time period prescribed for delivery in a notice to such candidate given by or on behalf of the Board) to the Secretary at the principal executive offices of the Corporation (a) a completed written questionnaire (in a form provided by the Corporation) with respect to the background, qualifications, stock ownership and independence of such proposed nominee, and such additional information with respect to such proposed nominee as would be required to be provided by the Corporation pursuant to Schedule 14A if such proposed nominee were a participant in the solicitation of proxies by the Corporation in connection with such annual or special meeting and (b) a written representation and agreement (in form provided by the Corporation) that such candidate for nomination (A) is not and, if elected as a director during his or her term of office, will not become a party to (1) any agreement, arrangement or understanding with, and has not given and will not give any commitment or assurance to, any person or entity as to how such proposed nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) or (2) any Voting Commitment that could limit or interfere with such proposed nominee’s ability to comply, if elected as a director of the Corporation, with such proposed nominee’s fiduciary duties under applicable law, (B) is not, and will not become a party to, any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation or reimbursement for service as a director that has not been disclosed therein or to the Corporation, (C) if elected as a director of the Corporation, will comply with all applicable corporate governance, conflict of interest, confidentiality, stock ownership and trading and other policies and guidelines of the Corporation applicable to directors and in effect during such person’s term in office as a director (and, if requested by any candidate for nomination, the Secretary of the Corporation shall provide to such candidate for nomination all such policies and guidelines then in effect), (D) if elected as director of the Corporation, intends to serve the entire term until the next meeting at which such candidate would face re-election and (E) consents to being named as a nominee in the Corporation’s proxy statement pursuant to Rule 14a-4(d) under the Exchange Act and any associated proxy card of the Corporation and agrees to serve if elected as a director.
7
(ii) The Board may also require any proposed candidate for nomination as a Director to furnish such other information as may reasonably be requested by the Board in writing prior to the meeting of stockholders at which such candidate’s nomination is to be acted upon in order for the Board to determine the eligibility of such candidate for nomination to be an independent director of the Corporation in accordance with the Corporation’s Corporate Governance Guidelines.
(iii) A candidate for nomination as a director shall further update and supplement the materials delivered pursuant to this Section 2.6, if necessary, so that the information provided or required to be provided pursuant to this Section 2.6 shall be true and correct as of the record date for stockholders entitled to vote at the meeting and as of the date that is 10 business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary at the principal executive offices of the Corporation (or any other office specified by the Corporation in any public announcement) not later than five business days after the record date for stockholders entitled to vote at the meeting (in the case of the update and supplement required to be made as of such record date), and not later than eight business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of 10 business days prior to the meeting or any adjournment or postponement thereof). For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other Section of these bylaws shall not limit the Corporation’s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or to submit any new proposal, including by changing or adding nominees, matters, business or resolutions proposed to be brought before a meeting of the stockholders.
(iv) No candidate shall be eligible for nomination as a director of the Corporation unless such candidate for nomination and the Nominating Person seeking to place such candidate’s name in nomination has complied with Section 2.5 and this Section 2.6, as applicable. The presiding officer at the meeting shall, if the facts warrant, determine that a nomination was not properly made in accordance with Section 2.5 and this Section 2.6, and if he or she should so determine, he or she shall so declare such determination to the meeting, the defective nomination shall be disregarded and any ballots cast for the candidate in question (but in the case of any form of ballot listing other qualified nominees, only the ballots cast for the nominee in question) shall be void and of no force or effect.
(v) Notwithstanding anything in these bylaws to the contrary, no candidate for nomination shall be eligible to be seated as a director of the Corporation unless nominated and elected in accordance with Section 2.5 and this Section 2.6.
2.7 Notice of Stockholders’ Meetings.
Unless otherwise provided by law, the Certificate of Incorporation or these bylaws, the notice of any meeting of stockholders shall be sent or otherwise given in accordance with Section 8.1 of these bylaws not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting. The notice shall specify the place, if any, date and time of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called.
8
2.8 Quorum.
Unless otherwise provided by law, the Certificate of Incorporation or these bylaws, the holders of a majority in voting power of the stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. A quorum, once established at a meeting, shall not be broken by the withdrawal of enough votes to leave less than a quorum. If, however, a quorum is not present or represented at any meeting of the stockholders, then either (i) the person presiding over the meeting or (ii) a majority in voting power of the stockholders entitled to vote at the meeting, present in person, or by remote communication, if applicable, or represented by proxy, shall have power to recess the meeting or adjourn the meeting from time to time in the manner provided in Section 2.9 of these bylaws until a quorum is present or represented. At any recessed or adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted at the meeting as originally noticed.
2.9 Adjourned Meeting; Notice.
When a meeting is adjourned to another time or place, unless these bylaws otherwise require, notice need not be given of the adjourned meeting if the time, place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken. At any adjourned meeting, the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than 30 days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. If after the adjournment a new record date for determination of stockholders entitled to vote is fixed for the adjourned meeting, the Board shall fix as the record date for determining stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote at the adjourned meeting, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such meeting as of the record date so fixed for notice of such adjourned meeting.
2.10 Conduct of Business.
The date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting by the person presiding over the meeting. The Board may adopt by resolution such rules and regulations for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board, the person presiding over any meeting of stockholders shall have the right and authority to convene and (for any or no reason) to recess and/or adjourn the meeting, to prescribe such rules, regulations and procedures (which need not be in writing) and to do all such acts as, in the judgment of such presiding person, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board or prescribed by the person presiding over the meeting, may include, without limitation, the following: (i) the establishment of an agenda or order of business for the meeting; (ii) rules and procedures for maintaining order at the meeting and the safety of those present (including, without limitation, rules and procedures for removal of disruptive persons from the meeting); (iii) limitations on attendance at or participation in the meeting to stockholders entitled to vote at the meeting, their duly authorized and constituted proxies or such other persons as the person presiding over the meeting shall determine; (iv) restrictions on entry to the meeting after the time fixed for the commencement thereof; and (v) limitations on the time allotted to questions or comments by participants. The presiding person at any meeting of stockholders, in addition to making any other determinations that may be appropriate to the conduct of the meeting (including, without limitation, determinations with respect to the administration and/or interpretation of any of the rules, regulations or procedures of the meeting, whether adopted by the Board or prescribed by the person presiding over the meeting), shall, if the facts warrant, determine and declare to the meeting that a matter of business was not properly brought before the meeting and if such presiding person should so determine, such presiding person shall so declare to the meeting and any such matter or business not properly brought before the meeting shall not be transacted or considered. Unless and to the extent determined by the Board or the person presiding over the meeting, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure.
9
2.11 Voting.
Except as may be otherwise provided in the Certificate of Incorporation or the DGCL, each stockholder shall be entitled to one vote for each share of capital stock held by such stockholder.
Except as otherwise provided in the Certificate of Incorporation, at all duly called or convened meetings of stockholders at which a quorum is present, for the election of directors, a plurality of the votes cast shall be sufficient to elect a director. Except as otherwise provided in the Certificate of Incorporation, these bylaws, the rules or regulations of any stock exchange applicable to the Corporation, or applicable law or pursuant to any regulation applicable to the Corporation or its securities, each other matter presented to the stockholders at a duly called or convened meeting at which a quorum is present shall be decided by the affirmative vote of the holders of a majority in voting power of the votes cast (excluding abstentions and broker non-votes) on such matter.
2.12 Record Date for Stockholder Meetings and Other Purposes.
In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board, and which record date shall, unless otherwise required by law, not be more than 60 days nor less than 10 days before the date of such meeting. If the Board so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be the close of business on the day immediately preceding the day on which notice is first given, or, if notice is waived, at the close of business on the day immediately preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board may fix a new record date for determination of stockholders entitled to vote at the adjourned meeting; and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance herewith at the adjourned meeting.
In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment or any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of capital stock, or for the purposes of any other lawful action, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto.
10
2.13 Proxies.
Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy authorized by an instrument in writing or by a transmission permitted by law filed in accordance with the procedure established for the meeting, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. The revocability of a proxy that states on its face that it is irrevocable shall be governed by the provisions of Section 212 of the DGCL. A proxy may be in the form of an electronic transmission that sets forth or is submitted with information from which it can be determined that the transmission was authorized by the stockholder.
2.14 List of Stockholders Entitled to Vote.
The Corporation shall prepare, at least 10 days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting (provided, however, that if the record date for determining the stockholders entitled to vote is less than 10 days before the date of the meeting, the list shall reflect the stockholders entitled to vote as of the tenth day before the meeting date), arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. The Corporation shall not be required to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of at least 10 days prior to the meeting: (i) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii) during ordinary business hours, at the Corporation’s principal executive office. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. If the meeting is to be held at a place, then the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the notice of the meeting. Such list shall presumptively determine the identity of the stockholders entitled to vote at the meeting and the number of shares held by each of them. Except as otherwise provided by law, the stock ledger shall be the only evidence as to who are the stockholders entitled to examine the list of stockholders required by this Section 2.14 or to vote in person or by proxy at any meeting of stockholders.
2.15 Inspectors of Election.
Before any meeting of stockholders, the Board may, and shall if required by law, appoint an inspector or inspectors of election to act at the meeting or its adjournment and make a written report thereof. The Board may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If any person appointed as inspector or any alternate fails to appear or fails or refuses to act, then the person presiding over the meeting shall appoint a person to fill that vacancy.
11
Such inspectors shall:
(i) determine the number of shares outstanding and the voting power of each, the number of shares represented at the meeting and the validity of any proxies and ballots;
(ii) count all votes or ballots;
(iii) count and tabulate all votes;
(iv) determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspector(s); and
(v) certify its or their determination of the number of shares represented at the meeting and its or their count of all votes and ballots.
Each inspector, before entering upon the discharge of the duties of inspector, shall take and sign an oath faithfully to execute the duties of inspection with strict impartiality and according to the best of such inspector’s ability. Any report or certificate made by the inspectors of election is prima facie evidence of the facts stated therein. The inspectors of election may appoint such persons to assist them in performing their duties as they determine. If there is more than one inspector, the report of a majority shall be the report of the inspectors.
2.16 Delivery to the Corporation.
Whenever this Article II requires one or more persons (including a record or beneficial owner of stock) to deliver a document or information to the Corporation or any officer, employee or agent thereof (including any notice, request, questionnaire, revocation, representation or other document or agreement), such document or information shall be in writing exclusively (and not in an electronic transmission) and shall be delivered exclusively by hand (including, without limitation, overnight courier service) or by certified or registered mail, return receipt requested, and the Corporation shall not be required to accept delivery of any document not in such written form or so delivered. For the avoidance of doubt, the Corporation expressly opts out of Section 116 of the DGCL with respect to the delivery of information and documents to the Corporation required by this Article II.
Article III - Directors
3.1 Powers.
Except as otherwise provided by the Certificate of Incorporation or the DGCL, the business and affairs of the Corporation shall be managed by or under the direction of the Board, which may exercise all such powers of the Corporation and do all such lawful acts and things as are not by statute or by the Certificate of Incorporation or by these bylaws required to be exercised or done by the stockholders.
3.2 Number of Directors.
Subject to the Certificate of Incorporation, the total number of directors constituting the Board shall initially be seven directors and shall be determined from time to time by resolution adopted by at least a majority of the Board. No reduction of the authorized number of directors shall have the effect of removing any director before that director’s term of office expires. Subject to the provisions set forth herein, stockholders representing more than 35% of the voting securities of the Corporation shall be entitled to nominate two (2) persons for election to the Board and stockholders representing 35% or less of the voting securities of the Corporation but more than 25% of the voting securities of the Corporation shall be entitled to nominate one (1) person for election to the Board.
12
3.3 Chairperson of the Board; Vice Chairperson of the Board; Executive Chairman.
The Board may appoint, in its discretion, from its members a Chairperson of the Board and a Vice Chairperson of the Board, neither of whom need be an employee or officer of the Corporation. The Board may appoint, in its discretion, from its members an Executive Chairman who shall not be an employee or officer of the Corporation. If the Board appoints a Chairperson of the Board, such Chairperson shall perform such duties and possess such powers as are assigned by the Board. If the Board appoints an Executive Chairman, the Executive Chairman shall be delegated the primary responsibility for overseeing and advising the senior management of the Corporation and shall perform such other duties and possess such powers as are assigned by the Board; provided that notwithstanding anything to the contrary herein, the Executive Chairman shall not have charge over the non-delegable duties of the Board. If the Board appoints a Vice Chairperson of the Board, such Vice Chairperson shall perform such duties and possess such powers as are assigned by the Board. Unless otherwise provided by the Board, the Chairman of the Board or, in the Chairman’s absence, the Vice Chairman of the Board, if any, shall preside at all meetings of the Board.
3.4 Election, Qualification and Term of Office of Directors.
Except as provided in Section 3.5 of these bylaws, and subject to the Certificate of Incorporation, each director, including a director elected to fill a vacancy or newly created directorship, shall hold office until the expiration of the term of the class, if any, for which elected and until such director’s successor is elected and qualified or until such director’s earlier death, resignation, disqualification, retirement or removal in accordance with the Certificate of Incorporation and applicable law. Directors need not be stockholders. The Certificate of Incorporation or these bylaws may prescribe qualifications for directors.
3.5 Resignation and Vacancies.
Any director may resign at any time upon notice given in writing or by electronic transmission to the Corporation. The resignation shall take effect at the time specified therein or upon the happening of an event specified therein, and if no time or event is specified, at the time of its receipt. When one or more directors so resigns and the resignation is effective at a future date or upon the happening of an event to occur on a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office as provided in Section 3.4.
Unless otherwise provided in the Certificate of Incorporation or these bylaws, vacancies resulting from the death, resignation, disqualification, retirement or removal of any director, and newly created directorships resulting from any increase in the authorized number of directors shall be filled only by a majority of the directors then in office, even if less than a quorum, or by a sole remaining director.
3.6 Place of Meetings; Meetings by Telephone.
The Board may hold meetings, both regular and special, either within or outside the State of Delaware.
Unless otherwise restricted by the Certificate of Incorporation or these bylaws, members of the Board, or any committee designated by the Board, may participate in a meeting of the Board, or any committee, by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting pursuant to these bylaws shall constitute presence in person at the meeting, except where a person participates in the meeting for the express purpose of objecting to the transaction of any business on the ground that the meeting was not lawfully called or convened
13
3.7 Regular Meetings.
Regularly scheduled, periodic meetings of the Board may be held within or outside the State of Delaware and at such time and at such place as which has been designated by the Board and publicized among all directors, either orally or in writing, by telephone, including a voice-messaging system or other system designed to record and communicate messages, facsimile, or by electronic mail or other means of electronic transmission. No further notice shall be required for regular meetings of the Board.
3.8 Special Meetings; Notice.
Special meetings of the Board for any purpose or purposes may be called at any time by the Chairperson of the Board, the Executive Chairman of the Board, the Chief Executive Officer, a President, or the Secretary.
Notice of the time and place of special meetings shall be:
(i) delivered personally by hand, by courier or by telephone;
(ii) sent by United States first-class mail, postage prepaid;
(iii) sent by facsimile or electronic mail;
(iv) sent by other means of electronic transmission; or
(v) sent by a nationally recognized overnight delivery service,
directed to each director at that director’s address, telephone number, facsimile number or electronic mail address, or other address for electronic transmission, as the case may be, as shown on the Corporation’s records.
If the notice is (i) delivered personally by hand, by courier or by telephone, (ii) sent by facsimile or electronic mail, or (iii) sent by other means of electronic transmission, it shall be delivered or sent at least 24 hours before the time of the holding of the meeting. If the notice is sent by a nationally recognized overnight delivery service, at least two days before the time of the holding of the meeting. If the notice is sent by U.S. mail, it shall be deposited in the U.S. mail at least five days before the time of the holding of the meeting. Except as may be otherwise expressly provided by applicable law, the Certificate of Incorporation, or these bylaws, the notice or the waiver of notice need not specify the place of the meeting (if the meeting is to be held at the Corporation’s principal executive office) nor the purpose of the meeting.
Any and all business that may be transacted at a regular meeting of the Board may be transacted at a special meeting. A special meeting may be held at any time without notice if all the directors are present or if those not present waive notice of the meeting in accordance with Section 7.13.
14
3.9 Quorum.
At all meetings of the Board, unless otherwise provided by the Certificate of Incorporation, a majority of the total number of directors shall constitute a quorum for the transaction of business. The vote of a majority of the directors present at any meeting at which a quorum is present shall be the act of the Board, except as may be otherwise specifically provided by statute, the Certificate of Incorporation or these bylaws. If a quorum is not present at any meeting of the Board, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present.
3.10 Board Action without a Meeting.
Unless otherwise restricted by the Certificate of Incorporation or these bylaws, any action required or permitted to be taken at any meeting of the Board, or of any committee thereof, may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing or by electronic transmission. After an action is taken, the consent or consents relating thereto shall be filed with the minutes of the proceedings of the Board, or the committee thereof, in the same paper or electronic form as the minutes are maintained. Such action by written consent or consent by electronic transmission shall have the same force and effect as a unanimous vote of the Board.
3.11 Fees and Compensation of Directors.
Unless otherwise restricted by the Certificate of Incorporation or these bylaws, the Board shall have the authority to fix the compensation, including fees and reimbursement of expenses, of directors for services to the Corporation in any capacity, subject to any applicable limit set forth in the Corporation’s equity compensation plan as in effect from time to time.
Article IV - Committees
4.1 Committees of Directors.
The Board may designate one or more committees, each committee to consist of one or more of the directors of the Corporation and shall have the power at any time to fill vacancies in, to change the membership of, or to dissolve any such committee. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board or in these bylaws, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require it. However, no such committee shall have the power or authority to (i) approve or adopt, or recommend to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL to be submitted to stockholders for approval, or (ii) adopt, amend or repeal any bylaw of the Corporation. Each committee shall keep regular minutes of its meetings and report the same to the Board when required by the resolution designating such committee. Meetings and Actions of Committees.
15
Meetings and actions of committees shall be governed by, and held and taken in accordance with, the provisions of:
(i) Section 3.6 (Place of Meetings; Meetings by Telephone);
(ii) Section 3.7 (Regular Meetings);
(iii) Section 3.8 (Special Meetings; Notice);
(iv) Section 3.10 (Board Action without a Meeting); and
(v) Section 7.13 (Waiver of Notice),
with such changes in the context of those bylaws as are necessary to substitute the committee and its members for the Board and its members. However:
(i) the time of regular meetings of committees may be determined either by resolution of the Board or by resolution of the committee;
(ii) special meetings of committees may also be called by resolution of the Board or the chairperson of the applicable committee; and
(iii) the Board may adopt rules for the governance of any committee to override the provisions that would otherwise apply to the committee pursuant to this Section 4.2, provided that such rules do not violate the provisions of the Certificate of Incorporation or applicable law.
4.2 Subcommittees.
Unless otherwise provided in the Certificate of Incorporation, these bylaws, the resolutions of the Board designating the committee or the charter of such committee adopted by the Board, a committee may create one or more subcommittees, each subcommittee to consist of one or more members of the committee, and delegate to a subcommittee any or all of the powers and authority of the committee.
Article V - Officers
5.1 Officers.
The officers of the Corporation shall include a Chief Executive Officer, one or more Presidents and a Secretary. The Corporation may also have, at the discretion of the Board, a Chief Financial Officer, a Treasurer, one or more Vice Presidents, one or more Assistant Vice Presidents, one or more Assistant Treasurers, one or more Assistant Secretaries, and any such other officers as may be appointed in accordance with the provisions of these bylaws. Any number of offices may be held by the same person. No officer need be a stockholder or director of the Corporation.
5.2 Appointment of Officers.
The Board shall appoint the officers of the Corporation, except such officers as may be appointed in accordance with the provisions of Section 5.3 of these bylaws.
5.3 Subordinate Officers.
The Board may appoint, or empower the Chief Executive Officer or, in the absence of a Chief Executive Officer, a President, to appoint, such other officers and agents as the business of the Corporation may require. Each of such officers and agents shall hold office for such period, have such authority, and perform such duties as are provided in these bylaws or as the Board may from time to time determine.
16
5.4 Removal and Resignation of Officers.
Subject to the rights, if any, of an officer under any contract of employment, any officer may be removed, either with or without cause, by the Board or, except in the case of an officer chosen by the Board, by any officer upon whom such power of removal may be conferred by the Board.
Any officer may resign at any time by giving written notice to the Corporation. Any resignation shall take effect at the date of the receipt of that notice or at any later time specified in that notice. Unless otherwise specified in the notice of resignation, the acceptance of the resignation shall not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party.
5.5 Vacancies in Offices.
Any vacancy occurring in any office of the Corporation shall be filled as provided in Section 5.2 or Section 5.3, as applicable.
5.6 Representation of Shares of Other Corporations.
The Chairperson of the Board, the Chief Executive Officer or a President of this Corporation, or any other person authorized by the Board, the Chief Executive Officer or a President, is authorized to vote, represent and exercise on behalf of this Corporation all rights incident to any and all shares or voting securities of any other corporation or other person standing in the name of this Corporation. The authority granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority.
5.7 Chief Executive Officer.
The Chief Executive Officer shall, subject to the provisions of these bylaws, any employment agreement, any employee plan and the control of the Board, have general supervision, direction and control over the business of the Corporation and over its officers, employees and agents and shall have full authority to execute all documents and take all actions that the Corporation may legally take. The Chief Executive Officer shall perform all duties incident to the office of the Chief Executive Officer, and any other duties as may be from time to time assigned to the Chief Executive Officer by the Board, in each case subject to the control of the Board.
5.8 Other Officers.
All officers of the Corporation shall respectively have such authority and perform such duties in the management of the business of the Corporation as may be provided herein or designated from time to time by the Board and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board.
17
5.9 Compensation.
The compensation of the officers of the Corporation for their services as such shall be fixed from time to time by or at the direction of the Board. An officer of the Corporation shall not be prevented from receiving compensation by reason of the fact that he or she is also a director of the Corporation.
Article VI - Records
A stock ledger consisting of one or more records in which the names of all of the Corporation’s stockholders of record, the address and number of shares registered in the name of each such stockholder, and all issuances and transfers of stock of the Corporation shall be recorded in accordance with Section 224 of the DGCL and shall be administered by or on behalf of the Corporation. Any records administered by or on behalf of the Corporation in the regular course of its business, including its stock ledger, books of account, and minute books, may be kept on, or by means of, or be in the form of, any information storage device, or method, or one or more electronic networks or databases (including one or more distributed electronic networks or databases), provided that the records so kept can be converted into clearly legible paper form within a reasonable time and, with respect to the stock ledger, that the records so kept (i) can be used to prepare the list of stockholders specified in Sections 219 and 220 of the DGCL, (ii) record the information specified in Sections 156, 159, 217(a) and 218 of the DGCL, and (iii) record transfers of stock as governed by Article 8 of the Uniform Commercial Code as adopted in the State of Delaware.
Article VII - General Matters
7.1 Execution of Corporate Contracts and Instruments.
The Board, except as otherwise provided in these bylaws, may authorize any officer or officers, or agent or agents, to enter into any contract or execute any instrument in the name of and on behalf of the Corporation; such authority may be general or confined to specific instances.
7.2 Stock Certificates.
The shares of the Corporation shall be represented by certificates, provided that the Board by resolution may provide that some or all of the shares of any class or series of stock of the Corporation shall be uncertificated. Certificates for the shares of stock, if any, shall be in such form as is consistent with the Certificate of Incorporation and applicable law. Every holder of stock represented by a certificate shall be entitled to have a certificate signed by, or in the name of the Corporation by, any two officers authorized to sign stock certificates representing the number of shares registered in certificate form. The Executive Chairman, Chairperson or Vice Chairperson of the Board, Chief Executive Officer, a President, the Treasurer, any Assistant Treasurer, the Secretary or any Assistant Secretary of the Corporation shall be specifically authorized to sign stock certificates. Any or all of the signatures on the certificate may be a facsimile or other electronic means. In case any officer, transfer agent or registrar who has signed or whose facsimile or other electronic signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he or she were such officer, transfer agent or registrar at the date of issue.
The Corporation may issue the whole or any part of its shares as partly paid and subject to call for the remainder of the consideration to be paid therefor. Upon the face or back of each stock certificate issued to represent any such partly paid shares, or upon the books and records of the Corporation in the case of uncertificated partly paid shares, the total amount of the consideration to be paid therefor and the amount paid thereon shall be stated. Upon the declaration of any dividend on fully paid shares, the Corporation shall declare a dividend upon partly paid shares of the same class, but only upon the basis of the percentage of the consideration actually paid thereon.
18
7.3 Special Designation of Certificates.
If the Corporation is authorized to issue more than one class of stock or more than one series of any class, then the powers, the designations, the preferences and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or on the back of the certificate that the Corporation shall issue to represent such class or series of stock (or, in the case of uncertificated shares, set forth in a notice provided pursuant to Section 151 of the DGCL); provided, however, that except as otherwise provided in Section 202 of the DGCL, in lieu of the foregoing requirements, there may be set forth on the face of back of the certificate that the Corporation shall issue to represent such class or series of stock (or, in the case of any uncertificated shares, included in the aforementioned notice) a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, the designations, the preferences and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights.
7.4 Lost Certificates.
Except as provided in this Section 7.4, no new certificates for shares shall be issued to replace a previously issued certificate unless the latter is surrendered to the Corporation and cancelled at the same time. The Corporation may issue a new certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner’s legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares.
7.5 Shares Without Certificates
The Corporation may adopt a system of issuance, recordation and transfer of its shares of stock by electronic or other means not involving the issuance of certificates, provided the use of such system by the Corporation is permitted in accordance with applicable law.
7.6 Construction; Definitions.
Unless the context requires otherwise, the general provisions, rules of construction and definitions in the DGCL shall govern the construction of these bylaws. Without limiting the generality of this provision, the singular number includes the plural and the plural number includes the singular.
7.7 Dividends.
The Board, subject to any restrictions contained in either (i) the DGCL or (ii) the Certificate of Incorporation, may declare and pay dividends upon the shares of its capital stock. Dividends may be paid in cash, in property or in shares of the Corporation’s capital stock.
The Board may set apart, out of any of the funds of the Corporation available for dividends, a reserve or reserves for any proper purpose and may abolish any such reserve. Such purposes shall include but not be limited to equalizing dividends, repairing or maintaining any property of the Corporation, and meeting contingencies.
19
7.8 Fiscal Year.
The fiscal year of the Corporation shall be the calendar year unless otherwise fixed by resolution of the Board, and may be changed by the Board.
7.9 Seal.
The Corporation may adopt a corporate seal, which shall be adopted and which may be altered by the Board. The Corporation may use the corporate seal by causing it or a facsimile or other electronic version thereof to be impressed or affixed or in any other manner reproduced.
7.10 Transfer of Stock.
Shares of stock of the Corporation shall be transferred on the books of the Corporation only by the holder of record thereof or by such holder’s attorney duly authorized in writing, upon surrender to the Corporation of the certificate or certificates representing such shares endorsed by the appropriate person or persons (or by delivery of duly executed instructions with respect to uncertificated shares), with such evidence of the authenticity of such endorsement or execution, transfer, authorization and other matters as the Corporation may reasonably require, and accompanied by all necessary stock transfer stamps. No transfer of stock shall be valid as against the Corporation for any purpose until it shall have been entered in the stock records of the Corporation by an entry showing the names of the persons from and to whom it was transferred.
7.11 Stock Transfer Agreements.
The Corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes or series of stock of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL or other applicable law.
7.12 Registered Stockholders.
The Corporation:
(i) shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner; and
(ii) shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of another person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of the State of Delaware.
7.13 Waiver of Notice.
Whenever notice is required to be given under any provision of the DGCL, the Certificate of Incorporation or these bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. All such waivers shall be kept with the books of the Corporation. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders need be specified in any written waiver of notice or any waiver by electronic transmission unless so required by the Certificate of Incorporation or these bylaws.
7.14 Compliance with the DGCL.
In the event any provision hereof conflicts with the DGCL or any other applicable law, such provision shall be deemed modified, consistent with the aforementioned intent, to the extent necessary to resolve such conflict.
20
Article VIII - Notice
8.1 Delivery of Notice; Notice by Electronic Transmission.
Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Corporation under any provisions of the DGCL, the Certificate of Incorporation, or these bylaws may be given in writing directed to the stockholder’s mailing address (or by electronic transmission directed to the stockholder’s electronic mail address, as applicable) as it appears on the records of the Corporation and shall be given (1) if mailed, when the notice is deposited in the U.S. mail, postage prepaid, (2) if delivered by courier service, the earlier of when the notice is received or left at such stockholder’s address or (3) if given by electronic mail, when directed to such stockholder’s electronic mail address unless the stockholder has notified the Corporation in writing or by electronic transmission of an objection to receiving notice by electronic mail. A notice by electronic mail must include a prominent legend that the communication is an important notice regarding the Corporation.
Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Corporation under any provision of the DGCL, the Certificate of Incorporation or these bylaws shall be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder by written notice or electronic transmission to the Corporation. Notwithstanding the provisions of this paragraph, the Corporation may give a notice by electronic mail in accordance with the first paragraph of this section without obtaining the consent required by this paragraph.
Any notice given pursuant to the preceding paragraph shall be deemed given:
(i) if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice;
(ii) if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of (A) such posting and (B) the giving of such separate notice; and
(iii) if by any other form of electronic transmission, when directed to the stockholder.
Notwithstanding the foregoing, a notice may not be given by an electronic transmission (including electronic mail) from and after the time that (1) the Corporation is unable to deliver by such electronic transmission two consecutive notices given by the Corporation and (2) such inability becomes known to the Secretary or an Assistant Secretary of the Corporation or to the transfer agent, or other person responsible for the giving of notice, provided, however, the inadvertent failure to discover such inability shall not invalidate any meeting or other action.
21
An affidavit of the Secretary or an Assistant Secretary or of the transfer agent or other agent of the Corporation that the notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein.
Article IX - Indemnification
9.1 Power to Indemnify in Actions, Suits or Proceedings other than Those by or in the Right of the Corporation.
Subject to Section 9.3 and Section 9.11, the Corporation shall indemnify any person who was or is a party or is threatened to be made a party to or is otherwise involved (as a witness or otherwise) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation), by reason of the fact that such person is or was a director or officer of the Corporation, or is or was a director or officer of the Corporation serving at the request of the Corporation as a director, officer, employee or agent of another enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that such person’s conduct was unlawful.
9.2 Power to Indemnify in Actions, Suits or Proceedings by or in the Right of the Corporation.
Subject to Section 9.3 and Section 9.11, the Corporation shall indemnify any person who was or is a party or is threatened to be made a party to or is otherwise involved (as a witness or otherwise) in any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that such person is or was a director or officer of the Corporation, or is or was a director or officer of the Corporation serving at the request of the Corporation as a director, officer, employee or agent of another enterprise, against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation; except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Corporation unless and only to the extent that the Court of Chancery of the State of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity by the Corporation for such expenses which the Court of Chancery or such other court shall deem proper.
22
9.3 Authorization of Indemnification.
Any indemnification under this Article IX (unless ordered by a court) shall be made by the Corporation only as authorized in the specific case upon a determination that indemnification of the present or former director or officer is proper in the circumstances because such person has met the applicable standard of conduct set forth in Section 9.1 or Section 9.2, as the case may be. Such determination shall be made, with respect to a person who is a director or officer at the time of such determination, (i) by a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than a quorum, or (ii) by a committee of such directors designated by a majority vote of such directors, even though less than a quorum, or (iii) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion or (iv) by the stockholders. Such determination shall be made, with respect to former directors and officers, by any person or persons having the authority to act on the matter on behalf of the Corporation. To the extent, however, that a present or former director or officer of the Corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding described above, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith, without the necessity of authorization in the specific case.
9.4 Good Faith Defined.
For purposes of any determination under Section 9.3, a person shall be deemed to have acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation, or, with respect to any criminal action or proceeding, to have had no reasonable cause to believe such person’s conduct was unlawful, if such person’s action is based on the records or books of account of the Corporation or another enterprise, or on information supplied to such person by the officers of the Corporation or another enterprise in the course of their duties, or on the advice of legal counsel for the Corporation or another enterprise or on information or records given or reports made to the Corporation or another enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Corporation or another enterprise. The provisions of this Section 9.4 shall not be deemed to be exclusive or to limit in any way the circumstances in which a person may be deemed to have met the applicable standard of conduct set forth in Section 9.1 or 9.2, as the case may be.
9.5 Indemnification by a Court.
Notwithstanding any contrary determination in the specific case under Section 9.3, and notwithstanding the absence of any determination thereunder, any director or officer may apply to the Court of Chancery of the State of Delaware or any other court of competent jurisdiction in the State of Delaware for indemnification to the extent otherwise permissible under Section 9.1 or 9.2; provided, that if no determination has been made pursuant to Section 9.3, no such application shall be permitted unless and until thirty (30) days shall have elapsed from the date such director or officer shall have notified the Corporation in writing requesting such determination. The basis of such indemnification by a court shall be a determination by such court that indemnification of the director or officer is proper in the circumstances because such person has met the applicable standard of conduct set forth in Section 9.1 or Section 9.2, as the case may be. Neither a contrary determination in the specific case under Section 9.3 nor the absence of any determination thereunder shall be a defense to such application or create a presumption that the director or officer seeking indemnification has not met any applicable standard of conduct. Notice of any application for indemnification pursuant to this Article IX shall be given to the Corporation promptly upon the filing of such application. If successful, in whole or in part, the director or officer seeking indemnification shall also be entitled to be paid the expense of prosecuting such application.
23
9.6 Expenses Payable in Advance.
Subject to Section 9.11, expenses (including without limitation attorneys’ fees) incurred by a current or former director or officer in defending any civil, criminal, administrative or investigative action, suit or proceeding to which such person is a party or is threatened to be made a party or otherwise involved as a witness or otherwise by reason of the fact that such person is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another enterprise, shall be paid by the Corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such current or former director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Corporation as authorized in this Article IX.
9.7 Nonexclusivity of Indemnification and Advancement of Expenses.
The indemnification and advancement of expenses provided by, or granted pursuant to, this Article IX shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under the Certificate of Incorporation, these bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person’s official capacity and as to action on another capacity while holding such office, it being the policy of the Corporation that indemnification of the persons specified in Section 9.1 or 9.2 shall be made to the fullest extent permitted by law. The provisions of this Article IX shall not be deemed to preclude the indemnification of any person who is not specified in Section 9.1 or Section 9.2 but whom the Corporation has the power or obligation to indemnify under the provisions of the DGCL, or otherwise.
9.8 Insurance.
The Corporation may purchase and maintain insurance on behalf of any person who is or was a director or officer of the Corporation, or is or was a director or officer of the Corporation serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the Corporation would have the power or the obligation to indemnify such person against such liability under the provisions of this Article IX.
9.9 Certain Definitions.
For purposes of this Article IX, references to “the Corporation” shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors or officers, so that any person who is or was a director or officer of such constituent corporation, or is or was a director or officer of such constituent corporation serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, shall stand in the same position under the provisions of this Article IX with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence had continued. The term “another enterprise” as used in this Article IX shall mean any other corporation or any partnership, joint venture, trust, employee benefit plan or other enterprise of which such person is or was serving at the request of the Corporation as a director, officer, employee or agent. For purposes of this Article IX, references to “fines” shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to “serving at the request of the Corporation” shall include any service as a director, officer, employee or agent of the Corporation which imposes duties on, or involves services by, such director or officer with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the Corporation” as referred to in this Article IX.
24
9.10 Survival of Indemnification and Advancement of Expenses.
The indemnification and advancement of expenses provided by, or granted pursuant to, this Article IX shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director or officer and shall inure to the benefit of the heirs, executors and administrators of such a person.
9.11 Limitation on Indemnification.
Notwithstanding anything contained in this Article IX to the contrary, except for proceedings to enforce rights to indemnification (which shall be governed by Section 9.5) or advancement of expenses (which shall be governed by Section 9.6), the Corporation shall not be obligated to indemnify any current or former director or officer (or his or her heirs, executors or personal or legal representatives) or advance expenses in connection with a proceeding (or part thereof) initiated by such person or in defending any counterclaim, cross-claim, affirmative defense, or like claim by the Corporation in such proceeding unless such proceeding (or part thereof) was authorized or consented to by the Board of the Corporation.
9.12 Indemnification of Employees and Agents.
The Corporation may, to the extent authorized from time to time by the Board, provide rights to indemnification and to the advancement of expenses to employees and agents of the Corporation similar to those conferred in this Article IX to directors and officers of the Corporation.
9.13 Primacy of Indemnification.
Notwithstanding that a director or officer (or, to the extent authorized pursuant to Section 9.12 from time to time, an employee or agent) of the Corporation (collectively, the “Covered Persons”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by other persons (collectively, the “Other Indemnitors”), with respect to the rights to indemnification, advancement of expenses and/or insurance set forth herein, the Corporation: (i) shall be the indemnitor of first resort (i.e., its obligations to Covered Persons are primary and any obligation of the Other Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Covered Persons are secondary); and (ii) shall be required to advance the full amount of expenses incurred by Covered Persons and shall be liable for the full amount of all liabilities, without regard to any rights Covered Persons may have against any of the Other Indemnitors. No advancement or payment by the Other Indemnitors on behalf of Covered Persons with respect to any claim for which Covered Persons have sought indemnification from the Corporation shall affect the immediately preceding sentence, and the Other Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Covered Persons against the Corporation. Notwithstanding anything to the contrary herein, the obligations of the Corporation under this Section 9.13 shall only apply to Covered Persons in their capacity as Covered Persons.
Article X - Amendments
The Board is expressly empowered to adopt, amend or repeal the bylaws of the Corporation. The stockholders also shall have power to adopt, amend or repeal the bylaws of the Corporation; provided, however, that such action by stockholders shall require, in addition to any other vote required by the Certificate of Incorporation or applicable law, the affirmative vote of the holders of at least two-thirds of the voting power of all the then-outstanding shares of voting stock of the Corporation with the power to vote, voting together as a single class.
25
Article XI - Definitions
As used in these bylaws, unless the context otherwise requires, the following terms shall have the following meanings:
An “electronic transmission” means any form of communication, not directly involving the physical transmission of paper, including the use of, or participation in, one or more electronic networks or databases (including one or more distributed electronic networks or databases), that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process.
An “electronic mail” means an electronic transmission directed to a unique electronic mail address (which electronic mail shall be deemed to include any files attached thereto and any information hyperlinked to a website if such electronic mail includes the contact information of an officer or agent of the Corporation who is available to assist with accessing such files and information).
An “electronic mail address” means a destination, commonly expressed as a string of characters, consisting of a unique user name or mailbox (commonly referred to as the “local part” of the address) and a reference to an internet domain (commonly referred to as the “domain part” of the address), whether or not displayed, to which electronic mail can be sent or delivered.
The term “person” means any individual, general partnership, limited partnership, limited liability company, corporation, trust, business trust, joint stock company, joint venture, unincorporated association, cooperative or association or any other legal entity or organization of whatever nature, and shall include any successor (by merger or otherwise) of such entity.
* * * * *
Adopted as of: [·], 2024
Last amended as of: N/A
26
Exhibit 4.2
THE HOLDER OF THIS WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS WARRANT EXCEPT AS HEREIN PROVIDED AND THE HOLDER OF THIS WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE LATER OF THE DATE THAT THE REGISTRATION STATEMENT (AS DEFINED BELOW) IS DECLARED EFFECTIVE BY THE SECURITIES AND EXCHANGE COMMISSION OR THE COMMENCEMENT OF SALES OF THE OFFERING TO WHICH THIS WARRANT RELATES TO ANYONE OTHER THAN (I) AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF ANY SUCH UNDERWRITER OR SELECTED DEALER.
THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO {_____}, 202{5}1. VOID AFTER 11:59 P.M., EASTERN TIME, ON THE EXPIRATION DATE.
zSpace, INC.
Warrant To Purchase Common Stock
Warrant No.: {__}
Number of Shares of Common Stock: {____}2
Date of Issuance: {____}, 20243 (“Issuance Date”)
zSpace, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Roth Capital Partners, LLC, the registered holder hereof or its permitted assigns (the “Holder”), is entitled, upon the terms and subject to the conditions set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or after {____}, 202{5}4 (the “Initial Exercisability Date”), but not after 11:59 p.m., Eastern time, on the Expiration Date (as defined below), up to {____} ({_________})5 fully paid non-assessable shares of Common Stock (as defined below), subject to adjustment as provided herein (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, this “Warrant”), shall have the meanings set forth in Section 16. This Warrant is one of the Representative’s Warrants issued pursuant to (i) that certain Underwriting Agreement, dated as of [______], 2024, by and among the Company, Roth Capital Partners, LLC and Craig-Hallum Capital Group LLC, as representatives of the underwriters named therein (the “Representatives”) (the “Underwriting Agreement”), (ii) the Company’s Registration Statement on Form S-1 (File number 333-280427) (the “Registration Statement”) and (iii) the Company’s prospectus dated [______], 2024 relating to the offering (the “Offering”) of the securities referenced therein (the “Securities”).
1 Date that is 180 days from the Closing Date or the Option Closing Date, as applicable.
2 Aggregate of 5.0% of the Firm Shares or Option Shares, as applicable.
3 The Closing Date or the Option Closing Date, as applicable.
4 Date that is 180 days from the Closing Date or the Option Closing Date, as applicable.
5 Aggregate of 5.0% of the Firm Shares or Option Shares, as applicable.
1. EXERCISE OF WARRANT.
(a) Mechanics of Exercise. Upon the terms and subject to the conditions hereof (including, without limitation, the limitations set forth in Section 1(f)), this Warrant may be exercised by the Holder at any time or times on or after the Initial Exercisability Date and prior to the Expiration Date (as defined below), in whole or in part, by delivery (whether via facsimile, electronic mail or otherwise) of a written notice, in the form attached hereto as Exhibit A (the “Exercise Notice”), of the Holder’s election to exercise this Warrant. Within one (1) Trading Day following the delivery of the Exercise Notice, the Holder shall make payment to the Company of an amount equal to the Exercise Price in effect on the date of such exercise multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the “Aggregate Exercise Price”) in cash by wire transfer of immediately available funds (a “Cash Exercise”) or by notifying the Company that this Warrant is being exercised pursuant to a Cashless Exercise (as defined in Section 1(d)). The Holder shall not be required to surrender this Warrant in order to effect an exercise hereunder (until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full), nor shall any ink-original signature or medallion guarantee (or other type of guarantee or notarization) with respect to any Exercise Notice be required. Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares shall have the same effect as cancellation of the this Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares and the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within a reasonable time after such exercise, but in any event within five (5) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. On or before the first (1st) Trading Day following the date on which the Holder has delivered the applicable Exercise Notice, the Company shall transmit by facsimile or electronic mail an acknowledgment of confirmation of receipt of the Exercise Notice, in the form attached to the Exercise Notice, to the Holder and the Company’s transfer agent (the “Transfer Agent”). So long as the Holder delivers the Aggregate Exercise Price (or notice of a Cashless Exercise, if applicable) on or prior to the first (1st) Trading Day following the date on which the Exercise Notice has been delivered to the Company, then on or prior to the earlier of (i) the first (1st) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period, in each case following the date on which the Exercise Notice has been delivered to the Company, or, if the Holder does not deliver the Aggregate Exercise Price (or notice of a Cashless Exercise, if applicable) on or prior to the first (1st) Trading Day following the date on which the Exercise Notice has been delivered to the Company, then on or prior to the first (1st) Trading Day following the date on which the Aggregate Exercise Price (or notice of a Cashless Exercise, if applicable) is delivered (such earlier date, or if later, the earliest day on which the Company is required to deliver Warrant Shares pursuant to this Section 1(a), the “Share Delivery Date”), the Company shall (X) provided that the Transfer Agent is participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program (the “FAST Program”), and as long as the certificates therefor are not required by this Warrant to bear a legend regarding restriction on transferability, upon the request of the Holder, credit such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with DTC through its Deposit / Withdrawal At Custodian system, or (Y) if the Transfer Agent is not participating in the FAST Program or if the certificates are required by this Warrant to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise. The Company shall be responsible for all fees and expenses of the Transfer Agent and all fees and expenses with respect to the issuance of Warrant Shares via DTC, if any, including without limitation for same day processing. Upon delivery of the Exercise Notice, the Holder shall be deemed for all corporate purposes to have become the holder of record and beneficial owner of the Warrant Shares with respect to which this Warrant has been exercised (including for purposes of Section 6 hereof), irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be. If this Warrant is physically delivered to the Company in connection with any exercise pursuant to this Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable and in no event later than three (3) Trading Days after any exercise and at its own expense, issue and deliver to the Holder (or its designee) a new Warrant (in accordance with Section 7(d) of this Warrant) representing the right to purchase the number of Warrant Shares issuable immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant has been and/or is exercised. No fractional Warrant Shares are to be issued upon the exercise of this Warrant, but rather the number of Warrant Shares to be issued shall be rounded to the nearest whole number. The Company shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses (including, without limitation, fees and expenses of the Transfer Agent) which may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant. The Company’s obligations to issue and deliver Warrant Shares in accordance with the terms and subject to the conditions hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination; provided, however, that the Company shall not be required to deliver Warrant Shares with respect to an exercise prior to the Holder’s delivery of the Aggregate Exercise Price (or notice of a Cashless Exercise, if applicable) with respect to such exercise; and provided further, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or Warrants in a name other than that of the Holder or an affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.
2
(b) Exercise Price. For purposes of this Warrant, “Exercise Price” means $[●]6 per share, subject to adjustment as provided herein.
(c) Company’s Failure to Timely Deliver Securities. If the Company fails for any reason to deliver to the Holder a certificate for the number of Warrant Shares to which the Holder is entitled and register such Warrant Shares on the Company’s share register or to credit the Holder’s balance account with DTC for such number of Warrant Shares to which the Holder is entitled upon the Holder’s exercise of this Warrant, subject to a Notice of Exercise by the Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 1(a) above pursuant to an exercise on or before the Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. The Company’s current transfer agent participates in the FAST Program. In the event that the Company changes transfer agents while this Warrant is outstanding, the Company shall use commercially reasonable efforts to select a transfer agent that participates in the FAST Program. While this Warrant is outstanding, the Company shall request its transfer agent to participate in the FAST Program with respect to this Warrant.
(d) Cashless Exercise. Notwithstanding anything contained herein to the contrary, the Holder may, in its sole discretion, exercise this Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the “Net Number” of shares of Common Stock determined according to the following formula (a “Cashless Exercise”):
Net Number = (A x B) - (A x C)
B
6 Note to Draft: 150% of the public offering price.
3
For purposes of the foregoing formula:
A= | the total number of shares with respect to which this Warrant is then being exercised. |
B= | the average of the Closing Sale Prices of the shares of Common Stock (as reported by Bloomberg) for five consecutive Trading Days ending on the date immediately preceding the Exercise Date. |
C= | the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise. |
If Warrant Shares are issued in such a cashless exercise, the Company acknowledges and agrees that in accordance with Section 3(a)(9) of the Securities Act of 1933, as amended, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised, and the holding period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this Section 1(d). Except as expressly set forth in Section 4 herein, nothing in this Warrant shall require the Company to effect cash settlement of this Warrant.
(e) Disputes. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance with Section 11.
4
(f) Beneficial Ownership. Notwithstanding anything to the contrary contained herein, the Holder shall not be entitled to receive shares of Common Stock upon exercise this Warrant to the extent that after giving effect to such exercise, the Holder together with the other Attribution Parties collectively would beneficially own in excess of 4.99% (the “Maximum Percentage”) of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (A) exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of the other Attribution Parties and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including the other Warrants) beneficially owned by the Holder or any other Attribution Party subject to a limitation on conversion or exercise analogous to the limitation contained in this Section 1(f). For purposes of this Section 1(f), beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “1934 Act”), it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the 1934 Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 1(f) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the Company shall have no obligation to verify or confirm the accuracy of such determination. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock the Holder may acquire upon the exercise of this Warrant without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and Current Reports on Form 8-K or other public filing with the Securities and Exchange Commission (the “SEC”), as the case may be, (y) a more recent public announcement by the Company or (z) any other written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding (the “Reported Outstanding Share Number”). If the Company receives an Exercise Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i) notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Exercise Notice would otherwise cause the Holder’s beneficial ownership, as determined pursuant to this Section 1(f), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of Warrant Shares to be purchased pursuant to such Exercise Notice (the number of shares by which such purchase is reduced, the “Reduction Shares”) and (ii) as soon as reasonably practicable, the Company shall return to the Holder any exercise price paid by the Holder for the Reduction Shares. For any reason at any time, upon the written request of the Holder, the Company shall within two (2) Business Days confirm orally and in writing or by electronic mail to such Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of Common Stock to the Holder upon exercise of this Warrant results in the Holder and the other Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section 13(d) of the 1934 Act), the number of shares so issued by which the Holder’s and the other Attribution Parties’ aggregate beneficial ownership exceeds the Maximum Percentage (the “Excess Shares”) shall be deemed null and void and shall be cancelled ab initio, and the Holder shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified in such notice; provided that (i) any such increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered to the Company and (ii) any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to any other holder of Warrants that is not an Attribution Party of the Holder. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of exercisability. The provisions of this paragraph shall not be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 1(f) to the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section 1(f) or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant.
5
(g) Required Reserve Amount. So long as this Warrant remains outstanding, the Company shall at all times keep reserved for issuance under this Warrant a number of shares of Common Stock at least equal to 100% of the maximum number of shares of Common Stock as shall be necessary to satisfy the Company’s obligation to issue shares of Common Stock under the Warrants then outstanding (without regard to any limitations on exercise) (the “Required Reserve Amount”); provided that at no time shall the number of shares of Common Stock reserved pursuant to this Section 1(g) be reduced other than in connection with any exercise of Warrants or such other event covered by Section 2 below. The Required Reserve Amount (including, without limitation, each increase in the number of shares so reserved) shall be allocated pro rata among the holders of the Warrants based on the number of shares of Common Stock issuable upon exercise of Warrants held by each holder thereof on the Issuance Date (without regard to any limitations on exercise) (the “Authorized Share Allocation”). In the event that a holder shall sell or otherwise transfer any of such holder’s Warrants, each transferee shall be allocated a pro rata portion of such holder’s Authorized Share Allocation. Any shares of Common Stock reserved and allocated to any Person which ceases to hold any Warrants shall be allocated to the remaining holders of Warrants, pro rata based on the number of shares of Common Stock issuable upon exercise of the Warrants then held by such holders thereof (without regard to any limitations on exercise).
(h) Insufficient Authorized Shares. If at any time while this Warrant remains outstanding the Company does not have a sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve for issuance the Required Reserve Amount (an “Authorized Share Failure”), then the Company shall promptly take all action reasonably necessary to increase the Company’s authorized shares of Common Stock to an amount sufficient to allow the Company to reserve the Required Reserve Amount for this Warrant then outstanding. Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than ninety (90) days after the occurrence of such Authorized Share Failure, the Company shall hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock. In connection with such meeting, the Company shall provide each stockholder with a proxy statement and shall use its reasonable best efforts to solicit its stockholders’ approval of such increase in authorized shares of Common Stock and to cause its board of directors to recommend to the stockholders that they approve such proposal. Notwithstanding the foregoing, if any such time of an Authorized Share Failure, the Company is able to obtain the written consent of a majority of the shares of its issued and outstanding shares of Common Stock to approve the increase in the number of authorized shares of Common Stock, the Company may satisfy this obligation by obtaining such consent and submitting for filing with the SEC an Information Statement on Schedule 14C.
(i) Warrant Redemption. The Company may not call or redeem any portion of this Warrant without the prior written consent of the Holder.
6
2. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES. The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:
(a) Adjustment upon Subdivision or Combination of Common Stock. If the Company at any time on or after the Issuance Date subdivides (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased. If the Company at any time on or after the Issuance Date combines (by combination, reverse stock split, recapitalization, reorganization, scheme or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will be proportionately decreased. Any adjustment under this Section 2(a) shall become effective at the close of business on the date the subdivision or combination becomes effective.
(b) Voluntary Adjustment by Company. The Company may at any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company.
(c) Purchase Rights. In addition to any adjustments pursuant to those described in paragraphs (a) and (b) of this Section 2 above, if at any time prior to the Expiration Date the Company grants, issues or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights.
(d) Other Events. If any event occurs of the type contemplated by the provisions of this Section 2 but not expressly provided for by such provisions (including, without limitation, the granting of stock appreciation rights or phantom stock rights), then the Company’s Board of Directors will make an appropriate adjustment in the Exercise Price and the number of Warrant Shares so as to protect the rights of the Holder; provided that no such adjustment pursuant to this Section 2(d) will increase the Exercise Price or decrease the number of Warrant Shares as otherwise determined pursuant to this Section 2.
3. RIGHTS UPON DISTRIBUTION OF ASSETS. If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Common Stock (and not to the Holders) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe for or purchase any security (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction), then in each such case the Exercise Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution by a fraction of which the denominator shall be the Weighted Average Price determined as of the record date mentioned above, and of which the numerator shall be such Weighted Average Price on such record date less the then per share fair market value at such record date of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share of Common Stock as determined by the Board of Directors in good faith. In either case, the adjustments shall be described in a statement provided to the Holder of the portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such adjustment shall be made whenever any such distribution is made to the holders of Common Stock and shall become effective immediately after the record date mentioned above.
7
4. FUNDAMENTAL TRANSACTIONS. The Company shall not enter into or be party to a Fundamental Transaction unless the Successor Entity assumes in writing (unless the Company is the Successor Entity) all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 4 pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder prior to such Fundamental Transaction, including agreements to deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant, including, without limitation, which is exercisable for a corresponding number of shares of capital stock equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such adjustments to the number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction). Notwithstanding the foregoing, in the event of an all-cash sale of the Company, at the Company’s option, the Company or the Successor Entity shall have the right to purchase this Warrant from the Holder by paying to the Holder on the effective date of the Fundamental Transaction, cash in an amount equal to the Black-Scholes Value of the remaining unexercised portion of this Warrant on the date of such Fundamental Transaction. Except in the case of the purchase of this Warrant pursuant to the terms of the immediately preceding sentence, upon the consummation of each Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for the Company (so that from and after the date of the applicable Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Notwithstanding the foregoing, and without limiting Section 1(f) hereof, the Holder may elect, at its sole option, by delivery of a signed written notice to the Company to waive this Section 4 to permit the Fundamental Transaction without the assumption of this Warrant. In addition to and not in substitution for any other rights hereunder, prior to the consummation of each Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a “Corporate Event”), the Company shall make appropriate provision to ensure that the Holder will thereafter have the right to receive upon an exercise of this Warrant at any time after the consummation of the applicable Fundamental Transaction but prior to the Expiration Date, in lieu of the shares of the Common Stock (or other securities, cash, assets or other property (except such items still issuable under Sections 3 and 4 above, which shall continue to be receivable thereafter)) issuable upon the exercise of the Warrant prior to such Fundamental Transaction, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights) which the Holder would have been entitled to receive upon the happening of the applicable Fundamental Transaction had this Warrant been exercised immediately prior to the applicable Fundamental Transaction (without regard to any limitations on the exercise of this Warrant). The provision made pursuant to the preceding sentence shall be in a form and substance reasonably satisfactory to the Holder. The provisions of this Section 4 shall apply similarly and equally to successive Fundamental Transactions and Corporate Events.
8
5. NONCIRCUMVENTION. The Company hereby covenants and agrees that the Company will not, by amendment of its certificate of incorporation or bylaws, or through any reorganization, transfer of assets, consolidation, merger, scheme, arrangement, dissolution, issuance or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all of the provisions of this Warrant and take all action as may be required to protect the rights of the Holder and consistent with effectuating the purposes of this Warrant. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock, not subject to preemptive rights of any shareholder, upon the exercise of this Warrant, and (iii) shall, so long as any of the Warrants are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the exercise of the Warrants, the number of shares of Common Stock as shall from time to time be necessary to effect the exercise of the Warrants then outstanding (without regard to any limitations on exercise).
6. WARRANT HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided herein, the Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of capital stock of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this Section 6, the Company shall provide the Holder with copies of the same notices and other information given to the stockholders of the Company generally, contemporaneously with the giving thereof to the stockholders; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of any corporate action required to be specified in such notice.
9
7. REISSUANCE OF WARRANTS.
(a) Transfer of Warrant. If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company and deliver a completed and executed form or assignment, substantially in the form of the Assignment Form attached hereto as Exhibit B, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 7(d)), registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section 7(d)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred. The acceptance of the new Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the new Warrant that the Holder has in respect of this Warrant.
(b) Lost, Stolen or Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary form (but without the obligation to post a bond) and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 7(d)) representing the right to purchase the Warrant Shares then underlying this Warrant.
(c) Exchangeable for Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the Company, for a new Warrant or Warrants (in accordance with Section 7(d)) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender.
(d) Issuance of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 7(a) or Section 7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrants issued in connection with such issuance, do not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant.
10
8. NOTICES. Whenever notice is required to be given under this Warrant, including, without limitation, an Exercise Notice, unless otherwise provided herein, such notice shall be given in writing, (i) if delivered (a) from within the domestic United States, by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, electronic mail or by facsimile or (b) from outside the United States, by International Federal Express, electronic mail or facsimile, and (ii) will be deemed given (A) if delivered by first-class registered or certified mail domestic, three (3) Business Days after so mailed, (B) if delivered by nationally recognized overnight carrier, one (1) Business Day after so mailed, (C) if delivered by International Federal Express, two (2) Business Days after so mailed, (D) at the time of transmission, if delivered by electronic mail to the email address specified in this Section 8 prior to 5:00 p.m. (New York time) on a Trading Day, (E) the next Trading Day after the date of transmission, if delivered by electronic mail to the email address specified in this Section 8 on a day that is not a Trading Day or later than 5:00 p.m. (New York time) on any Trading Day and (F) if delivered by facsimile, upon electronic confirmation of delivery of such facsimile, and will be delivered and addressed as follows:
(i) if to the Company, to:
zSpace, Inc.
65 Nicholson Lane
San Jose, California 95134
Attention: Paul Kellenberger
Tel: (408) 498-4050
Fax: [_____]
with a copy to:
Pryor Cashman LLP
7 Times Square
New York, NY 10036
Attention: M. Ali Panjwani, Esq.
Tel: (212) 421-4100
Fax: (212) 326-0806
(ii) if to the Holder, at such address or other contact information delivered by the Holder to Company or as is on the books and records of the Company.
with a copy to:
Pillsbury Winthrop Shaw Pittman LLP
31 West 52nd Street
New York, New York 10019
Attn: Jonathan J. Russo, Esq.
Alexandra F. Calcado, Esq.
Tel: (212) 858-1000
Fax: (212) 858-1500
The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant, including in reasonable detail a description of such action and the reason therefor. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least fifteen (15) days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation; provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder; provided, further, that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. It is expressly understood and agreed that the time of exercise specified by the Holder in each Exercise Notice shall be definitive and may not be disputed or challenged by the Company.
11
9. AMENDMENT AND WAIVER. Except as otherwise provided herein, the provisions of this Warrant may be amended or waived and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the prior written consent of the Holders of Warrants to purchase a majority of the Warrant Shares sold pursuant to the Registration Statement.
10. GOVERNING LAW; JURISDICTION; JURY TRIAL. This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. The Company hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to the Company at the address set forth in Section 8(i) above or such other address as the Company subsequently delivers to the Holder and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Company’s obligations to the Holder, to realize on any collateral or any other security for such obligations, or to enforce a judgment or other court ruling in favor of the Holder. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be promptly reimbursed by the other party for their reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED HEREBY.
12
11. DISPUTE RESOLUTION. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile or electronic mail within two (2) Business Days of receipt of the Exercise Notice or other event giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three (3) Business Days of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two (2) Business Days submit via facsimile or electronic mail (a) the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the Company in good faith by its Board of Directors and approved by the Holder or (b) the disputed arithmetic calculation of the Warrant Shares to the an independent, nationally-recognized outside accountant that is not the Company’s current independent auditor, selected by the Company in good faith by the Board of Directors. The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten (10) Business Days from the time it receives the disputed determinations or calculations. The prevailing party (which, for purposes of this Warrant, is the party whose determinations or calculations is closest to those of the investment bank or the accountant, as the case may be) in any dispute resolved pursuant to this Section 11 shall be entitled to the full amount of all reasonable expenses, including all costs and fees paid or incurred in good faith, in relation to the resolution of such dispute. Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error.
12. REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies, to seek an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.
13. TRANSFER. The registered Holder of this Warrant agrees by his, her or its acceptance hereof, that such Holder will not: (a) sell, transfer, assign, pledge or hypothecate this Warrant for a period of one hundred eighty (180) days following the later of the date that the Registration Statement is declared effective by the SEC or the commencement of sales of the Offering (the later of such dates, the “Transferability Date”) to anyone other than: (i) an underwriter or a selected dealer participating in the Offering, or (ii) a bona fide officer or partner of any such underwriter or selected dealer, in each case in accordance with FINRA Conduct Rule 5110(e)(1), or (b) cause this Warrant or the securities issuable hereunder to be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of this Warrant or the securities hereunder, except as provided for in FINRA Rule 5110(e)(2). On and after the Transferability Date, transfers to others may be made subject to compliance with or exemptions from applicable securities laws. In order to make any permitted assignment, the Holder must deliver to the Company the Assignment Form attached hereto as Exhibit B duly executed and completed, together with this Warrant. The Company shall within three (3) Business Days transfer this Warrant on the books of the Company and shall execute and deliver a new Warrant or Warrants of like tenor to the appropriate assignee(s) expressly evidencing the right to purchase the aggregate number of shares of Common Stock purchasable hereunder or such portion of such number as shall be contemplated by any such assignment in accordance with Section 7 hereunder. In addition, notwithstanding the other terms of this Warrant or any agreement between the Company and the Holder, the Holder agrees that, consistent with FINRA Rule 5110(g)(8): (i) this Warrant may not be exercised more than five (5) years from the Issuance Date; (ii) this Warrant may not have anti-dilution terms that allow the Holder and related persons to receive more shares or to exercise at a lower price than originally agreed upon at the time of the public offering, when the public shareholders have not been proportionally affected by a stock split, stock dividend, or other similar event; and (iii) this Warrant may not have anti-dilution terms that allow the Holder and related persons to receive or accrue cash dividends prior to the exercise or conversion of this Warrant.
13
14. SEVERABILITY; CONSTRUCTION; HEADINGS. If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s). This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against any Person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant.
15. DISCLOSURE. Upon receipt or delivery by the Company of any notice in accordance with the terms of this Warrant, unless the Company has in good faith determined that the matters relating to such notice do not constitute material, nonpublic information relating to the Company or its subsidiaries, the Company shall contemporaneously with any such receipt or delivery publicly disclose such material, nonpublic information on a Current Report on Form 8-K or otherwise. In the event that the Company believes that a notice contains material, nonpublic information relating to the Company or its subsidiaries, the Company so shall indicate to such Holder contemporaneously with delivery of such notice, and in the absence of any such indication, the Holder shall be allowed to presume that all matters relating to such notice do not constitute material, nonpublic information relating to the Company or its subsidiaries.
14
16. CERTAIN DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:
(a) “Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act of 1933, as amended.
(b) “Attribution Parties” means, collectively, the following Persons and entities: (i) any investment vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the Issuance Date, directly or indirectly managed or advised by the Holder’s investment manager or any of its Affiliates or principals, (ii) any direct or indirect Affiliates of the Holder or any of the foregoing, (iii) any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and (iv) any other Persons whose beneficial ownership of the Company’s Common Stock would or could be aggregated with the Holder’s and the other Attribution Parties for purposes of Section 13(d) of the 1934 Act. For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage.
(c) “Black-Scholes Value” means the value of this Warrant calculated using the Black-Scholes Option Pricing Model obtained from the “OV” function on Bloomberg determined as of the day immediately following the public announcement of the applicable Fundamental Transaction, or, if the Fundamental Transaction is not publicly announced, the date the Fundamental Transaction is consummated, for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant as of such date of request, (ii) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, or, if the Fundamental Transaction is not publicly announced, the date the Fundamental Transaction is consummated, (iii) the underlying price per share used in such calculation shall be the greater of (x) the highest Weighted Average Price of the Common Stock during the period beginning on the Trading Day prior to the execution of definitive documentation relating to the applicable Fundamental Transaction and ending on (A) the Trading Day immediately following the public announcement of such Fundamental Transaction, if the applicable Fundamental Transaction is publicly announced or (B) the Trading Day immediately following the consummation of the applicable Fundamental Transaction if the applicable Fundamental Transaction is not publicly announced and (y) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in the Fundamental Transaction, (iv) a zero cost of borrow and (v) a 365 day annualization factor.
(d) “Bloomberg” means Bloomberg Financial Markets.
(e) “Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law or executive order to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law or executive order to close due to “stay at home”, “shelter-in-place”, “non-essential employee” or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental entity so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in such location generally are open for use by customers on such day.
15
(f) “Closing Bid Price” and “Closing Sale Price” means, for any security as of any date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid price or the closing trade price, as the case may be, then the last bid price or the last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the OTC Link or “pink sheets” by OTC Markets Group Inc. (formerly Pink OTC Markets Inc.). If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price, as the case may be, of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 11. All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or other similar transaction during the applicable calculation period.
(g) “Common Stock” means (i) the Company’s Common Stock, par value $0.00001 per share, and (ii) any capital stock into which such Common Stock shall have been changed or any capital stock resulting from a reclassification of such Common Stock.
(h) “Convertible Securities” means any stock or securities (other than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock.
(i) “Eligible Market” means The Nasdaq Capital Market, the NYSE American LLC, The Nasdaq Global Select Market, The Nasdaq Global Market or The New York Stock Exchange, Inc.
(j) “Expiration Date” means the five-year anniversary of the effective date of the Registration Statement for the offering, or, if such date falls on a day other than a Trading Day or on which trading does not take place on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock are then traded (a “Holiday”), the next date that is not a Holiday.
16
(k) “Fundamental Transaction” means (A) that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation) another Subject Entity (but excluding a merger effected solely for the purpose of changing the jurisdiction of incorporation of the Company), or (ii) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company or any of its “significant subsidiaries” (as defined in Rule 1-02 of Regulation S-X) to one or more Subject Entities, or (iii) make, or allow one or more Subject Entities to make, or allow the Company to be subject to or have its shares of Common Stock be subject to or party to one or more Subject Entities making, a purchase, tender or exchange offer that is accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all Subject Entities making or party to, or Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding; or (z) such number of shares of Common Stock such that all Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or (iv) consummate a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with one or more Subject Entities whereby all such Subject Entities, individually or in the aggregate, acquire, either (x) at least 50% of the outstanding shares of Common Stock, (y) at least 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all the Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such stock purchase agreement or other business combination were not outstanding; or (z) such number of shares of Common Stock such that the Subject Entities become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or (v) reorganize, recapitalize or reclassify its shares of Common Stock, (B) that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any Subject Entity individually or the Subject Entities in the aggregate to be or become the “beneficial owner” (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, whether through acquisition, purchase, assignment, conveyance, tender, tender offer, exchange, reduction in outstanding shares of Common Stock, merger, consolidation, business combination, reorganization, recapitalization, spin-off, scheme of arrangement, reorganization, recapitalization or reclassification or otherwise in any manner whatsoever, of either (x) at least 50% of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock, (y) at least 50% of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock not held by all such Subject Entities as of the Issuance Date calculated as if any shares of Common Stock held by all such Subject Entities were not outstanding, or (z) a percentage of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock or other equity securities of the Company sufficient to allow such Subject Entities to effect a statutory short form merger or other transaction requiring other stockholders of the Company to surrender their Common Stock without approval of the stockholders of the Company or (C) directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, the issuance of or the entering into any other instrument or transaction structured in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this definition or any portion of this definition which may be defective or inconsistent with the intended treatment of such instrument or transaction.
17
(l) “Group” means a “group” as that term is used in Section 13(d) of the 1934 Act and as defined in Rule 13d-5 thereunder.
(m) “Options” means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.
(n) “Parent Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person, including such entity whose common stock or equivalent equity security is quoted or listed on an Eligible Market (or, if so elected by the Holder, any other market, exchange or quotation system), or, if there is more than one such Person or such entity, the Person or such entity designated by the Holder or in the absence of such designation, such Person or entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction.
(o) “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof.
(p) “Principal Market” means The Nasdaq Capital Market.
(q) “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, for the Company’s primary trading market or quotation system with respect to the Common Stock that is in effect on the date of delivery of an applicable Exercise Notice.
(r) “Subject Entity” means any Person, Persons or Group or any Affiliate or associate of any such Person, Persons or Group.
(s) “Successor Entity” means one or more Person or Persons (or, if so elected by the Holder, the Company or Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or one or more Person or Persons (or, if so elected by the Holder, the Company or the Parent Entity) with which such Fundamental Transaction shall have been entered into.
(t) “Trading Day” means any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded.
(u) “Weighted Average Price” means, for any security as of any date, the dollar volume-weighted average price for such security on the Principal Market during the period beginning at 9:30:01 a.m., New York time (or such other time as the Principal Market publicly announces is the official open of trading), and ending at 4:00:00 p.m., New York time (or such other time as the Principal Market publicly announces is the official close of trading), as reported by Bloomberg through its “Volume at Price” function or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the over-the-counter market on the electronic bulletin board for such security during the period beginning at 9:30:01 a.m., New York time (or such other time as such market publicly announces is the official open of trading), and ending at 4:00:00 p.m., New York time (or such other time as such market publicly announces is the official close of trading), as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest Closing Bid Price and the lowest closing ask price of any of the market makers for such security as reported in the OTC Link or “pink sheets” by OTC Markets Group Inc. (formerly Pink OTC Markets Inc.). If the Weighted Average Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Weighted Average Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 11 but with the term “Weighted Average Price” being substituted for the term “Exercise Price.” All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or other similar transaction during the applicable calculation period.
[Signature Page Follows]
18
IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out above.
ZSPACE, INC.
By: | ||
Name: | ||
Title: |
EXHIBIT A
EXERCISE NOTICE
TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE
THIS
WARRANT TO PURCHASE COMMON STOCK
zSPACE, INC.
The undersigned holder hereby exercises the right to purchase _________________ shares of Common Stock (“Warrant Shares”) of zSpace, Inc., a Delaware corporation (the “Company”), evidenced by the attached Warrant to Purchase Common Stock (the “Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.
1. Form of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as:
____________ a “Cash Exercise” with respect to _________________ Warrant Shares; and/or
____________ a “Cashless Exercise” with respect to _______________ Warrant Shares.
2. Payment of Exercise Price. In the event that the holder has elected a Cash Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the holder shall pay the Aggregate Exercise Price in the sum of $___________________ to the Company in accordance with the terms of the Warrant.
3. Delivery of Warrant Shares. The Company shall deliver to the holder __________ Warrant Shares in accordance with the terms of the Warrant and, after delivery of such Warrant Shares Warrant shares remain subject to the Warrant.
Date: _______________ __, ______
________________________________
Name of Registered Holder
By: | ||
Name: | ||
Title: |
ACKNOWLEDGMENT
The Company hereby acknowledges this Exercise Notice and hereby directs [__________]7 to issue the above indicated number of shares of Common Stock on or prior to the applicable Share Delivery Date.
ZSPACE, INC.
By: | ||
Name: | ||
Title: |
7 Name of transfer agent.
EXHIBIT B
ASSIGNMENT FORM
ZSPACE, INC.
(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)
FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to
Name: |
(Please Print)
Address: |
(Please Print)
Dated: _______________ __, ______
Holder’s Signature: |
Holder’s Address: |
NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.
Exhibit 5.1
zSpace, Inc.
55 Nicholson Lane
San Jose, CA 95134
Telephone: (408) 498-4045
Ladies and Gentlemen:
We have acted as legal counsel to zSpace, Inc., a Delaware corporation (the Company”), in connection with the Registration Statement on Form S-1 (File No. 333-280427) (the “Registration Statement”), originally filed with the U.S. Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “1933 Act”), on June 21, 2024, as amended, for the registration of (1) the issuance of up to shares (the “Public Shares”) of the common stock, par value $0.00001 per share (the “Common Stock”), of the Company including the underwriters’ over-allotment option, (2) the issuance of a warrant to Roth Capital Partners LLC., as representative of the underwriters (the “Representative”), to purchase up to shares of Common Stock (the “Representative Shares”), which warrant is exercisable at a price per share equal to 150% of the public offering price (the “Representative Warrant”), (3) the issuance of the Representative Shares upon exercise of the Representative Warrant, (4) the offering for resale of up to shares of our common stock consisting of: (i) up to shares of Common Stock issuable to Kuwait Investment Authority (“KIA”) upon the automatic conversion of 7,500 shares of the Company’s NCNV 1 preferred stock and 5,752 shares of the Company’s NCNV 2 preferred stock at the consummation of the offering, and (ii) up to shares of Common Stock issuable to Compal Electronics, Inc. (“Compal” upon the automatic conversion of $2,038,665 of a SAFE Agreement at the consummation of the offering, each for the account of the persons listed as selling stockholders identified in the Registration Statement (the “Selling Stockholders”, and such shares issued, the “Selling Stockholder Shares”).
You have requested our opinion as to the matters set forth below in connection with the Registration Statement. For purposes of rendering that opinion, we have examined the following:
1. the Registration Statement;
2. the Company’s Certificate of Incorporation, as in effect as of the date hereof;
3. the Bylaws, as amended and restated of as of the date hereof;
4. the corporate actions of the Company that provide for the issuance of the Public Shares, the Representative Warrant, and the Representative Shares;
5. the Underwriting Agreement between the Company and the Representative, as representative of the underwriters named therein, as amended (the “Underwriting Agreement”);
6. the Representative Warrant;
7. the SAFE agreement dated July 12, 2024 by and between the Company and Compal;
8. the corporate actions of the Company that provided for the issuance of the NCNV 1 preferred stock and NCNV 2 preferred stock to KIA; and
9. the corporate actions of the Company that provided for the entry into the SAFE Agreement (together with item 4 and item 8, the “Authorizing Resolutions”).
We have made such other investigation as we have deemed appropriate. As to certain matters of fact that are material to our opinion, we have relied on a fact certificate of an officer of the Company. In rendering our opinion, we also have made the assumptions that are customary in opinion letters of this kind, including without limitation, that we have assumed: (i) that each document submitted to or reviewed by us is accurate and complete; (ii) that each such document that is an original is authentic and each such document that is a copy conforms to an authentic original; (iii) that all signatures on each such document are genuine; (iv) that any entity that is a party to any of the documents reviewed by us has been duly organized, incorporated or formed, and is validly existing and, if applicable, in good standing under the laws of its respective jurisdiction of organization, incorporation or formation; (v) that each party to each document reviewed by us has the full power, authority, and legal right to execute, deliver and perform each such document; (vi) the due authorization, execution and delivery by each party thereto of each document reviewed by us; (vii) that any amendment or restatement of any document reviewed by us has been accomplished in accordance with, and was permitted by, the relevant provisions of applicable law and the relevant provisions of such document (and/or any other applicable document) prior to its amendment or restatement from time to time; (viii) that each of the documents submitted to or reviewed by us constitutes the legal, valid, and binding obligation of each party thereto, enforceable against each such party in accordance with its terms; and (ix) that there are no documents or agreements by or among any of the parties to the transaction described in the Registration Statement, other than those referenced in this opinion letter, that could affect any of the opinions expressed herein and no undisclosed modifications, waivers or amendments (whether written or oral) to any of the documents reviewed by us in connection with this opinion letter. In addition, we have assumed that (a) the Company will have sufficient authorized and unissued shares of Common Stock to provide for the issuance of the Representative Shares at the time of issuance upon exercise of the Representative Warrant, the issuance of Common Stock to KIA upon conversion of the NCVN 1 preferred stock and NCNV 2 preferred stock, and the issuance of Common Stock to Compal upon conversion of the SAFE agreement, (b) the issuance of the Representative Shares, the Public Shares, and the Selling Stockholder Shares, will be duly noted in the Company’s stock ledger upon issuance, (c) the Company will receive consideration for the Representative Shares and the Public Shares in the amount required by the Authorizing Resolutions, the Representative Warrant, the Underwriting Agreement and the Registration Statement, as applicable, in an amount at least equal per Public Share or Representative Share, as the case may be, to the par value of such share and (d) the Representative Shares, the Public Shares, and the Selling Stockholder Shares will be issued in accordance with the Authorizing Resolutions, the Representative Warrant, the Underwriting Agreement and the Registration Statement, as applicable.
We have not verified any of those assumptions.
Our opinions set forth below are based on the facts in existence as of the date of this opinion letter and limited to (i) the Delaware General Corporation Law, and (ii) solely in connection with the opinion given in numbered paragraph 2, the law of the State of New York. We are not opining on, and we assume no responsibility for, the applicability to or effect on any of the matters covered herein of (a) any other laws; (b) the laws of any other jurisdiction; or (c) the law of any county, municipality or other political subdivision or local governmental agency or authority.
Based upon and subject to the foregoing, it is our opinion that:
1. The Public Shares are duly authorized for issuance by the Company, and when the Registration Statement becomes effective under the 1933 Act and the Public Shares are issued and paid for in accordance with the Underwriting Agreement and as contemplated in the Registration Statement, the Public Shares will be validly issued, fully paid, and nonassessable.
2. The Representative Warrant is duly authorized for issuance by the Company, and when the Registration Statement becomes effective under the 1933 Act, and when the Representative Warrant is issued, delivered and paid for in accordance with the terms of the Representative Warrant and the Underwriting Agreement, and as contemplated by the Registration Statement, the Representative Warrant will be a valid and legally binding obligation of the Company enforceable against the Company in accordance with their terms.
3. The Representative Shares are duly authorized for issuance by the Company, and when the Registration Statement becomes effective under the 1933 Act, and when the Representative Shares are issued and paid for in accordance with the terms of the Representative Warrant, including payment of the exercise price therefor, and as contemplated in the Registration Statement, the Representative Shares will be validly issued, fully paid, and nonassessable.
4. The Selling Stockholder Shares are duly authorized for issuance by the Company, and when the Registration Statement becomes effective under the 1933 Act, and when the Selling Stockholder Shares are issued in accordance with the terms of the NCNV 1 preferred stock, NCNV 2 preferred stock, and the SAFE agreement, as applicable, and as contemplated in the Registration Statement, the Representative Shares will be validly issued, fully paid, and nonassessable.
Our opinions are subject to and limited by (i) the effect of bankruptcy, insolvency, fraudulent conveyance, reorganization, receivership, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or secured parties generally, (ii) the application of general principles of equity (regardless of whether considered in a proceeding in equity or at law), including, without limitation, the possible unavailability of specific performance, injunctive relief or another equitable remedy, (iii) concepts of materiality, reasonableness, good faith and fair dealing, and (iv) the public policy against indemnifications for an indemnified party’s gross negligence or for violations of securities law.
Our opinions in numbered paragraph 2 above are given in reliance on Section 5-1401 of the New York General Obligations Law (“GOL 5-1401”). GOL 5-1401 provides, in pertinent part, that “the parties to any contract . . . may agree that the law of this state shall govern their rights and duties in whole or in part, whether or not such contract, agreement or undertaking bears a reasonable relation to this state.” Although the New York Court of Appeals has upheld the application of that statute in IRB-Brasil Resseguros, S.A. v. Inepur Invs., S. A., 82 N.E.2d 609 (N.Y. 2012), we note that legal commentators have questioned the validity thereof under the Constitution of the United States, and we express no opinion as to the constitutionality of such law. We draw your attention to the fact that at least one federal court has, notwithstanding the terms of GOL 5-1401, in dictum noted possible constitutional limitations upon GOL 5-1401, in both domestic and international transactions. See e.g., Lehman Brothers Commercial Corp. v. Minmetals Non-Ferrous Metals Trading Co., No. 94 Civ. 8301, 2000 WL 1702039 (S.D.N.Y. Nov. 13, 2000).
Our opinion is based on facts and laws as in effect on the date hereof and as of the effective date of the Registration Statement, and we assume no obligation to revise or supplement this opinion after the effective date of the Registration Statement should the law be changed by legislative action, judicial decision or otherwise. Where our opinions expressed herein refer to events to occur at a future date, we have assumed that there will have been no changes in the relevant law or facts between the date hereof and such future date. Our opinions expressed herein are limited to the matters expressly stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. Not in limitation of the foregoing, we are not rendering any opinion as to the compliance with any other federal or state law, rule or regulation relating to securities, or to the sale or issuance thereof.
We hereby consent to the filing of this opinion letter with the Commission as Exhibit 5.1 to the Registration Statement and to the reference to this firm under the heading “Legal Matters” in the prospectus forming a part thereof. In giving this consent, we do not thereby admit that we are experts with respect to any part of the Registration Statement or prospectus within the meaning of the term “expert” as used in Section 11 of the 1933 Act or the rules and regulations promulgated thereunder by the Commission, nor do we admit that we are within the category of persons whose consent is required under Section 7 of the 1933 Act or the rules and regulations of the Commission promulgated thereunder.
Sincerely, | |
/s/ PRYOR CASHMAN LLP |
Exhibit 10.4
zSPACE, INC.
2024 EQUITY INCENTIVE PLAN
FORM OF RESTRICTED STOCK UNIT AWARD AGREEMENT
This Restricted Stock Unit Agreement (this “Agreement”) is made and entered into as of [MONTH] [●], 202_ (the “Grant Date”) by and between zSPACE, Inc., a Delaware corporation (the “Company”) and [Insert Grantee’s Name] (the “Grantee”).
WHEREAS, the Company has adopted the zSpace, Inc. 2024 Equity Incentive Plan (the “Plan”) pursuant to which awards of Restricted Stock Units may be granted; and
WHEREAS, the Committee has determined that it is in the best interests of the Company and its shareholders to grant the award of Restricted Stock Units provided for herein.
NOW, THEREFORE, the parties hereto, intending to be legally bound, agree as follows:
1. | Grant of Restricted Stock Units. |
1.1 Pursuant to Article VI of the Plan, the Company hereby issues to the Grantee on the Grant Date an Award consisting of, in the aggregate, [#] Restricted Stock Units (the “Restricted Stock Units”). Each Restricted Stock Unit represents the right to receive one share of Common Stock, subject to the terms and conditions set forth in this Agreement and the Plan. Capitalized terms that are used but not defined herein have the meaning ascribed to them in the Plan.
1.2 The Restricted Stock Units shall be credited to a separate account maintained for the Grantee on the books and records of the Company (the “Account”). All amounts credited to the Account shall continue for all purposes to be part of the general assets of the Company.
2. | Consideration. | The grant of the Restricted Stock Units is made in consideration of the services to be rendered by the Grantee to the Company. |
3. | Vesting. |
3.1 Except as otherwise provided herein, provided that the Grantee remains in service with the Company or an affiliate, whether as an employee, consultant or director (“Continuous Service”) through the applicable vesting date, the Restricted Stock Units will vest in accordance with the following schedule (the period during which restrictions apply, the “Restricted Period”):
Vesting Date | Number of Restricted Stock Units That Vest |
[ ] | [ ] |
Once vested, the Restricted Stock Units become “Vested Units.”
3.2 The foregoing vesting schedule notwithstanding, if the Grantee’s Continuous Service terminates as a result of the Grantee’s death, Disability, or a termination by the Company or an Affiliate without Cause, [100]% of the unvested Restricted Stock Units shall vest as of the date of such termination.
3.3 [The foregoing vesting schedule notwithstanding, upon the occurrence of a Change of Control, 100% of the unvested Restricted Stock Units shall vest as of the date of the Change of Control.]
4. Restrictions. Subject to any exceptions set forth in this Agreement or the Plan, during the Restricted Period and until such time as the Restricted Stock Units are settled in accordance with Section 6, the Restricted Stock Units or the rights relating thereto may not be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by the Grantee. Any attempt to assign, alienate, pledge, attach, sell or otherwise transfer or encumber the Restricted Stock Units or the rights relating thereto shall be wholly ineffective and, if any such attempt is made, the Restricted Stock Units will be forfeited by the Grantee and all of the Grantee’s rights to such units shall immediately terminate without any payment or consideration by the Company.
5. | Rights as Shareholder; Dividend Equivalents. |
5.1 The Grantee shall not have any rights of a shareholder with respect to the shares of Common Stock underlying the Restricted Stock Units unless and until the Restricted Stock Units vest and are settled by the issuance of such shares of Common Stock.
5.2 Upon and following the settlement of the Restricted Stock Units, the Grantee shall be the record owner of the shares of Common Stock underlying the Restricted Stock Units unless and until such shares are sold or otherwise disposed of, and as record owner shall be entitled to all rights of a shareholder of the Company (including voting rights).
5.3 The Grantee shall [not] be entitled to any dividend equivalents with respect to the Restricted Stock Units to reflect any dividends payable on shares of Common Stock.
6. | Settlement of Restricted Stock Units. |
6.1 Subject to Section 9 hereof, shares of unrestricted Common Stock (“Shares”) shall be issued with respect to vested Restricted Stock Units [on the earliest to occur of: (1) [Specified Date]; (2) Grantee’s separation from service (within the meaning of Code Section 409A); (3) a Change of Control; or (4) Participant’s death]/[promptly following the date on which the Restricted Stock Units vest] ([as applicable,] the “Settlement Date”). In all instances, subject to the terms of this Award Agreement, the Shares will be issued within sixty (60) days of the applicable Settlement Date and if the sixty (60) day period straddles two calendar years, Participant will not under any circumstances be permitted, directly or indirectly, to designate the taxable year in which the Restricted Stock Units are settled.
Promptly following the Settlement Date, the Company shall (a) issue and deliver to the Grantee the number of shares of Common Stock equal to the number of Vested Units; and (b) enter the Grantee’s name on the books of the Company as the shareholder of record with respect to the shares of Common Stock delivered to the Grantee.
2 of 6
6.2 If the Grantee is deemed a “specified employee” within the meaning of Section 409A of the Code, as determined by the Committee, at a time when the Grantee becomes eligible for settlement of the RSUs upon his “separation from service” within the meaning of Section 409A of the Code, then to the extent necessary to prevent any accelerated or additional tax under Section 409A of the Code, such settlement will be delayed until the earlier of: (a) the date that is six months following the Grantee’s separation from service and (b) the Grantee’s death.
6.3 To the extent that the Grantee does not vest in any Restricted Stock Units, all interest in such Restricted Stock Units shall be forfeited. The Grantee has no right or interest in any Restricted Stock Units that are forfeited.
7. No Right to Continued Service. Neither the Plan nor this Agreement shall confer upon the Grantee any right to be retained in any position, as an employee, consultant or director of the Company. Further, nothing in the Plan or this Agreement shall be construed to limit the discretion of the Company to terminate the Grantee’s Continuous Service at any time, with or without Cause.
8. Adjustments. If any change is made to the outstanding Common Stock or the capital structure of the Company, if required, the Restricted Stock Units shall be adjusted or terminated in any manner as contemplated by Article VIII of the Plan.
9. Tax Liability and Withholding.
9.1 The Grantee shall be required to pay to the Company, and the Company shall have the right to deduct from any compensation paid to the Grantee pursuant to the Plan, the amount of any required withholding taxes in respect of the Restricted Stock Units and to take all such other action as the Committee deems necessary to satisfy all obligations for the payment of such withholding taxes. The Committee may permit the Grantee to satisfy any federal, state or local tax withholding obligation by any of the following means, or by a combination of such means:
(a) tendering a cash payment.
(b) authorizing the Company to withhold shares of Common Stock from the shares of Common Stock otherwise issuable or deliverable to the Grantee as a result of the vesting of the Restricted Stock Units; provided, however, that no shares of Common Stock shall be withheld with a value exceeding the minimum amount of tax required to be withheld by law.
(c) delivering to the Company previously owned and unencumbered shares of Common Stock.
9.2 Notwithstanding any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related withholding (“Tax-Related Items”), the ultimate liability for all Tax-Related Items is and remains the Grantee’s responsibility and the Company (a) makes no representation or undertakings regarding the treatment of any Tax- Related Items in connection with the grant, vesting or settlement of the Restricted Stock Units or the subsequent sale of any shares; and (b) does not commit to structure the Restricted Stock Units to reduce or eliminate the Grantee’s liability for Tax-Related Items.
3 of 6
10. Compliance with Law. The issuance and transfer of shares of Common Stock shall be subject to compliance by the Company and the Grantee with all applicable requirements of federal and state securities laws and with all applicable requirements of any stock exchange on which the Company’s shares of Common Stock may be listed. No shares of Common Stock shall be issued or transferred unless and until any then applicable requirements of state and federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel.
11. Notices. Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary of the Company at the Company’s principal corporate offices. Any notice required to be delivered to the Grantee under this Agreement shall be in writing and addressed to the Grantee at the Grantee’s address as shown in the records of the Company. Either party may designate another address in writing (or by such other method approved by the Company) from time to time.
12. Governing Law. This Agreement will be construed and interpreted in accordance with the laws of the State of Delaware without regard to conflict of law principles.
13. Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by the Grantee or the Company to the Committee for review. The resolution of such dispute by the Committee shall be final and binding on the Grantee and the Company.
14. Restricted Stock Units Subject to Plan. This Agreement is subject to the Plan as approved by the Company’s shareholders. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. Any capitalized term not defined in this Agreement shall have the same meaning as is ascribed thereto under the Plan. In the event of a conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail.
15. Successors and Assigns. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be binding upon the Grantee and the Grantee’s beneficiaries, executors, administrators and the person(s) to whom the Restricted Stock Units may be transferred by will or the laws of descent or distribution.
16. Severability. The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and enforceable to the extent permitted by law.
17. Discretionary Nature of Plan. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion. The grant of the Restricted Stock Units in this Agreement does not create any contractual right or other right to receive any Restricted Stock Units or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the Plan shall not constitute a change or impairment of the terms and conditions of the Grantee’s employment with the Company.
18. Amendment. The Committee has the right to amend, alter, suspend, discontinue or cancel the Restricted Stock Units, prospectively or retroactively; provided, that, no such amendment shall adversely affect the Grantee’s material rights under this Agreement without the Grantee’s consent.
4 of 6
19. Section 409A. This Agreement is intended to comply with Section 409A of the Code or an exemption thereunder and shall be construed and interpreted in a manner that is consistent with the requirements for avoiding additional taxes or penalties under Section 409A of the Code. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A of the Code and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by the Grantee on account of non-compliance with Section 409A of the Code.
20. No Impact on Other Benefits. The value of the Grantee’s Restricted Stock Units is not part of his or her normal or expected compensation for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.
21. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.
22. Acceptance. The Grantee hereby acknowledges receipt of a copy of the Plan and this Agreement. The Grantee has read and understands the terms and provisions thereof, and accepts the Restricted Stock Units subject to all of the terms and conditions of the Plan and this Agreement. The Grantee acknowledges that there may be adverse tax consequences upon the vesting or settlement of the Restricted Stock Units or disposition of the underlying shares and that the Grantee has been advised to consult a tax advisor prior to such vesting, settlement or disposition.
[SIGNATURE PAGE FOLLOWS]
5 of 6
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.
zSPACE, INC. | ||
By: | ||
Name: | ||
Title: | ||
Employee: [Insert Grantee’s Name] |
6 of 6
Exhibit 10.5
FORM OF INCENTIVE STOCK OPTION AGREEMENT
pursuant to the
zSPACE, INC.
2024 EQUITY INCENTIVE PLAN
* * * * *
Optionee: [OPTIONEE NAME]
Grant Date: [GRANT DATE]
Per Share Exercise Price: $ [●]
Number of Option Shares subject to this Option: [#]
* * * * *
THIS INCENTIVE STOCK OPTION AGREEMENT (this “Agreement”), dated as of the Grant Date specified above, is entered into by and between zSPACE, Inc., a Delaware corporation (the “Company”), and the Optionee specified above, pursuant to the zSPACE, Inc. 2024 Equity Incentive Plan, as in effect and as amended from time to time (the “Plan”); and
WHEREAS, it has been determined under the Plan that it would be in the best interests of the Company to grant the incentive stock option provided for herein to the Optionee.
NOW, THEREFORE, in consideration of the mutual covenants and premises hereinafter set forth and for other good and valuable consideration, the parties hereto hereby mutually covenant and agree as follows:
1. Incorporation By Reference; Plan Document Receipt. This Agreement is subject in all respects to the terms and provisions of the Plan (including, without limitation, any amendments thereto adopted at any time and from time to time unless such amendments are expressly intended not to apply to the grant of the option hereunder), all of which terms and provisions are made a part of and incorporated in this Agreement as if they were each expressly set forth herein. Any capitalized term not defined in this Agreement shall have the same meaning as is ascribed thereto under the Plan. The Optionee hereby acknowledges receipt of a true copy of the Plan and that the Optionee has read the Plan carefully and fully understands its content. In the event of any conflict between the terms of this Agreement and the terms of the Plan, the terms of the Plan shall control.
2. Grant of Option. The Company hereby grants to the Optionee, as of the Grant Date specified above, an incentive stock option (this “Option”) to acquire from the Company at the Per Share Exercise Price specified above the aggregate number of shares of the Common Stock specified above (the “Option Shares”). This Option is to be treated as (and is intended to qualify as) an incentive stock option within the meaning of Section 422 of the Code.
3. No Dividends Equivalents. The Optionee shall not be entitled to receive a cash payment in respect of the Option Shares underlying this Option on any dividend payment date for the Common Stock.
4. Exercise of this Option.
4.1 Unless otherwise provided in Section 4.4 below or determined by the Committee, this Option shall become exercisable in accordance with and to the extent provided by the terms and provisions of Article V of the Plan.
4.2 Unless earlier terminated in accordance with the terms and provisions of the Plan and/or this Agreement, this Option shall expire and shall no longer be exercisable after the expiration of ten (10) years from the Grant Date (the “Option Period”).
4.3 In no event shall this Option be exercisable for a fractional share of Common Stock.
4.4 The Option shall vest [INSERT APPLICABLE VESTING CONDITIONS], provided that Optionee remains continuously engaged as a director, officer, or employee of, or consultant or advisor to, the Company or an affiliate thereof from the date hereof through the applicable vesting date.
5. Method of Exercise and Payment. This Option shall be exercised by the Optionee by delivering to the Secretary of the Company or his designated agent on any business day (the “Exercise Date”) a written notice, in such manner and form as may be required by the Company, specifying the number of the Option Shares the Optionee then desires to acquire (the “Exercise Notice”). The Exercise Notice shall be accompanied by payment of the aggregate Per Share Exercise Price for such number of the Option Shares to be acquired upon such exercise. Such payment shall be made in the manner set forth in Section 5.6 of the Plan.
2
6. Termination; Change of Control.
6.1 If the Optionee’s employment with the Company and/or one of its Subsidiaries terminates for any reason, any then unexercisable portion of this Option shall be forfeited and cancelled by the Company.
6.2 If the Optionee’s employment with the Company and/or its Subsidiaries terminates for any reason other than due to the Optionee’s death or Disability, the Optionee’s rights, if any, to exercise any then exercisable portion of this Option, shall terminate ninety (90) days after the date of such termination, but not beyond the expiration of the Option Period, and thereafter such Option shall be forfeited and cancelled by the Company.
6.3 If Optionee’s termination of employment with the Company and/or its Subsidiaries is due to the Optionee’s death or Disability, the Optionee (or the Optionee’s estate, designated beneficiary or other legal representative, as the case may be and as determined by the Committee) shall have the right, to the extent exercisable immediately prior to any such termination, to exercise this Option at any time within the one (1) year period following such termination due to death or Disability, but not beyond the expiration of the Option Period, and thereafter such Option shall be forfeited and cancelled by the Company.
6.4 The Board or the Committee, in its sole discretion, may determine that all or any portion of this Option, to the extent exercisable immediately prior to the Optionee’s termination of employment with the Company and/or its Subsidiaries for any reason, may remain exercisable for an additional specified time period after the period specified above in this Section 6 expires (subject to any other applicable terms and provisions of the Plan and this Agreement), but not beyond the expiration of the Option Period.
6.5 If the Optionee’s employer ceases to be a Subsidiary of the Company, that event shall be deemed to constitute a termination of employment under Section 6.2 above.
6.6 Optionee shall be deemed to have a “termination of employment” upon (i) the date Optionee ceases to be employed by the Company or any Subsidiary, or any corporation (or any of its subsidiaries) which assumes Optionee’s award in a transaction to which Section 424(a) of the Code applies.
6.7 [Notwithstanding the vesting and/or exercisability provisions otherwise applicable to the Option, the Option shall be fully vested and exercisable upon a Change of Control and shall remain exercisable for the remainder of the Option Period.]
7. Non-transferability. This Option, and any rights or interests therein, shall not be sold, exchanged, transferred, assigned or otherwise disposed of in any way at any time by the Optionee (or any beneficiary(ies) of the Optionee), other than by testamentary disposition by the Optionee or the laws of descent and distribution. This Option shall not be pledged, encumbered or otherwise hypothecated in any way at any time by the Optionee (or any beneficiary(ies) of the Optionee) and shall not be subject to execution, attachment or similar legal process. Any attempt to sell, exchange, pledge, transfer, assign, encumber or otherwise dispose of or hypothecate this Option, or the levy of any execution, attachment or similar legal process upon this Option, contrary to the terms of this Agreement and/or the Plan shall be null and void and without legal force or effect. This Option shall be exercisable during the Optionee’s lifetime only by the Optionee.
3
8. Entire Agreement; Amendment. This Agreement contains the entire agreement between the parties hereto with respect to the subject matter contained herein, and supersedes all prior agreements or prior understandings, whether written or oral, between the parties relating to such subject matter. The Board or the Committee shall have the right, in its sole discretion, to modify or amend this Agreement from time to time in accordance with and as provided in the Plan; provided, however, that no such modification or amendment shall materially adversely affect the rights of the Optionee under this Option without the consent of the Optionee. The Company shall give written notice to the Optionee of any such modification or amendment of this Agreement as soon as practicable after the adoption thereof. This Agreement may also be modified or amended by a writing signed by both the Company and the Optionee.
9. Notices. Any Exercise Notice or other notice which may be required or permitted under this Agreement shall be in writing, and shall be delivered in person or via facsimile transmission, overnight courier service or certified mail, return receipt requested, postage prepaid, properly addressed as follows.
9.1 If such notice is to the Company, to the attention of the Secretary of zSPACE, Inc., 55 Nicholson Lane, San Jose, California 95134, or at such other address as the Company, by notice to the Optionee, shall designate in writing from time to time.
9.2 If such notice is to the Optionee, at his or her address as shown on the Company’s records, or at such other address as the Optionee, by notice to the Company, shall designate in writing from time to time.
10. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without reference to the principles of conflict of laws thereof.
11. Compliance with Laws. The issuance of this Option (and the Option Shares upon exercise of this Option) pursuant to this Agreement shall be subject to, and shall comply with, any applicable requirements of any federal and state securities laws, rules and regulations (including, without limitation, the provisions of the Securities Act of 1933, the Exchange Act and the respective rules and regulations promulgated thereunder) and any other law or regulation applicable thereto. The Company shall not be obligated to issue this Option or any of the Option Shares pursuant to this Agreement if any such issuance would violate any such requirements.
12. Binding Agreement; Assignment. This Agreement shall inure to the benefit of, be binding upon, and be enforceable by the Company and its successors and assigns. The Optionee shall not assign any part of this Agreement without the prior express written consent of the Company.
4
13. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same instrument.
14. Headings. The titles and headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not be deemed to be a part of this Agreement.
15. Further Assurances. Each party hereto shall do and perform (or shall cause to be done and performed) all such further acts and shall execute and deliver all such other agreements, certificates, instruments and documents as any party hereto reasonably may request in order to carry out the intent and accomplish the purposes of this Agreement and the Plan and the consummation of the transactions contemplated thereunder.
16. Severability. The invalidity or unenforceability of any provisions of this Agreement in any jurisdiction shall not affect the validity, legality or enforceability of the remainder of this Agreement in such jurisdiction or the validity, legality or enforceability of any provision of this Agreement in any other jurisdiction, it being intended that all rights and obligations of the parties hereunder shall be enforceable to the fullest extent permitted by law.
[remainder of page intentionally left blank; signature page follows]
5
IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer, and the Optionee has hereunto set his hand, all as of the Grant Date specified above.
zSPACE, INC. | ||
By: | ||
Name: | ||
Title: | ||
Optionee: [OPTIONEE NAME] |
6
Exhibit 10.6
FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT
pursuant to the
zSPACE, INC.
2024 EQUITY INCENTIVE PLAN
* * * * *
Optionee: [OPTIONEE NAME]
Grant Date: [GRANT DATE]
Per Share Exercise Price: $ [●]
Number of Option Shares subject to this Option: [#]
* * * * *
THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”), dated as of the Grant Date specified above, is entered into by and between zSPACE, Inc., a Delaware corporation (the “Company”), and the Optionee specified above, pursuant to the zSPACE, Inc. 2024 Equity Incentive Plan, as in effect and as amended from time to time (the “Plan”); and
WHEREAS, it has been determined under the Plan that it would be in the best interests of the Company to grant the non-qualified stock option provided for herein to the Optionee.
NOW, THEREFORE, in consideration of the mutual covenants and premises hereinafter set forth and for other good and valuable consideration, the parties hereto hereby mutually covenant and agree as follows:
1. Incorporation By Reference; Plan Document Receipt. This Agreement is subject in all respects to the terms and provisions of the Plan (including, without limitation, any amendments thereto adopted at any time and from time to time unless such amendments are expressly intended not to apply to the grant of the option hereunder), all of which terms and provisions are made a part of and incorporated in this Agreement as if they were each expressly set forth herein. Any capitalized term not defined in this Agreement shall have the same meaning as is ascribed thereto under the Plan. The Optionee hereby acknowledges receipt of a true copy of the Plan and that the Optionee has read the Plan carefully and fully understands its content. In the event of any conflict between the terms of this Agreement and the terms of the Plan, the terms of the Plan shall control.
2. Grant of Option. The Company hereby grants to the Optionee, as of the Grant Date specified above, a non-qualified stock option (this “Option”) to acquire from the Company at the Per Share Exercise Price specified above the aggregate number of shares of the Common Stock specified above (the “Option Shares”). This Option is not intended to be treated as, or intended to qualify as, an incentive stock option within the meaning of Section 422 of the Code.
3. No Dividends Equivalents. The Optionee shall not be entitled to receive a cash payment in respect of the Option Shares underlying this Option on any dividend payment date for the Common Stock.
4. Exercise of this Option.
4.1 Unless otherwise provided in Section 4.4 below or determined by the Committee, this Option shall become exercisable in accordance with and to the extent provided by the terms and provisions of Article V of the Plan.
4.2 Unless earlier terminated in accordance with the terms and provisions of the Plan and/or this Agreement, this Option shall expire and shall no longer be exercisable after the expiration of ten (10) years from the Grant Date (the “Option Period”).
4.3 In no event shall this Option be exercisable for a fractional share of Common Stock.
4.4 The Option shall vest [INSERT APPLICABLE VESTING CONDITIONS], provided that Optionee remains continuously engaged as a director, officer, or employee of, or consultant or advisor to, the Company or an affiliate thereof from the date hereof through the applicable vesting date.
5. Method of Exercise and Payment. This Option shall be exercised by the Optionee by delivering to the Secretary of the Company or his designated agent on any business day (the “Exercise Date”) a written notice, in such manner and form as may be required by the Company, specifying the number of the Option Shares the Optionee then desires to acquire (the “Exercise Notice”). The Exercise Notice shall be accompanied by payment of the aggregate Per Share Exercise Price for such number of the Option Shares to be acquired upon such exercise. Such payment shall be made in the manner set forth in Section 5.6 of the Plan.
2
6. Termination; Change of Control.
6.1 If the Optionee’s employment with the Company and/or one of its Subsidiaries terminates for any reason, any then unexercisable portion of this Option shall be forfeited and cancelled by the Company.
6.2 If the Optionee’s employment with the Company and/or its Subsidiaries terminates for any reason other than due to the Optionee’s death or Disability, the Optionee’s rights, if any, to exercise any then exercisable portion of this Option, shall terminate ninety (90) days after the date of such termination, but not beyond the expiration of the Option Period, and thereafter such Option shall be forfeited and cancelled by the Company.
6.3 If Optionee’s termination of employment with the Company and/or its Subsidiaries is due to the Optionee’s death or Disability, the Optionee (or the Optionee’s estate, designated beneficiary or other legal representative, as the case may be and as determined by the Committee) shall have the right, to the extent exercisable immediately prior to any such termination, to exercise this Option at any time within the one (1) year period following such termination due to death or Disability, but not beyond the expiration of the Option Period, and thereafter such Option shall be forfeited and cancelled by the Company.
6.4 The Board or the Committee, in its sole discretion, may determine that all or any portion of this Option, to the extent exercisable immediately prior to the Optionee’s termination of employment with the Company and/or its Subsidiaries for any reason, may remain exercisable for an additional specified time period after the period specified above in this Section 6 expires (subject to any other applicable terms and provisions of the Plan and this Agreement), but not beyond the expiration of the Option Period.
6.5 If the Optionee’s employer ceases to be a Subsidiary of the Company, that event shall be deemed to constitute a termination of employment under Section 6.2 above.
6.6 Optionee shall be deemed to have a “termination of employment” upon (i) the date Optionee ceases to be employed by the Company or any Subsidiary, or any corporation (or any of its subsidiaries) which assumes Optionee’s award in a transaction to which Section 424(a) of the Code applies.
6.7 [Notwithstanding the vesting and/or exercisability provisions otherwise applicable to the Option, the Option shall be fully vested and exercisable upon a Change of Control and shall remain exercisable for the remainder of the Option Period.]
7. Non-transferability. This Option, and any rights or interests therein, shall not be sold, exchanged, transferred, assigned or otherwise disposed of in any way at any time by the Optionee (or any beneficiary(ies) of the Optionee), other than by testamentary disposition by the Optionee or the laws of descent and distribution. This Option shall not be pledged, encumbered or otherwise hypothecated in any way at any time by the Optionee (or any beneficiary(ies) of the Optionee) and shall not be subject to execution, attachment or similar legal process. Any attempt to sell, exchange, pledge, transfer, assign, encumber or otherwise dispose of or hypothecate this Option, or the levy of any execution, attachment or similar legal process upon this Option, contrary to the terms of this Agreement and/or the Plan shall be null and void and without legal force or effect. This Option shall be exercisable during the Optionee’s lifetime only by the Optionee.
3
8. Entire Agreement; Amendment. This Agreement contains the entire agreement between the parties hereto with respect to the subject matter contained herein, and supersedes all prior agreements or prior understandings, whether written or oral, between the parties relating to such subject matter. The Board or the Committee shall have the right, in its sole discretion, to modify or amend this Agreement from time to time in accordance with and as provided in the Plan; provided, however, that no such modification or amendment shall materially adversely affect the rights of the Optionee under this Option without the consent of the Optionee. The Company shall give written notice to the Optionee of any such modification or amendment of this Agreement as soon as practicable after the adoption thereof. This Agreement may also be modified or amended by a writing signed by both the Company and the Optionee.
9. Notices. Any Exercise Notice or other notice which may be required or permitted under this Agreement shall be in writing, and shall be delivered in person or via facsimile transmission, overnight courier service or certified mail, return receipt requested, postage prepaid, properly addressed as follows.
9.1 If such notice is to the Company, to the attention of the Secretary of zSPACE, Inc., 55 Nicholson Lane, San Jose, California 95134, or at such other address as the Company, by notice to the Optionee, shall designate in writing from time to time.
9.2 If such notice is to the Optionee, at his or her address as shown on the Company’s records, or at such other address as the Optionee, by notice to the Company, shall designate in writing from time to time.
10. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without reference to the principles of conflict of laws thereof.
11. Compliance with Laws. The issuance of this Option (and the Option Shares upon exercise of this Option) pursuant to this Agreement shall be subject to, and shall comply with, any applicable requirements of any federal and state securities laws, rules and regulations (including, without limitation, the provisions of the Securities Act of 1933, the Exchange Act and the respective rules and regulations promulgated thereunder) and any other law or regulation applicable thereto. The Company shall not be obligated to issue this Option or any of the Option Shares pursuant to this Agreement if any such issuance would violate any such requirements.
12. Binding Agreement; Assignment. This Agreement shall inure to the benefit of, be binding upon, and be enforceable by the Company and its successors and assigns. The Optionee shall not assign any part of this Agreement without the prior express written consent of the Company.
4
13. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same instrument.
14. Headings. The titles and headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not be deemed to be a part of this Agreement.
15. Further Assurances. Each party hereto shall do and perform (or shall cause to be done and performed) all such further acts and shall execute and deliver all such other agreements, certificates, instruments and documents as any party hereto reasonably may request in order to carry out the intent and accomplish the purposes of this Agreement and the Plan and the consummation of the transactions contemplated thereunder.
16. Severability. The invalidity or unenforceability of any provisions of this Agreement in any jurisdiction shall not affect the validity, legality or enforceability of the remainder of this Agreement in such jurisdiction or the validity, legality or enforceability of any provision of this Agreement in any other jurisdiction, it being intended that all rights and obligations of the parties hereunder shall be enforceable to the fullest extent permitted by law.
[remainder of page intentionally left blank; signature page follows]
5
IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer, and the Optionee has hereunto set his hand, all as of the Grant Date specified above.
zSPACE, INC. | ||
By: | ||
Name: | ||
Title: | ||
Optionee: [OPTIONEE NAME] |
6
Exhibit 10.17
AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT
This Amendment No. 1 to Loan and Security Agreement (this “Amendment”) is entered into as of July 11, 2024 (the “Effective Date”) by and between FIZA INVESTMENTS LIMITED, an entity organized under the laws of the Cayman Islands (together with its assigns, “Lender”), and ZSPACE, INC., a Delaware corporation (“Borrower”). The parties agree as follows:
RECITALS
Lender and Borrower have entered into that certain Loan and Security Agreement dated November 3, 2022 as the same may from time to time be amended, modified, supplemented or restated, the “Loan Agreement”).
The Borrower has requested that Lender amend certain provisions of the Loan Agreement as more specifically set forth herein.
Certain Events of Defaults described in Section 3 below have occurred and are continuing under the Loan Agreement (the “Existing Defaults”) and the Borrower has requested that Lender waive such Existing Defaults.
The Lender is willing to (i) agree to such amendments and (ii) waive the Existing Defaults, in each case, in accordance with, and subject to, the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the agreements and covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1. Definitions. Capitalized terms used but not defined in this Amendment, including its preamble and recitals, shall have the meanings given to them in the Loan Agreement.
2. Amendment.
(a) Schedule A to the Loan Agreement is hereby amended as follows:
(i) The “Maturity Date” section set forth on Schedule A is hereby amended and restated in its entirety to read as follows:
“July 31, 2026 (the “Maturity Date”).”
(ii) The “Repayment/Prepayment” section set forth on Schedule A is hereby amended to replace the first paragraph of the section in its entirety to read as follows:
“Mandatory payment of each Loan shall be due upon the earlier of (i) the Maturity Date, (ii) an Event of Default and (iii) any Change of Control or other liquidation event other than a Public Offering, in each case, including without limitation, any voluntary pre-payments, or payments after the Maturity Date and such payment shall include all outstanding principal, all accrued and unpaid interest, all unpaid Lender Expenses. For purposes of clarity, all Loans may be voluntarily prepaid in full (or part) within three (3) Business Days’ notice to Lender on the same terms of the mandatory prepayment listed in the preceding sentence.
(b) Schedule C to the Loan Agreement is hereby amended as follows:
(i) The “Qualified Public Offering” definition set forth on Schedule C is hereby amended and restated in its entirety to read as follows:
““Qualified Public Offering” means a firm commitment underwritten public offering (i) pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $15,000,000 of gross proceeds to the Borrower, or (ii) pursuant to a similar regulatory framework applicable to a non-U.S. public offering resulting in at least $10,000,000 of gross proceeds to the Borrower, in either case, with such offering resulting in the Common Stock of Borrower being listed for trading on an exchange or marketplace approved by the Borrower’s Board of Directors and a pre-money valuation for such offering at which GII receives equity in exchange for the entire principal and interest payable under each Loan as provided herein.”
3. Waivers.
(a) Effective as of the Effective date, the Lender hereby waives the Event of Default that has occurred and is continuing under Section 6(iii) of the Loan Agreement due to the Borrower’s failure to pay when due the Loan or other monetary obligation within three (3) Business Days after the due date.
(b) Effective as of the Effective date, the Lender hereby waives the Event of Default that has occurred and is continuing under Section 6(i) of the Loan Agreement as a result of the Borrower’s noncompliance with Financial Reporting and Sales Process Requirements set forth in Schedule A of the Loan Agreement due to the Borrower’s failure to deliver monthly and audited consolidated financial statements of the Borrower and its Subsidiaries within the time periods stipulated.
4. Entire Agreement. This Amendment shall be binding upon Borrower and its successors and assigns and shall inure to the benefit of Lender and its respective successors and assigns. This Amendment and all documents, instruments, and agreements executed in connection herewith incorporate all of the discussions and negotiations between Borrower and Lender, either expressed or implied, concerning the matters included herein and in such other documents, instruments and agreements, any statute, custom, or usage to the contrary notwithstanding. No such discussions or negotiations shall limit, modify, or otherwise affect the provisions hereof. No modification, amendment, or waiver of any provision of this Amendment, or any provision of any other document, instrument, or agreement between Borrower and Lender shall be effective unless executed in writing by the party to be charged with such modification, amendment, or waiver, and if such party be Lender, then by a duly authorized officer thereof.
5. Illegality or Unenforceability. Any determination that any provision or application of this Amendment is invalid, illegal, or unenforceable in any respect, or in any instance, shall not affect the validity, legality, or enforceability of any such provision in any other instance, or the validity, legality, or enforceability of any other provision of this Amendment.
2
6. Consistent Changes; Conflicts. The Loan Documents are hereby amended wherever necessary to reflect the changes described above. To the extent any term or provision herein conflicts with any term or provision contained in any of the Loan Documents, the term or provision provided for herein shall control.
7. Continuing Validity. Except as expressly modified pursuant to this Amendment, the terms of the Loan Documents remain unchanged and in full force and effect. Nothing in this Amendment shall constitute a satisfaction of the Obligations. It is the intention of Lender and Borrower to retain as liable parties all makers and endorsers of Loan Documents, unless the party is expressly released by Lender in writing. No maker, endorser, or guarantor will be released by virtue of this Amendment. The terms of this Section 6 apply not only to this Amendment, but also to all subsequent loan modification agreements.
8. No Waiver. This Amendment is not applicable to any Event of Default under any Loan Document arising after the Effective Date or as a result of the transactions contemplated hereby.
9. Reservation of Rights. Lender hereby reserves all rights and remedies under the Loan Documents, at law, in equity or otherwise.
10. Successors and Assigns. This Amendment shall inure to the benefit of and be binding upon the heirs, successors, and permitted assigns of the parties.
11. Governing Law and Jurisdiction. This Amendment shall be construed and enforced in accordance with the terms of the laws of the State of New York without regard to its conflicts of laws principles. If any provision of this Amendment is not enforceable, the remaining provisions of the Amendment shall be enforced in accordance with their terms. Borrower, and Lender represent and warrant to each other that each is duly authorized to execute and deliver this Amendment on their respective behalves.
12. Counterparts. This Amendment may be executed in two or more counterparts each of which shall constitute an original and all of which shall, when taken together, constitute one and the same agreement, notwithstanding that all parties may not have signed all counterparts of this Amendment.
[Signatures Appear on the Following Page]
3
IN WITNESS WHEREOF, the parties hereto have executed, or caused this Amendment to be executed by the respective officer or authorized signatory thereunto duly authorized, as of the date first written above.
Borrower: | ||
ZSPACE, INC. | ||
By: | /s/ Paul Kellenberger | |
Name: | Paul Kellenberger | |
Title: | Chief Executive Officer | |
Lender: | ||
FIZA INVESTMENTS LIMITED | ||
By: | /s/ Husain Zariwala | |
Name: | Husain Zariawala | |
Title: | Authorised Signatory | |
By: | Imran Ladhani | |
Name: | Imran Ladhani | |
Title: | Authorised Signatory |
SIGNATURE PAGE
AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT
Exhibit 10.34
Certain confidential information contained in this document, marked by “[***]”, has been omitted because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. |
[***] SPECIALISED APPLICATION
LICENCE AGREEMENT
This [***] Specialised Application Licence Agreement is made as of [***] (“Effective Date”) and is between [***], a California corporation with its offices at [***] “[***]”) and the company whose details are set out below (“Company”).
This [***] Specialised Application Licence Agreement incorporates the [***] Specialised Application Terms and Conditions included as Schedule 1.
1. | Business Contacts and Address for Notice |
2. | Description of Company Distributables: zSpace’s [***] products. |
3. | Initial Term: 3 years. |
4. | Products/Fees: |
a. | The hardware, software, and licence included in the table below may be purchased from [***] as a single unit (hereafter, an “Enterprise Bundle”) for the fees specified (save for units ordered pursuant to clause 5). |
Software | [***] Device | Licence description | Per Unit fee (USD) | |
[***] | [***] | [***] |
Per order:
• [***][***][***] • [***] |
Page 1 of 3
b. | [***] Enterprise Bundle [***] of the Company Distributable prior to its distribution to Company’s customers. |
5. | Initial Purchase Commitment. Company shall provide [***] with initial purchase order(s) for [***]Enterprise Bundles on the Effective Date, which shall be delivered in the following instalments: |
a. | [***] Enterprise Bundles to ship on or before [***]; and |
b. | [***] Enterprise Bundles to ship on or before [***]. |
6. | Minimum Purchase Quantities. Company shall only purchase Enterprise Bundles in multiples of [***]. |
7. | Payment Terms: |
a. | In respect of the initial purchase pursuant to clause 5: the total sum due shall be paid by Company in [***] monthly instalments of [***] between [***] and [***] inclusive, each instalment to be received by [***] in cleared funds on or before the last day of each month. |
b. | For all other purchases: 30 days after receipt of invoice. |
8. | Ordering Procedures. Upon approval of a numbered purchase order from Company, [***] will process order promptly in accordance with [***]’s standard order terms and conditions provided to the Company from time to time. |
9. | Marketing special terms. |
a. | Company shall exhibit at least one minimally viable demo that incorporates the Enterprise Bundle at the [***], subject to the [***] feature of the Company Distributable working to a mutually agreed level at such time (“[***] Demo”). |
b. | Company and [***] shall make one public press release regarding the [***] Demo in the Company Distributable prior to the [***], which shall include as a minimum at least one quote from each party’s executive leadership team. |
c. | Either party may at its option mention the other party and its products in press releases, press briefings, social media accounts, and/or website, or other analogous marketing activities, and may use the other party’s trademarks for such purpose, provided that at least two weeks written notice with details of the proposed activity is provided to the other party and the other party does not object to such activity prior to the two week notice elapsing. In the case of [***], should such marketing activities be regarding [***], they shall not relate to [***] [***]. |
Page 2 of 3
10. | Device warranty special terms. |
10.1. | [***] warrants that the [***] Devices shall: |
a. | be safe, of good quality and free from any defect in manufacturing or material; and |
b. | shall correspond strictly with any and all representations, descriptions, advertisements, brochures, drawings, specifications and samples made or given by [***] prior to the Effective Date. |
10.2. | Company shall inspect the received [***] Devices within 14 days of receipt of the delivery and shall inform [***] within a further period of 3 working days of any apparent defect. Non-apparent defects shall be informed to [***] within 14 days after they have become apparent. If the [***] Devices are defective and/or do not conform with the warranty given in Section 11.1 above (‘Defective Devices’), [***] shall, at the option of Company: |
a. | provide a like for like replacement of the Defective Device(s) as soon as reasonably possible without any additional cost to Company, or |
b. | repair the Defective Device without any additional cost to Company, or |
c. | reimburse Company the Per Unit Fee (or a proportionate sum if purchased as part of a bulk purchase) paid for each Defective Product. |
10.3. | Claims under this clause 10 must be made within twelve months of the date of delivery of the relevant [***] Devices. |
COMPANY | [***] | |||
By: | By: | |||
Name: | Name: | |||
Title: | Title: | |||
Date: | November 10, 2023 | Date: |
Page 3 of 3
Certain confidential information contained in this document, marked by “[***]”, has been omitted because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. |
SCHEDULE 1- [***] SPECIALISED APPLICATION TERMS AND CONDITIONS
BACKGROUND
A. | [***] has developed the [***] Software that works with an [***] Device to create a [***] space to precisely interact with and control software through [***]. |
B. | Company has developed the Company Distributable that is a Specialised Application under the SDK Agreement Company wishes to distribute, and [***] wishes to license the [***] Technology for use in the Company Distributables for distribution and/or multi-user use. |
C | Company may wish to purchase [***] Devices from [***] for use in connection with the Company Distributables. |
AGREEMENT |
For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, [***] and Company hereby agree as follows:
1. | Definitions |
Whenever capitalised in these terms and conditions:
1.1. | “Agreement” means this Specialised Application Licence Agreement between [***] and the Company including the cover sheet and this Schedule 1. |
1.2. | “Company Distributable” means the Company’s application and/or device set out in the Specialised Application Licence Agreement |
1.3. | “Confidential Information” means this Agreement and its terms, schedules and attachments, and all other technical, business, product, marketing and financial information, plans and data provided orally, in writing, or by inspection of tangible objects provided or disclosed under or pursuant to this Agreement. Confidential Information does not include information that, as supported by documentation, (i) has become generally publicly known without any improper action or inaction; (ii) was in the rightful possession of the recipient without any obligation of confidentiality; (iii) was rightfully disclosed by a third party without restriction on disclosure; (iv) is independently developed by the receiving party; or (v) is disclosed if required by law or court order (but only to the extent of such disclosure), provided that the recipient will make reasonable efforts to give the disclosing party prior notice of the law or court order and cooperate with any attempts to obtain a protective order or similar treatment. |
1.4. | “End User” means an end user of Company Distributable. |
1.5. | “Enterprise Licence” means the licence agreement included as Annex 1 as amended by [***] from time to time. |
1.6. | “Fee” means the fees set out on this Specialised Application Licence Agreement |
Page 1 of 12
1.7. | “SDK” means, collectively, the [***] Redistributables, tools, APIs, sample code, software, documentation, other materials and any updates to the foregoing that may be provided or made available to you by [***] in connection with this Agreement, via the [***] developer portal or otherwise for use in connection with the [***] development program to develop [***] enabled applications. |
1.8. | “Specialised Application Licence Agreement” means this [***] Specialised Application Licence Agreement between [***] and the Company as of the Effective Date, together with any amendments, supplements or replacements thereto. |
1.9. | “[***] Device” means an [***] peripheral device or [***]-authorised embedded optical module, including but not limited to the [***], that obtains images and passes them to the [***] Software. |
1.10. | “[***] Redistributables” has the meaning given the term in the SDK Agreement. |
1.11. | “[***] Software” means the following and includes any updates thereto. |
(1) | Version 5 of the [***] core services application and related applications (vs [***] software) that interact with an [***] Device and an operating system to make motion control functionality available to other applications and software through an interface. |
(2) | For the [***] Devices supplied hereunder, within two weeks of the effective date of this agreement [***] shall provide an unlock tool set which unlocks the [***] module permanently for the duration of the [***] module’s expected life (“Unlock Tool”). The Unlock Tool shall be (i) implemented as a Windows command line application, compatible with Windows 11 OS and (fi) the unlock procedure must NOT require an active internet connection so that it will succeed on any offline Windows computer before or after the sale of Company Distributables. During execution, the Unlock Tool shall display status information, notifying the user about a) the progress of the unlock operation, b) the final successor failure status of the unlock operation and c) upon execution completion, return success or failure codes as described in the accompanying documentation. |
(3) | For the [***] Devices supplied hereunder, a firmware update tool which updates the cameral module firmware to the most current version made available for the duration of the [***] module’s expected life (“FW Update Tool”). The FW Update Tool shall be (i) implemented as a Windows command line application, compatible with Windows 11 OS and subsequent Windows OS release(s), (ii) only rely on USB video device class and (iii) the firmware update procedure must NOT require an active internet connection so that it will succeed on any offline Windows computer before or after the sale of Company Distributables. During execution, the FW Update Tool shall display status information, notifying the user about a) the progress of the firmware update operation, b) the final success or failure status of the update operation and c) upon execution completion, return success or failure codes as described in the accompanying documentation. |
Page 2 of 12
1.12. | “[***] Technology” means the [***] Device, [***] Software, [***] Redistributable and any other technology provided by [***] from time to time. |
1.13. | “Unit” refers to one Enterprise Bundle. |
1.14. | “Updates” means changes to the [***] Software produced from time to time by [***] to keep a released version of the [***] Software current as to functionality, or to correct any errors, install patches, fix bugs, or perform similar enhancements, and generally indicated by a change in the digit to the right of the decimal point (e.g. a change from version cx to version icy) or other similar indicia, with any corrections and updates to associated documentation. |
1.15. | “Upgrade” means an [***] Software release containing new enhancements, features or functionality which is generally indicated by a change in the digit to the left of the first decimal point (e.g. a change from version x.x. to y.x) or other similar indicia, with associated documentation. |
Other capitalised terms used in the Agreement have the meaning given to them elsewhere in the Agreement.
2. | Purchase / Licence of Units |
2.1. | Purchases of Enterprise Bundles. Company shall purchase the Enterprise Bundles directly from [***]. |
2.2. | Purchase/Licence. Company agrees to purchase and license that minimum number of Units set out in the Specialised Application Licence Agreement (if any). The Fee for each Unit as well as any Units ordered pursuant to Section 2.3 is set out in the Specialised Application Licence Agreement Pricing will be in effect for the Initial Term. |
2.3. | Ordering of [***] Enterprise Bundles. Company may initiate purchases of Enterprise Bundles under this Agreement only by submitting electronic or written purchase orders to [***]. No purchase order will be binding until accepted by [***] electronically or in writing, and such acceptance is only in accordance with the terms of this Agreement and any applicable [***] programs. Such acceptance may be evidenced by [***]’s shipment of the order, in whole or in part. No terms or conditions found on Company’s purchase order will be binding on [***]. No partial shipment of an order will constitute the acceptance of the entire order, absent the written acceptance of the entire order. Company may not cancel or reschedule the delivery date for Units under orders accepted by [***] without [***]’s prior written approval. |
2.4. | Delivery Terms. Unless otherwise set out in the Specialised Application Licence Agreement or agreed to in separate writing between the parties, all [***] Devices ordered by Company from [***] will be delivered Free Carrier (FCA) (Incoterms 2020) from [***]’s premises. The risk in the [***] Devices shall pass to the Company on delivery to the carrier. Title to the [***] Devices shall not pass to the Company until [***] receives payment in full for the [***] Devices.. Delivery of the [***] Software will be via download from [***] servers on configuration by Company or its End Users of the [***] Device. |
Page 3 of 12
2.5. | Payment. Payment will be made in accordance with the Specialised Application Licence Agreement, without any withholding of taxes. If Company fails to make any payment due under the Agreement by the due date for payment, then Company shall pay interest on the overdue amount at the rate of [***]% per annum. Such interest shall accrue on a daily basis from the due date until actual payment of the overdue amount, whether before or after judgment Company shall pay the interest together with the overdue amount. |
2.6. | Taxes. Prices are exclusive of sales and use tax, VAT, GST and other similar taxes. Such taxes, if applicable, will be added separately to [***]’s invoice, and Company will remit such taxes to [***]. |
3. | Licence and Restrictions |
3.1. | Licence. To the extent permitted by and subject to any conditions in the Specialised Application Licence Agreement, including its referenced schedules, and in consideration of Company’s payment of all Fees, [***] hereby grants Company a limited, non-exclusive, personal, royalty-bearing licence under [***]’s applicable intellectual property rights to the extent necessary to: (a) copy and distribute (or have copied and distributed including through its resellers), the [***] Redistributables solely as compiled with, incorporated into, or packaged with, the Company Distributables; (b) to make (but not have made), use, sell, offer for sale and import the Company Distributables; and (c) to install on a single Company Distributable one copy of the [***] Software for each Unit purchased or licensed by Company solely for use in connection with a unit of the Company Distributables. Company may transfer the [***] Software only to its End Users solely in connection with a transfer of Units purchased or licensed by Company to its End Users. |
3.2. | Updates. The licence granted in Section 3.1 includes a licence to any Updates that [***] may, in its sole discretion, make available to Company and its End Users. Company acknowledges and agrees that Updates to the [***] Software may impact the functionality of the Company Distributables, including the ability of the Company Distributables to interact with the [***] Software. Company will be solely responsible for the functionality of the Company Distributables, and solely responsible for disabling any auto-update functionality in the [***] Software. |
3.3. | Restrictions. The licences granted to Company in Section 3.1 are subject to the following restrictions, as well as others listed in the SDK Agreement: |
3.3.1. | except as specifically permitted in Section 3.1 Company may not, and may not enable others to, sell, re-distribute, rent, lease or sublicense the [***] Software. Company may not make the [***] Software available over a network where it could be used by multiple computers at the same time, or accessed remotely in a virtual operating system environment, or otherwise. |
3.3.2. | Company may not, directly or indirectly, publish, post or otherwise make available the [***] Redistributables other than as compiled with, incorporated into, or packaged with, the Company Distributables. |
Page 4 of 12
3.3.3. | Company may not reverse engineer, decompile, disassemble or otherwise attempt to reconstruct, identify or discover any source code, underlying ideas, techniques, or algorithms in the [***] Software or SDK or attempt to read the FPGA code embedded in [***] Devices (except as and only to the extent any foregoing restriction is prohibited by applicable law or permitted by applicable law or licence notwithstanding the foregoing restriction). |
3.3.4. | Company may not remove, obscure, or alter any proprietary rights or confidentiality notices within the [***] Software or any documentation or other materials in it or supplied with it (where relevant, and where distributed alongside the Company Distributable). |
3.3.5. | Company may not represent [***] Software as Company technology or that of third parties. |
3.3.6. | Company may not use [***] Technology for applications relating to the following: (a) the production of or trade in tobacco, alcoholic beverages, and related products, (b) the production or trade in weapons of any kind or any military applications, (c) casinos, gambling and equivalent enterprises, (d) human cloning, human embryos, or stem cells, or (e) nuclear energy. |
3.3.7. | Save for its use with the Company Distributables as permitted under this Agreement, Company may not use the SDK to create, or aid in the creation, directly or indirectly, of any software or hardware which provides [***] functionality, or which is otherwise substantially similar to the features or functionality of [***] products. For clarification, the above limitation does not prevent Company from developing features and functionality similar to [***] without the use of the SDK or [***] Software. |
3.3.8. | Company must not allow the [***] Software or SDK to fall under the terms of any license which would obligate Company or [***] to make available or publish any part of the [***] Software or SDK. |
3.3.9. | You and/or your Company Distributable may access the Image API (being the tools included within the [***] Software that facilitates the accessing of images and image associated data) and use image data available through the Image API only for the purpose of developing, testing, or using the Company Distributable. You may not use the Image API to develop or aid development of competing [***] hardware or software. | |
If you or your Company Distributable collects, uploads, stores, transmits, or shares images, videos, or other personal information available through the Image API, either through or in connection with your Company Distributable, you agree to comply with all applicable criminal, civil, and statutory privacy and data protection laws and regulations. |
Page 5 of 12
3.4. | High Risk Uses. Notwithstanding anything in this Agreement, Company is not licensed to, an agrees not to, use, copy, sell, offer for sale, or distributed the [***] Technology (whether compiled with, incorporated into, or packaged with the Company Distributable) for or in connection with uses where failure of fault of the [***] Technology or the Company Distributable could lead to death or serious bodily injury of any person, or to severe physical or environmental damage (“High Risk Use”). Any such use is strictly prohibited. |
3.5. | Acknowledgment and Waiver. Company agrees that it is solely responsible for the Company Distributables and ensuring that they are safe and free of defects in design and operation, so that any integration by Company causing a failure of an [***] Device, the [***] Software, an [***] Redistributable and/or other [***] technology used by Company does not cause personal injury, death, or property damage (each Company Distributable complying which such requirements being a ‘Compliant Device). Company acknowledges that the [***] Device, the [***] Software, and the [***] Redistributables may not always function as intended. If Company chooses to distribute the Company Distributables that are not Compliant Devices, in respect of each such Company Distributable, (i) Company assumes all risk that the integration by Company of the [***] Device, the [***] Software, an [***] Redistributable and/or other [***] technology used by Company or by any others causes any harm or loss, including to the End Users of the Company Distributables or to third parties, (6) Company hereby waives, on behalf of itself and its affiliates, subsidiaries, officers, directors, employees and contractors, all claims against [***] and its affiliates related to such use, harm or loss, and (iii) Company agrees to defend, indemnify and hold [***] and its affiliates harmless from such claims and any claims of Company’s End Users or other third parties. |
3.6. | Compliance with Laws. Company is entirely responsible for ensuring that the development, manufacturing and commercialisation of the Company Distributables is in accordance with applicable laws. Without limiting the generality of the foregoing if the Company Distributables are used in the medical field, Company will be solely responsible for compliance with all applicable laws and regulations related to the development, marketing, commercialisation and use of medical or therapeutic technologies. |
3.7. | Software Licensed, Not Sold. Notwithstanding the use of terms such as “purchase” and “sale” in this Agreement, copies of the [***] Software are licensed, not sold, and “purchase” and “sale” when used in relation to the [***] Software refers to the purchase and sale of a licence to use the [***] Software, as set forth in this Agreement |
3.8. | Upgrades. Company’s licence does not include a licence to any Upgrades or to any additional functionality beyond [***] that [***] may develop or offer for licence, including but not limited to, [***] or other functionality. |
4. | Multi-User Licence. To the extent permitted by and subject to any conditions in this Specialised Application Agreement and conditioned upon compliance with its terms and conditions [***] hereby grants to Company a limited non-exclusive licence, with the right to grant sub-licence to Company’s resellers and End Users, to use the [***] Software in a multi-user environment solely in connection with the Company Distributables. |
Page 6 of 12
5. | Trademark Licence; Marketing |
5.1. | Trademark Licence. Conditioned upon compliance with the terms and conditions of this Agreement, and In consideration of Company’s payment of all Fees, [***] hereby grants Company a limited, nonexclusive, personal, licence to reproduce and use [***] trademarks solely to mark the Company Distributables, related collateral, and to promote and market the Company Distributables, solely in accordance with the [***] trademark guidelines that [***] may provide Company from time to time. Such licence includes the right of Company to sublicence Company’s, resellers, and other third parties to achieve the foregoing. Company will, on request of [***], submit any uses of [***] marks by Company or its sub-licensees to [***] for review to determine if such uses are in accordance with [***] trademark guidelines. If the uses are not in accordance with the guidelines, Company will promptly correct the misuses. Company acknowledges and agrees that all uses of the [***] marks will inure to the benefit of [***]. |
5.2. | Marketing. Company and [***] agree to the following marketing efforts: |
5.2.1. | For so long as [***] Technology is included with the Company Distributables, Company will specifically identify on the packaging of the Company Distributables, the loading screen and start-up messages for the Company Distributables and list on its website and marketing collateral, as prominently as other listed features and functionality, that [***] Technology is included with the Company Distributables, in accordance with such guidelines and conditions as [***] may reasonably require. Where requested by [***], Company will apply a sticker including [***]’s logo to each Company Distributable with includes [***] Technology for [***]. All references to [***] or [***] Technology will be subject to [***]’s prior approval, which will not be unreasonably withheld. |
5.2.2. | Company will include a hyperlink to the [***] website in the first and most prominent mention of [***] or [***] on the Company website. |
6. | End User Licensing. Company shall require its End Users to agree to Company’s own end user licence agreement (“Company EULA”) that incorporates the [***] enterprise licence attached as Annex 1, and shall provide a copy of such Company EULA to [***] on request. Company shall ensure that affirmative assent to the Company EULA is gained prior to use of each Company Distributable. If Company learns of any breach of terms relevant to the use of the [***] Software in the Company EULA by an End User, Company shall notify [***] as soon as reasonably possible in writing of such breach. Company shall use all reasonable endeavours to enforce the terms of the Company EULA. |
7. | Support. [***] and its parents, subsidiaries or affiliates and suppliers will not be required to provide any support to Company or its End Users under this Agreement_ [***] and its parents, subsidiaries or affiliates and suppliers have no obligation to modify, or provide any support to assist with modifications of the [***] Software for use with the Company Distributables. Company is solely responsible for the support of its own customers for the Units. Company will be solely responsible for, and [***] and its parents, subsidiaries or affiliates and suppliers will have no obligation to honour, any warranties that Company or any of its Company’s or resellers provides to End Users with respect to the [***] Software, the [***] Device or the Company Distributables. |
Page 7 of 12
8. | Company Reporting Obligations. Beginning [***], Company will provide [***] a rolling quarterly forecast for Units within 10 days after the end of each calendar quarter. [***] may provide a standardised template for the reports specified in this provision. Subject to anything to the contrary set out in the Specialised Application Licence Agreement, forecasts are for planning purposes only and are not a commitment by Company to buy or licence or by [***] to sell or licence. |
9. | Audit Rights. During the term of the Agreement and for three years thereafter, not more than once per 12-month period during normal business hours and upon reasonable notice, [***] will have the right to, or to have an independent auditor, perform an audit of Company’s business records and/or physical inventory related to the performance of its obligations under this Agreement. [***] will pay the cost of the audit, unless the audit reveals that Company is materially in non-compliance with the terms of this Agreement, in which case [***] may, in addition to any other remedy set forth hereunder, require Company to: (a) promptly refund or credit to [***] all amounts owing to [***] that were revealed by such audit; and (b) reimburse [***] for the reasonable costs of the audit (including without limitation attorneys’ fees in connection therewith). For purposes of this section, “materially in non-compliance” will include without limitation a discrepancy of more than five percent (5%) of the amounts that should have been paid by Company to [***] during the period covered by the audit as indicated by [***]. My audit pursuant to this Section will not unreasonably interfere with Company’s business or operations. |
10. | Warranty Disclaimer. |
10.1 | SAVE FOR AND TO THE EXTENT OF THE WARRANTY PROVIDED AT CLAUSE 11 OF THE COVER PAGE TO THIS AGREEMENT RELATING TO HARDWARE [***] DEVICES ONLY, THE [***] TECHNOLOGY IS PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND. [***], ON BEHALF OF ITSELF AND ITS SUPPLIERS, HEREBY DISCLAIMS ALL REPRESENTATIONS, PROMISES, OR WARRANTIES, WHETHER EXPRESS, IMPUED, STATUTORY, OR OTHERWISE, WITH RESPECT TO THE [***] TECHNOLOGY, INCLUDING THEIR CONDITION, AVAILABILITY, OR THE EXISTENCE OF ANY LATENT DEFECTS. [***] SPECIFICALLY DISCLAIMS ALL IMPUED WARRANTIES OF MERCHANTABILITY, TITLE, NONINFRINGEMENT, SUITABILITY, AND FITNESS FOR ANY PURPOSE. [***] DOES NOT WARRANT THAT THE [***] TECHNOLOGY WILL BE ERROR-FREE OR THAT THEY WILL WORK WITHOUT INTERRUPTION. |
11. | Confidentiality |
11.1. | Confidentiality Obligations. Company and [***] (receiving party) shall keep in strict confidence all technical or commercial know-how, specifications, inventions, processes or initiatives which are of a confidential nature and have been disclosed to the receiving party by Company and [***] (disclosing party) as confidential. The receiving party shall only disclose such confidential information to those of its affiliates, employees, agents and subcontractors who need to know it for the purpose of discharging the receiving party’s obligations under the Agreement. The receiving party may also disclose such of the disclosing party’s confidential information as is required to be disclosed by law, any governmental or regulatory authority or by a court of competent jurisdiction. |
Page 8 of 12
11.2. | This clause 11 shall survive the termination of the Agreement for a period of 3 years. |
11.3. | Other Publicity. The parties may not issue any press releases or other public communications that refer to the other party without prior written consent. |
12. | Company’s Obligations and Warranties |
In addition to Company’s other obligations under this Agreement, Company warrants and agrees that:
12.1. | Company has the right and authority to enter into this Agreement on its own behalf and that of its authorised users and this Agreement, when executed, shall constitute legal, valid and binding obligations of the Company and shall be enforceable against the Company in accordance with its terms; and |
12.2. | the Company Distributables will be in compliance with all applicable laws and regulations [***] and local or foreign export and re-export restrictions applicable to the technology and documentation provided under this Agreement (including privacy and data security laws and regulations). |
13. | Term and Termination |
13.1. | Term. This Agreement begins as of the Effective Date and continues for the Initial Term (as set out in the Specialised Application Licence Agreement) with automatic renewals for successive one (1) war periods unless either party provides notice of non-renewal at least three (3) months prior to the expiration of the Initial Term, or any renewal term, or, in the case of the Initial Term or any renewal term, unless earlier terminated as set out in Section 13.2, Section 13.3 or Section 13.4 below. The Initial Term together with any renewal terms are the “Term”. |
13.2. | Termination by Company. Company may terminate this Agreement after the Initial Term by giving not less than thirty (30) days’ written notice to [***]. |
13.3. | Termination by [***]. [***] may terminate this Agreement in the case of Company’s uncured material breach on thirty (30) days’ notice, or, if the breach is not capable of cure, immediately upon notice. |
13.4. | Automatic Termination. Notwithstanding sections 13.1 - 13.3 above, this Agreement may be terminated at any time by each party on written notice with immediate effect in the event that (i) proceedings in bankruptcy or insolvency are instituted by or against the other party or a receiver, trustee, administrator or liquidator is appointed in respect of any part of the other part’s assets or any similar relief is granted under any applicable bankruptcy or equivalent law or (H) one party (the defaulting party) shall be in breach, non-observance or non-performance of any of its obligations in this Agreement and does not remedy the same within fourteen (14) days of notice of such failure or breach being served upon it by the other party (the non-defaulting party). |
Page 9 of 12
13.5. | Effect of Expiration or Termination. Upon expiration or termination of this Agreement: (i) Company will accept delivery of, and pay for, Units ordered by it before expiration or termination, (H) unless [***] has terminated this Agreement pursuant to Section 13.3, or this Agreement automatically terminates under Section 13.4: (a) [***] will continue to supply Units ordered by Company before expiration or termination, and (b) if the Company Distributables incorporate [***] Redistributables, Company may continue to distribute the Company Distributables for up to six months after expiration or termination, and (Hi) any licence rights of Company’s End Users will continue despite expiration or termination of this Agreement. Sections 1, 2.5, 9, 10, 11, 12.2, 13.5, 14 and 15 will survive termination or expiration of this Agreement. |
14. | Limitation of Liability. |
14.1. | [***] SHALL NOT IN ANY CIRCUMSTANCES WHATEVER BE LIABLE TO THE COMPANY, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), BREACH OF STATUTORY DUTY, OR OTHERWISE, ARISING UNDER OR IN CONNECTION WITH THE AGREEMENT FOR: |
(A) | LOSS OF PROFITS, SALES, BUSINESS, OR REVENUE; |
(B) | BUSINESS INTERRUPTION; |
(C) | LOSS OF ANTICIPATED SAVINGS; |
(D) | LOSS OR CORRUPTION OF DATA OR INFORMATION; |
(E) | LOSS OF BUSINESS OPPORTUNITY, GOODWILL OR REPUTATION; OR |
(F) | ANY INDIRECT OR CONSEQUENTIAL LOSS OR DAMAGE. |
14.2. | OTHER THAN THE LOSSES SET OUT ABOVE (FOR WHICH [***] IS NOT LIABLE), [***]’S MAXIMUM AGGREGATE LIABILITY UNDER OR IN CONNECTION WITH THE AGREEMENT WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), BREACH OF STATUTORY DUTY, OR OTHERWISE, SHALL IN ALL CIRCUMSTANCES BE LIMITED TO THE PAYMENT ACTUALLY PAID BY THE COMPANY IN THE TWELVE MONTHS PRIOR TO THE DEFAULT GMNG RISE TO THE CLAIM ARISING. THIS MAXIMUM CAP DOES NOT APPLY TO DEATH OR PERSONAL INJURY RESULTING FROM [***]’S NEGUGENCE; FRAUD OR FRAUDULENT MISREPRESENTATION; OR ANY OTHER LIABIUTY THAT CANNOT BE EXCLUDED OR LIMITED BY APPLICABLE LAW. |
Page 10 of 12
14.3. | THE AGREEMENT SETS OUT THE FULL EXTENT OF [***]’S OBLIGATIONS AND LIABILITIES IN RESPECT OF THE SUPPLY OF THE [***] DEVICES, DELIVERABLES AND SOFTWARE. EXCEPT AS EXPRESSLY STATED IN THE AGREEMENT, THERE ARE NO CONDITIONS, WARRANTIES, REPRESENTATIONS OR OTHER TERMS, EXPRESS OR IMPLIED, THAT ARE BINDING ON [***]. ANY CONDMON, WARRANTY, REPRESENTATION OR OTHER TERM CONCERNING THE SUPPLY OF THE [***] DEVICES, DELIVERABLES AND SOFTWARE WHICH MIGHT OTHERWISE BE IMPLIED INTO, OR INCORPORATED IN THE AGREEMENT WHETHER BY STATUTE, COMMON LAW OR OTHERWISE, INCLUDING ANY WARRANTY OR CONDITION OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, IS EXCLUDED TO THE FULLEST EXTENT PERMITTED BY LAW. THESE LIMITATIONS WILL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. THE PARTIES AGREE THAT THE FOREGOING LIMITATIONS REPRESENT A REASONABLE ALLOCATION OF RISK UNDER THIS AGREEMENT. |
15. | Miscellaneous. |
15.1. | Assignment. Neither party may assign this Agreement without the prior written consent of the other party. My assignment without such consent is void and of no effect Either party may assign this Agreement without the consent in connection with (1) a merger or consolidation, (2) a sale or assignment of substantially all its assets, or (3) any other transaction which results in another entity or person owning substantially all of the party’s assets. In the event of a permitted assignment, this Agreement will inure to the benefit of and be binding upon the parties and their respective successors and permitted assigns. |
15.2. | Waiver; Severability. The failure of the other party to enforce any rights under this Agreement will not be deemed a waiver of any rights. The rights and remedies of the parties in this Agreement are not exclusive and are in addition to any other rights and remedies provided by law. If any provision of this Agreement is held by a court of competent jurisdiction to be contrary to law, the remaining provisions of this Agreement will remain in full force and effect. |
15.3. | Reservation. All licenses not expressly granted in this Agreement are reserved and no other licenses, immunity or rights, express or implied, are granted by [***], by implication, estoppel, or otherwise. |
15.4. | Export Restrictions. Company must comply with all domestic and international export laws and regulations that apply to the software. These laws include restrictions on destinations, end users, and end use. |
15.5. | [***] Affiliates. Affiliates of [***] may enter into one or more adoption addenda (each an “Adoption Addendum”) under which the [***] affiliate may agree to be bound by the terms of this Agreement as if the affiliate was an original party to it. Company shall not be required to be a party to any Adoption Addendum unless such Adoption Addendum imposes additional obligations on Company or otherwise seeks to make changes to the Agreement. |
Page 11 of 12
15.6. | Governing Law and Jurisdiction. This Agreement will be exclusively governed by and construed under the laws of California, without reference to or application of rules governing choice of laws. The parties agree that the United Nations Convention on Contracts for the International Sale of Goods (1980) is specifically excluded from application to this Agreement. All disputes arising out of or related to this Agreement will be subject to the exclusive jurisdiction of the courts of San Jose County, California, and Company hereby consents to such jurisdiction. However, [***] may apply to any court or tribunal worldwide, including but not limited to those having jurisdiction over Company, to seek injunctive relief. |
15.7. | Relationship of the Parties. This Agreement does not create any agency, partnership, or joint venture relationship between [***] and Company. This Agreement is for the sole benefit of [***] and Company (and indemnified parties), and no other persons will have any right or remedy under this Agreement |
15.8. | Notice. All notices required to be given under this Agreement will be in writing and will be sent, in the case of [***] at the address below and, in the case of the Company, as set out in the Specialised Application Licence Agreement, or to such other person or address as each party may designate by notice given in accordance with this Section. Any notice under this Agreement may be delivered by hand or express courier and will be deemed to have been received: (i) by hand delivery, at the time of delivery; or (ii) by express courier, on the second business day after delivery to the carrier. If an email address is provided below, a copy must also be sent via email, but such copy is for convenience only and the effective time of notice will be calculated as provided In the second sentence of this Section. |
[***]
15.9. | Counterparts; Amendments. This Agreement may be executed in any number of counterparts, any one of which need not contain the signature of more than one party, but all such counterparts taken together will constitute one and the same agreement No amendment, waiver, or modification of this Agreement will be valid unless in writing signed by each Party. This Agreement, including any amendment, waiver or modification to it, may be executed by facsimile, e• signature or scanned signatures and such signatures will be deemed to bind each party as if they were original signatures. |
15.10. | Entire Agreement. This Agreement, together with the SDK Agreement, is the entire understanding of the parties with respect to its subject matter and supersedes any previous or contemporaneous communications, whether oral or written with respect to such subject matter. |
ANNEX 1- [***] ENTERPRISE LICENSE FOR THE [***] BUNDLE
Supplied with this SLA as “[***] Commercial Licence for [***]”.
Rest of page intentionally blank.
Page 12 of 12
Exhibit 10.35
Certain confidential information contained in this document, marked by “[***]”, has been omitted because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.
Master Supply Agreement
This Master Supply Agreement (“Agreement”) is made as of [***] (“Effective Date”) between [***], located at [***] (“[***]”) and zSpace, Inc., located at 2050 Gateway Place, Ste. 100-302, San Jose, California, 95110 USA (“zSpace”).
Whereas, [***] and zSpace (collectively, the “Parties” and individually “Party”) have entered into a Memorandum of Understanding (“MoU”) as of [***] aimed at the creation of a special SKU of [***]’s [***] branded laptops tailored for zSpace;
Whereas, the Parties wish to enter into a collaboration in which [***], through its regional [***] Affiliates, sells customized Products exclusively to zSpace and zSpace in turn distributes such products through its sales channels to the education markets in the Territory in accordance with the terms and conditions of this Agreement;
Therefore, the Parties agree as follows:
1. | Definitions |
1.1 | “Agreement” means this Master Supply Agreement including all Exhibits. |
1.2 | “[***] Affiliate” means an entity that is owned or controlled by [***]. Such entity shall be deemed to be “owned or controlled” if [***] has a direct or indirect right to vote a sufficient portion of the subject entity’s equity securities (or other voting interests) to control management’s policies and directives. |
1.3 | “Product Logo(s)” means the [***] and zSpace® logos, respectively, to be co-branded on the Product as specified in Exhibit B - Brand Placement. |
1.4 | “Product(s)” means the [***] products of the customized [***] as defined in the Exhibit A— Products or as otherwise mutually agreed upon in writing, subject to its acceptance by the relevant [***] Affiliate. |
1.5 | “Purchase Order” means a purchase order for Products issued by zSpace to the relevant [***] Affiliate. |
1.6 | “Regional Agreement(s)” means the separate Product distribution, service/support agreement(s) that shall be entered between zSpace and the relevant [***] Affiliate(s) in the Territory. |
1.7 | “Territory” means world-wide, initially including USA, Canada, China, Europe, with other regions or countries to be added through mutual agreement. |
1.8 | “Trademarks” means any and all trademarks, product or trade names, logos, trade or service marks, whether registered or not, owned or used by a party. |
2. | Appointment of zSpace as Distributor; Minimum Order Quantity |
2.1 | [***] appoints zSpace as an exclusive distributor for the marketing and resale of the Products through multiple levels of distribution in the education markets of the Territory, and zSpace agrees to act in that capacity on the terms and conditions of this Agreement. |
2.2 | zSpace shall provide to [***] an initial [***] rolling forecast by [***] for future production and shipments. Upon acceptance of this forecast by [***], zSpace shall place noncancellable purchase orders for Product equal to the quantity of the initial [***] months of this forecast, the first purchase order of which shall be as provided in Section 5.3. zSpace shall provide continuous monthly updates to the [***] rolling forecast by the end of each calendar month (e.g. at the end of November 2021, zSpace will update the [***] rolling forecast to include April 2022, and at the end of December 2021, zSpace will update the [***] rolling forecast to include May 2022, etc.). |
2.3 | Pursuant to Section 5.4, zSpace acknowledges responsibility for the purchase of up to [***] camera chips ([***] at an estimated cost of $[***] each) should zSpace fail to purchase [***] units of Product during the term of this Agreement. |
2.4 | zSpace shall only bundle the Products with zSpace’s own accessory and software product(s) as specified in Exhibit A - Products and may not sell them separately. |
2.5 | All sales requests made to [***] from [***] channels and/or end-user customers interested in the Product will be referred to zSpace pursuant to a detailed referral program established with relevant [***] Affiliates. |
3. | Obligations of the Parties |
3.1 | [***] shall deliver (i) the most currently available versions of the Product and (ii) the software and technology incorporated therein free from viruses, and other disabling features. [***] will be responsible for ensuring conformance to the Product specifications, availability and last time buy as described in Exhibit A - Products and product warranty as published by [***] to customers purchasing such Products. |
3.2 | zSpace shall not make any representations with respect to the Products beyond the scope of information set forth in [***]’s product documentation or as mutually agreed. |
3.3 | zSpace shall be responsible for accessories or other products sold in combination with the Products after they have been delivered to zSpace. |
3.4 | The Parties shall obtain and keep in force all authorizations required for the sale and marketing of the Products in the Territory, including compliance with all export control laws and regulations that may apply to the manufacture, distribution and sale of the Products. |
2 |
3.5 | zSpace shall not make any changes to the Products, their packaging or the preloaded software other than as described in Exhibit A - Products. |
3.6 | [***] shall provide standard [***] promotional and advertising material and business and technical support to zSpace as provided herein. Any addition promotional, advertising, business and technical support will be in [***]’s sole discretion and to the extent it deems necessary. |
3.7 | The Parties shall follow Trademark and Product message guidelines provided by the respective other party (and as set forth in Exhibit C - Marketing Messaging) when using the other party’s Trademarks. In the event that the Parties desire to refer to or use the other Party’s Trademarks or mention their business relationship in any press release, media tool, or article, such use and or mention must be done with mutual review and approval. |
3.8 | [***] will provide standard warranty, service and support for the Products which shall include service hotline and email for zSpace and its resellers/system integrators to contact. Any Additional service/support terms shall be subject to the relevant Regional Agreements in the Territory. The [***] Product warranty does not apply to any errors or malfunctions to the extent attributable to zSpace software or to combinations of the Product with zSpace software or hardware or third-party software or hardware other than in accordance with the published [***] specifications. [***] agrees to maintain and support the Product distributed by zSpace, as set forth herein, for a minimum of up to [***] years with additional paid service extended from the standard warranty period. Additional support terms shall be subject to the applicable Regional Agreement. zSpace will have no warranty obligations for the products manufactured by [***]. |
3.9 | After taking delivery of the Products from [***] or the relevant [***] Affiliate, zSpace will provide a visible notification on the Product or in-box to instruct customers to contact the zSpace service center for initial Level 1 Support when Products are delivered to end customers. Level 1 Support consists of data collection and documentation of issues/problems and support on installation and set-up of the Products and basic trouble shooting of the issues/problems. [***] will provide support to zSpace or to the zSpace customer required to resolve issues beyond Level 1. |
3.10 | While each of the Parties herein desires to collaborate with the other as described in this Agreement, both Parties will endeavor to avoid the creation of joint intellectual property. In the event that the Parties herein both desire to jointly create any technology, materials or intellectual property under or in connection with this Agreement, the Parties will enter into a separate written agreement. This Agreement does not provide for the creation of jointly- owned intellectual property. |
3 |
4. | Trademark License |
4.1 | Each Party grants to the other Party a limited, non-exclusive, non-transferable, revocable, royalty-free license to use, reproduce and display their Trademarks identified in Exhibit D —Trademarks and Usage Guidelines (i) on the Products under this Agreement as per the specifications in Exhibit B - Brand Placement and (ii) on any advertising materials, promotions, flyers, documentation, collateral and packaging material related to the Products. All use of the Trademarks will be subject to each Party’s Trademark usage guidelines as provided in Exhibit D - Trademarks and Usage Guidelines, as updated from time to time. |
4.2 | Each Party agrees that it shall not use the other Party’s Trademarks, or any marks that are confusingly similar, assert any right, license, or interest with respect to any Trademarks of the other Party, or represent or suggest any affiliation between the Parties. Each Party agrees that it will not file any applications or assert any rights to the other Party’s Trademarks in the United States, or any other country or territory. |
5. | Ordering and Delivery of Products, Payment Terms |
5.1 | In the following, all references to “[***]” shall include [***] and [***] Affiliates, as the case may be, for the purpose of this Section 5. In the event of a conflict between this Section 5 and the applicable Regional Agreement, this Agreement shall govern. |
5.2 | All orders for Products must be made through a written (including in electronic form) Purchase Order (“PO”) to an [***] Affiliate. [***] shall not be bound by a PO made by zSpace until [***] has expressly confirmed its acceptance by notice in writing or by electronic mail. Notwithstanding, PO’s not rejected within ten (10) business days of its receipt will be deemed accepted. |
5.3 | Pursuant to Section 2.2, the initial PO shall be for [***] units with mutually agreed shipment dates (i.e. the date of shipment via ocean transport from the applicable port in Asia), of which no less than [***] units shall be shipped from ODM by [***] and is non-cancellable (“Initial PO”). All subsequent PO’s must be placed at least [***] months before the requested shipment date from the ODM to account for long lead-time components. |
5.4 | [***] shall use reasonable efforts to ship the Products on the scheduled ship date(s) in the order confirmation. [***] reserves the right to make partial deliveries. If [***] is unable to meet the delivery schedule, it shall provide notice as soon as it is reasonably aware of the situation. If [***] fails to ship on the scheduled ship date(s), and an alternative ship date(s) is not agreed to within thirty (30) days of the scheduled ship date, zSpace may cancel all or a portion of the PO and shall place another PO when [***] is able to meet a ship date. If zSpace in its sole discretion terminates this agreement, upon termination, zSpace will pay for all deliverable Product and for any components purchased which are directly related to the quantity of Product cancelled and not otherwise useable by [***] in the production of other [***] products. zSpace has the right to delay the ship date for up to sixty (60) days from the originally scheduled ship date, provided zSpace notifies [***] within fourteen (14) business days of the requested ship date that it is requesting a shipment delay. The Parties understand that a delay in this situation means the manufacturing of the Product at the factory will also be delayed by a similar amount of time. The Parties understand that Product which has already been manufactured (i.e. finished Product) cannot be delayed due to logistical limitations at the factory and the applicable ports in Asia. |
4 |
5.5 | Products will be shipped per the delivery terms set forth in the applicable Regional Agreement. For shipments into China, delivery terms will be as mutually agreed. |
5.6 | zSpace shall inspect any shipment immediately after receipt and shall report any defects, shortages or discrepancies among the transaction documents without delay within seventy-two hours of receipt of the Product. Products shall be deemed accepted and shipments shall be deemed to be complete in the absence of reported irregularities. Products shall be deemed to be without any latent defects unless latent defects are reported within ninety (90) days after delivery. [***]’s obligations vis-a-vis zSpace are limited to the replacement of any defective or missing Products within a reasonable time. |
5.7 | [***] may charge zSpace interest on overdue amounts at a rate of [***] percent ([***]%) per annum above the 90-day Average SOFR rate at the time when a receivable falls due. Interest shall accrue at this rate from the due date until full payment is received. |
5.8 | Prices for the Products as agreed by the Parties are in U.S. currency as set forth in the applicable Regional Agreement and shall only be valid for the corresponding time period as specified therein. The Parties will mutually agree in writing on prices for the Products for future time periods. Payment will be in U.S. currency unless otherwise stated. Payment terms shall follow the terms and conditions of the applicable Regional Agreement. |
5.9 | Each Party shall be respectively responsible for all taxes, customs and other duties or charges according to the delivery terms and conditions specified provided in this Agreement or applicable Purchase Order and applicable law, and regulations, which may be levied or assessed to them in connection with this Agreement and any Purchase Order. |
6. | Term & Termination |
6.1 | This Agreement shall come into force on the Effective Date for an initial term of [***] year (the “Expiration Date”) unless terminated earlier in accordance with the provisions of this Agreement. This Agreement shall automatically be extended for subsequent one-year-periods ending on anniversaries of the Expiration Date, unless either Party receives a written termination notice from the other Party not later than three (3) months prior to the Expiration Date or an anniversary of the Expiration Date. |
5 |
6.2 | [***] shall be entitled to terminate this Agreement ten (10) calendar days following written notice if zSpace fails to pay the purchase price for any of the Products in accordance with the payment terms hereunder (time being of the essence). |
6.3 | Either Party shall be entitled to terminate this Agreement by giving notice in writing to the other Party to take immediate effect if (a) the other Party commits any material breach of this Agreement and, if the breach may be remedied, fails to remedy the same within thirty (30) days after receipt of a written notice giving full particulars of the breach and requiring it to be remedied; or (b) the other Party becomes unable to meet its obligations as they fall due, makes an assignment for the benefit of creditors, files a petition for bankruptcy, permits a petition in bankruptcy to be filed against it which is not dismissed within ninety (90) days or if a receiver is appointed for a substantial part of its assets. |
6.4 | Any obligations of the Parties pursuant to those sections which by their nature are intended to survive the expiration or termination of this Agreement, including without limitation, Section 4 (Trademark License), Section 5 ( Ordering and Delivery of Product, Payment Terms), Section 8 (Indemnification, Limitation of Liability) and Section 9 (Confidentiality) shall survive such expiration or termination of this Agreement and remain valid in accordance with their terms. |
7. | Warranties and Representations |
[***] and zSpace each represent and warrant to each other that:
7.1 | It is a company duly incorporated and validly existing under the law of the applicable jurisdiction, that is in a good standing, and is lawfully qualified to engage in the relevant business activities in such jurisdiction as set forth in this Agreement; |
7.2 | It has all rights, title, interests, power and authority to execute this Agreement and to perform its rights and obligations under this Agreement; |
7.3 | Its execution, delivery and performance of this Agreement are not in violation of any laws, regulations or policies of any courts, government authorities or government agencies in the country of its incorporation or where it conducts its business activities; |
7.4 | Its execution, delivery and performance of this Agreement does not and will not constitute any breach or inconsistency of any other agreement to which it is a party or by which it is bound, and any third-party agreement to which it is a party or by which it is bound will not cause the other Party of this Agreement to incur any liability or suffer any damage; |
6 |
7.5 | Its execution, delivery and performance of this Agreement to its best knowledge will not infringe upon any rights of any third party and will not breach any terms of any other separate agreements, contracts or documents; and |
7.6 | It has not made any false or misleading representations or omitted any material facts that will have any material adverse impact on the execution, delivery and performance of this Agreement. |
8. | Indemnification and Limitation of Liability |
8.1 | Each Party shall indemnify and hold the other Party itself and its subsidiaries as well as the respective Party’s affiliates, officers, directors, employees, and agents, harmless against any and all direct losses, liabilities, costs, fees, claims, damage and expenses, penalties and all reasonable attorney’s fees, incurred by the affected Party arising out of or in connection with any of the other Party’s material breach of any agreements, covenants, representations, warranties, other contractual obligations or undertakings set forth under this Agreement. |
8.2 | [***] will defend, hold harmless and indemnify, including reasonable attorney’s fees, zSpace and zSpace personnel from claims that Products infringe the intellectual property rights of a third party, except to the extent such claim arises out of modifications and/or combinations to the Product by zSpace, if such claim would not have arisen but for such modifications and/or combinations. If, as a result of a claim, zSpace is enjoined from distributing or selling the Product, [***] will, at its option: (i) obtain for zSpace the right to continue to use and sell the Products consistent with this Agreement; (ii) modify the Products so they are non-infringing and in compliance with this Agreement; or (iii) replace the Products with non-infringing ones that comply with this Agreement. In the event that none of the options in the preceding sentence are exercised by [***] within a commercially reasonable timeframe, [***] shall accept the return of infringing Products from zSpace, refund to zSpace the amounts paid in respect of such infringing Products and zSpace may terminate the Agreement. |
8.3 | [***] will indemnify zSpace against and defend and settle any claim, suit, or proceeding brought against zSpace which is based on a claim involving product liability, strict product liability, or any variation thereof in connection with the Product, except to the extent such claim arises out of modifications to the Product by zSpace if such claim would not have arisen but for such modifications. In such latter case zSpace shall defend, hold harmless and indemnify [***] as set forth below. |
8.4 | zSpace will defend, hold harmless and indemnify, including reasonable attorney’s fees, [***] and [***] Affiliates and its respective personnel from claims that zSpace’s Trademark(s) or modifications / combinations to the Products infringe the intellectual property rights of a third party. |
7 |
8.5 | Each Party will promptly notify the other Party if it learns of any claim or any facts upon which a claim subject to indemnification hereunder could be based. The indemnifying Party’s obligations are conditioned upon the indemnified Party giving the indemnifying Party prompt notice of any claim for which indemnification is required, permitting the indemnifying Party sole control, through counsel of its choice, of the defense and/or settlement of the claim, as well as all authority, information, and assistance necessary to defend and/or settle the claim. Subject to [***]s’s obligations hereunder, zSpace shall, within a reasonable time following [***]’s notice, cease to further use or distribute the allegedly infringing Products. |
8.6 | Except for each Party’s express indemnification obligations hereunder, or any breach of confidentiality obligations under section 9, or any instance of a Party’s gross negligence or willful misconduct, the Parties’ liability under this Agreement shall be limited to exclude indirect or consequential damages, loss of revenue, loss of business opportunities, any compensation for goodwill, and loss of profits. The foregoing notwithstanding, nothing in this Agreement is intended to or shall be construed to limit or exclude liabilities that cannot be limited or excluded under applicable law. |
9. | Confidentiality |
“Confidential Information” means any proprietary and confidential information delivered by one Party to the other pursuant to this Agreement. The Mutual Non-disclosure Agreement dated [***] entered into between Parties (“MNDA”) shall govern all disclosures during the term of this Agreement by one Party to the other of Confidential Information, provided that the disclosure period as defined in the MNDA for such Confidential Information shall be coterminous with the term of this Agreement, and further provided that the Confidential Tracking Record in the MNDA shall include the Confidential Information of this Agreement.
The Parties acknowledge and agree that permitted uses of Confidential Information under the CDA shall include such uses which are directly necessary to their respective performance of obligations under this Agreement. zSpace agrees and ensures that [***] may forward Confidential Information to any of its [***] Affiliates, provided such affiliates adhere to the terms of the MNDA.
10. | Force Majeure |
Except for Buyer’s payment obligations, neither Party shall be liable for any failure or delay to perform its obligations for strikes, shortages, riots, insurrection, fires, flood, storm, explosions, earthquakes, acts of God, war, governmental action, pandemics, supplier problems or any other force majeure event beyond the reasonable control of such Party; provided, however, that if such failure or delay in performance continues for over ninety (90) calendar days, the other Party shall have the right to terminate this Agreement immediately upon written notice. Each Party shall use reasonable efforts to notify the other party of the occurrence of such an event as soon as possible or within three (3) business days of its occurrence, whichever is sooner.
8 |
11. | Notices |
All notices under this Agreement shall be in writing and shall be considered given upon personal delivery or delivery by electronic means (e.g. email or facsimile) subject to physical delivery by another approved method, upon forty-eight hours after sending by air courier, or upon seventy-two hours after deposit in the United States Mail, certified mail return receipt requested. All notices shall be addressed as specified below:
12. | Miscellaneous |
zSpace
2050 Gateway Place,
Chief Financial Officer |
[***] Inc.
[***] |
12.1 | Modifications to this Agreement including this clause shall only be valid if reduced to writing and signed by the authorized representatives of both Parties. |
12.2 | This Agreement shall be governed by and construed in accordance with the laws of the California excluding any conflict of laws rules and excluding the U.N. Convention on Contracts for the International Sales of Goods. The Parties agree to the exclusive jurisdiction and venue of the competent federal and state courts located in Santa Clara County, California, USA. |
12.3 | This Agreement may not be assigned to any third party without the written consent of the respective other Party, which consent shall not be unreasonably withheld. Notwithstanding the foregoing, either Party may assign or transfer this Agreement without such consent as a consequence of a merger, acquisition, consolidation, reorganization or sale of substantially all of its assets or of the business to which this Agreement pertains. This Agreement will inure to the benefit of and will be binding on the permitted successors and assigns of the Parties. |
12.4 | Neither Party is an agent or representative of the other Party. Neither Party has the right to bind the other Party, or to contract in the name of the other Party, or to create a liability against the other Party in any way or for any purpose. The Parties are not joint-venturers or partners. |
9 |
12.5 | Failure or neglect by either Party to enforce at any time any of the provisions hereof shall not be deemed to be a waiver of that Party’s rights under this Agreement, will not affect the validity of the whole or any part of this Agreement, and shall not prejudice the right of that Party to take subsequent action. |
12.6 | Should provisions of this Agreement be or become legally invalid, this shall not affect the validity of the remaining provisions of this Agreement, and the Parties will negotiate in good-faith substitute, valid and enforceable provisions which most nearly reflects the Parties’ intent in the original provisions. |
12.7 | This Agreement may be executed by electronic means and in counterparts, each of which will be deemed an original and together shall constitute one and the same instrument. |
12.8 | Neither Party shall publicize or disclose to any third party, without the written consent of the other Party, the terms of this Agreement. |
12.9 | This Agreement and the Exhibits attached hereto constitute the entire and exclusive agreement between the Parties and supersedes all previous agreements, written or oral, with respect to the subject matter of this Agreement. |
10 |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorized representatives.
For [***] | For zSpace |
Name (printed): | Name (printed):
|
Signature:
|
Signature: |
Date: | Date: [***] |
SIGNATURE PAGE TO MASTER SUPPLY AGREEMENT
Exhibit A
Products
Exhibit B
Brand Placement
Exhibit C
Marketing Messaging
Exhibit D
Trademarks and Usage Guidelines
Exhibit 10.36
Certain confidential information contained in this document, marked by “[***]”, has been omitted because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.
AMENDMENT 1 TO THE
COMMERCIAL TERMS AND GENERAL TERMS AND CONDITIONS OF SALE
This is Amendment 1 to the COMMERCIAL TERMS AND GENERAL TERMS AND CONDITIONS OF SALE effective November 1, 2021, by and between zSpace, Inc., a Delaware corporation, acting on behalf of itself and its Affiliates (collectively, “Buyer”), and [***], a California corporation (“[***]”) (“Agreement”). The effective date of this Amendment 1 is March 11, 2024 (“Amendment 1 Effective Date”). [***] and Buyer may be referred to individually as a “Party” or collectively as “Parties.” Capitalized terms used in this Amendment are either defined herein or are set forth in the Agreement.
The Parties agree as follows:
1. | The parties agree to delete Section 6 in its entirety and replace with the following: |
“6. Credit facility. [***] agrees to provide Buyer with a credit line of up to [***] USD ($[***] USD) as a part of this Agreement (the “Credit Limit”), subject to the following:
(i) | Buyer will pay any amounts due from the credit line associated with a purchase order within thirty (30) days of [***]’s invoice for Product shipment from its applicable port in Asia and/or U.S. warehouse. |
(ii) | Buyer can only use the credit line for up to [***] ([***]%) of the amount owed on a purchase order, up to a maximum purchase order amount of [***] USD ($[***] USD). By way of example, if the purchase order total is $[***], Buyer can only use $[***] from the Credit Limit, with the other $[***] payable pursuant to the terms in Section 5(ii). By way of further example, if the purchase order total is $[***], Buyer can only use $[***] from the Credit Limit, with the other $[***] payable pursuant to the terms in Section 5(ii). |
(iii) | [***] may increase, decrease, or cancel Buyer’s credit line at any time and in [***]’s sole discretion.” |
2. | All the terms, provisions and conditions set forth in the Agreement which are not specifically modified by this Amendment shall remain in full force and effect. |
IN WITNESS WHEREOF, the Parties hereto have executed this Amendment 1 as of the Amendment 1 Effective Date.
[***] | zSPACE, INC. | |||
By: | By: | |||
[***] | Joseph B. Powers | |||
Vice President | Chief Financial Officer |
Exhibit 10.37
Certain confidential information contained in this document, marked by “[***]”, has been omitted because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.
SUPPLY AGREEMENT
This Supply Agreement (“Agreement”) is made and effective on and from the date of signing hereof (“Effective Date”) by and between zSpace, Inc., a Delaware corporation (“Buyer” / “zSpace”) headquartered at 2050 Gateway Place, Suite 100-302, San Jose, CA 95110 and [***], commercial registration number [***], a company duly incorporated and organized under the laws of [***] with its principal place of business at [***] (“Supplier” / “[***]”).
BACKGROUND
Buyer desires to purchase certain products as defined below to be developed, manufactured, and supplied by Supplier for incorporation into Buyer’s products; and Supplier desires to sell such products to Buyer on the terms and conditions set forth in this Agreement. zSpace is engaged in the business of building and developing unique zSpace AR/VR experiences focused on the education sector; and [***] is engaged in the business of developing computing devices.
AGREEMENT
1. PRODUCTS.
1.1. General Scope. The terms of this Agreement shall apply to the products described on Exhibit A (“Products”) and the related services and support described on Exhibit A or generally offered by Supplier (“Services”). Products shall be manufactured and assembled in compliance with the Specifications (as defined on Exhibit A), such Specifications to be finalized within thirty (30) days of the Effective Date. Buyer may request that (i) Supplier purchase specific material or parts for the manufacture or assembly of the Products or adjust the manufacturing process and (ii) to add additional Products to this Agreement or delete current Products from this Agreement by updating Exhibit A. Such requests shall require Supplier’s written consent, which consent shall not be unreasonably withheld.
1.2. Engineering Changes.
a) | By Buyer. Within ten (10) business days of Buyer’s notification of a proposed engineering change, Supplier shall provide Buyer with a written quotation, which includes any proposed increase or decrease in the unit price of the Products. The parties shall agree upon the unit price of the Product within thirty (30) days from the date of Buyer’s notification of the proposed engineering change, and the pricing exhibit shall be amended. |
b) | By Supplier. Supplier shall notify Buyer thirty (30) business days prior to making or incorporating any change in the Specifications for the Products and not make or incorporate any change in the Specifications for the Products that affects price, form, fit, function, or reliability without prior written approval of Buyer. Supplier shall notify Buyer of any engineering change proposed by Supplier to the Products, and shall supply a written description of the expected effect of the engineering change on the Products, including the possible effect on price, performance, reliability and serviceability as part of the proposed engineering change. Buyer, at its discretion, may elect to incorporate or not to incorporate any Supplier-proposed engineering change to the Product design. |
c) | Changes to the Costs of Manufacture. If any Supplier engineering, manufacturing or materials changes result in the change of the cost of manufacture, Supplier may at its sole discretion to reflect such change to the Buyer. |
1.3. Buyer Property. Buyer may loan to Supplier certain testing equipment as defined by the parties , whether loaned directly by Buyer or sold to Buyer by Supplier and then loaned to Supplier, solely for use in Supplier’s manufacturing, testing or adapting Product or to provide Services. Buyer property may not be transferred, assigned, loaned or otherwise encumbered by Supplier except that such property may be loaned to Buyer approved third party subcontractors performing services for Supplier, such approval not to be withheld unreasonably. Supplier assumes all responsibility and liability for the property and will return it in good condition, reasonable wear and tear excepted, upon Buyer’s request or upon termination or expiration of this Agreement. Upon five (5) business days notice Buyer shall have the right to request the return of its loaned property. All cost incurred upon the return of the Buyer’s property shall be paid by the Buyer, unless the supplier commits violation under the Loan Agreement. In such case, Supplier shall upon request reimburse Buyer for the cost of returning the loaned property, so long as such costs s are reasonably related to the violation. For purposes of this section, Loan Agreement shall mean the loan agreement entered into between the parties on or within thirty (30) days of the Effective Date.
2. ORDERING AND DELIVERY.
2.1. Purchase Orders. Supplier will provide Products and Services in accordance with purchase orders issued by Buyer (“Purchase Orders”). Each Purchase Order shall specify the applicable information and may reference this Agreement. Supplier will accept all Purchase Orders issued that conform to this Agreement. The Supplier shall accept or reject the Purchase Orders within five (5) business days of its receipt. Purchase Orders not rejected within this time frame will be deemed cancelled.
2.2. Governing Terms. The terms and conditions of this Agreement replace in their entirety any and all of the pre-printed terms and conditions appearing on any purchase or sales forms of Supplier. In the event of any conflict between the terms of this Agreement and the terms of any Exhibit or on the face of any Purchase Order, the order of precedence is as follows: (1) the terms on the face of the Purchase Order, (2) the terms of any Exhibits to this Agreement and (3) the terms of this Agreement. Except as provided on Exhibit B, each Purchase Order shall include a minimum of [***] ([***]) units of the Supplier’s products. Any Purchase Order issued during the Term will remain in full force and effect and governed by this Agreement, even if the Agreement expires or terminates prior to delivery.
2.3. Changes to Purchase Orders. Buyer may by notice to Supplier within thirty (30) Calendar Days of the Supplier accepting a Purchase Order, make changes to quantities or delivery dates or suspend, in whole or in part, delivery of goods. Such changes are not accepted until approved by Supplier in writing.
2
2.4. Delivery. All Products delivered hereunder will be suitably packed for shipment and delivered to an address specified in the applicable Purchase Order by the delivery date specified and accepted by Supplier. Supplier shall bear the risk of loss until delivery to Buyer. All freight, insurance and other shipping expenses will be borne by Supplier. Time is of the essence and Supplier shall notify Buyer immediately if it suspects it may be unable to meet the delivery date or quantity.
2.5. Inspection. Supplier shall test all Products for conformance with the Specifications before delivery and will certify conformance with the tests results. Products shall be subject to incoming inspection and testing by Buyer. Products or lots not meeting applicable acceptance criteria may be rejected and returned for a full refund or replacement, subject to the Buyer providing satisfactory evidence that such failed acceptance is solely attributable to the Supplier’s noncompliance to the inspection standards.
The Buyer shall provide the Standards of testing and inspection prior to submitting the first Purchase Order, such standards shall be subject to the Supplier’s acceptance and amendment. The approved Standards shall be applicable to all Purchase Orders governed by this Agreement.
2.6. Product Availability. Within a reasonable time period prior to notice of a discontinuation of the availability of any Product or version thereof, the parties shall meet in an effort to mutually agree upon the terms necessary to meet last time buy requirements. Within [***] months thereafter, Buyer shall place a last time buy Purchase Order for the Product to be discontinued, which may include Buyer scheduling deliveries of Product for a period of up to [***] months following the issuance of such last time buy Purchase Order. In connection with the submittal of such discontinuance notice, the Supplier shall provide Buyer with appropriate plans related to the Product discontinuance, including but not limited to the configuration, performance and price of (i) the replacing Product and (ii) its update from the discontinued Product, in order to ensure continuous delivery of Product. Buyer shall be entitled to order the Products that are affected by the discontinuation before or on the last Purchase Order date. Provided a forecast is furnished by Buyer, Supplier will use reasonable efforts to ensure the availability of the quantities Buyer orders after the notice of discontinuation but prior to the last Purchase Order date.
The Supplier guarantees that the Products or an equivalent replacing product compatible with Product specifications shall be available to Buyer at in accordance with the terms of this agreement at least for a period of [***] years from the last purchase of the respective Product.
3. PRICE AND PAYMENT
3.1. Prices. Prices for the Products and Services will be as set forth on Exhibit B. Prices are quoted in US Dollars. The Buyer shall make an advance payment amounting to [***] percent ([***]%) of the total purchase price payable in accordance of Exhibit B upon the Supplier’s acceptance of the Initial Purchase Order. Such payment shall be made within fifteen (15) business days of the Supplier’s acceptance of the Initial Purchase order and receipt of a valid invoice. The Buyer will issue payment after receipt of a valid invoice. The remaining [***] percent ([***]%) of the price shall be due within three (3) business days prior to shipment of the products and receipt of a valid invoice.
3
3.2. Taxes. Prices are exclusive of sales and similar taxes. Such taxes, if applicable, shall be separately stated on Supplier’s invoice. The Supplier shall not be responsible for any import taxes, Buyer will not be responsible for any taxes measured by Supplier’s net income, taxes measured by Supplier’s costs in providing the Product or Services, or taxes imposed through withholding. If Buyer is required by law to withhold and remit tax relating to a purchase under this Agreement, Buyer shall be entitled to reduce its payment by the amount of such tax.
3.3. Payment Instructions.
Payment to be made to the Supplier per the instruction below.
Wiring Instructions:
Account name: [***]
Account No. : [***]
Swift code: [***]
Currency: USD
Bank: [***]
Branch: [***]
4. TERM AND TERMINATION.
4.1. Term. This Agreement shall be in effect for an initial term of [***] years from the Effective Date unless terminated earlier in accordance with its terms. The term shall automatically renew for successive [***] month periods unless one party gives the other written notice of non-renewal at least [***] days in advance of the renewal date to the other party.
4.2. Termination.
a) | Termination for Cause. Either party may terminate this Agreement upon written notice if the other party is in material breach and fails to cure the breach within thirty (30) days from the date of receipt of notice to cure. |
b) | Termination for Insolvency. Either party may terminate this Agreement immediately upon notice, if the other party ceases to conduct business in the ordinary course, makes an assignment for the benefit of creditors, files a petition in bankruptcy, permits a petition in bankruptcy to be filed against it which is not dismissed within sixty (60) days or if a receiver is appointed for a substantial part of its assets. |
4.3. Effect of Termination.
Notwithstanding any termination, the applicable provisions of the Agreement will survive until all the Products and/or Services ordered during the term are delivered by the Supplier. Upon termination or expiration of this Agreement, each party shall return to the other party all items provided to it under this Agreement, including without limitation all Confidential Information. Sections 2.2, 3.2, 4.3, 4.4 and 5 through 10 will survive any termination of this Agreement.
4
4.4. Limitation of Liability on Termination or Expiration. NEITHER PARTY SHALL, BY REASON OF THE EXPIRATION OR TERMINATION OF THIS AGREEMENT, BE LIABLE TO THE OTHER FOR COMPENSATION, REIMBURSEMENT OR DAMAGES ON ACCOUNT OF ANY LOSS OF PROSPECTIVE PROFITS OR ANTICIPATED SALES OR ON ACCOUNT OF EXPENDITURES, INVESTMENTS, LEASES, OR COMMITMENTS MADE IN CONNECTION WITH THIS AGREEMENT OR THE ANTICIPATION OF EXTENDED PERFORMANCE HEREUNDER.
5. WARRANTIES AND REMEDIES
5.1. Product Warranties. Supplier represents and warrants that all Product will: (a) be manufactured, processed, and assembled by Supplier or Supplier’s authorized subcontractors; (b) conform to Product Specifications; (c) be new and free from defects and are identical in all material respects to approved samples as defined in the Specification; (d) be free from defects in design, manufacturing processes, material and workmanship; and (e) be free and clear of all liens, encumbrances, and restrictions. Except for the Product Intellectual Property Warranties set forth in Section 7, which survive indefinitely, all other warranties specified survive delivery, inspection, acceptance, or payment by Buyer and will be in effect for the longer of [***] months following acceptance at place of delivery.
5.2. Epidemic Failure. In addition to the foregoing warranty, Supplier warrants the Product against epidemic failure. An epidemic failure shall be deemed to have occurred if more than [***] percent ([***]%), or [***] units whichever is greater, of the then current total installed base of any Product should fail exhibiting the same root cause symptom(s) within any time period of ninety (90) days, excluding any failures that are attributable to wear and tear if the affected Products are no longer under warranty. In the event of epidemic failure, Supplier shall establish within two (2) business days notice by Buyer of such failure a plan for diagnosing the problem. Supplier and Buyer shall jointly use commercially reasonable efforts to plan a work-around to resolve and replace all defective Products. Any and all costs associated with the emergency procedure are to be borne by Supplier. Supplier also agrees to inform Buyer in writing of any other epidemic failure occurring in similar products sold to Supplier’s other customers and Supplier shall apply its engineering change order procedure as reasonably necessary to prevent or correct Buyer Products from such failure.
5.3. Product Warranty Remedies. If Supplier breaches any warranty Buyer may return the affected Products to Supplier at Supplier’s expense for correction, replacement, or refund, as Buyer may direct, in addition to other remedies available to Buyer. Any Product corrected or furnished in replacement will be warranted for the remainder of the warranty period of the Product replaced.
5.4. Supplier Compliance Warranties. Supplier represents and warrants that it will comply with all applicable laws and regulations in performance of this Agreement, including but not limited to (a) laws and regulations governing freedom of association, labor and employment, employee health and safety, protection of the environment, and ethical practices of the [***] and the United States including compliance with the U.S. Foreign Corrupt Practices Act. (b) all laws regarding export and import of products and technology, and (c) all applicable national and international transportation requirements including, where applicable, regulations regarding chemicals and hazardous materials.
5
5.5. Product Recalls. Buyer may perform a recall of Product (a) if Supplier breaches its Product warranties or (b) to prevent or remedy any substantiated health or safety risk arising from such Product Recall. Supplier will reimburse Buyer’s losses, liabilities, costs, including, but not limited to, labor costs, return costs, cost of field recall, freight, and rework incurred in effecting any product recall (“Recall Costs”). Supplier is not liable for Recall Costs, to the extent the cause of recall is due solely to compliance with Buyer Specifications.
5.6. Services and Support Warranty. In addition to the warranties applicable to Products, Supplier represents and warrants that all Services will be provided in a professional and workmanlike manner by experienced personnel with suitable expertise in the subject matter. Supplier’s obligations to provide Services and support will continue throughout the term and for five (5) years after the last delivery of Product even if (i) the subject Product is discontinued, (ii) this Agreement is terminated or expires, or (iii) Buyer notifies Supplier that Buyer is ending its purchases for a Product. During the term mentioned herein , Supplier will provide service parts in accordance with the terms and conditions under this agreement.
6. LICENSES
6.1. Licenses to Software. If software is provided with or as part of any Product including but not limited to the operating system software and any application installed on or in conjunction with the operating system (“Software”), Supplier hereby grants to Buyer, a nonexclusive, worldwide, irrevocable, perpetual, fully paid-up license to use, reproduce, and distribute such Software with Products. The rights granted herein include the right to use and distribute updates to such Software directly with the Product or indirectly (without the Product) to end users of the Product. If any Software is licensed from a third party or subject to a third party license (including, without limitation, open source software), Supplier will identify each software component and identify the corresponding third party license. If any Software is subject to a license that requires distribution of source code (e.g., the GNU General Public License (“GPL”), the GNU Lesser General Public License (“LGPL”)), Supplier will provide Buyer the required source code.
6.2. Licenses to Product Documentation. Supplier hereby grants Buyer a non-exclusive, perpetual, irrevocable, worldwide, fully paid-up license to use, reproduce, distribute and prepare derivative works (in Buyer’s name) of all documentation furnished by Supplier in connection with the sale or support of Products.
6.3. Intellectual Property of Buyer. All protocols, drawings, data, software, files, designs, products, by-products, tools, layouts, artwork, models, procedures, documents and materials provided by Buyer with respect to the Product and all derivative works thereof created, conceived or reduced to practice under this Agreement (collectively “Works”) shall be owned by Buyer. Buyer hereby grants to Seller a royalty-free, non-exclusive, worldwide, revokable, non-transferable license, (without the right to sublicense) during the term of this Agreement, to use the Works solely as necessary to manufacture Products for Buyer as set forth in this Agreement. Except as expressly provided for herein, nothing in this Agreement will be construed as granting to Seller or conferring on Seller any rights by license or otherwise to Buyer intellectual property rights or Works.
6
6.4. Intellectual Property of Supplier. To the extent Supplier incorporates any of its intellectual property into the Products, Supplier hereby grants to Buyer a non-exclusive, perpetual, irrevocable, royalty-free license (without the right to sublicense on a standalone basis) to such intellectual property to use, offer to sell, sell the Products whereby such intellectual property may be incorporated and otherwise fully exploit the Products. Seller grants no other rights or license to Buyer relating to Seller’s intellectual property.
7. REPRESENTATIONS AND INDEMNDIFICATION
7.1. Intellectual Property Warranties. Supplier represents and warrants that: (a) the manufacture, use and sale of the Product does not infringe or misappropriate any third-party Intellectual Property Rights; (b) Buyer does not and will not need to procure any rights or licenses to any third party’s Intellectual Property Rights to exploit the Product; (c) any software included does not contain any virus or harmful code, will not activate, alter or erase without control of a person operating the computer equipment on which the Software resides, and does not contain functionality that restricts access or use; (d) Supplier will pass through to Buyer the benefits of all transferable warranties applicable to any third party software acquired by Buyer from Supplier; (e) Supplier complies with and will continue to comply with all licenses (including, without limitation, all open source licenses) associated with any software component included in the Product; and (f) there are no patent markings required on any part of the external housing of the Product and if patent markings are required in the future Supplier will notify Buyer in advance prior to implementing the markings on the Product. If Supplier breaches any of these Intellectual Property warranties, then in addition to Buyer’s remedies specified in this Agreement, Buyer may immediately cancel any unfilled Purchase Orders without liability.
7.2. Remedies for Infringing Product. If a Product is alleged to infringe a third party’s Intellectual Property Rights and its use, manufacture, sale, combination, or importation is enjoined, Supplier will, at its sole expense and option: (a) procure for Buyer the right to continue using or combining the Product, as the case may be; (b) replace the Product with a non-infringing product of equivalent form, fit, function and performance; or (c) modify the Product to be non-infringing, without materially detracting from form, fit, function or performance.
7.3. Indemnity. Supplier will defend, indemnify, and hold harmless Buyer and its affiliates and customers (including without limitation end users, distributors and resellers), officers, directors, employees, agents and representatives (“Indemnitees”) from and against any and all claims, demands, causes of action, lawsuits or liabilities (collectively “Claims”) arising out of or related to:
a) | any negligent act, omission, willful misconduct, or breach of Agreement by Supplier, its subcontractors, employees, or agents, or tangible property loss, personal injury or death caused by Supplier, its subcontractors, employees, or agents or by any Product; or |
7
b) | the unauthorized use, misappropriation or infringement of any third party’s Intellectual Property Rights by (i) the manufacture, use or sale of any Product; (ii) any combination of the Product with another Buyer product where the Product has no substantial non-infringing use, (iii) any Software, (iv) any Documentation, (v) a Supplier Mark, or (vi) anything provided as part of Supplier’s support. Supplier will pay all claims, losses and damages, liabilities, judgments, awards, costs and expenses including reasonable attorneys’ fees, expert witness fees and bonds incurred by Indemnitees as a result of the Claim, and will pay any award in connection with, arising from or with respect to any such Claim, including any settlement. |
7.4. Notice and Authority to Defend. Buyer will give Supplier prompt notice of any Claim. Buyer will provide Supplier the authority, information, and assistance (at Supplier’s expense) reasonably necessary to defend. Supplier will control defense. Buyer and any other Indemnitee may, in its or their discretion, participate in the defense of such Claim at their own expense. However, if Supplier does not diligently pursue resolution of such Claim, then Buyer may, without in any way limiting its other rights and remedies, defend the Claim and collect its costs of doing so from Supplier. Any settlement or compromise Supplier desires to enter into will be subject to Buyer’s prior approval and will include a full and complete release of any and all claims that the third party claimant may have against Indemnitees.
8. CONFIDENTIALITY.
8.1. Confidential Information. “Confidential Information” means all commercially valuable, proprietary and confidential information and trade secrets with respect to the business and products, whether of a technical, business or other nature (including, without limitation, know-how and information relating to the technology, customers, business plans, promotional and marketing activities, finances and other business affairs disclosed by any party hereunder, either directly or indirectly, in writing, electronically, orally, by drawing or by inspections, which is marked by the disclosing party as “Confidential” or “Proprietary” or which the receiving party has reason to know is treated as confidential by the discloser. For clarification, all information provided by Buyer to Supplier relating to the design and manufacture of the Products shall be deemed confidential.
8.2. Exclusions. Notwithstanding the foregoing, Confidential Information shall not include information which:
a) | is now in the public domain or becomes a part of public domain after disclosure without breach of this Agreement; |
b) | is known to the receiving party at the time of disclosure, as shown by the receiving party’s written records, or becomes known to the receiving party without breach of this Agreement; |
c) | is furnished to any third party by the disclosing party without restriction on its disclosure; |
d) | is independently developed by the receiving party; or |
e) | is approved for release upon a prior written consent of the disclosing party. |
8
8.3. Nondisclosure. The receiving party agrees that it will not disclose any Confidential Information to any third party and will not use Confidential Information of the disclosing party for any purpose other than for the performance of obligations under this Agreement without the prior written consent of the disclosing party. The receiving party further agrees that Confidential Information shall remain the sole property of the disclosing party and that it will take all reasonable precautions to prevent any unauthorized disclosure of Confidential Information by its employees and independent contractors. No license shall be granted by the disclosing party to the receiving party with respect to Confidential Information disclosed hereunder unless otherwise expressly provided herein. Notwithstanding the restrictions in this section, each party may disclose Confidential Information to its advisors, in connection with financings and similar transactions and to the extent required by law. In case of a disclosure required by law the party required to disclose will use reasonable efforts to provide the other party with notice.
8.4. Nondisclosure Agreements. Each party agrees that it (i) has or that it shall obtain the execution of proprietary nondisclosure agreements with its agents and consultants having access to Confidential Information of the other party, (ii) shall diligently enforce such agreements, and (iii) shall be responsible for the actions of such employees, agents, and consultants in this respect.
8.5. Return of Confidential Information. After expiration or termination of this Agreement, upon the request of the disclosing party, the receiving party will promptly return, or certify as destroyed, all Confidential Information furnished hereunder and all copies thereof.
8.6. Remedy for Breach of Confidentiality. If a party breaches any of its obligations with respect to confidentiality and unauthorized use of Confidential Information hereunder, the nonbreaching party shall be entitled to equitable relief to protect its interest therein, including but not limited to injunctive relief.
9. LIMITATION OF LIABILITY
IN NO EVENT SHALL BUYER BE LIABLE UNDER THIS AGREEMENT FOR ANY SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT, HOWEVER CAUSED, AND WHETHER BASED IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, OR OTHERWISE. THESE LIMITATIONS SHALL APPLY EVEN IF SUPPLIER HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE, AND NOTWITHSTANDING THE FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY HEREIN. UNDER NO CIRCUMSTANCES SHALL BUYER’S TOTAL CUMULATIVE LIABILITY UNDER THIS AGREEMENT EXCEED [***].
10. MISCELLANEOUS PROVISIONS
10.1. Governing Law. This Agreement will be governed by and interpreted in accordance with the laws of the England and Wales without regard to conflict of laws principles. The Parties agree to the exclusive jurisdiction of the courts of England to settle any dispute arising out of or in connection with this Agreement.
9
10.2. Force Majeure. The parties shall not be liable to one another for delay in preforming, or failure to perform any part of its obligations under this Agreement when such delay or failure results from events, circumstances, or causes beyond the party’s reasonable control such as fire, flood, strikes, war (declared or undeclared), embargoes, blockades, legal restrictions, governmental regulations or orders, insurrections, or any similar cause beyond the control of either party. The party so prevented from performance shall use diligent efforts to resume its performance as soon as reasonably possible or as otherwise mutually agreed between the parties. If any events or circumstances described in this section prevent a party from resuming the performance of its obligations under this agreement for more than ninety (90)) days, then either party may without limiting its other rights or remedies, terminate this Agreement upon giving a thirty (30) days notice.
10.3. Assignment. The parties shall not assign or transfer this Agreement, in whole or in part, or any right or obligation hereunder to any third party without the prior written consent of the other party, which consent shall not be withheld unreasonably, except that Buyer may assign or otherwise transfer this Agreement where such transfer or assignment is in connection with a merger, acquisition, reorganization or other transfer of all or substantially all of the business or assets of Buyer related to this Agreement. Subject to the foregoing, this Agreement and the parties’ rights and obligations hereunder shall be binding upon and inure to the benefit of the parties hereto and to their respective successors and assigns.
10.4. Notice. Any notice required or permitted to be given under this Agreement shall be delivered (i) by hand, (ii) by registered or certified mail, postage prepaid, return receipt requested, to the address of the other party, (iii) by overnight courier, or (iv) by electronic transmission with confirming letter mailed under the conditions described in any of (i) through (iii). Notice so given shall be deemed effective when received, or if not received by reason of fault of addressee, when delivered.
10.5. Relationship of Parties. The relationship between the parties under this Agreement is that of independent contractors and neither shall be, nor represent itself to be, the joint venturer, partner, agent, or representative of the other for any purpose whatsoever. Neither party is granted any right or authority to assume or create any obligation or responsibility, express or implied, on behalf of, or in the name of, the other, or to bind the other in any matter or thing whatsoever.
10.6. Waiver. If either party fails to exercise or enforce any provision of this Agreement or to waive any rights in respect thereto, such waiver or failure shall not be construed as constituting a continuing waiver or a waiver of any other right.
10.7. Severability. In the event that any provision or provisions of this Agreement shall be held to be unenforceable, the parties shall renegotiate those provisions in good faith to be valid, enforceable substitute provisions which provisions shall reflect as closely as possible the intent of the original provisions of this Agreement. If the parties fail to negotiate a substitute provision, this Agreement will continue in full force and effect without said provision and will be interpreted to reflect the original intent of the parties.
10
10.8. Entire Agreement. This Agreement, including the Exhibits referred to herein, contains the entire understanding of the parties, and supersedes any prior agreement between or among the parties with respect to its subject matter. This Agreement shall not be amended or modified except by written instrument signed by the duly authorized representatives of both parties.
10.9. No Third Party Beneficiary. This Agreement does not create any third party beneficiaries.
BUYER | SUPPLIER | |||
zSpace, Inc | [***] | |||
By: | By: | |||
Name: | Name: | |||
Title: | Title: | |||
Date: | Date: |
11
EXHIBIT A
Products and Services
12
EXHIBIT B
PRICING, EXCLUSVITY & VOLUME COMMITMENT
13
APPENDIX 1
PRODUCT SPECIFICATIONS & BRANDING
14
Exhibit 10.38
Loan and Security Agreement
Borrower: ZSPACE, INC., a Delaware Corporation | Date: July 11, 2024 |
This LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of the date set forth above (the “Effective Date”) by and between Fiza Investments Limited, an entity organized under the laws of the Cayman Islands (together with its assigns, “Lender”), and the borrower(s) named above (each and collectively, “Borrower”).
Capitalized terms used but not otherwise defined herein shall have the meanings given them on Schedule C - Definitions.
WHEREAS, Lender and Borrower have entered into those certain Short Form Agreements dated May 29, 2023 and November 18, 2023 whereby the Lender loaned amounts of $3,000,000 and $1,300,000, respectively (“Short Form Agreements”) under the terms of those agreements in advance of completing a definitive loan and security agreement for the total amount of $4,300,000 (“Loan Amount”) to be used for the purposes set out in this Agreement;
WHEREAS, Borrower’s failure to repay the advanced loan amounts by the initial maturity dates as specified in the respective Short Form Agreements (the “Existing Defaults”) has occurred and exists on the Efective Date, and for which the Borrower has notified Lender in writing as specified in Section 6 of this Agreement;
WHEREAS, the Lender has agreed to provide the Loan Amount as a secured loan on the terms and conditions set out in this Agreement; and
WHEREAS, the Lender and the Borrower are entering into this Agreement to record the terms and conditions in respect of the provision and repayment of the Loan Amount.
The parties agree as follows:
1. Loan. Lender will make extensions of credit or other financial accommodations for Borrower’s benefit in a multiple tranches up to the Loan Amount as set forth on Schedule A (collectively, the “Loans”) for general corporate purposes and to meet working capital requirements of the Borrower that are not prohibited by this Agreement, and Borrower promises to pay Lender the amount of the Loan and other debts, principal, interest, Lender Expenses and other amounts Borrower owes Lender now or later, including interest, premiums and fees accruing after any Insolvency Proceedings begins, and debts, liabilities, or obligations of Borrower assigned to Lender pursuant to the terms and conditions of this Agreement or any Loan Document and as set forth on Schedule A. Lender’s obligation to make the Loans is subject to its receipt of the agreements, documents and fees it reasonably requires, including without limitation the agreements, documents and fees set forth on Schedule A.
2. Security Interest. As security for all present and future Obligations and for Borrower’s performance for each of its duties hereunder, Borrower grants Lender a continuing security interest in all of Borrower’s interest in the Collateral. In the event there is more than one Borrower, each and every Borrower entity’s obligations hereunder shall be joint and several with the obligations of the other Borrower entities.
3. Representations, Warranties and Covenants of Borrower. Borrower represents, warrants and covenants to Lender as follows, as of the Effective Date and with respect to covenants, for so long as this Agreement is in effect or any Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) remain outstanding:
3.1 Corporate Existence; Authority. Each of Borrower and its Subsidiaries is and will continue to be, duly existing and in good standing in its state of formation and qualified and licensed to do business in, and in good standing in, any state where such qualification or licensing is necessary, except for jurisdictions in which failure to do so would not have a Material Adverse Effect on Borrower. The execution, delivery and performance by Borrower of this Agreement and all other related documents have been duly and validly authorized, do not conflict with Borrower’s charter documents, corporate governance documents and/or shareholder agreements, third party loan agreement or other material contractual obligation of the Company (or any similar equivalents), and do not constitute an event of default under any material agreement by which Borrower is bound.
3.2 Collateral. Lender has and will at all times continue to have a perfected security interest in all of the Collateral (including, but not limited to, all Intellectual Property) except for Permitted Liens, on such seniority as set out in the Subordination Agreement. Borrower has, and will continue to have, good title to the Collateral, free of any liens except Permitted Liens. Borrower will immediately advise Lender in writing of any material loss or damage to the Collateral. If, at any time, Borrower has knowledge that it shall have acquired a material commercial tort claim, Borrower shall promptly provide written notice thereof to Lender and grant to Lender in writing a security interest therein and in the proceeds thereof. Borrower represents that all of its Intellectual Property, comprising (i) copyrights, copyright applications, copyright registrations and mask works and (ii) patents, patent applications, patent registrations, and (iii) trademarks, trademark applications, trademark registrations, service marks and service mark applications.
-1-
3.3 Financial Matters. All financial statements (including notes and schedules) now or in the future delivered to Lender, (i) have presented, and will present, fairly in all material respects Borrower’s financial condition and its results of operations, and (ii) have been, and will be, prepared in conformity with generally accepted accounting principles (“GAAP”) (except for the absence of footnotes in unaudited financial statements and subject to year-end audit adjustments). Since the last date covered by any such statement delivered to Lender, there has been no further material impairment in the financial condition or business of Borrower. Borrower will provide Lender with all financial reports as set forth on Schedule A attached hereto, as well as any other financial information reasonably requested by Lender from time to time, including budgets, projections and plans.
3.4 Statement of Borrower’s Information. All of Borrower’s information provided to the Lender is true and correct as of the Effective Date in all material respects, and Borrower shall provide written notice to Lender of any material changes within the prescribed periods of time set forth therein.
3.5 Taxes; Legal Compliance. Borrower has filed, and will file, when due (subject to any applicable extensions), all tax returns and reports required by applicable law. Borrower has paid, and will pay when due, all taxes, assessments, deposits and contributions now or in the future owed (except for (a) taxes and assessments being contested in good faith with adequate reserves under GAAP and (b) those taxes and assessments that do not, individually or in the aggregate, exceed One Hundred Thousand Dollars ($100,000)). Borrower has complied, and will comply, in all material respects, with all applicable laws, rules and regulations.
3.6 Insurance. Borrower shall at all times insure, at its own cost and expense, all of the tangible personal property Collateral and carry such other business insurance as is customary for companies similarly situated to Borrower. All property policies will have a lender’s loss payable endorsement showing Lender as a lender loss payee and all liability policies will show Lender as an additional insured and provide that the insurer must give Lender at least twenty (20) days’ (ten (10) days’ for nonpayment of premium) notice before canceling its policy.
3.7 Access. Upon three (3) Business Days’ prior notice, Lender or its agents shall have the right to inspect the Collateral where such Collateral is located from time to time and to audit and copy Borrower’s books and records during Borrower’s regular business hours. Notwithstanding the foregoing, if an Event of Default has occurred and is continuing, Lender shall not be required to provide written notice to Borrower of any inspection or audit.
3.8 Insolvency. Borrower is able, and will continue to be able, to pay its debts (including trade debts) as they mature.
-2-
3.9 Additional Agreements. Borrower will not, and will not permit any of its Subsidiaries to, without Lender’s prior written consent (which may be by email), do any of the following:
(i) (A) convey, sell, lease, transfer or otherwise dispose of (“Transfer”) any property other than Permitted Transfers, or (B) any Change of Control;
(ii) engage in any business other than the business currently engaged in by Borrower or reasonably related thereto;
(iii) fail to provide notice to Lender of any Key Person departing from or ceasing to be employed by Borrower within five (5) Business Days after his or her departure from Borrower;
(iv) increase the authorized number of shares of Preferred Stock or any additional class or series of capital stock of Borrower or permit or suffer to exist a change in its ownership existing as of the Effective Date, except for equity issuances to service providers pursuant to the Company’s 2017 Equity Incentive Plan that are approved by the Board of Directors, including the Series A Director, if any;
(v) merge or consolidate with any party, or acquire all or substantially all of the capital stock or assets of another party (provided, however, that a Subsidiary may merge or consolidate into another Subsidiary or into Borrower);
(vi) incur or become liable for any indebtedness other than Permitted Indebtedness;
(vii) assign or convey any rights to income or incur or allow any lien, security interest or other encumbrance on any of its property other than Permitted Liens;
(viii) make any investments except for Permitted Investments;
(ix) pay or declare any dividends on Borrower’s stock other than dividends paid solely in Borrower’s stock;
(x) redeem, retire, purchase or otherwise acquire, directly or indirectly, any of Borrower’s stock, options or warrants other than (a) stock, options and warrants repurchased in connection with the termination of employment or service as an employee, consultant, officer or director at cost, (b) purchases of fractional shares of stock arising out of stock dividends, splits, combinations or business combinations, (c) , repurchases of stock, options and warrants to the extent deemed to occur upon exercise of stock options or warrants if (x) such repurchased stock, options, or warrants represent a portion of the exercise price of such options or warrants and (y) such repurchase is in the form of non-cash consideration or in the form of a cashless net exercise;
(xi) directly or indirectly enter into any material transaction with any affiliate except (a) those that are entered into in the ordinary course of business upon reasonable terms no less favorable than those in an arm’s-length transaction with a non-affiliate, (b) transactions of the type described in and permitted pursuant to Sections 4.9(ix)-(x), (c) Investments permitted under sub-clauses (e) and (h) of the definition of “Permitted Investments”, and (d) reasonable and customary director, officer and employee compensation and other customary benefits including retirement, health, stock option and other benefit plans and indemnification arrangements approved by Borrower’s Board of Directors; and if excess of 25% such persons existing compensation, then with Lender’s consent;
(xii) make any payment on, or materially change any term relating to, any Subordinated Debt, except under the terms of the subordination, intercreditor or other similar agreement to which such subordination agreement is subject;
(xiii) without at least thirty (30) days’ prior written notice (or such shorter period as approved by Lender) to Lender, relocate its principal offices from Borrower’s address set forth on the signature page hereof or change its state of formation or name;
-3-
(xiv) directly or indirectly list any of its equity on any exchange; or
(xv) until the redemption of the New Preferred Stock, any of the following:
(a) enter or amend any material agreement of Borrower, including any amendment of any agreement with KIA or affiliates thereof, other than in the ordinary course of business; incur any aggregate indebtedness in excess of $100,000 that is not incurred in the ordinary course of business, other than trade credit incurred in the ordinary course of business;
(b) hire, terminate, or materially change the compensation of the executive officers, including approving any option grants or stock awards to executive officers;
(c) sell, assign, license, pledge, or encumber material technology or Intellectual Property, other than licenses granted in the ordinary course of business;
(d) liquidate, dissolve or wind-up the business and affairs of Borrower, effect any merger or consolidation or any other Deemed Liquidation Event (as defined in the Amended and Restated Certificate of Incorporation);
(e) amend, alter or repeal any provision of the Amended and Restated Certificate of Incorporation or Bylaws of Borrower;
(f) create, or authorize the creation of, or issue or obligate itself to issue shares of, or reclassify, any capital stock other than equity issuances to non-executive service providers pursuant to the Company’s 2017 Equity Incentive Plan that are approved by the Board of Directors, including the Series A Director, if any;
(g) increase the authorized number of shares of Preferred Stock or any additional class or series of capital stock of Borrower;
(h) purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of capital stock of Borrower;
(i) create, adopt, amend, terminate or repeal any equity (or equity-linked) compensation plan;
(j) create, or authorize the creation of, or issue, or authorize the issuance of any debt security or create any lien or security interest (except for purchase money liens or statutory liens of landlords, mechanics, materialmen, workmen, warehousemen and other similar persons arising or incurred in the ordinary course of business);
(k) incur other indebtedness for borrowed money, including but not limited to obligations and contingent obligations under guarantees, or permit any subsidiary to take any such action with respect to any debt security lien, security interest or other indebtedness for borrowed money;
(l) create, or hold capital stock in, any subsidiary that is not wholly owned (either directly or through one (1) or more other subsidiaries) by Borrower, or permit any subsidiary to create, or authorize the creation of, or issue or obligate itself to issue, any shares of any class or series of capital stock, or sell, transfer or otherwise dispose of any capital stock of any direct or indirect subsidiary of Borrower or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively license or otherwise dispose (in a single transaction or series of related transactions) of all or substantially all of the assets of such subsidiary; or
-4-
(m) increase or decrease the authorized number of directors constituting Borrower’s Board of Directors, change the number of votes entitled to be cast by any director or directors on any matter.
Notwithstanding anything to the contrary set forth in this Section 3.9, Lender’s consent will not be required under any circumstance (A) to initiate an Insolvency Proceeding (including for the avoidance of doubt a filing under Chapter 7 or Chapter 11 of the United States Bankruptcy Code), and/or (B) to pursue or consummate a Qualified Public Offering.
3.10 Further Actions. Borrower shall take or authorize any further actions (including Lender’s filing of financing statements to perfect Lender’s security interest in the Collateral) and execute any further instruments as Lender reasonably requests to perfect or continue Lender’s security interests or to effect the purposes of this Agreement.
3.11 Full Disclosure. No written representation, warranty or other statement of Borrower in any certificate or other written statement submitted to Lender, as of the date such representation, warranty or other statement was made, in the aggregate, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statement contained in such certificates or other written statements not misleading (it being recognized by Lender that the projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions as of the time made are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from projected or forecasted results).
4. Term. This Agreement shall continue in effect until the last of the Maturity Date as more fully set forth in Schedule A. On the relevant Maturity Date or on any earlier effective date of termination of this Agreement, Borrower shall pay in cash all Obligations in full, whether or not such Obligations are otherwise then due and payable. No termination shall in any way affect or impair any security interest or other right or remedy of Lender, nor shall any such termination relieve Borrower of any obligation to Lender, until all of the Obligations have been paid and performed in full. So long as Borrower has satisfied the Obligations (other than inchoate indemnity obligations and any other obligations which by their terms, are to survive termination of this Agreement, but, for the avoidance of doubt, including the Repayment provisions of Schedule A), this Agreement may be terminated prior to the last Maturity Date by Borrower, effective three (3) Business Days after written notice of termination is given to Lender. Those obligations that are expressly specified in this Agreement as surviving this Agreement’s termination shall continue to survive notwithstanding this Agreement’s termination. Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations), Lender’s liens in the Collateral and all rights therein shall automatically revert to Borrower and upon Borrower’s request, Lender shall, at the sole cost and expense of Borrower, promptly take such steps to evidence the release of its liens in the Collateral as Borrower shall reasonably request.
5. Conditions Subsequent
5.1 The Borrower shall fulfill the following conditions to the satisfaction of the Lender:
(i) within 10 Business Days from the Effective Date, deliver a Corporate Borrowing Certificate, substantially in the form attached hereto as Schedule D, duly executed and delivered by Borrower, together with (a) copies of the organizational and charter documents of Borrower (e.g., Articles or Certificate of Incorporation and Bylaws), as amended through the Effective Date, and (b) a copy of the resolutions of the Board of Directors of Borrower authorizing the execution, delivery and performance by Borrower of the Loan Documents;
(ii) within 10 Business Days from the Effective Date, deliver executed counterparts of this Agreement and the other Loan Documents ((including, without limitation, the Subordination Agreement) in form acceptable to Lender in its sole discretion);
-5-
(ii) within 10 Business Days from the Effective Date, deliver a certificate of status or good standing of Borrower as of a date acceptable to Lender from the jurisdiction of Borrower’s organization and any foreign jurisdictions where Borrower is qualified to do business and the failure to be so qualified could reasonably be expected to have a Material Adverse Change;
(iii) within 20 Business Days from the Effective Date, deliver filing copies (or other evidence of filing satisfactory to Lender and its counsel) of such UCC financing statements, collateral assignments, and termination statements, with respect to the Collateral as Lender shall reasonably request;
(iv) within 2 Business Days from the Effective Date, deliver a Note in the form attached hereto as Schedule E (the “Note”); and such other documents and instruments as Lender may reasonably request (including any requested Intellectual Property security agreements and the like) to effectuate the intents and purposes of this Agreement and the other Loan Documents.
Notwithstanding the above, Lender may waive any conditions subsequent listed in Section 5.1 in its sole discretion.
6. Events of Default. The occurrence of any of the following events, upon delivery of a notice by the Lender in such regard, shall constitute an “Event of Default” hereunder; provided however that there shall be no Event of Default as a result of an event, condition or circumstance in existence on the Effective Date that is disclosed in writing to the Lender: (i) Borrower fails to deliver the financial statements and other information pursuant to Section 3.3 above within the prescribed period of time; (ii) Borrower violates any of the covenants set forth in Sections 3.4 or 3.9 above or the Additional Agreements and Limitations section of Schedule A below; (iii) Borrower fails to pay when due the Loan or other monetary Obligation within three (3) Business Days after the due date; (iv) Borrower fails to perform any obligation (other than payment of the Loan or other Obligations or those pursuant to Sections 3.3 and 3.9 above) or covenant hereunder, which, if such default can be reasonably cured, is not cured within twenty (20) days after the date due (or a later date, as approved in writing by Lender); (v) the occurrence or existence of any circumstance that would reasonably be expected to have a Material Adverse Change; provided, that notwithstanding anything to the contrary herein, no Material Adverse Change shall be deemed to arise solely as a result of: (A) Borrower’s investors declining to further financially support the Borrower; (B) resignations by members of the Borrower’s Board of Directors; and/or (C) the occurrence or existence of any circumstances prior to the Effective Date as otherwise disclosed to Lender or Lender’s representatives; (vi) there is a material impairment in the perfection or priority of Lender’s security interest in the Collateral or in the value of such Collateral (other than normal depreciation) which is not covered by adequate insurance; (vii) any representation, or written statement given to Lender by or on behalf of Borrower, now or in the future, is untrue or misleading in a material respect; (viii) a default, after the Effective Date, in respect of any agreement between Borrower and a third party that gives the third party the right to accelerate any indebtedness exceeding the Threshold Amount or that could reasonably be expected to cause any material impairment in Borrower’s business, operations or financial condition of Borrower; (ix) one or more fines, penalties or final judgments, orders or decrees for the payment of money in an amount, individually or in the aggregate, of at least the Threshold Amount (not covered by independent third-party insurance as to which liability has been accepted by such insurance carrier) shall be rendered against Borrower by any governmental authority, and the same are not, within twenty (20) days after the entry, assessment or issuance thereof, discharged, satisfied, or paid, or after execution thereof, stayed or bonded pending appeal, or such judgments are not discharged prior to the expiration of any such stay; (x) the attachment, seizure, levy or possession by a trustee or receiver of any material portion of Borrower’s assets which is not removed within twenty (20) days from its occurrence; (xi) the enjoinment, restraint or prevention by court order from conducting a material part of Borrower’s business, which is not terminated within twenty (20) days of its occurrence; (xii) the dissolution, winding up or insolvency of Borrower; (xiii) the failure of Paul Kellenberger to serve as Chief Executive Officer for any reason for a period of greater than 60 days before the Maturity Date, provided that shall the Board of Directors of Borrower replace Paul Kellenberger with an equivalently qualified Chief Executive Officer acceptable to Lender (such approval not to be unreasonably withheld) within 120 days of such failure of Paul Kellenberger to serve, such action and such replacement shall not constitute an Event of Default hereunder; (xiv) the appointment of a receiver, trustee or custodian, for all or part of the property of, assignment for the benefit of creditors by Borrower, Borrower begins an Insolvency Proceeding or an Insolvency Proceeding is begun against Borrower and not dismissed or stayed within forty-five (45) days, (xv) failure of Borrower to provide an executed Note in the form attached hereto as Schedule E on the within the time period specified in this Agreement, (xvi) a default by the Borrower (payment default or otherwise) in respect of any Pre-Existing Agreement, and (xvii) Borrower fails to comply with the conditions subsequent in violation of Section 5.1.
-6-
7. Rights and Remedies. If an Event of Default occurs and continues, Lender may during the continuance of such Event of Default, without notice or demand do any or all of the following: (i) accelerate and declare all of the Loan and other Obligations to be immediately due and payable (but if an Event of Default described in Sections 6(xi) or 6(xii) occurs, all Obligations are immediately due and payable without any action by Lender); (ii) stop advancing money or extending credit for Borrower’s benefit under this Agreement or any other agreement between Borrower and Lender; (iii) settle or adjust disputes and claims directly with account debtors for amounts, on terms and in any order that Lender considers advisable; (iv) make any payments and do any acts it considers necessary or reasonable to protect its security interest in the Collateral (and Borrower will reasonably cooperate with Lender accordingly); (v) apply to the Obligations any balances and deposits of Borrower that Lender holds or any amount held by Lender owing to or for the credit or the account of Borrower; (vi) impose the Default Rate (as defined in Schedule A); (vii) ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale and sell or otherwise dispose the Collateral; (viii) deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any control agreement or similar agreements providing control of any Collateral on such seniority and in such manner as set out in the Subordination Ageement; and/or (ix) exercise any other rights and remedies permitted by applicable law. Effective only when an Event of Default occurs and continues, Borrower irrevocably appoints Lender as its lawful attorney to: (a) endorse Borrower’s name on any checks or other forms of payment or security; (b) sign Borrower’s name on any invoice or bill of lading for any account or drafts against account debtors, (c) make, settle, and adjust all claims under Borrower’s insurance policies; (d) settle and adjust disputes and claims about the accounts directly with account debtors for amounts and on terms Lender determines reasonable; and (e) transfer the Collateral into the name of Lender or a third party as the applicable UCC permits. Lender may exercise the power of attorney to sign Borrower’s name on any documents necessary to perfect or continue the perfection of any security interest regardless of whether an Event of Default has occurred. Lender’s appointment as Borrower’s attorney in fact, and all of Lender’s rights and powers, coupled with an interest, are irrevocable until all Obligations (other than inchoate indemnity obligations and any obligations which, by their terms, are to survive the termination of this Agreement) have been fully repaid and performed. All of Lender’s rights and remedies under this Agreement or any other agreement between Lender and Borrower are cumulative. Borrower waives demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Lender on which Borrower is liable. In the event there is more than one Borrower, the Obligations of each Borrower entity hereunder shall be independent of the Obligations of any other Borrower entities or any security for the Obligations, and Lender may proceed in the enforcement hereof independently of any other right or remedy that Lender may at any time hold with respect to the Obligations or any security or other guarantee therefor. In the event there is more than one Borrower, Lender may file a separate action or actions against any Borrower entity hereunder, whether action is brought and prosecuted with respect to any security or against any Borrower entity or any other Person.
-7-
8. General.
8.1 No Waivers; Amendments. The failure of Lender at any time to require Borrower to comply strictly with any of the provisions of this Agreement shall not waive Lender’s right to later demand and receive strict compliance. Any waiver of a default shall not waive any other default. None of the provisions of this Agreement may be waived except by a specific written waiver signed by Lender and delivered to Borrower. The provisions of this Agreement may not be amended except in a writing signed by Borrower and Lender.
8.2 Indemnification. Borrower will indemnify, defend and hold harmless Lender and its affiliates, and each of their officers, directors, employees, attorneys, accountants and agents against: (i) all obligations, demands, claims, and liabilities asserted by any other party in connection with the transactions contemplated hereunder; and (ii) all losses and expenses incurred, or paid by Lender arising from transactions between Lender and Borrower contemplated by the Loan Documents (including reasonable attorneys’ fees and expenses), except, as to both “(i)” and “(ii)” in this Section 8.2, for losses caused by Lender’s gross negligence or willful misconduct. This Section 8.2 shall survive termination of this Agreement.
8.3 Lender Expenses; Attorneys’ Fees. Borrower shall reimburse Lender for all reasonable and documented out-of-pocket audit fees and expenses and reasonable and documented out-of-pocket costs and expenses (including, but not limited to the reasonable and documented attorneys’ fees and expenses) for preparing, negotiating, administering, defending and enforcing this Agreement and the other loan documents with Lender (including appeals or insolvency proceedings) (collectively, “Lender Expenses”). Nothwithstanding the prior sentence, the maximum amount of reimburseable fees for preparation and negotiation of this Agreement shall be $25,000. If, subject to the foregoing, Lender or Borrower files any lawsuit against the other predicated on a breach of this Agreement, the prevailing party shall be entitled to recover its costs and reasonable attorneys’ fees from the non-prevailing party.
8.4 Binding Effect; Assignment. This Agreement is binding upon and for the benefit of the successors and permitted assignees of each party. Borrower may not assign any rights under this Agreement without Lender’s prior written consent. The Lender, acting solely for this purpose as an agent of the Borrower, shall maintain a register for the recordation of the names and addresses of the Lenders, and the principal amounts (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive absent manifest error, and the Borrower and the Lenders shall treat each person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement. The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice.
8.5 Notices. All notices by any party required or permitted under this Agreement or any other related agreement must be in writing and be personally delivered or sent by overnight delivery, certified mail (postage prepaid and return receipt requested), or facsimile to the addresses and numbers below.
8.6 Governing Law; Jurisdiction. This Agreement shall be governed by the laws of the State of New York without regard to principles of conflicts of law. Borrower and Lender each submit to the exclusive jurisdiction of the federal and state courts in the County of New York, the City of New York.
8.7 Other. If any provision hereof is unenforceable, the remainder of this Agreement shall continue in full force and effect. This Agreement (including the schedules attached hereto) and any other written agreements and, documents executed in connection herewith are the complete agreement between Borrower and Lender and supersede all prior and contemporaneous negotiations and oral representations and agreements, all of which are merged and integrated herein. This Agreement may be executed in one or more counterparts, all of which when taken together will constitute one agreement.
9. Confidentiality. In handling any confidential information (including Borrower’s financial statements and all information and data therein), Lender will exercise the same degree of care that it exercises for its own proprietary information, but disclosure of information may be made: (i) to Lender’s Subsidiaries or affiliates; (ii) to prospective transferees or purchasers of any interest in the Loan (provided that Lender shall use commercially reasonable efforts to obtain such transferee’s or purchaser’s agreement of the terms of this provision); (iii) as required by law, regulation, subpoena, or other order; (iv) as required in connection with Lender’s examinations and audits; (v) as Lender considers appropriate in exercising remedies under this Agreement; or (vi) to third-party service providers of Lender so long as such service providers have executed a confidentiality agreement with Lender with terms no less restrictive than those contained herein. Confidential information does not include information that is either: (a) in the public domain or in Lender’s possession when disclosed to Lender or becomes part of the public domain (other than as a result of its disclosure by Lender in violation of this Agreement) after disclosure to Lender; or (b) disclosed to Lender by a third party, if Lender does not know that the third party is prohibited from disclosing the information.
-8-
10. Taxes.
10.1 Payments Free of Taxes. Any and all payments by or on account of any obligation of the Borrower under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable law. If any applicable law requires the deduction or withholding of any Tax from any such payment by the Borrower, then the Borrower shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant governmental authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by the Borrower shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section) the applicable Lender receives an amount equal to the sum it would have received had no such deduction or withholding been made.
10.2 Payment of Other Taxes by Borrower. The Borrower shall timely pay to the relevant governmental authority in accordance with applicable law, or at the option of the applicable Lender timely reimburse it for the payment of, any Other Taxes.
10.3 Indemnification by Borrower. The Borrower shall indemnify the Lender, promptly after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section) payable or paid by such Lender or required to be withheld or deducted from a payment to the Lender and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant governmental authority. A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender, shall be conclusive absent manifest error.
10.4 Evidence of Payments. As soon as practicable after any payment of Taxes by the Borrower to a governmental authority pursuant to this Section, the Borrower shall deliver to the applicable recipient the original or a certified copy of a receipt issued by such governmental authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to such Lender.
-9-
10.5 Status of Lenders. The Borrower shall provide the Lender (or any transferee of a Lender) with written notice of any payments to be made under any Loan Document potentially subject to withholding Tax as soon as reasonably practicable but in all cases at least fifteen (15) days in advance thereof. The Lender (or any transferee of a Lender) that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower, at the time or times reasonably requested by the Borrower, such properly completed and executed documentation (including IRS Form W-9 or an applicable IRS Form W-8) reasonably requested by the Borrower as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, the Lender (or transferee of a Lender), if reasonably requested by the Borrower, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower as will enable the Borrower to determine whether or not the Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than the documentation described in clauses (i) through (iv) of the following sentence) shall not be required if in the Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of the Lender. The Lender (or any transferee of a Lender) that is not a “U.S. Person” as defined in Section 7701(a)(30) of the Code (a “Non-U.S. Lender”) shall, to the extent it is legally entitled to do so, deliver to Borrower two copies of whichever of the following is applicable: (i) in the case of a Non-U.S. Lender claiming the benefits of an income tax treaty to which the United States is a party, duly completed copies of IRS Form W-8BEN or W-8BEN-E (or any subsequent versions thereof or successors thereto), as applicable, claiming eligibility for benefits of an income tax treaty to which the United States of America is a party; (ii) duly completed copies of IRS Form W-8ECI (or any subsequent versions thereof or successors thereto); (iii) in the case of a Non-U.S. Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate in substantially the form of Schedule F to the effect that such Non-U.S. Lender is not (A) a “bank” within the meaning of section 881(c)(3)(A) of the Code, (B) a “10 percent shareholder” of Borrower within the meaning of section 881(c)(3)(B) of the Code, or (C) a “controlled foreign corporation” described in section 881(c)(3)(C) of the Code and (y) duly completed copies of IRS Form W-8BEN or W-8BEN-E (or any subsequent versions thereof or successors thereto); (iv) to the extent a Non-U.S. Lender is not the beneficial owner, duly completed copies of IRS Form W-8IMY, together with forms and certificates described in clauses (i) through (iii) above with respect to the beneficial owner (and additional IRS Form W-8IMYs) as applicable or (v) any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in United States federal withholding tax duly completed together with such supplementary documentation as may be prescribed by applicable law to permit Borrower to determine the withholding or deduction required to be made. For the avoidance of doubt, if a Lender provides documentation described in clause (iii) above in advance of amounts payable to or for the account of such Lender, any U.S. withholding Taxes imposed on such amounts shall not be Excluded Taxes, regardless of whether such documentation is sufficient to eliminate U.S. withholding Taxes, unless the Borrower has knowledge or reason to know of any facts that would render such documentation unreliable for purposes of Section 1441(c)(9) of the Code. If the Borrower determines it has knowledge or reason to know of any facts that would render such documentation unreliable, the Borrower shall, prior to deducting or withholding any Excluded Taxes from any amounts payable to or for the account of such Lender, notify such Lender in writing of such determination, specifying the specific factual basis therefor. The Borrower and such Lender shall negotiate in good faith and use their reasonable best efforts (including sharing information relevant to the Lender’s statements in the documentation described in clause (iii)) to resolve any such matter in a manner that permits such payments to be made without deduction for, or withholding of, any such Taxes. If the Borrower and such Lender are unable to so resolve such matter, the parties shall engage an independent third-party tax counsel mutually acceptable to the parties to determine whether the Borrower has knowledge of or reason to know that such documentation described in clause (iii) is unreliable or whether the Borrower may on any basis make such payments without deduction for, or withholding of, any such Taxes, and such determination by tax counsel shall be final. The costs, fees and expenses of tax counsel shall be borne by the non-prevailing party.
10.6 FATCA. If a payment made to the Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if the Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower at the time or times prescribed by law and at such time or times reasonably requested by the Borrower Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower as may be necessary for the Borrower to comply with its obligations under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. Solely for purposes of this clause (d), “FATCA” shall include any amendments made to FATCA after the date of this Agreement.
11. Mutual Waiver of Jury Trial. BORROWER AND LENDER EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF THIS AGREEMENT OR ANY RELATED DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR BOTH PARTIES TO ENTER INTO THIS AGREEMENT. EACH PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL.
-10-
12. FOR AND IN CONSIDERATION OF LENDER’S AGREEMENTS CONTAINED HEREIN, BORROWER, TOGETHER WITH ITS, SUCCESSORS AND ASSIGNS (INDIVIDUALLY AND COLLECTIVELY, “RELEASORS”) HEREBY VOLUNTARILY AND KNOWINGLY RELEASES AND FOREVER WAIVES AND DISCHARGES LENDER AND EACH OF ITS RESPECTIVE PARENTS, DIVISIONS, SUBSIDIARIES, AFFILIATES, MEMBERS, MANAGERS, PARTICIPANTS, PREDECESSORS, SUCCESSORS, AND ASSIGNS, AND EACH OF THEIR RESPECTIVE CURRENT AND FORMER DIRECTORS, OFFICERS, SHAREHOLDERS, MEMBERS, MANAGERS, PARTNERS, AGENTS, AND EMPLOYEES, AND EACH OF THEIR RESPECTIVE PREDECESSORS, SUCCESSORS, HEIRS, AND ASSIGNS (INDIVIDUALLY AND COLLECTIVELY, THE “RELEASED PARTIES”) FROM ALL POSSIBLE CLAIMS, COUNTERCLAIMS, DEMANDS, ACTIONS, CAUSES OF ACTION, DAMAGES, COSTS, EXPENSES AND LIABILITIES WHATSOEVER, WHETHER KNOWN OR UNKNOWN, ANTICIPATED OR UNANTICIPATED, SUSPECTED OR UNSUSPECTED, FIXED, CONTINGENT OR CONDITIONAL, OR AT LAW OR IN EQUITY, IN ANY CASE ORIGINATING IN WHOLE OR IN PART ON OR BEFORE THE EFFECTIVE DATE THAT ANY OF THE RELEASORS MAY NOW HAVE AGAINST THE RELEASED PARTIES, IF ANY, IRRESPECTIVE OF WHETHER ANY SUCH CLAIMS ARISE OUT OF CONTRACT, TORT, VIOLATION OF LAW OR REGULATIONS, OR OTHERWISE, INCLUDING WITHOUT LIMITATION ARISING DIRECTLY OR INDIRECTLY FROM THE LOAN, ANY PRIOR OR EXISTING LOANS BETWEEN RELEASORS ANY RELEASED PARTIES, ANY OF THE LOAN DOCUMENTS, THE EXERCISE OF ANY RIGHTS AND REMEDIES UNDER ANY OF THE LOAN DOCUMENTS, AND/OR NEGOTIATION FOR AND EXECUTION OF THIS AGREEMENT, INCLUDING, WITHOUT LIMITATION, ANY CONTRACTING FOR, CHARGING, TAKING, RESERVING, COLLECTING OR RECEIVING INTEREST IN EXCESS OF THE HIGHEST LAWFUL RATE APPLICABLE. EACH OF THE RELEASORS WAIVES THE BENEFITS OF ANY LAW INCLUDING SECTION 1542 OF THE CALIFORNIA CIVIL CODE, WHICH MAY PROVIDE IN SUBSTANCE: “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN ITS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY IT MUST HAVE MATERIALLY AFFECTED ITS SETTLEMENT WITH THE DEBTOR.”
By entering into this release, Borrower recognizes that no facts or representations are ever absolutely certain and it may hereafter discover facts in addition to or different from those which it presently knows or believes to be true, but that it is the intention of Borrower hereby to fully, finally and forever settle and release all matters, disputes and differences, known or unknown, suspected or unsuspected; accordingly, if Borrower should subsequently discover that any fact that it relied upon in entering into this release was untrue, or that any understanding of the facts was incorrect, Borrower shall not be entitled to set aside this release by reason thereof, regardless of any claim of mistake of fact or law or any other circumstances whatsoever. Borrower acknowledges that it is not relying upon and has not relied upon any representation or statement made by Lender with respect to the facts underlying this release or with regard to any of such party’s rights or asserted rights.
This release may be pleaded as a full and complete defense and/or as a cross-complaint or counterclaim against any action, suit, or other proceeding that may be instituted, prosecuted or attempted in breach of this release. Borrower acknowledges that the release contained herein constitutes a material inducement to Lender to enter into this Agreement, and that Lender would not have done so but for Lender’s expectation that such release is valid and enforceable in all events.
Borrower hereby represents and warrants to Lender, and Lender is relying thereon, as follows:
(a) | Except as expressly stated in this Agreement, neither Lender nor any agent, employee or representative of Lender has made any statement or representation to Borrower regarding any fact relied upon by Borrower in entering into this Agreement. | |
(b) | Borrower has made such investigation of the facts pertaining to this Agreement and all of the matters appertaining thereto, as it deems necessary. | |
(c) | The terms of this Agreement are contractual and not a mere recital. | |
(d) | This Agreement has been carefully read by Borrower, the contents hereof are known and understood by Borrower, and this Agreement is signed freely, and without duress, by Borrower. |
-11-
Borrower represents and warrants that it is the sole and lawful owner of all right, title and interest in and to every claim and every other matter which it releases herein, and that it has not heretofore assigned or transferred, or purported to assign or transfer, to any person, firm or entity any claims or other matters herein released. Borrower shall indemnify Lender, defend and hold it harmless from and against all claims based upon or arising in connection with prior assignments or purported assignments or transfers of any claims or matters released herein.
13. Mutual Waiver of Jury Trial. This Agreement amends, restates, replaces and supersedes in its entirety that certain Preexisting Agreement and does not constitute a novation, payment and reborrowing or termination of the obligations under the Preexisting Agreement, which obligations remain in full force and effect in all respects
[Signature page follows.]
-12-
In Witness Whereof, the parties hereto have executed this Agreement as of the date initially set forth above.
Borrower: | ||
ZSPACE, INC. | ||
By: | /s/ Paul Kellenberger | |
Name: Paul Kellenberger | ||
Title: Chief Executive Officer |
Address: | 55 Nicholson Lane |
San Jose, CA 95134 | |
Attention: Chief Financial Officer | |
Email: contracts@zspace.com | |
With a copy (which shall not constitute notice) to: | |
Pryor Cashman | |
7 Times Square, New York, NY 10036-6569 | |
Attn: Ali Panjwani | |
MPanjwani@pryorcashman.com |
Lender: | ||
FIZA INVESTMENTS LIMITED | ||
By: | /s/ Husain Zariwala |
Name: | Husain Zariwala |
Title: | Authorised Signatory |
By: | /s/ Imran Ladhani |
Name: | Imran Ladhani |
Title: | Authorised Signatory |
Address: | c/o Gulf Islamic Investments LLC |
PO Box 215931, Emaar Square 4, 7th Floor | |
Downtown Dubai, United Arab Emirates | |
Email: pgupta@gii.ae | |
With a copy (which shall not constitute notice) to: | |
Orrick, Herrington & Sutcliffe LLP | |
405 Howard Street | |
San Francisco, CA 94105 | |
Attn: Dolph Hellman | |
Email: dolphhellman@orrick.com |
SIGNATURE PAGE TO LOAN AND SECURITY AGREEMENT – ZSPACE, INC.
Schedule
A
LOAN TERMS
Borrower: ZSPACE, INC., a Delaware corporation
LOAN |
REPAYMENT AND INTEREST | |
Repayment/Prepayment: | Mandatory payment of each Loan shall be due upon the earlier of (i) the applicable Maturity Date, (ii) an Event of Default (in which case all Loans shall be mandatorily payable), and (iii) any Change of Control or other liquidation event other than a Public Offering, in each case, including without limitation, any voluntary pre-payments, or payments after the Maturity Date and shall include payment of all outstanding principal, all accrued and unpaid interest, all unpaid Lender Expenses. For purposes of clarity, any Loan may be voluntarily prepaid in full (or part) within three (3) Business Days’ notice to Lender on the same terms of the mandatory prepayment listed in the preceding sentence provided that any prepayment of any portion of the Loan Amount shall also include payment of prepayment interest of 2% per annum on the principal amount being prepaid. |
Interest: | On and after the Effective Date and through to the relevant Maturity Date, each Loan shall accrue interest on the outstanding principal balance of such Loan at a per annum interest rate of 25% payable (together with the principal amount) in accordance with the payment schedule set out in Exhibit 1. Interest shall be computed on a 360 day year for the actual number of days elapsed. |
Any amounts outstanding during the continuance of an Event of Default shall bear an additional interest at the rate of 3% per annum (the “Default Rate”). | |
Application of Payments: | Payments received after 12:00 noon Pacific Time are considered received at the opening of business on the next Business Day. When a payment is due on a day that is not a Business Day, the payment is due the next Business Day and additional interest, if applicable, shall accrue. |
FEES | |
Legal Fee: | Borrower will pay reasonable and documented attorneys’ fees and expenses actually incurred, including fees for the documentation and negotiation of this Agreement through the Effective Date, and any additional reasonable and documented out-of-pocket attorney’s fees and expenses incurred thereafter, including with respect to any amendment thereto up to a maximum of $25,000. |
-2-
FINANCIAL REPORTING AND SALES PROCESS REQUIREMENTS | |
Financial Reports: | Borrower shall provide Lender: |
§ Monthly Financial Statements. Within 30 days after the end of each month, monthly financial statements prepared by Borrower in accordance with GAAP. | |
§ Monthly MIS. Monthly MIS reports showing profit and loss accounts, balance sheet and bookings pipeline for each calendar month, within 5 Business Days from the end of each calendar month. The report shall be provided in the format agreed with the Lender. | |
§ Annual Audited/Reviewed Financial Statements. If Borrower’s Board of Directors requires CPA-audited or reviewed annual financial statements, then, as soon as available, and in any event within 210 days following the end of Borrower’s fiscal year beginning with the 2023 fiscal year, annual, audited or reviewed, consolidated financial statements prepared under GAAP, consistently applied, together with (i) an unqualified opinion (other than with respect to a “going concern” qualification typical for venture backed companies) in the financial statements from independent public accountants reasonably acceptable to Lender, in the case of CPA-audited financial statements, or (ii) a report on the financial statements from independent public accountants reasonably acceptable to Lender, in the case of CPA-reviewed financial statements. | |
§ Annual Company-Prepared Financial Statements. If Borrower’s Board of Directors does not require CPA-audited or reviewed annual financial statements for any period, then, as soon as available, and in any event within 60 days after the end of Borrower’s fiscal year beginning with the 2023 fiscal year, company-prepared consolidated financial statements for such fiscal year certified by a Responsible Officer. | |
§ Annual Financial Projections. As soon as available, but no later than 60 days after fiscal year-end, annual Board-approved financial projections and operating budgets for the following fiscal year commensurate in form and substance with those provided to Borrower’s venture capital investors. | |
§ Additional Financial Information. Borrower shall provide Lender a copy of all 409A valuation approved by the Borrower’s Board of Directors after the Effective Date promptly after approval by the Board of Directors. | |
§ Weekly Reports. Reports on the collections, sales and bookings, inventory purchases and shipments of orders for each calendar week, within 2 Business Days from the end of each calendar week. The report shall be provided in the format agreed with the Lender. |
-3-
§ Cash Balance. Cash balance report for each calendar week, within 1 Business Day from the end of each calendar week. The report shall be provided in the format agreed with the Lender. | |
§ Cash reconciliation. Reports showing cash reconciliation for each calendar month, within 3 Business Days from the end of each calendar month. The report shall be provided in the format agreed with the Lender. | |
§ Board Materials and Observer. Borrower shall provide Lender copies of all materials that Borrower provides to its Board of Directors in connection with meetings, including any reports with respect to Borrower’s operation or performance; provided, that the foregoing may be subject to such exclusions and redactions as Borrower deems reasonably necessary in the exercise of its good faith judgment in order to (a) preserve the confidentiality of highly sensitive proprietary information, or (b) prevent impairment of the attorney-client privilege. Following the Effective Date, Borrower grants Lender the right to designate a Board of Directors representative (the “Observer Representative”) to be present (whether in person or by telephone) in a nonvoting observer capacity at all meetings of the Board of Directors of Borrower or any committees of the Board of Directors of Borrower, unless exclusion of such Observer Representative is necessary to preserve the attorney-client privilege or to protect highly confidential or proprietary information or trade secrets or other similar reasons. Borrower shall deliver, or cause to be delivered, to the Observer Representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors, unless withholding such materials is necessary to preserve the attorney-client privilege or to protect highly confidential or proprietary information or trade secrets or other similar reasons. | |
§ Sales Process. Upon Lender’s reasonable request, Borrower shall (i) update the Lender on any and all sale or listing process of the Company and (ii) provide Lender copies of any summary written materials relating to the sales process promptly after being provided to Borrower’s Board of Directors; provided, that the foregoing may be subject to such exclusions and redactions as Borrower deems reasonably necessary in the exercise of its good faith judgment in order to (a) preserve the confidentiality of highly sensitive proprietary information, or (b) prevent impairment of the attorney-client privilege. Without additional request being required by Lender, Borrower shall provide a high-level summary of any material updates or changes in any and all sales process not less than monthly. | |
§ Financial Covenants Reports. Monthly report certifying compliance with the financial covenants set out in this Agreement, within 3 Business Days from the end of each calendar month. | |
§ Bank Statements. Borrower shall provide Lender with monthly statements to all of its deposit and securities accounts on a monthly basis. | |
§ Other Information. Other financial, business or sales information as may reasonably be requested by Lender. |
-4-
Exhibit 1
Payment ScheduleS
TRANCHE I LOAN
As of the Effective date, the following principal and accrued interest amounts are as follows:
Principal |
Interest |
Balance |
$2,190,873.61 |
$127,585.47 | $ 2,318,459.08 |
Pmt Date | Pmt Ref | Loan Amount | Principal | Interest | Balance | Payment Amount | ||||||||||||||||||
5/31/23 | $ | 3,000,000.00 | $ | 3,000,000.00 | $ | 3,000,000.00 | ||||||||||||||||||
6/30/23 | a | $ | 3,000,000.00 | $ | (17,557.28 | ) | $ | (62,500.00 | ) | $ | 2,982,442.72 | $ | (80,057.28 | ) | ||||||||||
7/30/23 | b | $ | 2,982,442.72 | $ | (17,923.06 | ) | $ | (62,134.22 | ) | $ | 2,964,519.66 | $ | (80,057.28 | ) | ||||||||||
8/30/23 | c | $ | 2,964,519.66 | $ | (18,296.45 | ) | $ | (61,760.83 | ) | $ | 2,946,223.21 | $ | (80,057.28 | ) | ||||||||||
9/30/23 | d | $ | 2,946,223.21 | $ | (18,677.63 | ) | $ | (61,379.65 | ) | $ | 2,927,545.58 | $ | (80,057.28 | ) | ||||||||||
10/30/23 | e | $ | 2,927,545.58 | $ | (19,066.75 | ) | $ | (60,990.53 | ) | $ | 2,908,478.83 | $ | (80,057.28 | ) | ||||||||||
11/30/23 | f | $ | 2,908,478.83 | $ | (19,463.97 | ) | $ | (60,593.31 | ) | $ | 2,889,014.86 | $ | (80,057.28 | ) | ||||||||||
12/30/23 | 1 | $ | 2,889,014.86 | $ | (133,930.34 | ) | $ | (60,187.81 | ) | $ | 2,755,084.52 | $ | (194,118.15 | ) | ||||||||||
1/30/24 | 2 | $ | 2,755,084.52 | $ | (136,720.56 | ) | $ | (57,397.59 | ) | $ | 2,618,363.96 | $ | (194,118.15 | ) | ||||||||||
2/29/24 | 3 | $ | 2,618,363.96 | $ | (139,568.90 | ) | $ | (54,549.25 | ) | $ | 2,478,795.05 | $ | (194,118.15 | ) | ||||||||||
3/29/24 | 4 | $ | 2,478,795.05 | $ | (142,476.59 | ) | $ | (51,641.56 | ) | $ | 2,336,318.46 | $ | (194,118.15 | ) | ||||||||||
4/29/24 | 5 | $ | 2,336,318.46 | $ | (145,444.85 | ) | $ | (48,673.30 | ) | $ | 2,190,873.61 | $ | (194,118.15 | ) | ||||||||||
5/29/24 | 6 | $ | 2,190,873.61 | $ | (148,474.95 | ) | $ | (45,643.20 | ) | $ | 2,042,398.66 | $ | (194,118.15 | ) | ||||||||||
6/29/24 | 7 | $ | 2,042,398.66 | $ | (151,568.18 | ) | $ | (42,549.97 | ) | $ | 1,890,830.48 | $ | (194,118.15 | ) | ||||||||||
7/29/24 | 8 | $ | 1,890,830.48 | $ | (154,725.85 | ) | $ | (39,392.30 | ) | $ | 1,736,104.63 | $ | (194,118.15 | ) | ||||||||||
8/29/24 | 9 | $ | 1,736,104.63 | $ | (157,949.31 | ) | $ | (36,168.85 | ) | $ | 1,578,155.32 | $ | (194,118.15 | ) | ||||||||||
9/29/24 | 10 | $ | 1,578,155.32 | $ | (161,239.92 | ) | $ | (32,878.24 | ) | $ | 1,416,915.40 | $ | (194,118.15 | ) | ||||||||||
10/29/24 | 11 | $ | 1,416,915.40 | $ | (164,599.08 | ) | $ | (29,519.07 | ) | $ | 1,252,316.32 | $ | (194,118.15 | ) | ||||||||||
11/29/24 | 12 | $ | 1,252,316.32 | $ | (168,028.23 | ) | $ | (26,089.92 | ) | $ | 1,084,288.09 | $ | (194,118.15 | ) | ||||||||||
12/29/24 | 13 | $ | 1,084,288.09 | $ | (171,528.82 | ) | $ | (22,589.34 | ) | $ | 912,759.27 | $ | (194,118.15 | ) | ||||||||||
1/29/25 | 14 | $ | 912,759.27 | $ | (175,102.34 | ) | $ | (19,015.82 | ) | $ | 737,656.94 | $ | (194,118.15 | ) | ||||||||||
2/28/25 | 15 | $ | 737,656.94 | $ | (178,750.30 | ) | $ | (15,367.85 | ) | $ | 558,906.64 | $ | (194,118.15 | ) | ||||||||||
3/28/25 | 16 | $ | 558,906.64 | $ | (182,474.26 | ) | $ | (11,643.89 | ) | $ | 376,432.37 | $ | (194,118.15 | ) | ||||||||||
4/28/25 | 17 | $ | 376,432.37 | $ | (186,275.81 | ) | $ | (7,842.34 | ) | $ | 190,156.56 | $ | (194,118.15 | ) | ||||||||||
5/28/25 | 18 | $ | 190,156.56 | $ | (190,156.56 | ) | $ | (3,961.59 | ) | $ | - | $ | (194,118.15 | ) |
-5-
Tranche iI Loan
As of the Effective date, the following principal and accrued interest amounts are as follows:
Principal |
Accrued Interest |
Balance |
$1,260,340.83 |
$77,210.78 |
$ 1,337,551.61 |
Pmt Date | Pmt Ref | Loan Amount | Principal | Interest | Balance | Payment Amount | ||||||||||||||||||
12/31/23 | a | $ | 1,300,000.00 | $ | (7,608.15 | ) | $ | (27,083.33 | ) | $ | 1,292,391.85 | $ | (34,691.49 | ) | ||||||||||
1/31/24 | b | $ | 1,292,391.85 | $ | (7,766.66 | ) | $ | (26,924.83 | ) | $ | 1,284,625.19 | $ | (34,691.49 | ) | ||||||||||
2/29/24 | c | $ | 1,284,625.19 | $ | (7,928.46 | ) | $ | (26,763.02 | ) | $ | 1,276,696.72 | $ | (34,691.49 | ) | ||||||||||
3/29/24 | d | $ | 1,276,696.72 | $ | (8,093.64 | ) | $ | (26,597.85 | ) | $ | 1,268,603.08 | $ | (34,691.49 | ) | ||||||||||
4/29/24 | e | $ | 1,268,603.08 | $ | (8,262.26 | ) | $ | (26,429.23 | ) | $ | 1,260,340.83 | $ | (34,691.49 | ) | ||||||||||
5/29/24 | f | $ | 1,260,340.83 | $ | (8,434.39 | ) | $ | (26,257.10 | ) | $ | 1,251,906.44 | $ | (34,691.49 | ) | ||||||||||
6/29/24 | 1 | $ | 1,251,906.44 | $ | (58,036.48 | ) | $ | (26,081.38 | ) | $ | 1,193,869.96 | $ | (84,117.87 | ) | ||||||||||
7/29/24 | 2 | $ | 1,193,869.96 | $ | (59,245.58 | ) | $ | (24,872.2 | ) | $ | 1,134,624.38 | $ | (84,117.87 | ) | ||||||||||
8/29/24 | 3 | $ | 1,134,624.38 | $ | (60,479.86 | ) | $ | (23,638.01 | ) | $ | 1,074,144.52 | $ | (84,117.87 | ) | ||||||||||
9/29/24 | 4 | $ | 1,074,144.52 | $ | (61,739.86 | ) | $ | (22,378.01 | ) | $ | 1,012,404.67 | $ | (84,117.87 | ) | ||||||||||
10/29/24 | 5 | $ | 1,012,404.67 | $ | (63,026.10 | ) | $ | (21,091.76 | ) | $ | 949,378.56 | $ | (84,117.87 | ) | ||||||||||
11/29/24 | 6 | $ | 949,378.56 | $ | (64,339.15 | ) | $ | (19,778.72 | ) | $ | 885,039.42 | $ | (84,117.87 | ) | ||||||||||
12/29/24 | 7 | $ | 885,039.42 | $ | (65,679.55 | ) | $ | (18,438.32 | ) | $ | 819,359.87 | $ | (84,117.87 | ) | ||||||||||
1/29/25 | 8 | $ | 819,359.87 | $ | (67,047.87 | ) | $ | (17,070.00 | ) | $ | 752,312.00 | $ | (84,117.87 | ) | ||||||||||
2/28/25 | 9 | $ | 752,312.00 | $ | (68,444.70 | ) | $ | (15,673.17 | ) | $ | 683,867.30 | $ | (84,117.87 | ) | ||||||||||
3/28/25 | 10 | $ | 683,867.30 | $ | (69,870.63 | ) | $ | (14,247.24 | ) | $ | 613,996.67 | $ | (84,117.87 | ) | ||||||||||
4/28/25 | 11 | $ | 613,996.67 | $ | (71,326.27 | ) | $ | (12,791.60 | ) | $ | 542,670.40 | $ | (84,117.87 | ) | ||||||||||
5/28/25 | 12 | $ | 542,670.40 | $ | (72,812 .23 | ) | $ | (11,305.63 | ) | $ | 469,858.17 | $ | (84,117.87 | ) | ||||||||||
6/28/25 | 13 | $ | 469,858.17 | $ | (74,329.15 | ) | $ | (9,788.71 | ) | $ | 395,529.02 | $ | (84,117.87 | ) | ||||||||||
7/28/25 | 14 | $ | 395,529.02 | $ | (75,877.68 | ) | $ | (8,240.19 | ) | $ | 319,651.34 | $ | (84,117.87 | ) | ||||||||||
8/28/25 | 15 | $ | 319,651.34 | $ | (77,458.46 | ) | $ | (6,659.40 | ) | $ | 242,192.88 | $ | (84,117.87 | ) | ||||||||||
9/28/25 | 16 | $ | 242,192.88 | $ | (79,072.18 | ) | $ | (5,045.68 | ) | $ | 163,120.69 | $ | (84,117.87 | ) | ||||||||||
10/28/25 | 17 | $ | 163,120.69 | $ | (80,719.52 | ) | $ | (3,398.35 | ) | $ | 82,401.18 | $ | (84,117.87 | ) | ||||||||||
11/28/25 | 18 | $ | 82,401.18 | $ | (82,401.18 | ) | $ | (1,716.69 | ) | $ | - | $ | (84,117.87 | ) |
-6-
Schedule
B
COLLATERAL
The Collateral consists of all of Borrower’s right, title and interest in and to the following personal property as such terms are defined under the UCC:
All goods, equipment, inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, general intangibles (including payment intangibles), accounts (including health-care receivables), documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), Intellectual Property, securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and
all Borrower’s Books relating to the foregoing and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.
Notwithstanding the foregoing, the Collateral does not include: (a) more than 65% of the presently existing and hereafter arising issued and outstanding shares of capital stock owned by Borrower of any Foreign Subsidiary which shares entitle the holder thereof to vote for directors or any other matter, provided that the Collateral shall include one hundred percent (100%) of the issued and outstanding non-voting capital stock of such Subsidiary, (b) any interest of Borrower as a lessee or sublessee under a real property lease; (c) rights held under a license or sublicense that are not assignable by their terms without the consent of the licensor thereof (but only to the extent and for so long as such restriction on assignment is enforceable under applicable law and such consent has not been obtained); or (d) any interest of Borrower as a lessee under an equipment lease if Borrower is prohibited by the terms of such lease from granting a security interest in such lease or under which such an assignment or lien would cause a default to occur under such lease; provided, however, that upon termination of such prohibition, such interest shall immediately become Collateral without any action by Borrower or Lender.
For purposes hereof, the following terms have the following meanings:
“Borrower’s Books” means all Borrower’s books and records including ledgers, records regarding Borrower’s assets or liabilities, the Collateral, business operations or financial condition and all computer programs or discs or any equipment containing the information.
Schedule
C
DEFINiTIONS
As used in this Agreement, the following words shall have the following meanings:
“$”, “Dollars” or “USD” each mean United States Dollars.
“Amended and Restated Certificate of Incorporation” means Borrower’s Amended and Restated certificate of Incorporation dated as of December 29, 2023.
“Business Day” means any day that is not a Saturday, Sunday or a day on which Lender is closed.
“Change of Control” means (a) the acquisition of the Borrower by another corporation or entity, (b) the sale, transfer or lease of substantially all of the Borrower’s assets, (c) any other transaction where there is an acquisition of the Borrower’s capital stock representing more than 50.0% of the outstanding voting power of Borrower, (d) any “Deemed Liquidation Event” as such term is used in the Borrower’s Certificate of Incorporation, as amended from time to time, or (e) a Public Offering; provided, however, that a merger effected exclusively for the purpose of changing the domicile of the Borrower shall not constitute a Change of Control.
“Closing Date” shall mean in respect of the: (i) Tranche I Loan, the date of disbursal of the Tranche I Loan; and (ii) Tranche II Loan, the date of disbursal of the Tranche II Loan.
“Collateral” has the meaning given to such term on Schedule B.
“Default” means an event which with the giving of notice, passage of time, or both would constitute an Event of Default.
“Equipment” has the meaning given to such term in the UCC.
“Event of Default” has the meaning given to such term in Section 6.
“Excluded Taxes” means any of the following Taxes imposed on or with respect to a Lender or required to be withheld or deducted from a payment to a Lender: (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed as a result of such Lender being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes, (b) U.S. withholding Taxes imposed on amounts payable to or for the account of a Lender attributable to such Lender’s failure or inability to deliver, prior to the payment of such amounts, either (x) the forms described in clause (iii) of Section 10.5 or (y) documentation otherwise necessary to establish an exemption or reduction of U.S. withholding tax under Section 10.5 or Borrower’s knowledge or reason to know of any facts that would render any such forms unreliable, and (c) any U.S. federal withholding Taxes imposed under FATCA. “FATCA” means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Code.
“Foreign Subsidiary” means a Subsidiary not organized under the laws of the United States or any state or territory thereof or the District of Columbia.
“Indemnified Taxes” means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of the Borrower under any Loan Document and (b) to the extent not otherwise described in (a), Other Taxes.
“Insolvency Proceeding” means any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief.
“Intellectual Property” means any copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, patent applications, patent registrations and like protections, including improvements, divisions, continuations, renewals, reissues, extensions, and continuations-in-part of the same, trademarks, service marks and applications therefor, whether registered or not, and like protections, and the goodwill of the business of Borrower connected with and symbolized thereby, know-how, operating manuals, trade secret rights, rights to unpatented inventions, and any claims for damage by way of any past, present, or future infringement of any of the foregoing. “IRS” means the U.S. Internal Revenue Service.
“Key Person” means Borrower’s Chief Executive Officer, who is Paul Kellenberger, Chief Financial Officer, who is Erick DeOliveira, as of the Effective Date.
“Loan Documents” means, collectively, this Agreement, any subordination agreement, any note, or notes or guaranties executed by Borrower or any guarantor, and any other present or future agreement between Borrower and/or for the benefit of Lender in connection with this Agreement, all as amended, extended or restated.
“Material Adverse Change” means the occurrence of (a) any material impairment in the business, operations, or financial condition of Borrower, (b) a material impairment of the prospect of repayment of any portion of the Obligations; or (c) a material impairment in the perfection or priority of Lender’s security interest in the Collateral or in the value of such Collateral (other than normal depreciation) which is not covered by adequate insurance.
“Non-Qualified Public Offering” means an initial listing or offering of Borrower’s equity on a public stock exchange that is not a Qualified Public Offering
“Note” means any promissory note delivered in connection with this Agreement.
“Obligations” means Borrower’s obligation to pay when due any debts, principal, interest, premiums, Lender Expenses, and other amounts Borrower owes Lender now or later, whether under this Agreement, the other Loan Documents, or otherwise, including, without limitation, any interest accruing after Insolvency Proceedings begin and debts, liabilities, or obligations of Borrower assigned to Lender, and the performance of Borrower’s duties under the Loan Documents.
“Other Connection Taxes” means, with respect to any Lender, Taxes imposed as a result of a present or former connection between such Lender and the jurisdiction imposing such Tax (other than connections arising from such Lender having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).
-2-
“Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an Assignment.
“Permitted Indebtedness” means (a) Borrower’s indebtedness to Lender, indebtedness under the Pre-Existing Agreements; (b) indebtedness existing on the Effective Date and informed to the Lender in writing prior to the Effective Date; (c) indebtedness to trade creditors incurred in the ordinary course of business; (d) indebtedness secured by Permitted Liens; (e) indebtedness arising from the endorsement of instruments in the ordinary course of business; (f) Subordinated Debt; (g) Indebtedness that constitutes a Permitted Investment; h) Indebtedness consisting of reimbursement obligations pursuant to letters of credit; (i) Indebtedness incurred in connection with cash management services, including treasury, depository, overdraft, credit or debit card, purchasing cards, electronic funds transfer, automatic clearing house arrangements, cash pooling arrangements, netting services, merchant services, foreign exchange contracts and other similar arrangements, in each case in the ordinary course of business; (j) Indebtedness (other than for borrowed money) incurred under performance, surety, bid, statutory and appeal bonds, completion guarantees and other similar obligations incurred in the ordinary course of business; (k) Indebtedness owed to any Person providing worker’s compensation, health, disability or other employee benefits or property, casualty, liability, or other insurance, so long as the amount of such Indebtedness is not in excess of the amount of the unpaid cost of, and shall be incurred only to defer the cost of, such insurance for the year in which such Indebtedness is incurred and such Indebtedness is outstanding only during such year; and (l) extensions, refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness described in (a) through (k) above, provided that the principal amount thereof is not increased or the terms thereof are not modified to impose materially more burdensome terms upon Borrower or its Subsidiaries, as the case may be.
“Permitted Investments” means (a) investments informed to the Lender in writing prior the Effective Date and existing on the Effective Date; (b) (i) marketable direct obligations issued or unconditionally guaranteed by the United States or its agency or any State maturing within 1 year from its acquisition, (ii) commercial paper maturing no more than 1 year after its creation and having the highest rating from either Standard & Poor’s Ratings Service or Moody’s Investors Service, Inc., (iii) certificates of deposit issued maturing no more than 1 year from the date of investment therein, (iv) money market funds at least ninety-five percent (95%) of the assets of which constitute Permitted Investments of the kinds described in clauses (b)(i) through b(iii) of this definition; (v) [reserved]; (c) investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; (d) investments consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the ordinary course of business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee stock purchase plans or agreements approved by Borrower’s Board of Directors; (e) deposit and investment accounts of Borrower in which Lender has a lien prior to any other lien (other than liens securing customary fees and expenses (but no credit/debt relationship or margin account) of the depository or investment intermediary); (f) investments accepted in connection with Permitted Transfers; (g) investments by Borrower in its Subsidiaries of up to $250,000 per year in the aggregate and by Subsidiaries in other Subsidiaries or in the Borrower; (g) investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrowers’ business; (h) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business, (i) repurchases of Borrower’s equity interests from employees, officers and directors to the extent permitted under Section 3.9; (j) deposits of cash made in the ordinary course of business to secure performance of operating leases or appeal bonds or to secure performance of letters of credit issued in connection with such operating leases or appeal bonds; (k) investments not otherwise permitted in an aggregate amount of not more than $100,000 in each fiscal year; and (l) the license of Borrower’s Intellectual Property in conjunction with joint ventures and corporate collaborations and similar business arrangements made in the ordinary course of business on an arms’-length basis provided Borrower’s contributions hereunder shall not exceed $250,000 in the aggregate.
-3-
“Permitted Liens” means (a) liens existing on the Effective Date and informed to the Lender in writing prior to the Effective Date or that are in favor of Lender; (b) liens for taxes, fees, assessments or other government charges or levies, either not delinquent or being contested in good faith and for which Borrower maintains adequate reserves on its books in accordance with GAAP, if they have no priority over any of Lender’s security interests; (c) purchase money liens (i) on equipment and related software acquired or held by Borrower or its Subsidiaries incurred for financing the acquisition of the equipment and related software, if any, including the financing of the costs of shipping, taxes and installation, or (ii) existing on equipment and related software when acquired, if the lien is confined to such property, improvements thereon, and proceeds thereof; (d) liens in favor of other financial institutions arising in connection with Borrower’s deposit or investment accounts held at such institutions to secure customary fees and charges for deposit services and other and other cash management services, including treasury, depository, overdraft, credit or debit card, purchasing cards, electronic funds transfer, automatic clearing house arrangements, cash pooling arrangements, netting services, merchant services, foreign exchange contracts and other similar arrangements, provided that Lender has a perfected security interest in the amounts held in such deposit accounts to the extent required hereunder; (e) statutory liens securing claims or demands of materialmen, mechanics, carriers, warehousemen, landlords and other Persons imposed without action of such parties, provided, they have no priority over any of Lender’s security interests; (f) liens arising from the filing of any financing statement on operating leases, to the extent such operating leases are permitted under this Agreement; (g) liens on cash collateral securing reimbursement obligations to Lender under letters of credit; (h) easements, reservations, rights-of-way, restrictions, minor defects or irregularities in title and other similar charges or encumbrances affecting real property not likely to result in a Material Adverse Change; (i) licenses and sublicenses granted by Borrower in the ordinary course of its business and not otherwise prohibited by this Agreement; (j) liens to secure payment of workers’ compensation, employment insurance, old-age pensions, social security and other like obligations incurred in the ordinary course of business; (k) leases or subleases of real property granted in the ordinary course of Borrower’s business (or, if referring to another Person, in the ordinary course of such Person’s business), and leases, subleases, non-exclusive licenses or sublicenses of personal property granted in the ordinary course of Borrower’s business (or, if referring to another Person, in the ordinary course of such Person’s business); (l) liens arising from attachments or judgments, orders, or decrees in circumstances not constituting an Event of Default; (m) Liens on deposits of cash made to secure bids, tenders, contracts (other than contracts for the payment of money), leases, surety, and appeal bonds and other obligations of a like nature arising in the ordinary course of business; (n) licenses of Intellectual Property which constitute a Permitted Transfer; and (o) liens incurred in the extension, renewal, or refinancing of indebtedness secured by liens described in clauses (a) through (d) hereof of this definition, but any extension, renewal or replacement lien must be limited to the property encumbered by the existing lien and the principal amount of the indebtedness may not increase.
“Permitted Transfer” means Transfers of (a) Inventory in the ordinary course of business; (b) non-exclusive licenses and similar arrangements for the use of the property of Borrower or its Subsidiaries in the ordinary course of business and other non-perpetual licenses that may be exclusive in some respects, such as, by way of example, with respect to field of use or geographic territory, but that do not result, under applicable law, in a sale of all of Borrower’s interest in the property that is the subject of the license; (c) worn-out, surplus or obsolete equipment in the ordinary course of business that is, in the reasonable judgment of Borrower, no longer economically practicable to maintain or useful; (d) assets consisting of Permitted Liens and Permitted Investments; and (e) other Transfers of assets having a fair market value of not more than One Hundred Thousand Dollars ($100,000) in the aggregate in any fiscal year.
-4-
“Person” means any individual, sole proprietorship, partnership, limited liability company, joint venture, company association, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.
“Pre-Existing Agreements” means (i) Loan and Security Agreement dated November 3, 2022 executed by and between Fiza Investments Limited and the Borrower and all documents executed pursuant thereto (as amended from time to time); (ii) Convertible Promissory Note dated March 9, 2024 executed by and between Fiza Investments Limited and the Borrower and all documents executed pursuant thereto (as amended from time to time); (iii) Business Loan and Security Agreements executed by and between Itria Ventures LLC and the Borrower dated as of and for the amounts as follows, collectively the “Itria Agreements” and the loan amounts disbursed pursuant to the Itria Agreements, collectively the “Itria Loans”)):
(a) | February 1, 2023 (effective January 31, 2023) for an amount of USD 4,000,0000 | |
(b) | February 1, 2023 (effective January 31, 2023) for an amount of USD 2,530,0000 | |
(c) | April 12, 2023 for an amount of USD 680,000 | |
(d) | May 17, 2024 for an amount of USD 1,000,000 | |
(e) | May 17, 2024 for an amount of USD 500,000 | |
(f) | May 17, 2024 for an amount of USD 500,000 | |
(g) | June 4, 2024 for an amount of USD 1,500,000 |
“Preferred Stock” has the meaning given to it in the Amended and Restated Certificate of Incorporation.
“Public Offering” means a Qualified Public Offering or a Non-Qualified Public Offering.
“Qualified Public Offering” means a firm commitment underwritten public offering (i) pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $15,000,000of gross proceeds to the Borrower, or (ii) pursuant to a similar regulatory framework applicable to a non-U.S. public offering resulting in at least $10,000,000 of gross proceeds to the Borrower, in either case, with such offering resulting in the Common Stock of Borrower being listed for trading on an exchange or marketplace approved by the Borrower’s Board of Directors and a pre-money valuation for such offering at which GII receives equity in exchange for the entire principal and interest payable under each Loan as provided herein.
“Responsible Officer” means each of the Chief Executive Officer, the President, the Chief Financial Officer, Secretary, Treasurer and the Controller of Borrower.
“Series A Director” has the meaning given to it in the Amended and Restated Certificate of Incorporation.
“Subsidiaries” means any entity of which more than 50% of the voting stock or other equity interests is owned or controlled, directly or indirectly, by Borrower.
“Subordination Agreement” means that certain subordination agreement to be executed to provide that the seniority of the Loans and the security created in respect of the Loans together with its repayment against the indebtedness availed under the Pre-Existing Agreements.
“Subordinated Debt” means indebtedness (a) approved by Borrower in its sole discretion and subject to a subordination agreement for both liens and payments with Lender, or (b) convertible subordinated debt on terms reasonably acceptable to Lender and subject to a subordination agreement for both liens and payment (but not for conversion).
“Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any governmental authority, including any interest, additions to tax or penalties applicable thereto.
-5-
“Threshold Amount” means Two Hundred Fifty Thousand Dollars ($250,000).
“Total Commitment” has the meaning given to such term on Schedule A.
“UCC” means the Uniform Commercial Code as in effect in the State of New York; provided, that if, by applicable law, the perfection or effect of perfection or non-perfection of the security interest created hereunder in any Collateral is governed by the Uniform Commercial Code as in effect on or after the date of this Agreement in any other jurisdiction, “UCC” means the Uniform Commercial Code as in effect in such other jurisdiction for purposes of the provisions of this Agreement relating to such perfection or the effect of perfection or non-perfection.
-6-
SCHEDULE
D
CORPORATE BORROWING certificatE
Borrower: ZSPACE, INC. Date: July 11, 2024
Lender : Fiza Investments Limited
I hereby certify, in my capacity as an officer of the Borrower and not in any personal capacity, as follows, as of the date set forth above:
1. I am the Secretary, Assistant Secretary or other officer of Borrower. My title is as set forth below.
2. Borrower’s exact legal name is set forth above. Borrower is a corporation existing under the laws of the State of Delaware.
3. Attached hereto as Annex I are true, correct and complete copies of Borrower’s Certificate of Incorporation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth above. Such Certificate of Incorporation have not been amended, annulled, rescinded, revoked or supplemented, and remain in full force and effect as of the date hereof.
4. Attached hereto as Annex II are true, correct and complete copies of Borrower’s Bylaws (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth above. Such Certificate of Incorporation have not been amended, annulled, rescinded, revoked or supplemented, and remain in full force and effect as of the date hereof.
5. The following resolutions were duly and validly adopted by Borrower’s Board of Directors at a duly held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate action). Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and Fiza Investments Limited (“Lender”) may rely on them until Lender receives written notice of revocation from Borrower.
Resolved, that any one of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower:
Name | Title | Signature | Authorized to Add or Remove Signatories |
Paul Kellenberger | Chief Executive Officer | ¨ | |
Erick DeOliveira | Chief Financial Officer | ¨ |
Resolved Further, that any one of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.
Resolved Further, that such individuals may, on behalf of Borrower:
Borrow Money. Borrow money from Lender.
Execute Loan Documents. Execute any loan documents Lender requires.
Grant Security. Grant Lender a security interest in any of Borrower’s assets.
Negotiate Items. Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.
Issue Warrants. Issue warrants for Borrower’s capital stock.
Further Acts. Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower’s right to a jury trial) they believe to be necessary to effect these resolutions.
Resolved Further, that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.
[Signature page follows.]
The persons listed above are Borrower’s officers or employees with their titles and signatures shown next to their names.
By: | ||
Name: Paul Kellenberger | ||
Title: Chief Executive Officer |
*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.
I, Erick DeOliveira, the Chief Financial Officer of Borrower, hereby certify as to paragraphs 1 through 5 above, as of the date set forth above.
By: | ||
Name: Erick DeOliveira | ||
Title: Chief Financial Officer |
ANNEX I
CHARTER DOCUMENTS
[see attached]
-3-
ANNEX II
BYLAWS
[see attached]
SCHEDULE
E
FORM OF PROMISSORY NOTE FOR LOAN
Note No. X-XXX
US$4,300,000 | July __, 2024 |
San Jose, California
The undersigned (“Borrower”) promises to pay to US$4,300,000, an entity organized under the laws of the Cayman islands or its registered assigns (“Lender”), at its office at c/o Gulf Islamic Investments LLC, PO Box 215931, Emaar Square 4, 7th Floor, Downtown Dubai, United Arab Emirates, or at such other place as Lender may designate in writing, in lawful money of the United States of America, the principal sum of US$4,300,000, with interest thereon from the date hereof until maturity, whether scheduled or accelerated, at a fixed rate per annum of twenty five percentage points (25%) (the “Designated Rate”), plus the Default Rate (if applicable), plus all other amounts according to the payment schedule described herein.
This Promissory Note (this “Promissory Note”) is one of the Promissory Notes referred to in, and is entitled to all the benefits of, the Loan and Security Agreement dated as of July __, 2024, between Borrower and Lender (as amended, restated or supplemented from time to time, the “Agreement”). Each capitalized term not otherwise defined herein shall have the meaning set forth in the Agreement. The Agreement contains provisions for the acceleration of the maturity of this Promissory Note upon the happening of certain stated events.
This Promissory Note shall be payable as follows:
Any and all unpaid expenses, fees, any accrued and unpaid interest (including default interest) and principal, shall be due and payable on the earlier of the (i) the Maturity Date, (ii) an Event of Default, (iii) the consummation of the business combination in accordance with and pursuant to the Business Combination Agreement; and (iv) any Change of Control or other liquidation event, or other repayment, prepayment or termination date of this Note.
This Promissory Note may be prepaid only as permitted in the Agreement. In the event there is more than one Borrower, each and every Borrower entity’s obligations hereunder shall be joint and several with the obligations of the other Borrower entities.
Any unpaid payments of principal or interest on this Promissory Note shall bear interest from their respective maturities, whether scheduled or accelerated, at a rate per annum equal to the three percent (3%) above the Designated Rate, or such lesser amount designated by Lender in its sole discretion. Borrower shall pay such interest on demand.
Interest, charges and fees shall be calculated for actual days elapsed on the basis of a 360-day year, which results in higher interest, charge or fee payments than if a 365-day year were used. In no event shall Borrower be obligated to pay interest, charges or fees at a rate in excess of the highest rate permitted by applicable law from time to time in effect.
If Borrower is late in making any payment under this Promissory Note by more than five (5) Business Days, Borrower agrees to pay, if required by Lender in its sole discretion, a “late charge” of two percent (2%) of the installment due, but not less than fifty dollars ($50) for any one such delinquent payment. This late charge may be charged by Lender for the purpose of defraying the expenses incidental to the handling of such delinquent amounts. Borrower acknowledges that such late charge represents a reasonable sum considering all of the circumstances existing on the date of this Promissory Note and represents a fair and reasonable estimate of the costs that will be sustained by Lender due to the failure of Borrower to make timely payments. Borrower further agrees that proof of actual damages would be costly and inconvenient. Such late charge shall be paid without prejudice to the right of Lender to collect any other amounts provided to be paid or to declare a default under this Promissory Note or any of the other Loan Documents or from exercising any other rights and remedies of Lender.
This Promissory Note shall be governed by, and construed in accordance with, the laws of the State of New York without reference to its conflict of laws principles.
ZSPACE, INC. | ||
By: | ||
Name: | Paul Kellenberger | |
Its: | Chief Executive Officer |
SCHEDULE F
FORM OF U.S. TAX COMPLIANCE CERTIFICATE
U.S.
TAX COMPLIANCE CERTIFICATE
(For Non-U.S. Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes)
Reference is hereby made to the Loan and Security Agreement, dated as of July __, 2024 (as amended, supplemented or otherwise modified from time to time, the “Loan Agreement”) by and between zSpace, Inc., a Delaware corporation (the “Borrower”), and Fiza Investments Limited, an entity organized under the laws of the Cayman Islands (the “Lender”).
Pursuant to the provisions of Section 10.5 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the Loan (as well as any Note(s) evidencing such Loan) in respect of which it is providing this certificate, (ii) it is not a bank within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a “10 percent shareholder” of any Borrower within the meaning of Section 871(h)(3)(B) of the Code and (iv) it is not a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the Code.
The undersigned has furnished the Borrower with a certificate of its non-U.S. Person status on IRS Form W-8BEN or W-8BEN-E, as applicable. By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform the Borrower, and (2) the undersigned shall have at all times furnished the Borrower with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.
Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.
Fiza Investments Limited
By: | ||
Name: | ||
Title: | ||
Date: | ______________ __, 2024 |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated May 13, 2024, relating to the consolidated financial statements of zSpace, Inc. (the Company), which are contained in that Prospectus. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, P.C
Spokane, Washington
July 22, 2024
Exhibit 107
Calculation of Filing Fee Table
Form S-1
(Form Type)
zSpace, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type |
Security Class Title | Fee Calculation |
Amount Registered |
Proposed Maximum Per Unit |
Maximum Aggregate Offering Price(1)(2) |
Fee Rate | Amount
of Registration Fee | |||||||||
Fees
to Be Paid |
Equity | Common
Stock, par value $0.00001 per share |
457(o) | — | — | $15,000,000.00 | 0.0001476 | $2,214.00 | ||||||||
Fees
to Be Paid |
Equity | Overallotment Option Shares of Common Stock(3) | 457(o) | — | — | $2,250,000.00 | 0.0001476 | $332.10 | ||||||||
Other | Representative’s warrants(4) | 457(g) | — | — | — | — | — | |||||||||
Equity | Common
Stock, par value $0.00001 per share, underlying the Representative’s warrants(5) |
457(a) | — | — | $750,000.00 | 0.0001476 | $110.70 | |||||||||
Secondary Offering | Equity | Common
Stock, par value $0.00001 per share(6) |
457(o) | — | — | $12,209,835.00 | 0.0001476 | $1,802.17 | ||||||||
Total Offering Amounts | $30,209,835.00 | $4,458.97 | ||||||||||||||
Total Fees Previously Paid | $4,428.00 | |||||||||||||||
Total Fee Offsets | — | |||||||||||||||
Net Fee Due | $30.97 |
(1) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”). |
(2) | Includes the aggregate offering price of additional shares that the underwriters have the option to purchase. |
(3) | Represents 15% of additional shares of common stock related to the exercise in full of the over-allotment option by the underwriters. |
(4) | No fee required pursuant to Rule 457(g) under the Securities Act. |
(5) | The registrant will issue to Roth Capital Partners, LLC, as underwriter, warrants to purchase up to a number of shares of common stock equal to 5% of the number of shares of common stock to be issued and sold in the offering. The exercise price of the warrants is equal to 150% of the offering price of the common stock offered hereby. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(a) under the Securities Act, the proposed maximum aggregate offering price of the common stock underlying the warrants is $750,000, excluding the underwriter’s over-allotment option, based on the proposed maximum offering of $15,000,000. The section entitled “Commissions and Expenses” in the registration statement contains additional information regarding compensation to Roth Capital Partners, LLC. |
(6) | For purposes of calculating the proposed maximum offering price, we have multiplied 2,219,970, representing the number of shares being registered for resale, by an assumed price of $5.50 per share. |